

=> d his

(FILE 'HOME' ENTERED AT 09:36:01 ON 04 MAY 2007)

FILE 'REGISTRY' ENTERED AT 09:36:14 ON 04 MAY 2007

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 1920 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:37:28 ON 04 MAY 2007

L4 129 S L3

FILE 'REGISTRY' ENTERED AT 09:38:18 ON 04 MAY 2007

L5 3 S L3 AND REF.CAPLUS>10


L6 1917 S L3 NOT L5

FILE 'CAPLUS' ENTERED AT 09:40:37 ON 04 MAY 2007

L7 51 S L6

=> d que 17 stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 1920 SEA FILE=REGISTRY SSS FUL L1

L5 3 SEA FILE=REGISTRY ABB=ON PLU=ON L3 AND REF.CAPLUS>10

L6 1917 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L5

L7 51 SEA FILE=CAPLUS ABB=ON PLU=ON L6

=> d 1-51 bib abs hitstr

L7 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1048888 CAPLUS

DN 146:40918

TI Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated

Solvent Anchoring

AU Cihlar, Tomas; He, Gong-Xin; Liu, Xiaohong; Chen, James M.; Hatada, Marcos; Swaminathan, Swami; McDermott, Martin J.; Yang, Zheng-Yu; Mulato, Andrew S.; Chen, Xiaowu; Leavitt, Stephanie A.; Stray, Kirsten M.; Lee, William A.

CS Gilead Sciences, Inc., Foster City, CA, 94404, USA

SO Journal of Molecular Biology (2006), 363(3), 635-647

CODEN: JMOBAK; ISSN: 0022-2836

PB Elsevier Ltd.

DT Journal

LA English

AB The introduction of human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) markedly improved the clin. outcome and control of HIV-1 infection. However, cross-resistance among PIs due to a wide spectrum of mutations in viral protease is a major factor limiting their broader

clin. use. Here we report on the suppression of PI resistance using a covalent attachment of a phosphonic acid motif to a peptidomimetic inhibitor scaffold. The resulting phosphonate analogs maintain high binding affinity to HIV-1 protease, potent antiretroviral activity, and unlike

the parent mols., display no loss of potency against a panel of clin. important PI-resistant HIV-1 strains. As shown by crystallog. anal., the phosphonate moiety is highly exposed to solvent with no discernable interactions with any of the enzyme active site or surface residues. We term this effect "solvent anchoring" and demonstrate that it is driven by a favorable change in the inhibitor binding entropy upon the interaction with mutant enzymes. This type of thermodyn. behavior, which was not

found with the parent scaffold fully buried in the enzyme active site, is a result of the increased degeneracy of inhibitor binding states, allowing effective mol. adaptation to the expanded cavity volume of mutant proteases.

This strategy, which is applicable to various PI scaffolds, should facilitate the design of novel PIs and potentially other antiviral therapeutics.

IT 622865-00-3D, GS-6373, complexes with HIV-1 protease

RN 622865-01-4D, complexes with HIV-1 protease

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)


(phosphonate inhibitors can inhibit M46I/I47V/I50V and L10F/M46I/I50V mutants of HIV-1 protease)

RN 622865-00-3 CAPLUS

CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-01-4 CAPLUS

CN Carbamic acid,

N-[(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 622865-00-3, GS 8373 622865-01-4, GS 8374

622866-91-5, GS 16571


RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring)

RN 622865-00-3 CAPLUS

CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-01-4 CAPLUS

CN Carbamic acid,

N-[(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-91-5 CAPLUS

CN L-Alanine,

N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1030273 CAPLUS
 DN 145:397501
 TI Substituted carbamates as HIV protease inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection, AIDS and AIDS-related conditions
 IN McLean, Ed, W.; Miller, John Franklin
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 73pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CMT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006/104646	A1	20061005	WO 2006-US8102	20060307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-660706P	P	20050311		
OS MARPAT 145:397501				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention features compds. of formula I that are HIV protease inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. Compds. of formula I wherein X is (un)substituted C1-5 alkylene; R1 is amino, C1-8 alkyl, C1-8 alkoxy, NR2, N(R2)2 and (un)substituted heterocycle; R2 is C1-8 alkyl and C1-8 alkoxy; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by in several steps (procedure given). All the invention compds.

were evaluated for their HIV protease inhibitory activity. The key mean pharmacokinetic parameters, C_{max} and AUC_{0-∞} values were determined to be < 1 ng/mL and < 1 ng/mL·hr, resp.

IT 911384-40-2P 911384-41-3P 911384-42-4P
 911384-43-5P 911384-44-6P 911384-45-8P
 911384-46-0P 911384-47-4P 911384-48-8P
 911384-49-0P 911384-50-4P 911384-51-5P
 911384-52-7P 911384-53-9P 911384-54-0P
 911384-55-7P 911384-56-0P 911384-57-1P
 911384-58-2P 911384-59-3P 911384-60-8P
 911384-61-7P 911384-62-8P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic)

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-42-4 CAPLUS
 CN Glycine, N,N-diethyl-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonylethyl)-(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolylmethoxy)phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911384-43-5 CAPLUS
 CN 4-Morpholineacetic acid, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonylethyl)-(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolylmethoxy)phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 [drug candidate; prepn. of substituted carbamates as HIV protease inhibitors useful in treatment and prevention of HIV infection, AIDS and AIDS-related conditions)
 RN 911384-40-2 CAPLUS
 CN Glycine, N-(2-methoxyethyl)-N-methyl-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonylethyl)-(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolylmethoxy)phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911384-41-3 CAPLUS
 CN Glycine, N-methyl-N-[2-(2-pyridinyl)ethyl]-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonylethyl)-(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolylmethoxy)phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 911384-44-6 CAPLUS
 CN Glycine, N,N-bis(2-methoxyethyl)-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonylethyl)-(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolylmethoxy)phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911384-46-8 CAPLUS
 CN L-Lysine, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonylethyl)-(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolylmethoxy)phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-oxoethyl ester, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911384-45-7
CMF C41 H55 N5 O13 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 911384-48-0 CAPLUS
CN L-Leucine, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911384-47-9

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 911384-51-5 CAPLUS
CN 5,8,11,14,17-Pentaoxa-2-azanonadecanoic acid, 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]-6,9-dioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C41 H54 N4 O13 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 911384-50-4 CAPLUS
CN Glycine, N-methyl-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911384-49-1
CMF C38 H48 N4 O13 S2

Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 911384-53-7 CAPLUS
CN Acetic acid, [2-(1H-imidazol-1-yl)ethoxy]-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911384-52-6
CMF C40 H49 N5 O12 S2

Absolute stereochemistry.



CM 2

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 76-05-1
 CMF C2 H F3 O2




RN 911384-55-9 CAPLUS
 CN 5,8-Dioxo-2,11-diazadodecanoic acid,
 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-11-methyl-12-(6-methyl-2-pyridinyl)-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]-6-oxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911384-54-8
 CMF C45 H57 N5 O12 S2

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-56-0 CAPLUS
 CN Acetic acid, [2-oxo-2-(1H-pyrazol-3-ylamino)ethoxy]-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911384-57-1 CAPLUS
 CN 5,8-Dioxo-2,11-diazadodecanoic acid,
 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]-6,10-dioxo-12-(2-pyridinyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-58-2 CAPLUS
 CN 5,8-Dioxo-2,11-diazadodecanoic acid,
 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]-6,10-dioxo-12-(2-thienyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911384-59-3 CAPLUS
 CN 5,8,11-Trioxa-2,14-diazahexadecanoic acid, 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-14-methyl-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]-6,13-dioxo-16-(2-pyridinyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 911384-61-7 CAPLUS
 CN Glycine, N-(aminoiminomethyl)-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911384-60-6
 CMF C36 H46 N6 O11 S2

Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMP C2 H F3 O2

RN 911384-62-8 CAPLUS
CN Pyridinium, 1-[2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl]-, chloride (9CI) (CA INDEX NAME)
Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A


● Cl⁻

IT 911384-45-7P 911384-47-9P 911384-49-1P
911384-52-6P 911384-54-8P 911384-60-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted carbamates as HIV protease inhibitors useful in treatment and prevention of HIV infection, AIDS and AIDS-related conditions)
RN 911384-45-7, CAPLUS
CN L-Lysine, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)
Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 911384-47-9 CAPLUS
CN L-Leucine, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 911384-49-1 CAPLUS
CN Glycine, N-methyl-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 911384-52-6 CAPLUS
CN Acetic acid, [2-(1H-imidazol-1-yl)ethoxy]-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)
Absolute stereochemistry.



RN 911384-54-8 CAPLUS
CN 5,8-Dioxo-2,11-diazadodecanoic acid, 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-11-methyl-12-(6-methyl-2-pyridinyl)-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]-6-oxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 911384-60-6 CAPLUS


CN Glycine, N-(aminoiminomethyl)-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 911384-63-9P 911384-64-0P 911384-65-1P
911384-66-2P 911384-67-3P 911384-68-4P
911384-69-5P 911384-70-8P 911384-71-9P
911384-72-0P 911384-73-1P 911384-74-2P
911384-75-3P 911384-76-4P


L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-65-1 CAPLUS

CN Acetic acid, hydroxy-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911384-66-2 CAPLUS

CN Acetic acid, chloro-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RL: RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate: prepn. of substituted carbamates as HIV protease inhibitors useful in treatment and prevention of HIV infection, AIDS and AIDS-related conditions)

RN 911384-63-9 CAPLUS

CN Acetic acid, chloro-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)

Acetic acid, chloro-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911384-64-0 CAPLUS

CN 5,8-Dioxo-2,13-diazatetradecanedioic acid, 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-3-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]-6,9-dioxo-, 14-(1,1-dimethylethyl)-1-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, (3S,4R)- (9CI) (CA INDEX NAME)

(CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-67-3 CAPLUS

CN L-Lysine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A




RN 911384-68-4 CAPLUS
 CN L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-71-9 CAPLUS
 CN Acetic acid, (2-iodoethoxy)-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911384-72-0 CAPLUS
 CN Acetic acid, [2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 911384-69-5 CAPLUS
 CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, 2-[(1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911384-70-8 CAPLUS
 CN Acetic acid, (2-chloroethoxy)-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-73-1 CAPLUS
 CN 5,8,11-Trioxa-2-azatridecanedioic acid, 4-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-6-oxo-, 1-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911384-74-2 CAPLUS
 CN Acetic acid, azido-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911384-75-3 CAPLUS
 CN Glycine, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911384-76-4 CAPLUS
 CN Glycine, N-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-, (1R,2S)-1-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 3 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:884745 CAPLUS
 DN 145:293291
 TI Process for the preparation of cyclic alditols for use as protease inhibitors in the treatment of HIV
 IN Linclau, Bruno
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 45pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006089942	A1	20060831	WO 2006-EP60246	20060224


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 PRAI EP 2005-101462 A 20050225
 US 2005-683699P P 20050523
 OS MARPAT 145:293291
 GI

L7 ANSWER 3 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (process for the prepn. of cyclic alditols for use as protease inhibitors in the treatment of HIV)
 RN 908011-36-9 CAPLUS
 CN Carbamic acid, [[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,4R,6aR)-hexahydro-4-(phenylmethoxy)furo[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB A process for the preparation of alditols, I, wherein X and Y are Si or C;
 C;
 R1-R4 are independently H or monovalent hydrocarbon radicals; Z is a formyl, hydroxymethyl or methylene group are useful intermediates for the preparation of cyclic alditols. Thus, II was prepared in 38% yield and tested as an HIV-antiviral agent (PEC50 between 5.7 and 8.8).
 IT 908011-36-9P

L7 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:367270 CAPLUS
 DN 144:398367
 TI Amorphous pharmaceutical compositions comprising rosiglitazone
 IN Ignatious, Francis; Sun, Linghong; Craig, Andrew; Crowe, David; Ho, Tim;
 Millan, Michael
 PA SmithKline Beecham Corporation, USA
 SO U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 523,835.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006083784	A1	20060420	US 2005-64890	20050224
WO 2004014304	A2	20040219	WO 2003-US24641	20030807
WO 2004014304	A3	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


US 2006013869	A1	20060119	US 2005-523835	20050207
WO 2006090150	A1	20060831	WO 2006-GB632	20060223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2002-401726P P 20020807
 WO 2003-US24641 W 20030807
 US 2005-523835 A2 20050207
 US 2005-64890 A 20050224
 AB The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under elec. forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers. The present invention is also directed to the process of making solid dispersions of amorphous forms and compns. of rosiglitazone and its pharmaceutically acceptable salts. A 3:1 weight solution of rosiglitazone mesylate 2-PrOH-water was spray dried to give an amorphous powder.
 IT 659727-44-3
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:189865 CAPLUS
 DN 144:432712
 TI Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
 AU Miller, John F.; Andrews, C. Webster; Brieger, Michael; Purfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew;
 Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G.
 CS GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(7), 1788-1794
 CODEN: BMCL88; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 144:432712
 AB A novel series of P1 modified HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and protease inhibitor-resistant viruses. Optimization of the P1 moiety resulted in compds. with femtomolar enzyme activities and cellular antiviral activities in the low nanomolar range culminating in the identification of clin. candidate GW0385.
 IT 313679-77-5P 313679-90-2P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and pharmacokinetics of nonracemic dioxabicyclooctyl arylmethoxybenzyl-substituted (benzodioxolylsulfonamino)propylcarbamates as potent HIV protease inhibitors and anti-HIV agents)
 RN 313679-77-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 313679-90-2 CAPLUS


L7 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Uses)
 (amorphous pharmaceutical compns. comprising rosiglitazone)
 RN 659727-44-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1
 CRN 313682-08-5
 CMF C33 H41 N3 O10 S2

Absolute stereochemistry.




CM 2
 CRN 104-15-4
 CMF C7 H8 O3 S




L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-thienyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313679-55-9P 884902-43-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of nonracemic dioxabicyclooctyl aryloxybenzyl- and arylmethoxybenzyl-substituted (benzodioxolylsulfonamino)propylcarbamates as potent HIV protease inhibitors and anti-HIV agents)
 RN 313679-55-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 884902-43-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-(hydroxymethyl)phenoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1-propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313679-83-3P 313679-89-9P 313682-06-3P
 313682-24-5P 884902-36-7P 884902-37-8P
 884902-38-9P 884902-39-0P 884902-40-3P
 884902-41-4P 884902-42-5P 884902-44-7P
 884902-45-8P 884902-46-9P 884902-47-0P
 884902-48-1P 884902-49-2P 884902-50-5P
 884902-51-6P 884902-52-7P 884902-53-8P
 884902-54-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of nonracemic dioxabicyclooctyl aryloxybenzyl- and arylmethoxybenzyl-substituted
 (benzodioxolylsulfonamino)propylcarbamates as potent HIV protease inhibitors and anti-HIV agents)

RN 313679-83-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-phenylethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313679-89-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-2-hydroxy-1-[[4-[2-(3-thienyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-06-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(3-cyanophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-24-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-naphthalenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-36-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-phenoxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 884902-37-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-(4-fluorophenoxy)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 884902-38-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-1-[[4-(3-fluorophenoxy)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 884902-39-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-methoxyphenoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-40-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(3-methoxyphenoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 884902-44-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-(4-morpholinylmethyl)phenoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-45-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-(1-pyrrolidinylmethyl)phenoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)


L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 884902-41-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(3-pyridinyloxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-42-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-pyrimidinyl)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 884902-46-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-(4-morpholinylmethyl)phenoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-47-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-[(methylsulfonyl)amino]methyl)phenoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 884902-48-1 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(1H-imidazol-2-ylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-52-7 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-thiazolylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 884902-53-8 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-50-5 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-quinolinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

methylpropyl]amino]-2-hydroxy-1-[[4-(5-thiazolylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 884902-54-9 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-thiazolylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313679-57-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
[preparation of nonracemic dioxabicyclooctyl aryloxybenzyl- and

L7 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 arylmethoxybenzyl-substituted
 (benzodioxolylsulfonylamino)propylcarbamates
 as potent HIV protease inhibitors and anti-HIV agents
 RN 313679-57-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-(2-methylpropyl)amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 2005:1240823 CAPLUS
 DN 144:6777
 TI Preparation of heterocyclyl sulfonylamino benzylhydroxypropylcarbamates as HIV protease inhibitors
 IN Eisenstat, Michael; Delahanty, Greg; Topin, Andrey; Rajendran, Gnana Ravi
 PA Sequoia Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 124 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005110428	A2	200511124	WO 2005-US16056	20050509
WO 2005110428	A3	20061214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 200524121	A1	20051124	AU 2005-244121	20050509
CA 2566340	A1	20051124	CA 2005-2566340	20050509
US 2005267074	A1	20051201	US 2005-124056	20050509
EP 1750696	A2	20070214	EP 2005-745707	20050509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 2006258627	A1	20061116	US 2006-490261	20060721
PRAI US 2004-368935P	P	20040507		
US 2005-124056	A1	20050509		
WO 2005-US16056	W	20050509		
OS MARPAT 144:6777				
GI				



AB XABA1X1 (X = (substituted) (fused) (bridged) 5-7 membered heterocyclyl containing 21 O, N, S, P; A = CONH, COCONH, SO2NH, etc.; B = Q1; D =


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (substituted) alkyl, alkenyl, alkynyl, aryl, cycloalkyl, aralkyl; A1 = ND1E1; D1 = (substituted) alkyl, alkenyl, alkynyl, aryl, cycloalkyl, aralkyl; E1 = CO, SO2; X1 = (substituted) Q2; G1 = NH, O; G2 = CZ2, N; Z2 = H, halo, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; Z3 = Z2, haloalkyl, etc.; were prep'd. Thus, (1-benzyl-2-hydroxy-3-isobutylaminopropyl)carbamate acid hexahydrofuro[2,3-b]furan-3-yl ester, benzofuran-5-sulfonyl chloride, and aq. NaHCO3 were stirred together for 16 h in CH2Cl2 to give 98.5% [3-[(benzofuran-5-sulfonyl)isobutylamino]-1-benzyl-2-hydroxypropyl]carbamate acid hexahydrofuro[2,3-b]furan-3-yl ester. The latter showed a KI = <0.10 nM.

IT 546085-74-9P 869985-74-9P 869985-45-0P
 869985-46-1P 869985-47-2P 869985-48-3P
 869985-49-4P 869985-50-7P 869985-51-8P
 869985-52-2P 869985-53-6P 869985-57-4P
 869985-58-5P 869985-59-6P 869987-58-6P
 869987-60-0P 869987-62-2P 869987-63-3P
 869987-64-4P 869987-65-5P 869987-66-6P
 869987-67-7P 869987-68-8P 869987-69-9P
 869987-70-2P 869987-71-3P 869987-72-4P
 869987-73-5P 869987-74-6P 869987-75-7P
 869987-76-8P 869987-77-9P 869987-79-1P
 869987-80-4P 869987-82-6P 869987-83-7P
 869987-84-8P 869987-85-9P 869987-86-0P
 869987-87-1P 869987-89-3P 869987-90-6P
 869987-92-8P 869987-94-0P 869987-96-2P
 869987-98-4P 869988-00-1P 869988-02-3P
 869988-04-5P 869988-06-7P 869988-08-9P
 869988-10-3P 869988-12-5P 869988-14-7P
 869988-16-9P 869988-18-1P 869988-20-5P
 869988-22-7P 869988-24-9P 869988-26-1P
 869988-28-3P 869988-29-4P 869988-30-7P
 869988-31-8P 869988-32-9P 869988-33-0P
 869988-34-1P 869988-35-2P 869988-36-3P
 869988-37-4P 869988-38-5P 869988-39-6P
 869988-40-9P 869988-41-0P 869988-42-1P
 869988-43-2P 869988-44-3P 869988-45-4P
 869988-46-5P 869988-47-6P 869988-48-7P
 869988-49-8P 869988-50-1P 869988-51-2P
 869988-52-3P 869988-53-4P 869988-54-5P
 869988-55-6P 869988-56-7P 869988-57-8P
 869988-58-9P 869988-59-0P 869988-60-3P
 869988-61-4P 869988-62-5P 869988-63-6P
 869988-64-7P 869988-65-8P 869988-66-9P
 869988-68-1P 869988-69-2P 869988-70-5P
 869988-71-6P 869988-72-7P 869988-73-8P
 869988-74-9P 869988-75-0P 869988-76-1P
 869988-77-2P 869988-78-3P 869988-79-4P
 869988-80-7P 869988-81-8P 869988-82-9P
 869988-83-0P 869988-84-1P 869988-85-2P
 869988-86-3P 869988-87-4P 869988-88-5P
 869988-89-6P 869988-90-9P 869988-91-0P
 869988-92-1P 869988-93-2P 869988-95-4P
 869988-96-5P 869988-98-7P 869988-99-8P
 869989-00-4P 869989-01-5P 869989-02-6P
 869989-04-8P 869989-06-0P 869989-08-2P
 869989-09-3P 869989-10-6P 869989-11-7P
 869989-12-8P 869989-13-9P 869989-14-0P
 869989-15-1P 869989-16-2P 869989-17-3P
 869989-19-5P 869989-20-8P 869989-21-9P

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 869989-23-1P 869989-25-3P 869989-27-5P
 869989-28-6P 869989-29-7P 869989-30-0P
 869989-31-1P 869989-32-2P 869989-33-3P
 869989-34-4P 869989-35-5P 869989-36-6P
 869989-37-7P 869989-38-8P 869989-39-9P
 869989-40-2P 869989-59-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of heterocyclyl sulfonylamino benzylhydroxypropylcarbamates as HIV protease inhibitors)


RN 546083-74-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-5-benzofuran-5-ylsulfonyl)-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869985-44-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzofuran-5-ylsulfonyl)-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869985-45-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-bromo-3-(bromomethyl)-5-benzofuran-5-ylsulfonyl)-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869885-46-1 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(aminomethyl)-2-bromo-5-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869885-47-2 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(aminomethyl)-5-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869885-48-3 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(benzoylamino)methyl]-5-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869885-51-8 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(butylsulfinyl)methyl]-5-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869885-55-2 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(2,3-dihydro-3-methyl-5-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B

RN 869885-49-4 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(aminomethyl)-2-hydroxy-1-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869885-50-7 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[3-methyl-1H-indazol-5-yl]sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 869885-56-3 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(2,3-dihydro-2-(hydroxymethyl)-5-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869885-57-4 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(2,3-dihydro-4-oxo-2H-1-benzopyran-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869885-58-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[3-[(2,3-dihydro-2-methyl-5-benzofuranyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869885-59-6 CAPLUS
 CN 2-Benzofurancarboxylic acid, 5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869987-58-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869987-60-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869987-62-2 CAPLUS

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



RN 869987-66-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869987-67-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869987-63-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869987-64-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869987-65-5 CAPLUS
 CN L-Alanine, N-[[[5-[[[2,3-bis(hydroxymethyl)furan-2-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]-2-benzofuranyl]methyl]-, ethyl ester (9CI)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869987-68-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]amino]sulfonyl]-2,3-dihydro-1-phenylbutyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 869987-69-9 CAPLUS
 CN Glycine, N-[[[5-[[[2,3-bis(hydroxymethyl)furan-2-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]-3-benzofuranyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869987-70-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(butylsulfinyl)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 869987-71-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(ethoxycarbonyl)amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869987-74-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[[1-(methylpropyl)sulfonyl]amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 869987-75-7 CAPLUS
 CN Carbamic acid, (2-[[[5-[[[(2R,3S)-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-3-benzofuranyl]methyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869987-72-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[1-(oxopropyl)amino]methyl]-5-benzofuranyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 869987-73-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(benzoylamino)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 869987-76-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[2-(pyridinyl)ethyl]amino]methyl]-5-benzofuranyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869987-77-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[3-(pyridinyl)carbonyl]amino]methyl]-5-benzofuranyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PAGE 1-A




PAGE 1-B




RN 869987-79-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[2-(phenylmethyl)thio]acetyl]amino]methyl]-5-benzofuranyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 869987-80-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[2-(phenylmethyl)sulfinyl]acetyl]amino]methyl]-5-benzofuranyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued).


RN 869987-83-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[(acetyloxy)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869987-84-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(methoxymethyl)-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869987-85-9 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(hydroxymethyl)-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869987-86-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[[[2-(furan-2-ylcarbonyl)amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



RN 869987-82-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-[[[ethoxycarbonyl]amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-A

PAGE 1-B



RN 869987-87-1 CAPLUS
CN Carbamic acid, [(5-[[[3-[[[2,3S]-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-3-benzofuranyl]methyl](2-methoxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 869987-89-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-(bromomethyl)-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869987-90-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(aminomethyl)-2-bromo-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869987-92-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-(4-morpholinylmethyl)-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B



RN 869988-00-1 CAPLUS
 CN Glycine, N-[[[2-bromo-5-[[[(2R,3S)-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-3-benzofuranyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B



RN 869988-02-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-[[[2-(2-pyridinyl)ethyl]amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 869987-94-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-[(butylthio)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869987-96-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-[(ethylamino)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869987-98-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-[(1-piperidinyl)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869988-04-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-[[[2-(ethylthio)ethyl]amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 869988-06-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-[[[2-(methoxyethyl)amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 869988-08-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-(methoxymethyl)-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-10-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-(methoxymethyl)-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-(1-piperidinylmethyl)-5-benzofuranyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869988-20-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-(4-morpholinylmethyl)-5-benzofuranyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 869988-12-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-bromo-3-(hydroxymethyl)-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869988-14-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(diethylamino)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-16-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(ethylamino)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869988-18-1 CAPLUS

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 869988-22-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(ethylmethylamino)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869988-24-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[[[(phenylmethyl)amino]methyl]-5-benzofuranyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869988-26-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(butylthio)methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 869988-28-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[2-(ethylthio)ethyl]amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 869988-29-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[[2-(methoxyethyl)amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 869988-31-8 CAPLUS
 CN Carbamic acid, ethyl[[[5-[[[2,3S]-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzofuranyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869988-32-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[2-(ethylamino)carbonyl]amino]methyl]-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869988-30-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl]([2-[[[3-pyridinylacetyl]amino]methyl]-5-benzofuranyl]sulfonyl]amino)-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 869988-33-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-methyl-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-34-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[[1-methylethyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino)-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869988-35-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(aminomethyl)-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 869988-36-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[[1-methylethyl)sulfonyl]amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

Pr-1

RN 869988-37-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(acetyloxy)methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-A

PAGE 1-B

Me

RN 869988-40-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(butylsulfinyl)methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

Bu-n

RN 869988-41-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[(1-methylethyl)thio]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 869988-38-5 CAPLUS
 CN 1,2-Benzisoxazole-3-propanoic acid, 5-[[[(2R,3S)-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-α-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

OEt

RN 869988-39-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[methylsulfonyl]amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869988-42-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[[methyl(methylsulfonyl)amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-43-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[[methyl[(4-methylphenyl)sulfonyl]amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 869988-44-3 CAPLUS
 CN Carbamic acid, [15-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-1,2-benzisoxazol-3-yl]methyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

OPr-1

RN 869988-45-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(hydroxymethyl)-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Pr-1


RN 869988-48-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(1H-imidazol-1-ylmethyl)-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-49-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(ethoxycarbonyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OEt


RN 869988-50-1 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [5-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-1,2-benzisoxazol-3-yl]methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869988-46-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(acetylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-47-6 CAPLUS
 CN Propanoic acid, 2-methyl-, [5-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-1,2-benzisoxazol-3-yl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

Bu-t

RN 869988-51-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[(2-methoxyethyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


OMe

RN 869988-52-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[(2-methyl-1-oxopropyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-Pr-i

RN 869988-53-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(benzoylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-Ph

RN 869988-54-5 CAPLUS
 CN Carbamic acid, [[5-[[[(2R,3S)-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl]methyl]-, propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869988-57-8 CAPLUS
 CN Carbamic acid, [[5-[[[(2R,3S)-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl]methyl](2-methoxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-OMe

RN 869988-58-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[2-(ethylthio)ethyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-OPr-n

RN 869988-55-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[2-(ethylthio)ethyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-Et

RN 869988-56-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[2-(2-pyridinyl)ethyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-SEt

RN 869988-59-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[2-(ethylthio)ethyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-OMe

RN 869988-60-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[2,2,3,3,3-pentafluoropropyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869988-61-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[3-[[[(2,2,2-trifluoroethyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869988-62-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[3-[[[(2-phenoxyethyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869988-65-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[3-[[[(2,2,2-trifluoroethyl)thio]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 869988-66-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[3-[[[(trifluoroacetyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

INDEX NAME

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869988-63-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(butylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869988-64-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[3-[[[(phenylmethyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 869988-68-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(cyclopentylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 869988-67-0
 CMF C34 H46 N4 O8 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-18-6
 CMF C H2 O2


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

 $\text{O}=\text{CH}-\text{OH}$

RN 869988-69-2 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[[[3-[[[2-[[[1,1-dimethylethoxy]carbonyl]amino]ethyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 869988-70-5 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869988-73-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[3-[[[2-(furan-2-yl)carbonyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 869988-74-9 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[2-(pyridin-2-yl)methyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 869988-71-6 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[3-[[[3-[(cyclohexylmethyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B



RN 869988-72-7 CAPLUS


CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[(4-morpholinylmethyl)-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869988-75-0 CAPLUS


CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[2-methyl-4-thiazolyl]methyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 869988-76-1 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[[[3-(methylsulfonyl)methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 869988-77-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(methoxymethyl)-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-78-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 869988-79-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-[(2,2,2-trifluoroethoxy)methyl]-1,2-benzisoxazol-5-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 869988-80-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[acetyl(2,2,2-trifluoroethyl)amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 869988-81-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[5-benzofuranylmethyl]amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869988-82-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(2,3-dihydro-3-oxo-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869988-83-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(bromomethyl)-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-84-1 CAPLUS
 CN 1,2-Benzisoxazole-3-acetic acid, 5-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869988-85-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[(methylamino)methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869988-86-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(dimethylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869988-87-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(cyanomethyl)-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869988-88-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(phenylmethylthio)methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 869988-91-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(thiocyanatomethyl)-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869988-92-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(2-cyanoethyl)ethylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Ph

RN 869988-89-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(2-methylpropyl)[[3-(phenylthio)methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869988-90-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[bis(2-pyridinylmethyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

CN

RN 869988-93-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[aminoiminomethyl]thio]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH2

RN 869988-95-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869988-96-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[[4-methylphenyl]sulfonyl]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B

RN 869988-98-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(2,5-dioxo-1-pyrrolidinyl)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869989-02-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(formylamino)-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869989-04-8 CAPLUS
 CN Glycine, N-[(2-ethoxy-2-oxoethyl)-N-[[[5-[[[2R,3S]-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869988-99-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(iodomethyl)-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-00-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(acetylamino)-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-01-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(ethoxycarbonyl)amino]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 869989-06-0 CAPLUS
 CN Glycine, N-[[[5-[[[2R,3S]-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl]methyl]-N-(2-(1-methylethoxy)-2-oxoethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B

RN 869989-08-2 CAPLUS
 CN Glycine, N-[[[5-[[[2R,3S]-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 869989-09-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl){3-[(1-oxoheptyl)amino]methyl}-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 869989-10-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[[4-methylphenyl]sulfonyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 869989-12-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(formylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869989-13-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[bis(phenylmethyl)amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 869989-14-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869989-11-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[methyl[(1-methylethyl)sulfonyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 869989-15-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl){3-[[[4-morpholinyl]carbonyl]amino]methyl]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 869989-16-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(benzoylbutylamino)methyl]-1,2-benzisoxazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 benzisoxazol-5-yl)sulfonyl (2-methylpropyl)amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Bu-n

RN 869989-17-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[butyl(2-furanylcarbonyl)amino]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 869989-25-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[1-methylbutyl]amino]-1H-indazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869989-27-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[cyclohexylamino]-1H-indazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 869989-19-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-[[butylthio]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869989-20-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[butylthio]methyl]-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-21-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-methyl-1H-indazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-23-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl] [[3-[[1-methylpropyl]amino]-1H-indazol-5-yl)sulfonyl]amino]-1-


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 869989-28-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl] [[3-[[propylamino]-1H-indazol-5-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-29-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl] [[3-[[phenylmethyl]amino]-1H-indazol-5-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869989-30-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[1-ethylpropyl]amino]-1H-indazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 869989-31-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(butylamino)-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-32-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(2,2-dimethylpropyl)amino]-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 869989-35-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-amino-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869989-36-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(bromomethyl)-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-37-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(dimethylamino)-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869989-38-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(diethylamino)-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

-OMe

RN 869989-33-3 CAPLUS
 CN Glycine, N-[5-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]](2-methylpropyl)amino]sulfonyl]-1H-indazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

-OEt


RN 869989-34-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-chloro-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

-(CH₂)₅Me

RN 869989-39-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[2-(diethylamino)ethyl]amino]-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

-NET₂

RN 869989-40-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(ethoxycarbonyl)amino]-1H-indazol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 869885-59-3 CAPLUS
CN Carbamic acid, [5-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl)methyl] (2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

CF₃


IT 869885-67-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocycl)
sulfonylaminobenzylhydroxypropylcarbamates as
HIV protease inhibitors)
RN 869885-67-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[(butylthio)methyl]-5-benzofuranyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1154157 CAPLUS
DN 143:422465
TI Preparation of phosphonate analogs of HIV protease inhibitors and methods for identifying anti-HIV therapeutic compounds
IN Arimilli, Murty N.; Becker, Mark M.; Birkus, Gabriel
PA USA
SO U.S. Pat. Appl. Publ., 1034 pp.
CODEN: USXXCO
DT Patent
LA English
FAN: CNF 8


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005239054	A1	20051027	US 2003-740694	20031222
WO 2003090690	A2	20031106	WO 2003-US12901	20030425
WO 2003090690	A3	20040624		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091264	A2	20031106	WO 2003-US12926	20030425
WO 2003091264	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003090691	A2	20031106	WO 2003-US12943	20030425
WO 2003090691	A3	20060209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004121316	A1	20040624	US 2003-424186	20030425
US 2005197320	A1	20050922	US 2003-424130	20030425
US 2005209197	A1	20050928	US 2003-423496	20030425
ZA 200409376	A	20050914	ZA 2004-9376	20041122
AU 2004309379	A1	20050714	AU 2004-309379	20041222
CA 2550730	A1	20050714	CA 2004-2550730	20041222
WO 2005064008	A1	20050714	WO 2004-US42991	20041222
WO 2005064008	A9	20060928		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

L7 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 869885-65-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocycl)
sulfonylaminobenzylhydroxypropylcarbamates as
HIV protease inhibitors)
RN 869885-65-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-cyano-4-fluorophenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
SM RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1711617 A1 20061018 EP 2004-817046 20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
PRAI US 2002-375622P P 20020426
US 2002-375665P P 20020426
US 2002-375779P P 20020426
US 2002-375834P P 20020426
US 2003-423496 A2 20030425
US 2003-424130 A2 20030425
US 2003-424186 A2 20030425
US 2003-465721P P 20030425
US 2003-465810P P 20030425
US 2003-465824P P 20030425
WO 2003-US12901 A2 20030425
WO 2003-US12926 A2 20030425
WO 2003-US12943 A2 20030425
WO 2003-740694 A 20031222
WO 2004-US42991 W 20041222
GI



AB The invention relates to phosphonate-substituted carbamates I and cyclic ureas II [wherein A = A1, A2, or W3 with the proviso that at least one of A = A1; A1 = [Y2(CR2R2)1-12]0-12Y2W6; A2 = [Y2(CR2R2)1-12]0-12Y2W3; W3 =

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
substituted (hetero)cyclyl, R5, C(Y1)R5, C(Y1)W5, SO2R5, or SO2W5; W5 = substituted (hetero)cyclyl; W6 = triphosphono-substituted W3; Y1 = O, S, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), or N(N(Rx)2); Y2 = independently a bond, O, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), N(N(Rx)2), SO2-2, or SOO-2SOO-2; Rx = independently H, R1, W3, a protecting group, etc.; R1 = independently H or alkyl; R2 = independently H, R1, halo, CN, N3, NO2,

Y1, Rx, N(Rx)2, SO-2Rx, substituted alkyl, alkenyl, alkynyl, etc.; R3 = halo, CN, N3, NO2, Y1, Rx, N(Rx)2, SRx, SO2Rx, OC(Y1)Rx, OC(Y1)ORx, C(Y1)Rx, etc. with provisos; R5 = substituted alkyl, alkenyl, or alkynyl; or pharmaceutically acceptable salts, hydrates, and formulations thereof and other phosphonate-substituted analogs of HIV protease inhibitors for treating AIDS and other antiviral infections, as well as for use in

assays for the detection of HIV protease. Comps. of the invention inhibit reverse transcriptase activity and have improved intracellular half-life compared to analogs not having the phosphonate or phosphonate prodrug. Libraries of such comps. were screened optionally using the novel enzyme GS-7340 ester hydrolase. Comps. and methods relating to GS-7340 ester hydrolase also are provided. Examples include preps. for non-nucleoside phosphonate protease inhibitors. In addn., extensive biol. data


regarding PMMC uptake and metab., serum stability, and alk. phosphatase protease inhibitor (ALPPI) activity of selected phosphonate-substituted prodrugs

is presented. For instance, a 9-step reaction sequence starting from N-tert-butoxycarbonyl-O-benzyl-L-tyrosine provided III (K_i ≤10 pM for ALPPI activity). The synthesis involved multiple protection and deprotection steps along with coupling reactions using isobutylamine, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate, and dibenzyl hydroxymethylphosphonate.


IT 622866-43-7P
RL: BYP (Byproduct); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622866-43-7 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxymethyl)phenyl)methyl]-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-85-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)-3-[[4-(4-methoxyphenyl)sulfonyl](4-piperidinylmethyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 622865-53-6P 622865-86-5P 622866-12-0P
622866-41-5P 622866-42-6P 622866-44-8P
622866-56-2P 622866-86-8P 622867-43-0P
622867-47-4P 622867-48-5P 622867-70-3P
622868-06-8P 622868-82-0P 622869-12-9P
622869-16-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622865-53-6 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 253266-01-2P 605654-08-8P 605654-10-2P


622865-85-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 253266-01-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[3-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 605654-08-8 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-(phenylmethoxy)phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 605654-10-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-86-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[1-(formyl-4-piperidinyl)methyl]-(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-12-0 CAPLUS


CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622866-41-5 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-42-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-formylphenyl)methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-44-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-(bromomethyl)phenyl)methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622867-43-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-ethenylphenyl)methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-47-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-48-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]-2-[[triethylsilyl]oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-70-3 CAPLUS
 CN Propanoic acid, 2-[[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]ester (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-56-2 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-86-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[[[(2-methylpropyl)amino]-4-[[[(4-nitrophenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622867-49-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-methoxyphenyl)methyl]-3-[[[(2-methylpropyl)amino]-4-[[[(4-methoxyphenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-06-8 CAPLUS
 CN Pyridinium, 1-[2-[[bis(phenylmethoxy)phosphinyl]ethyl]-4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-05-7
 CMF C43 H55 N3 O11 P S

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2
CRN 37181-39-8
CMF C F3 O3 S



RN 622868-82-0 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[6-[(diethoxyphosphinyl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl)methyl]-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-12-9 CAPLUS
CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 622868-31-9P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622868-31-9 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 546085-60-3P 622869-15-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 546085-60-3 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-16-3 CAPLUS
CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-6-[[4-[[[(1S)-1-methyl-2-[(1-methylethoxy)-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]methyl]-1-phenyl-3-(phenylmethoxy)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 622865-00-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622865-00-3 CAPLUS
CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-15-2 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 622868-57-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN 622868-57-9 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminophenyl)methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 622865-84-3P 622866-84-6P 622867-34-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622865-84-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[[4-methoxyphenyl]sulfonyl]phenyl]butyl] [(4-methoxyphenyl)sulfonyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-84-6 CAPLUS
 CN Pyridinium, 1-[[[(diethoxyphosphinyl)methyl]-4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]phenyl]butyl] [(2-methylpropyl)amino]butyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 622866-83-5
 CMF C32 H49 N3 O11 P S

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

methylpropyl]amino]-1-[[4-[[[(2-phosphonoethyl)amino]methyl]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 622867-04-3P 622870-49-9P 622870-91-1P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622867-04-3 CAPLUS
 CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]phenyl]butyl]amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-49-9 CAPLUS
 CN L-Alanine,
 N-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]phenyl]butyl]amino]butyl]phenyl]methyl]hydroxyphosphinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 37181-39-8
 CMF C F3 O3 S



RN 622867-34-9 CAPLUS
 CN Carbamic acid, [(1R,2R)-1-formyl-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-2-[[[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 622867-35-0P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN 622867-35-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (2-

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-91-1 CAPLUS
 CN Propanoic acid,
 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]phenyl]butyl]amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 622867-36-1P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622867-36-1 CAPLUS
 CN Propanoic acid,
 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]phenyl]butyl]amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 622865-08-1P 622866-91-5P 622866-97-1P
 622868-28-4P
 RI: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease inhibitors for treatment of AIDS and other viral infections)
 RN 622865-08-1 CAPLUS
 CN L-Alanine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-91-5 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 622868-58-0P 622868-59-1P
 RI: PAC (Pharmacological activity); PUR (Purification or recovery); RCT
 (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
 (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease inhibitors for treatment of AIDS and other viral infections)
 RN 622868-58-0 CAPLUS
 CN Propanoic acid, 2-[[[[(R)-[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]phen
 oxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-59-1 CAPLUS
 CN Propanoic acid, 2-[[[[(S)-[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]phen
 oxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yloxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyph
 ospinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-28-4 CAPLUS
 CN Butanoic acid, 2-[[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyph
 ospinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 622865-70-7P 622865-71-8P 622866-92-6P
 622866-93-7P 622866-95-9P 622866-96-0P
 622866-98-2P 622866-99-3P 622868-52-4P
 622868-54-6P
 RI: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease inhibitors for treatment of AIDS and other viral infections)

RN 622865-70-7 CAPLUS
 CN Propanoic acid,
 2-[[[[(R)-[14-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyph
 ospinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-71-8 CAPLUS
 CN Propanoic acid,
 2-[[[[(S)-[14-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyph
 ospinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-92-6 CAPLUS
 CN D-Alanine, N-[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-93-7 CAPLUS
 CN D-Alanine, N-[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-95-9 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)


* Absolute stereochemistry.



RN 622866-96-0 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-98-2 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-99-3 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-52-4 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-51-3
 CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622868-54-6 CAPLUS

CN Propanoic acid, 2-[[[R]-[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-


methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-53-5

CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 622864-99-7P 622865-02-5P 622865-30-9P

622865-39-8P 622865-45-6P 622865-55-8P

622865-56-9P 622865-61-6P 622865-62-7P

622865-67-6P 622865-69-8P 622865-92-3P

622865-97-8P 622865-98-9P 622866-08-4P

622866-09-5P 622866-13-1P 622866-15-3P

622866-33-5P 622866-34-6P 622866-37-9P

622866-38-0P 622866-39-1P 622866-40-4P

622866-59-5P 622866-67-5P 622866-71-1P

622866-76-6P 622866-79-9P 622866-80-2P

622866-81-3P 622866-87-9P 622867-02-1P

622867-03-2P 622867-22-5P 622867-23-6P

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622867-25-8P 622867-27-0P 622867-30-5P

622867-31-6P 622867-32-7P 622867-33-8P

622867-37-2P 622867-38-3P 622867-49-6P

622867-71-4P 622867-79-2P 622867-84-9P

622867-89-4P 622867-97-4P 622868-15-9P

622868-16-0P 622868-17-1P 622868-29-5P

622868-32-0P 622868-64-8P 622868-65-9P

622868-68-2P 622868-69-3P 622868-70-6P

622868-86-4P 622868-89-7P 622868-91-1P

622868-92-2P 622868-94-4P 622868-97-7P

622868-98-8P 622869-05-0P 622869-06-1P

622869-07-2P 622869-11-8P 622869-13-0P

622869-17-4P 622870-99-9P 622871-01-6P

622871-02-7P 622871-54-9P 622871-56-1P

622871-60-7P 622871-64-1P 622871-65-2P

622871-69-6P 622871-71-0P 622871-76-5P

622871-81-2P 622871-82-3P 622871-83-4P

622871-84-5P 622871-88-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; prepn. of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622864-99-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-02-5 CAPLUS

CN Carbamic acid,

[(1S,2R)-1-[[4-[[bis(diphenoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622865-30-9 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[[4-[(hydroxyphenoxyphosphinyl)methoxy]phenyl]methyl]-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

622865-30-9 CAPLUS
 Carbamic acid, [(1S,2R)-2-hydroxy-1-[[4-[(hydroxyphenoxyphosphinyl)methoxy]phenyl]methyl]-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-39-8 CAPLUS

CN 2,5-Dioxo-10,14-diaza-3-phosphapentadecan-15-oic acid, 12-hydroxy-10-[[[4-methoxyphenyl]sulfonyl]-8,8-dimethyl-1-phenyl-3-(phenylmethoxy)-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622865-45-6 CAPLUS

CN 2,5-Dioxo-9,13-diaza-3-phosphatetradecan-14-oic acid, 11-hydroxy-9-[[[4-methoxyphenyl]sulfonyl]-7,7-dimethyl-1-phenyl-3-(phenylmethoxy)-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-55-8 CAPLUS


CN Carbamic acid,

[(1S,2R)-3-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-hydroxyphenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—Ph

RN 622865-56-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—Ph

RN 622865-61-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—Ph

RN 622865-62-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methylpropyl] (4-phosphonomethoxy)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-87-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[1-formyl-4-piperidinyl]methyl] (4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-89-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[diethoxyphosphinyl]methoxy]phenyl]methyl]-3-[[[1-formyl-4-piperidinyl]methyl] (4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-92-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[diethoxyphosphinyl]methyl]phenyl]amino]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-97-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[bis(phenylmethoxy)phosphinyl]methyl]phenyl]amino]methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-98-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-((phosphonomethyl)phenyl)amino]methyl]propyl]-,


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-13-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-nitrophenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Ph

RN 622866-15-3 CAPLUS


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-08-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[diethoxyphosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-nitrophenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-09-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-aminophenyl]methyl]-3-[[[4-[[diethoxyphosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-1-[[4-aminophenyl]methyl]-2-hydroxy-3-[[[2-methylpropyl]([4-(phosphonomethoxy)phenyl]sulfonyl)amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-33-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[2-methylpropyl]([3-nitrophenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-34-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-aminophenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-37-9 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[2-methylpropyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-38-0 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[[4-[(diphenoxyphosphinyl)methoxy]phenyl]sulfonyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-39-1 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-[(hydroxyphenoxyphosphinyl)methoxy]phenyl]sulfonyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-40-4 CAPLUS
 CN L-Alanine,
 N-[[[4-[[[4-[(2R,3S)-3-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[[[4-[(phenylmethoxy)carbonyl]amino]phenyl]butyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622866-59-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 622866-67-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]-4-methoxyphenyl]sulfonyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-71-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-76-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]amino]butyl]phenyl]-C-(phenylmethyl) ester (9CI) (CA INDEX NAME)


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622866-79-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[(hydroxy(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-80-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[(ethoxy(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-81-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[(ethoxyhydroxyphosphinyl)methoxy]phenyl]methyl]-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-87-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-02-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-03-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-22-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-23-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

Ph


RN 622867-25-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(4-(1-piperazinyl)phenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-24-7
 CMF C43 H59 N4 O13 P S

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Ph

RN 622867-30-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(phenylsulfonamido)butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Ph

RN 622867-31-6 CAPLUS

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 622867-27-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-(phenylmethoxy)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622867-32-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-32-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-33-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(4-(phenylmethoxy)phenyl)sulfonyl]amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-37-2 CAPLUS
 CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, [4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-71-4 CAPLUS
 CN Propanoic acid, 2-[[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

OBU-t

RN 622867-38-3 CAPLUS
 CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, (1R,2S)-3-[4-[[[(1S)-2-ethoxy-

1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]methyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-49-6 CAPLUS
 CN Propanoic acid, 2-[[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-3-[[[(triethylsilyl)oxy]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

OEt

RN 622867-79-2 CAPLUS
 CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy)[2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-84-9 CAPLUS
 CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy)[2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, propyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-89-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[[2S]-2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-


hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-1-oxopropoxy]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-16-0 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[3-hydroxy-4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl] (phenylm ethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-17-1 CAPLUS


CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[3-hydroxy-4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622867-97-4 CAPLUS

CN Carbamic acid, [[1S,2R)-1-[[[1-[[[bis(phenylmethoxy)phosphinyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-15-9 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[3-(acetoxy)-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl] (phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-29-5 CAPLUS

CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl] (phenylm ethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-32-0 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-64-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(2,2,2-trifluoroethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-65-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[[4-[[hydroxy(2,2,2-trifluoroethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 622868-70-6 CAPLUS
 CN Propanoic acid, 2-[[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenoxy][[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-68-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-69-3 CAPLUS
 CN Benzoic acid, 3-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy][[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 622868-86-4 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-85-3
 CME C43 H60 N3 O13 P S

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 622868-89-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[4-[2-[[bis(phenylmethoxy)phosphinyl]methoxy]ethoxy]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-91-1 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[4-[2-[[diphenoxyphosphinyl]methoxy]ethoxy]phenyl]

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]([phenylmethoxy]phosphinyl)oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


OEt

RN 622868-97-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[5-[[diethoxyphosphinyl]methoxy]-1,3-dihydro-2H-isoindol-2-yl]methyl]-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[[triethylsilyl]oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-92-2 CAPLUS
CN Propanoic acid, 2-[[[2-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OEt


RN 622868-94-4 CAPLUS
CN Propanoic acid, 2-[[[2-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-98-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[5-[[diethoxyphosphinyl]methoxy]-1,3-dihydro-2H-isoindol-2-yl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622869-05-0 CAPLUS
CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[[triethylsilyl]oxy]butyl]amino]methyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




```

RN      622869-11-8  CAPLUS
CN      Carbamic acid,
[[1S,2R,2-dihydroxy-1-[(4-[2-[(hydroxyphenoxyphosphinyl)methoxy]ethoxy]phenyl)methyl]-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

```

Absolute stereochemistry.




```

RN  622869-13-0  CAPLUS
CN  2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-
methoxyphenyl)sulfonyl](2-methylpropyl)amino)methyl]-1-phenyl-3-
(phenylmethoxy)-6-(phenylmethyl)-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
3-yl ester, 3-oxide, (5R,6S)- (9CI)  (CA INDEX NAME)

```

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



The chemical structure of compound 10 is a complex molecule. It features a bicyclic system (a decalin derivative) with a carbamate group (-O-C(=O)-NH-) attached to one of the rings. The nitrogen of the carbamate is linked to a chiral center (S) which is part of a sulfonamide group (-NH-SO₂-). This sulfonamide group is further substituted with a 4-methoxyphenyl ring and a 4-(diisobutylamino)phenyl ring. The diisobutylamino group is linked to a phosphonate group (-P(=O)(PhO)-O-), which is in turn linked to a chiral center (S) that is part of a carbamate group (-O-C(=O)-NH-). The nitrogen of this carbamate is linked to a 4-(diisobutylamino)phenyl ring. The diisobutylamino group is linked to a phosphonate group (-P(=O)(PhO)-O-), which is in turn linked to a chiral center (S) that is part of a carbamate group (-O-C(=O)-NH-). The nitrogen of this carbamate is linked to a 4-(diisobutylamino)phenyl ring. The diisobutylamino group is linked to a phosphonate group (-P(=O)(PhO)-O-), which is in turn linked to a chiral center (S) that is part of a carbamate group (-O-C(=O)-NH-). The nitrogen of this carbamate is linked to a 4-(diisobutylamino)phenyl ring.

RN	622871-01-6	CAPLUS
CN	Carbamic acid, ([1S,2R)-1-[[[1-[2-[bis(phenylmethoxy)phosphinyl]ethyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]- (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9C1) (CA INDEX NAME)	

Absolute stereochemistry.




RN	622871-02-7	CAPLUS
CN	Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-54-9 CAPLUS
 CN Carbanic acid,
 Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-56-1 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-60-7 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[4-(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-64-1 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)[4-(trifluoromethyl)phenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-65-2 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)[4-(trifluoromethoxy)phenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-69-6 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-71-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-76-5 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)[1-oxido-3-pyridinyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-81-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]amino]-1-[(4-pyridinylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-82-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[4-formylphenyl]sulfonyl]amino]-2-methylpropyl]amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-83-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[4-[(4-formylphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-84-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(hydroxymethyl)phenyl]sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-88-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methyl-1-piperazinyl]sulfonyl]amino]-2-methylpropyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 313679-71-9P 313682-97-2P 546085-61-4P
 546086-53-7P 622865-01-4P 622865-03-6P
 622865-05-8P 622865-06-9P 622865-07-0P
 622865-09-2P 622865-10-5P 622865-11-6P
 622865-12-7P 622865-13-8P 622865-14-9P
 622865-28-5P 622865-29-6P 622865-31-0P
 622865-32-1P 622865-40-1P 622865-46-7P
 622865-51-4P 622865-54-7P 622865-57-0P
 622865-63-8P 622865-75-2P 622865-79-6P
 622865-83-2P 622865-88-7P 622865-90-1P
 622865-93-4P 622865-99-0P 622866-02-8P
 622866-10-8P 622866-14-2P 622866-16-4P
 622866-17-5P 622866-18-6P 622866-19-7P
 622866-58-4P 622866-60-8P 622866-68-6P
 622866-69-7P 622866-70-0P 622866-72-2P
 622866-73-3P 622866-74-4P 622866-82-4P
 622866-88-0P 622866-89-1P 622866-90-4P
 622866-94-8P 622867-00-9P 622867-01-0P
 622867-05-4P 622867-06-5P 622867-13-4P

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622867-14-5P 622867-15-6P 622867-16-7P
 622867-17-8P 622867-50-9P 622867-61-2P
 622867-72-5P 622867-73-6P 622867-80-5P
 622867-85-0P 622867-86-1P 622867-90-7P
 622867-91-8P 622867-92-9P 622868-03-5P
 622868-20-6P 622868-21-7P 622868-22-8P
 622868-23-9P 622868-24-0P 622868-26-2P
 622868-27-3P 622868-30-8P 622868-33-1P
 622868-37-5P 622868-46-6P 622868-47-7P
 622868-51-3P 622868-53-5P 622868-60-4P
 622868-61-5P 622868-62-6P 622868-63-7P
 622868-66-0P 622868-71-7P 622868-72-8P
 622868-73-9P 622868-74-0P 622868-75-1P
 622868-76-2P 622868-77-3P 622868-78-4P
 622868-79-5P 622868-80-8P 622868-83-1P
 622868-85-3P 622868-87-5P 622868-90-0P
 622868-93-3P 622869-08-3P 622869-10-7P
 622869-14-1P 622870-52-4P 622870-53-5P
 622870-54-6P 622870-55-7P 622870-56-8P
 622870-57-9P 622870-58-0P 622870-59-1P
 622870-60-4P 622870-61-5P 622870-62-6P
 622870-63-7P 622870-64-8P 622870-65-9P
 622870-66-0P 622870-67-1P 622870-68-2P
 622870-69-3P 622870-70-6P 622870-71-7P
 622870-75-1P 622870-76-2P 622870-77-3P
 622870-78-4P 622870-79-5P 622870-80-8P
 622870-81-9P 622870-82-0P 622870-83-1P
 622870-84-2P 622870-85-3P 622870-86-4P
 622870-87-5P 622870-88-6P 622870-89-7P
 622870-90-0P 622870-92-2P 622870-93-3P
 622870-94-4P 622870-95-5P 622870-96-6P
 622870-97-7P 622870-98-8P 622871-00-5P
 622871-03-8P 622871-04-9P 622871-05-0P
 622871-06-1P 622871-07-2P 622871-08-3P
 622871-09-4P 622871-10-7P 622871-11-8P
 622871-12-9P 622871-13-0P 622871-14-1P
 622871-15-2P 622871-16-3P 622871-17-4P
 622871-18-5P 622871-19-6P 622871-20-9P
 622871-21-0P 622871-22-1P 622871-23-2P
 622871-24-3P 622871-45-8P 622871-46-9P
 622871-47-0P 622871-48-1P 622871-49-2P
 622871-50-5P 622871-51-6P 622871-52-7P
 622871-53-8P 622871-55-0P 622871-57-2P
 622871-58-3P 622871-59-4P 622871-61-8P
 622871-62-9P 622871-63-0P 622871-66-3P
 622871-67-4P 622871-68-5P 622871-70-9P
 622871-72-1P 622871-73-2P 622871-74-3P
 622871-75-4P 622871-77-6P 622871-78-7P
 622871-79-8P 622871-80-1P 622871-85-6P
 622871-86-7P 622871-87-8P 622871-89-0P
 622871-90-3P 622871-91-4P 622871-92-5P
 622871-93-6P 622871-94-7P 622871-95-8P
 622871-96-9P 622871-97-0P 622871-98-1P
 622871-99-2P 622872-00-8P 623158-38-3P
 623158-39-4P 623158-40-7P 623158-44-1P
 623158-45-2P 623158-46-3P 623158-47-4P
 623158-49-6P 623158-51-0P 623158-55-4P
 623158-56-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


(Uses)
(protease inhibitor; prepn. of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 313679-71-9 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-97-2 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-61-4 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-05-8 CAPLUS

CN Glycine,

N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-06-9 CAPLUS


CN Glycine,

N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-53-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-01-4 CAPLUS

CN Carbamic acid,

N-[[[(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)]

Absolute stereochemistry.



RN 622865-03-6 CAPLUS



CN 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[4-[(2S,3R)-2-

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-

hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-, bis(1-methylethyl) ester, 5-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-07-0 CAPLUS

CN L-Alanine,

N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-09-2 CAPLUS


CN 8-Oxa-3,5-diaza-4-phosphadecanoic acid, 2,6-diethyl-4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-

hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-10-5 CAPLUS
 CN 8-Oxa-3,5-diaza-4-phosphadodecanoic acid, 2,6-diethyl-4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, butyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-11-6 CAPLUS
 CN L-Leucine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-14-9 CAPLUS
 CN L-Phenylalanine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-28-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]-1-[[4-phosphonophenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-12-7 CAPLUS
 CN L-Leucine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-13-8 CAPLUS
 CN L-Phenylalanine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-29-6 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]-1-[[4-(diethoxyphosphinyl)phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-31-0 CAPLUS
 CN L-Alanine, N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-32-1 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-40-1 CAPLUS
 CN 3-Oxa-8,12-diaza-1-phosphatridecan-13-oic acid, 1,1,10-trihydroxy-8-[(4-methoxyphenyl)sulfonyl]-6,6-dimethyl-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (10R,11S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-54-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-46-7 CAPLUS
 CN 3-Oxa-7,11-diaza-1-phosphadodecan-12-oic acid, 1,1,9-trihydroxy-7-[(4-methoxyphenyl)sulfonyl]-5,5-dimethyl-10-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (9R,10S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-51-4 CAPLUS
 CN 10,13-Dioxa-2,6-diaza-12-phosphapentadecanoic acid, 12-ethoxy-4-hydroxy-6-[[[4-methoxyphenyl)sulfonyl]-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 12-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Ph


RN 622865-57-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[[2-(dimethylamino)ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622865-56-9
 CMF C46 H60 N3 O12 P S

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


Ph

CM 2
 CRN 75-75-2
 CMF C H4 O3 S




RN 622865-63-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl
 1-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-75-2 CAPLUS
 CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-2,6-dimethyl-7-oxo-, ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-79-6 CAPLUS
 CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, ethyl ester, 4-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-83-2 CAPLUS
 CN Acetic acid,
 [[[(4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-88-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[(1-formyl-4-piperidinyl)methyl]-(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-90-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl]-(1-methyl-4-piperidinyl)methyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-93-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methyl]phenyl]methylamino]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622865-99-0 CAPLUS
 CN L-Alanine, N,N'-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]amino]phenyl]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-02-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methoxy]-1-piperidinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Ph

RN 622866-16-4 CAPLUS
 CN L-Alanine, N,N'-[[[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-10-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-(dimethylamino)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-14-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-(dimethylamino)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622866-17-5 CAPLUS
 CN L-Valine, N,N'-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-18-6 CAPLUS
 CN L-Valine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyldiene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-19-7 CAPLUS
 CN Glycine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-69-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxy-3-(phosphonomethoxy)phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-70-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-hydroxyphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-58-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-60-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-(phosphonomethoxy)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-68-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-72-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 622866-73-3 CAPLUS
 CN L-Alanine,
 N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 622866-74-4 CAPLUS
 CN L-Alanine, N,N'-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-89-1 CAPLUS
 CN Carbamic acid, [[[(1S,2R)-1-[[4-[[[bis(ethylamino)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-90-4 CAPLUS
 CN L-Alanine, N-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622866-82-4 CAPLUS
 CN Carbamic acid, [[[(1S,2R)-1-[[4-[(ethoxyphenoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-88-0 CAPLUS
 CN Carbamic acid, [[[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-94-8 CAPLUS
 CN L-Alanine, N-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-00-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-01-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyposphinyl]oxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-05-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyposphinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-14-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-(trifluoromethoxy)phenyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-15-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(formylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-16-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxymethyl)phenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-06-5 CAPLUS
 CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-2,6,9-trimethyl-7-oxo-, 1-methylethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-13-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylpropyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-17-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-(4-morpholinylmethyl)phenyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-50-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-3-[[triethylsilyl]oxy]butyl]methylanilino]phenyl]methoxy]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 622867-61-2 CAPLUS
 CN Propanoic acid, 2-[[[2-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]phosphonyloxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-72-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]hydroxyphosphonyloxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

-CO₂H

RN 622867-73-6 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[[4-(2-(diethoxyphosphinyloxy)ethyl)-3,6-dihydro-1(2H)-pyridinyl)methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-80-5 CAPLUS
 CN Propanoic acid, 2-[[[2-(6-dimethylphenoxy)-2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphonyloxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-79-2
 CMF C44 H62 N3 O13 P S

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 622867-85-0 CAPLUS
 CN Propanoic acid, 2-[[[2-(6-dimethylphenoxy)-2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphonyloxy]-, propyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-84-9
 CMF C45 H64 N3 O13 P S

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 622867-86-1 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-

methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phosphoryl]oxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622867-91-8 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl](4-morpholinyl)oxy]phosphoryl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-92-9 CAPLUS
CN Propanoic acid, 2-[[[4-[(dimethylamino)oxy]4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phosphoryl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-90-7 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phosphoryl]oxy]-, 2-(1-methyl-4-piperidinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-03-5 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[1-[2-(dimethoxyphosphoryl)ethyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-20-6 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[(dimethoxyphosphoryl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




```

RN      622868-21-7  CAPLUS
CN      Carbamic acid,
[(1S,2R)-1-[[4-[[bis(1-methylethoxy)phosphinyl]methoxy]phen
yl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-
methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
ester (9CI) (CA INDEX NAME)

```

Absolute stereochemistry.




```

RN      622868-22-8 CAPLUS
CN      Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(13R,3aS,6aR)-hexahydrofuro[2,3-
b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(
methoxyphenyl)sulfonyl]-2-methylpropyl]amino]butyl]phenoxy)methyl]phenoxy
phosphinoyl]oxy-, ethyl ester (9CI) (CA INDEX NAME)

```


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



methoxyphenyl)sulfonyl (2-methylpropyl amino)butyl phenoxy)methylphenoxypropyl
 heosphinyl oxy], ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




```

RN      62288-24-0 CAPLUS
CN      Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(
methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy
propyl]ethoxy]-, 1,1-dimethylethyl ester. (2S)- (9CI) (CA INDEX NAME

```

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-26-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(1R,3S,6R)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxypropenyl]oxy]-, 2-(4-morpholinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622868-27-3 CAPLUS
 CN Benzoic acid, 2-[[[4-(2S,3R)-2-[[[(13R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp
 hosphinoyloxy]-ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN	622868-30-8	CAPLUS
CN	Benzoic acid, 2-[[[4-{(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)butyl]phenoxy)methyl]hydroxyp	
	heptyl]oxyl-], (2S)- (9CI) [C.A. INDEX NAME]	


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-33-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-37-5 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-51-3 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-53-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-46-6 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-47-7 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-60-4 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-61-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[(2-phosphonoethyl)amino]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-62-6 CAPLUS


CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-36-1

CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622868-71-7 CAPLUS

CN Propanoic acid, 2-[[[2-ethoxyphenoxy][4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-72-8 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][2-(1-methylbutyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-63-7 CAPLUS

CN Propanoic acid, 2-[[ethoxy[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622868-66-0 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](2,2,2-trifluoroethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-73-9 CAPLUS

CN Propanoic acid, 2-[[[4-butylphenoxy][4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A




RN 622868-74-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][4-(1,1,3,3-tetramethylbutyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 622868-75-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622868-77-3 CAPLUS
 CN Benzoic acid, 3-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy][4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-78-4 CAPLUS
 CN Propanoic acid, 2-[[[3-[(dimethylamino)methyl]phenoxy][4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][1-methylethoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622868-76-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][1-methyl-4-piperidinyl]oxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-[(4-methyl-1-piperazinyl)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][1-


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
piperidinyloxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-83-1 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[6-[(diethoxyphosphinyl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-85-3 CAPLUS

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 622868-93-3 CAPLUS
CN Propanoic acid, 2-[[[2-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

RN 622869-08-3 CAPLUS
CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]methylamino]methyl]phenyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-87-5 CAPLUS
CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-90-0 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[(2-phosphonomethoxy)ethoxy]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-10-7 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methyl-1-piperazinyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-14-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-1-[(phenylmethyl)-2-(phosphonoxy)-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 Na

RN 622870-52-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[(methoxyphenoxyphosphinyl)methoxy]
 phenyl]methyl]-3-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-53-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-
 methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
 C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-56-8 CAPLUS
 CN Acetic acid,
 [[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-57-9 CAPLUS
 CN L-Alanine, N-[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-54-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethylphosphinyl)methoxy]phenyl]methyl]-2-
 hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-55-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
 C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-58-0 CAPLUS
 CN L-Alanine, N-[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-59-1 CAPLUS
 CN D-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-60-4 CAPLUS
 CN D-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-61-5 CAPLUS
 CN D-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-62-6 CAPLUS
 CN L-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-63-7 CAPLUS
 CN L-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-64-8 CAPLUS
 CN Butanoic acid, 2-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-65-9 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-66-0 CAPLUS
 CN Butanoic acid, 2-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]amino]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-67-1 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp hosphinyl]amino]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-68-2 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622870-69-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622870-71-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 3-(4-morpholinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622870-75-1 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-3-methyl-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-70-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



RN 622870-76-2 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-3-methyl-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-77-3 CAPLUS
 CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-2,2-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 RN 2004:99287 CAPLUS
 DN 140:339141
 TI Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains
 AU Miller, John F.; Furfine, Eric S.; Hanlon, Mary H.; Hazen, Richard J.; Ray, John A.; Robinson, Laurence; Samano, Vicente; Spaltenstein, Andrew
 CS GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(4), 959-963
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 140:339141
 GI




AB Furanofuryl analogs of the HIV protease inhibitor amprenavir such as I are prepared in which a terminally substituted n-alkyl group is appended to the N-iso-Bu group of amprenavir and in which the substituents on the N-arylsulfonyl moiety are varied. Some of the inhibitors such as I are found to have greatly enhanced inhibition of HIV protease; the amprenavir analogs also inhibit the growth of both wild-type and resistant strains of HIV and are more effective against the HIV strains than the currently marketed HIV protease inhibitors amprenavir, indinavir, and nelfinavir. E.g., I inhibits wild-type HIV protease with a K_i value of 0.014 μ M, and inhibits wild-type and resistant strains of HIV with IC_{50} values of between 1.6 nM and 15 nM.
 IT 288292-03-5P 288292-18-2P 288292-24-0P
 288292-58-0P 288292-59-1P 288292-65-9P
 288292-84-2P 288292-87-5P 288293-68-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 the preparation of furanofuryl amprenavir analogs with modifications at the N-arylsulfonyl and N-iso-Bu moieties which show improved HIV protease

L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-58-0 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-59-1 CAPLUS
 CN 2-Oxa-4,9,13-triazatetradecan-14-oic acid, 9-[(1,3-benzodioxol-5-ylsulfonyl)-11-hydroxy-7,7-dimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 288292-03-5 CAPLUS
 CN 2-Oxa-4,11,15-triazaheptadecan-16-oic acid, 11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-18-2 CAPLUS
 CN 2-Oxa-4,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-24-0 CAPLUS
 CN 2-Thia-3,9,13-triazatetradecan-14-oic acid, 9-[(1,3-benzodioxol-5-ylsulfonyl)-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 288292-65-9 CAPLUS
 CN 2-Oxa-4,12,16-triazaheptadecan-17-oic acid, 12-[(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-3-oxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-84-2 CAPLUS
 CN 2-Oxa-4,10,14-triazapentadecan-15-oic acid, 10-[(4-aminophenyl)sulfonyl]-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-87-5 CAPLUS
 CN 2-Oxa-4,10,14-triazapentadecan-15-oic acid, 10-[(3-aminophenyl)sulfonyl]-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-68-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[5-(acetylamino)-2,2-dimethylpentyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 288291-46-3P 288291-55-4P 288291-99-6P
288292-12-6P 288292-37-5P 288292-38-6P
288292-42-2P 288292-43-3P 288296-33-3P
288296-37-7P 288296-75-3P 681028-77-3P
681028-79-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of furanofuryl amprevanir analogs with modifications at the

N-arylsulfonyl and N-iso-Bu moieties which show improved HIV protease inhibition and inhibition of wild-type and resistant HIV strains)


RN 288291-46-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-aminophenyl]sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288292-12-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[5-amino-2,2-dimethylpentyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-37-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[4-amino-2,2-dimethylbutyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-38-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[7-amino-2,2-dimethylheptyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288291-55-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[6-amino-2,2-dimethylhexyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288291-99-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[6-amino-2,2-dimethylhexyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-42-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[5-amino-2,2-dimethylpentyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-43-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[5-amino-2,2-dimethylpentyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288296-33-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[1,3-benzodioxol-5-ylsulfonyl][4-bis(phenylmethyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-


L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (phenylmethylpropyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288296-37-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(6-cyano-2,2-dimethylhexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288296-75-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(5-cyano-2,2-dimethylpentyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 681028-77-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681028-79-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(6-chloro-2,2-dimethylhexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:21007 CAPLUS

DN 140:90648

TI Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance

IN De Meyer, Sandra; Azijn, Hilde; De Bethune, Marie-pierre T. M. M. G.

PA Tibotec Pharmaceuticals Ltd., Irc.

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004003817	A1	20040108	WO 2003-EP50277	20030630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490862	A1	20040108	CA 2003-2490862	20030630
AU 2003254500	A1	20040119	AU 2003-254500	20030630
EP 1520247	A1	20050406	EP 2003-761598	20030630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005233312	A1	20051020	US 2004-519035	20041222
US 2002-392753P	P	20020701		
WO 2003-EP50277	W	20030630		

AB The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences.

More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clin. management and diagnostic anal.

IT 473737-31-4

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (mutational profiles in HIV-1 protease correlated with phenotypic drug resistance)


RN 473737-31-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(2-(1-pyrrolidinyl)ethyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:106987 CAPLUS
DN 140:47540
TI Pseudopolymorphic forms of a HIV protease inhibitor
IN Vermeersch, Hans Wim Pieter; Thone, Daniel Joseph Christiaan; Janssens, Luc Donne Marie-Louise
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106461	A2	20031224	WO 2003-EP50176	20030516
WO 2003106461	A3	20040513		
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
CA 2485834	A1	20031224	CA 2003-2485834	20030516
AU 2003271740	A1	20031231	AU 2003-271740	20030516
BR 2003011176	A	20050315	BR 2003-11176	20030516
EP 1567529	A2	20050831	EP 2003-753571	20030516
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK</p>				
CN 1668623	A	20050914	CN 2003-816459	20030516
JP 2005533068	T	20051104	JP 2004-513292	20030516
NZ 536497	A	20060831	NZ 2003-536497	20030516
US 2005250845	A1	20051110	US 2004-514352	20041112
NO 2004005409	A	20041210	NO 2004-5409	20041210
ZA 2004010154	A	20051014	ZA 2004-10154	20041215
EP 2002-76929	A	20020516		
WO 2003-EP50176	W	20030516		
<p>AB New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]carbamate (I) and processes for producing them are disclosed. Thus, a solvate (1:1) of I with EtOH was prepared, and its stability and solubility were determined</p>				
<p>IT 635728-39-1P 635728-40-4P 635728-41-5P 635728-42-6P 635728-43-7P 635728-44-8P 635728-45-9P 635728-46-0P 635728-47-1P 635728-48-2P 635728-49-3P</p>				
<p>RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (pseudopolymorphic forms of HIV protease inhibitor)</p>				
<p>RN 635728-39-1 CAPLUS</p>				
<p>CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, hydrate (9CI) (CA INDEX NAME)</p>				

L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
3-yl ester, compd. with ethanol (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
CMF C27 H37 N3 O7 S

Absolute stereochemistry.




CM 2

CRN 64-17-5
CMF C2 H6 O

H3C-CH2-OH

RN 635728-40-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, hydrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x H2O


RN 635728-41-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-

L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
3-yl ester, compd. with methanol (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
CMF C27 H37 N3 O7 S

Absolute stereochemistry.



CM 2

CRN 67-56-1
CMF C H4 O


H3C-OH

RN 635728-42-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, compd. with 2-propanone (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
CMF C27 H37 N3 O7 S

Absolute stereochemistry.



CM 2

CRN 67-64-1
CMF C3 H6 O

L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 635728-43-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester, compd. with dichloromethane (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
 CMF C27 H37 N3 O7 S

Absolute stereochemistry.



CM 2

CRN 75-09-2
 CMF C H2 Cl2

Cl-CH2-Cl


RN 635728-44-8 CAPLUS
 CN Acetic acid ethyl ester, compd. with (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-
 hydroxy-1-(phenylmethyl)propyl]carbamate (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
 CMF C27 H37 N3 O7 S

Absolute stereochemistry.

L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 635728-46-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester, compd. with methoxybenzene (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
 CMF C27 H37 N3 O7 S

Absolute stereochemistry.



CM 2

CRN 100-66-3
 CMF C7 H8 O

Me-O-Ph


RN 635728-47-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester, compd. with tetrahydrofuran (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
 CMF C27 H37 N3 O7 S

Absolute stereochemistry.

L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 141-78-6
 CMF C4 H8 O2


Et-O-Ac

RN 635728-45-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester, compd. with 1-ethoxy-2-propanol (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
 CMF C27 H37 N3 O7 S


Absolute stereochemistry.



CM 2

CRN 1569-02-4
 CMF C5 H12 O2

L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 109-99-9
 CMF C4 H8 O




RN 635728-48-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester, compd. with 2-propanol (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
 CMF C27 H37 N3 O7 S

Absolute stereochemistry.



CM 2

CRN 67-63-0
 CMF C3 H8 O




L7 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 635728-49-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, compd. with ethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
 CMF C27 H37 N3 O7 S

Absolute stereochemistry.



CM 2


CRN 64-17-5
 CMF C2 H6 O

H₃C-CH₂-OH

L7 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 627869-95-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3-amino-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 627869-81-2 627869-81-2D, N-oxides and stereoisomers
 627869-88-9 627869-88-9D, N-oxides and stereoisomers
 627869-89-0 627869-89-0D, N-oxides and stereoisomers
 627869-90-3 627869-90-3D, N-oxides and stereoisomers
 627869-91-4 627869-91-4D, N-oxides and stereoisomers
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzisoxazole sulfonamide derivative HIV protease inhibitors,
 preparation,
 pharmaceutical compns., diagnostic kits, and combinations with other
 antiretroviral agents)

RN 627869-81-2 CAPLUS
 CN Carbamic acid, [3-[[[(3-amino-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 627869-81-2 CAPLUS
 CN Carbamic acid, [3-[[[(3-amino-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 627869-88-9 CAPLUS
 CN Carbamic acid, [2-hydroxy-3-[[[(3-methylamino)-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:931343 CAPLUS
 DN 140:704

TI Broad-spectrum substituted benzisoxazole sulfonamide HIV protease inhibitors, preparation thereof, pharmaceutical compositions, diagnostic kits, and combinations with other antiretroviral agents

IN Surleraux, Dominique Louis Nestor Ghislain; Vergouwen, Bernhard Joanna Bernard; De Kock, Herman Augustinus

PA Tibotec Pharmaceuticals Ltd, Ire.

SO PCT Int. Appl., 55 pp.

CODEM: PXXXX2

DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097616	A1	20031127	WO 2003-EP50173	20030516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OH, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2485903	A1	20031127	CA 2003-2485903	20030516
AU 2003238074	A1	20031202	AU 2003-238074	20030516
BR 2003010089	A	20050215	BR 2003-10089	20030516
EP 1517899	A1	20050330	EP 2003-735707	20030516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005171173	A1	20050804	US 2003-514539	20030516
CN 1668605	A	20050914	CN 2003-816458	20030516
JP 2005527607	T	20050915	JP 2004-505349	20030516
NZ 536496	A	20060630	NZ 2003-536496	20030516
NO 2004005444	A	20050216	NO 2004-5444	20041214
ZA 2004010156	A	20050905	ZA 2004-10156	20041215
PRAI EP 2002-76957	A	20020517		
WO 2003-EP50173	W	20030516		
OS MARPAT 140:704				


AB The invention discloses benzisoxazole sulfonamide derivs. and the N-oxides, salts, stereoisomers, racemic mixts., prodrugs esters, and metabolites thereof. Also disclosed are their use as broad-spectrum HIV protease inhibitors, processes for their preparation, and pharmaceutical compns. and diagnostic kits comprising them. Further disclosed are combinations of the compds. of the invention with another antiretroviral agent, and their use in assays as reference compds. or as reagents.

IT 627869-95-8P
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (benzisoxazole sulfonamide derivative HIV protease inhibitors, preparation,
 pharmaceutical compns., diagnostic kits, and combinations with other antiretroviral agents)


L7 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 627869-88-9 CAPLUS
 CN Carbamic acid, [2-hydroxy-3-[[[(3-methylamino)-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 627869-89-0 CAPLUS
 CN Carbamic acid, [3-[[[(3-(dimethylamino)-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 627869-89-0 CAPLUS
 CN Carbamic acid, [3-[[[(3-(dimethylamino)-1,2-benzisoxazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 627869-90-3 CAPLUS
 CN Carbamic acid, [2-hydroxy-3-[[[(2-methylpropyl)[(3-(1-pyrrolidinyl)-1,2-benzisoxazol-5-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 627869-90-3 CAPLUS
 CN Carbanic acid, [2-hydroxy-3-[(2-methylpropyl)[[3-[(1-pyrrolidinyl)-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 627869-91-4 CAPLUS
 CN Carbanic acid, [2-hydroxy-3-[(2-methylpropyl)[[3-[(2-(1-pyrrolidinyl)ethyl)amino]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 627869-91-4 CAPLUS
 CN Carbanic acid, [2-hydroxy-3-[(2-methylpropyl)[[3-[(2-(1-pyrrolidinyl)ethyl)amino]-1,2-benzisoxazol-5-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

2003:875072 CAPLUS
 DN 139:361610
 TI Preparation of phosphonate analogs of HIV protease inhibitors and methods for identifying anti-HIV therapeutic compounds
 IN Birkus, Gabriel; Chen, James M.; Chen, Xiaowu; Cihlar, Tomas; Eisenberg, Eugene J.; Hatada, Marcos; He, Gong-Xin; Kim, Choung U.; Lee, William A.; McDermott, Martin J.; Swaminathan, Sundaramoorthi
 PA Gilead Sciences, Inc., USA
 SO PCT Int. Appl., 814 pp.
 CODEN: PIKXD2
 DT Patent
 LA English
 FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090691	A2	20031106	WO 2003-US12943	20030425
WO 2003090691	A3	20060209		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2481449 A1 20031106 CA 2003-2481449 20030425
 AU 2003228707 A1 20031110 AU 2003-228707 20030425
 CN 1649885 A 20050803 CN 2003-814963 20030425
 CN 1656109 A 20050817 CN 2003-812478 20030425
 EP 1575486 A2 20050921 EP 2003-726472 20030425

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 200608634 T 20060316 JP 2003-587330 20030425
 WO 2004096818 A2 20041111 WO 2003-EPI2423 20031106
 WO 2004096818 A3 20050407

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

TG AU 2003291998 A1 20041123 AU 2003-291998 20031106
 EP 1620445 A2 20060201 EP 2003-767521 20031106
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK


JP 2006524487 T 20061102 JP 2004-571244 20031106
 US 2005239054 A 20051027 US 2003-740694 20031222
 US 2005136397 A1 20050623 US 2004-970389 20041022
 ZA 2004009376 A 20050914 ZA 2004-9376 20041122
 US 2006115815 A1 20060601 US 2005-511183 20050223

PRAI US 2002-375622P P 20020426
 US 2002-375665P P 20020426
 US 2002-375779P P 20020426

L7 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-A




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US 2002-375834P P 20020426
 US 2003-423496 A2 20030425
 US 2003-424130 A2 20030425
 US 2003-424186 A2 20030425
 US 2003-465721P P 20030425
 US 2003-465810P P 20030425
 US 2003-465824P P 20030425
 WO 2003-US12901 A 20030425
 WO 2003-US12926 A 20030425
 WO 2003-US12943 W 20030425
 US 2003-513532P P 20031024
 US 2003-513542P P 20031024
 US 2003-514241P P 20031024
 US 2003-514299P P 20031024
 US 2003-514894P P 20031029
 US 2003-514925P P 20031029
 WO 2003-EPI2423 W 20031106
 WO 2004-US35083 A 20041022

GI



I

II

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

III

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
for the detection of HIV protease. Comps. of the invention inhibit reverse transcriptase activity and have improved intracellular half-life compared to analogs not having the phosphonate or phosphonate prodrug. Libraries of such comps. were screened optionally using the novel enzyme GS-7340 ester hydrolase. Comps. and methods relating to GS-7340 ester hydrolase also are provided. Examples include preps. for non-nucleoside phosphonate protease inhibitors. In addn., extensive biol. data

regarding

PBMC uptake and metab., serum stability, and alk. phosphatase protease inhibitor (ALPPI) activity of selected phosphonate-substituted prodrugs

is

presented. For instance, a 9-step reaction sequence starting from N-tert-butoxycarbonyl-O-benzyl-L-tyrosine provided III (K_i ≤10 pM for ALPPI activity). The synthesis involved multiple protection and deprotection steps along with coupling reactions using isobutylamine, (3R,3aR,6aS)-hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate, and dibenzyl hydroxymethylphosphonate.


IT

622866-43-7P
RL: BVP (Byproduct); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN

622866-43-7 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxymethyl)phenyl)methyl]-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 253266-01-2P 605654-08-8P 605654-10-2P

622865-85-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN

253266-01-2 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



IT 622865-53-6P 622865-86-5P 622866-12-0P

622866-41-5P 622866-42-6P 622866-44-8P

622866-56-2P 622866-86-8P 622867-43-0P

622867-47-4P 622867-48-8P 622867-70-3P

622868-06-8P 622868-82-0P 622869-12-9P


622869-16-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN

622865-53-6 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[[4-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-86-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(1-formyl-4-piperidinyl)methyl] [(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 605654-08-8 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 605654-10-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-85-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[[4-(methoxyphenyl)sulfonyl](4-piperidinylmethyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-12-0 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-41-5 CAPLUS


CN Methanesulfonic acid, trifluoro-, 4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622866-42-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-formylphenyl)methyl]-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-44-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-(bromomethyl)phenyl)methyl]-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-56-2 CAPLUS
 CN L-Alanine, N-[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl)methyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622867-47-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-48-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]-2-[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-70-3 CAPLUS
 CN Propanoic acid, 2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[(triethylsilyl)oxy]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]oxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-86-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-43-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-ethenylphenyl)methyl]-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-06-8 CAPLUS
 CN Pyridinium, 1-[2-[bis(phenylmethoxy)phosphinyl]ethyl]-4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-05-7
 CMF C43 H55 N3 O11 P S

Absolute stereochemistry.



CM 2


CRN 37181-39-8
 CMF C F3 O3 S

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622868-82-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[6-[[diethoxyphosphinyl]methyl]-3,4-dihydro-2(1H)-isoquinolinyl]methyl]-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-12-9 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



IT 622868-31-9P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622868-31-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 546085-60-3P 622869-15-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 546085-60-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622869-16-3 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-6-[[4-[[[1S]-1-methyl-2-(1-methylethoxy)-2-oxoethoxy]phenoxy]phosphinyl]methoxy]phenyl]methyl]-1-phenyl-3-(phenylmethoxy)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 622865-00-3, GS 8373
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622865-00-3 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622869-15-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyposphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 622868-57-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN 622868-57-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-aminophenyl)methyl]-2-hydroxy-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 622865-84-3P 622866-84-6P 622867-34-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622865-84-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[(phenylmethoxy)phenyl]butyl][(4-methoxyphenyl)sulfonyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-84-6 CAPLUS
 CN Pyridinium, 1-[(diethoxyphosphinyl)methyl]-4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 622866-83-5
 CMF C32 H49 N3 O11 P S

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylpropyl]amino]-1-[[4-[(2-phosphonoethyl)amino]methyl]phenyl]methyl]p
 ropyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



IT 622867-04-3P 622870-49-9P 622870-91-1P, GS
 273842
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease
 inhibitors for treatment of AIDS and other viral infections)

RN 622867-04-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-
 methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]hydroxyp
 hosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-49-9 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]butyl]phenoxymethyl]hydroxyphosphinyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 37181-39-8
 CMF C F3 O3 S



RN 622867-34-9 CAPLUS
 CN Carbamic acid, [(1R,2R)-1-formyl-3-[[[(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[triethylsilyl]oxy]propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 622867-35-0P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
 (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease
 inhibitors for treatment of AIDS and other viral infections)


RN 622867-35-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[triethylsilyl]oxy]propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-91-1 CAPLUS
 CN Propanoic acid,
 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-
 methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]eth
 yl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 622867-36-1P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT
 (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
 (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease
 inhibitors for treatment of AIDS and other viral infections)

RN 622867-36-1 CAPLUS
 CN Propanoic acid,
 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-
 methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]eth
 yl]phenoxyp hosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 622865-08-1P, GS 16503 622866-91-5P, GS 16571
 622866-97-1P, GS 17394 622868-28-4P, GS 16576
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease inhibitors for treatment of AIDS and other viral infections)
 RN 622865-08-1 CAPLUS
 CN L-Alanine,
 N,N'-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-91-5 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 622868-58-0P 622868-59-1P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT
 (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
 (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease inhibitors for treatment of AIDS and other viral infections)
 RN 622868-58-0 CAPLUS
 CN Propanoic acid, 2-[[[[(R)-[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]phen
 oxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-59-1 CAPLUS
 CN Propanoic acid, 2-[[[[(S)-[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]phen
 oxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yloxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-
 methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, ethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[[(4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy
 phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-28-4 CAPLUS
 CN Butanoic acid, 2-[[[[(4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy
 phosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 622865-70-7P 622865-71-8P 622866-92-6P
 622866-93-7P 622866-95-9P 622866-96-0P
 622866-98-2P 622866-99-3P 622868-52-4P
 622868-54-6P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV
 protease inhibitors for treatment of AIDS and other viral infections)

RN 622865-70-7 CAPLUS
 CN Propanoic acid,
 2-[[[[(R)-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy
 phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-71-8 CAPLUS
 CN Propanoic acid,
 2-[[[[(S)-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy
 phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-92-6 CAPLUS
 CN D-Alanine, N-[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyposphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-93-7 CAPLUS
 CN D-Alanine, N-[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyposphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-95-9 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyposphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-96-0 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyposphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-98-2 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-99-3 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-52-4 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-51-3
 CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622868-54-6 CAPLUS
 CN Propanoic acid, 2-[[[R]-[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-53-5
 CMF C42 H58 N3 O13 P 5

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




IT 622864-99-7P 622865-02-5P 622865-30-9P
 622865-39-8P 622865-45-6P 622865-55-8P
 622865-56-9P 622865-61-6P 622865-62-7P
 622865-87-6P 622865-89-8P 622865-92-3P
 622865-97-8P 622865-98-9P 622866-08-4P
 622866-09-5P 622866-13-1P 622866-15-3P
 622866-33-5P 622866-34-6P 622866-37-9P
 622866-38-0P 622866-39-1P 622866-40-4P
 622866-59-5P 622866-67-5P 622866-71-1P
 622866-76-6P 622866-79-9P 622866-80-2P
 622866-81-3P 622866-87-9P 622867-02-1P
 622867-03-2P 622867-22-5P 622867-23-6P

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 622865-30-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[(hydroxyphenoxyphosphinyl)methoxy]phenyl]methyl]-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-39-8 CAPLUS
 CN 2,5-Dioxo-10,14-diaza-3-phosphapentadecan-15-oic acid, 12-hydroxy-1-[[4-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-1-phenyl-3-(phenylmethoxy)-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 622867-25-8P 622867-27-0P 622867-30-5P
 622867-31-6P 622867-32-7P 622867-33-8P
 622867-37-2P 622867-38-3P 622867-49-6P
 622867-71-4P 622867-79-2P 622868-84-9P
 622868-89-4P 622868-97-4P 622868-15-9P
 622868-16-0P 622868-17-1P 622868-29-5P
 622868-32-0P 622868-64-8P 622868-65-9P
 622868-68-2P 622868-69-3P 622868-70-6P
 622868-86-4P 622868-89-7P 622868-91-1P
 622868-92-2P 622868-94-4P 622868-97-7P
 622868-98-8P 622869-05-0P 622869-06-1P
 622869-07-2P 622869-11-8P 622869-13-0P
 622869-17-4P 622870-99-9P, GS 193786
 622871-01-6P, GS 173848 622871-02-7P, GS 277856
 622871-54-9P, GS 273847 622871-56-1P, GS 191477
 622871-60-7P, GS 191482 622871-64-1P, GS 191479
 622871-65-2P, GS 191508 622871-69-6P, GS 273805
 622871-71-0P, GS 273806 622871-76-5P, GS 277774
 622871-81-2P, GS 7521 622871-82-3P, GS 278052
 622871-83-4P, GS 278114 622871-84-5P, GS 278053
 622871-88-9P, GS 273835
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; prepn. of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622864-99-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-02-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-45-6 CAPLUS
 CN 2,5-Dioxo-9,13-diaza-3-phosphatetradecan-14-oic acid, 11-hydroxy-9-[[4-methoxyphenyl]sulfonyl]-7,7-dimethyl-1-phenyl-3-(phenylmethoxy)-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-55-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-hydroxyphenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—Ph

RN 622865-56-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—Ph

RN 622865-61-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—Ph

RN 622865-62-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-phosphonmethoxy)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-87-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-89-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-3-[[[(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-92-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methyl]phenyl]amino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-97-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methyl]phenyl]amino]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-98-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(4-(phosphonomethyl)phenyl)amino]methyl]propyl]-,


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-13-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Ph

RN 622866-15-3 CAPLUS


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-08-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[diethoxyphosphinyl]methoxy]phenyl]sulfonyl]amino]-2-hydroxy-1-[[4-(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-09-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminophenyl)methyl]-3-[[4-[[diethoxyphosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminophenyl)methyl]-2-hydroxy-3-[[4-[[diethoxyphosphinyl]methoxy]phenyl]sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-33-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]amino]-2-hydroxy-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-34-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[3-aminophenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-37-9 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[[4-(phosphonomethoxy)phenyl]sulfonyl]amino]butyl]phenyl]-, C-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-38-0 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-4-[[[4-[(diphenoxyphosphinyl)methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 622866-59-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-39-1 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-[(hydroxyphenoxyposphinyl)methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-40-4 CAPLUS
 CN L-Alanine,
 N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[[[4-[(phenylmethoxy)carbonyl]amino]phenyl]butyl] (2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 622866-67-5 CAPLUS
 CN Carbamic acid, [[(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]-4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-71-1 CAPLUS
 CN Carbamic acid,
 [[(1S,2R)-2-hydroxy-3-[[[4-[(hydroxyphenoxyposphinyl)methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-76-6 CAPLUS
 CN Carbamic acid,
 [[(1S,2R)-3-[[[4-[(diphenoxyphosphinyl)methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





```

RN      622866-81-3  CAPLIUS
CN      Carbamic acid,
        [(1S,2R)-1-[[4-[(ethoxyhydroxyphosphinyl)methoxy]phenyl]met
        hyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-
        , (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)  (CA INDEX
NAME)

```



Absolute stereochemistry.



RN 622866-87-9 CAPLUS
CN Carbamic acid,
[1S,2R]-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
2-hydroxy-3-[(2-methylpropyl){4-(nitrophenyl)sulfonyl}amino]propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





```

RN      622867-22-5 CAPLUS
CN      Phenoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[4-
(phenylmethoxy)phenyl]sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphiny
1]oxy-, ethyl ester, (2S)- (9CI) [CA INDEX NAME]

```

Absolute stereochemistry.




RN	622867-23-6 CAPLUS
CN	1-Piperazinacarboxylic acid, 4-[4-[[[(2R,3S)-4-[4-[[[1(S)-2-ethoxy-1-methyl-2-oxyethoxy]phenoxyporphinyl]methoxy]phenyl]-3-[[[1(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl]-2-methylpropyl]amino]sulfonyl]phenyl]-, phenylmethyl ester (9CI) [CA INDEX NAME]

Absolute stereochemistry

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 622867-25-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(4-(1-piperazinyl)phenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-24-7
 CMF C43 H59 N4 O13 P S

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622867-30-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(phenylsulfonyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622867-31-6 CAPLUS

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 622867-27-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-(phenylmethoxy)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-32-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-33-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(4-(phenylmethoxy)phenyl)sulfonyl]amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-37-2 CAPLUS
 CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-,
 [4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenyl]methyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

-OBU-t

RN 622867-38-3 CAPLUS
 CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-,
 (1R,2S)-3-[4-[[[(1S)-2-ethoxy-

1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]methyl]propyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-49-6 CAPLUS
 CN Propanoic acid, 2-[[[(4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-3-[[[(triethylsilyl)oxy]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-71-4 CAPLUS
 CN Propanoic acid, 2-[[[(2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

-OEt

RN 622867-79-2 CAPLUS
 CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy) [2-[[[(4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-84-9 CAPLUS
 CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy) [2-[[[(4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenyl]methyl]phenoxyphosphinyl]oxy]-, propyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-89-4 CAPLUS
 CN 1-piperidinecarboxylic acid, 4-[2-[(2S,3R)-2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-1-oxopropoxy]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-16-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[3-hydroxy-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-17-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[3-hydroxy-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622867-97-4 CAPLUS
 CN Carbamic acid, [[1S,2R)-1-[[[1-[[bis(phenylmethoxy)phosphinyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-15-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[3-(acetoxy)-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-29-5 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-32-0 CAPLUS
 CN Propanoic acid, 2-[[[3-(formylphenoxy)][4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-64-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(bis(2,2,2-trifluoroethoxy)phosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-65-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[[4-[(hydroxy(2,2,2-trifluoroethoxy)phosphinyl)methoxy]phenyl]methyl]-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 622868-70-6 CAPLUS
 CN Propanoic acid, 2-[[[3-[[[1,1-dimethylethoxy]carbonyl]amino]methyl]phenoxyl]4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-68-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-69-3 CAPLUS
 CN Benzoic acid, 3-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 622868-86-4 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 622868-85-3

CMF C43 H60 N3 O13 P S

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 622868-89-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[4-[2-[[bis(phenylmethoxy)phosphinyl]methoxy]ethoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-91-1 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[4-[2-[[diphenoxyphosphinyl]methoxy]ethoxy]phenyl]

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl] (phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

OEt


RN 622868-97-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[5-[[diethoxyphosphinyl]methoxy]-1,3-dihydro-2H-isoindol-2-yl]methyl]-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-[[triethylsilyl]oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


yl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-92-2 CAPLUS
CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OEt


RN 622868-94-4 CAPLUS
CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-98-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[5-[[diethoxyphosphinyl]methoxy]-1,3-dihydro-2H-isoindol-2-yl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-05-0 CAPLUS
CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-3-[[triethylsilyl]oxy]butyl]amino]methyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622869-06-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]amino]methyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-07-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]methylamino]methyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-17-4 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-6-[[[4-[[[(1S)-1-methyl-2-(1-methylethoxy)-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]methyl]-1-phenyl]-3-(phenylmethoxy)]-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-99-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-11-8 CAPLUS
 CN Carbamic acid, [[(1S,2R)-2-hydroxy-1-[[4-[2-[(hydroxyphenoxyphosphinyl)methoxy]ethoxy]phenyl]methyl]-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-13-0 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-1-phenyl]-3-(phenylmethoxy)]-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-01-6 CAPLUS
 CN Carbamic acid, [[(1S,2R)-1-[[[2-[[bis(phenylmethoxy)phosphinyl]ethyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-02-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-54-9 CAPLUS
 CN Carbanic acid,
 Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-hydroxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyposphinoyloxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-56-1 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-65-2 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)[4-(trifluoromethoxy)phenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-69-6 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-60-7 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[4-(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-64-1 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)[4-(trifluoromethyl)phenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-71-0 CAPLUS
 CN Carbanic acid,
 Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinoyloxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-76-5 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)(1-oxido-3-pyridinylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-81-2 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(4-pyridinylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-82-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[4-(formylphenyl)sulfonyl](2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-88-9 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313679-71-9P 313682-97-2P 546085-61-4P
 546086-53-7P 622865-01-4P 622865-03-6P
 622865-05-8P 622865-06-9P 622865-07-0P
 622865-09-2P 622865-10-5P 622865-11-6P
 622865-12-7P 622865-13-8P 622865-14-9P
 622865-28-5P 622865-29-6P 622865-31-0P
 622865-32-1P 622865-40-1P 622865-46-7P
 622865-51-4P 622865-54-7P 622865-57-0P
 622865-63-8P 622865-75-2P 622865-79-6P
 622865-83-2P 622865-88-7P 622865-90-1P
 622865-93-4P 622865-99-0P 622866-02-8P
 622866-10-8P 622866-14-2P 622866-16-4P
 622866-17-5P, GS 17389 622866-18-6P 622866-19-7P
 622866-58-4P 622866-60-8P 622866-68-6P
 622866-69-7P 622866-70-0P 622866-72-2P
 622866-73-3P 622866-74-4P 622866-82-4P
 622866-88-0P 622866-89-1P 622866-90-4P
 622866-94-8P 622867-00-9P 622867-01-0P
 622867-05-4P 622867-06-5P 622867-13-4P

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-83-4 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[4-(formylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-84-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(hydroxymethyl)phenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622867-14-5P, GS 192041 622867-15-6P
 622867-16-7P, GS 278118 622867-17-8P, GS 278117
 622867-50-9P 622867-61-2P 622867-72-5P
 622867-73-6P 622867-80-5P 622867-85-0P
 622867-86-1P 622867-90-7P 622867-91-8P
 622867-92-9P 622868-03-5P 622868-20-6P
 622868-21-7P 622868-22-8P 622868-23-9P
 622868-24-0P 622868-26-2P 622868-27-3P
 622868-30-8P 622868-33-1P 622868-37-5P
 622868-46-6P 622868-47-7P 622868-51-3P
 622868-53-5P 622868-50-4P 622868-55-0P
 622868-62-6P 622868-63-7P 622868-66-0P
 622868-71-7P 622868-72-8P 622868-73-9P
 622868-74-0P 622868-75-1P 622868-76-2P
 622868-77-3P 622868-78-4P 622868-79-5P
 622868-80-8P 622868-83-1P 622868-85-3P
 622868-87-5P 622868-90-0P 622868-93-3P
 622869-08-3P 622869-10-7P 622869-14-1P, GS
 273777 622870-52-4P 622870-53-5P 622870-54-6P
 622870-55-7P 622870-56-8P 622870-57-9P
 622870-58-0P 622870-59-1P 622870-60-4P
 622870-61-5P 622870-62-6P 622870-63-7P
 622870-64-8P 622870-65-9P 622870-66-0P
 622870-67-1P 622870-68-2P 622870-69-3P
 622870-70-6P 622870-71-7P 622870-75-1P, GS
 192771 622870-76-2P, GS 192772 622870-77-3P
 622870-78-4P, GS 192781 622870-79-5P
 622870-80-8P 622870-81-9P 622870-82-0P
 622870-83-1P 622870-84-2P 622870-85-3P
 622870-86-4P 622870-87-5P 622870-88-6P
 622870-89-7P 622870-90-0P 622870-92-2P
 622870-93-3P 622870-94-4P, GS 277957
 622870-95-5P, GS 277771 622870-96-6P
 622870-97-7P, GS 192711 622870-98-8P, GS 192710
 622871-00-5P, GS 193816 622871-03-8P, GS 277930
 622871-04-9P, GS 173850 622871-05-0P
 622871-06-1P 622871-07-2P 622871-08-3P, GS
 277929 622871-09-4P 622871-10-7P, GS 277935
 622871-11-8P 622871-12-9P 622871-13-0P
 622871-14-1P 622871-15-2P 622871-16-3P
 622871-17-4P 622871-18-5P 622871-19-6P
 622871-20-9P 622871-21-0P 622871-22-1P
 622871-23-2P 622871-24-3P 622871-45-8P
 622871-46-9P 622871-47-0P 622871-48-1P, GS
 17424 622871-49-2P 622871-50-5P 622871-51-6P
 622871-52-7P 622871-53-8P 622871-55-0P, GS
 273838 622871-57-2P, GS 192779 622871-58-3P, GS 224342
 622871-59-4P, GS 191483 622871-61-8P, GS 192776
 622871-62-9P, GS 224343 622871-63-0P, GS 191480
 622871-66-3P, GS 191717 622871-67-4P
 622871-68-5P 622871-70-9P, GS 273845
 622871-72-1P 622871-73-2P, GS 273834
 622871-74-3P 622871-75-4P 622871-77-6P, GS
 277775 622871-78-7P, GS 273851 622871-79-8P, GS 277777
 622871-80-1P 622871-85-6P, GS 278764
 622871-86-7P, GS 278115 622871-87-8P, GS 278116
 622871-89-0P 622871-90-3P 622871-91-4P
 622871-92-5P 622871-93-6P 622871-94-7P
 622871-95-8P 622871-96-9P 622871-97-0P
 622871-98-1P, GS 273811 622871-99-2P

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622872-00-8P 623158-38-3P, GS 77369 623158-39-4P
GS 77425 623158-40-7P, GS 191338 623158-44-1P, GS
273813 623158-45-2P, GS 273812 623158-46-3P, GS 277937
623158-47-4P, GS 278809 623158-49-6P, GS 278635
623158-51-0P, GS 278785 623158-55-4P, MF 1912-68
623158-56-5P, GS 191484

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(protease inhibitor; prepn. of phosphonate-substituted HIV protease
inhibitors for treatment of AIDS and other viral infections)

RN 313679-71-9 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-
2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-97-2 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-61-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-

hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-03-6 CAPLUS

CN Glycine,

N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-06-9 CAPLUS

CN Glycine,

N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-53-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-01-4 CAPLUS

CN Carbamic acid,


N-[[[(1S,2R)-1-[[[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-07-0 CAPLUS

CN L-Alanine,

N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-09-2 CAPLUS


CN 8-Oxa-3,5-diaza-4-phosphadecanoic acid, 2,6-diethyl-4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-10-5 CAPLUS
 CN 8-Oxa-3,5-diaza-4-phosphadodecanoic acid, 2,6-diethyl-4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, butyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-11-6 CAPLUS
 CN L-Leucine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-14-9 CAPLUS
 CN L-Phenylalanine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-28-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[(4-phosphonophenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-12-7 CAPLUS
 CN L-Leucine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-13-8 CAPLUS
 CN L-Phenylalanine, N,N'-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 Na

RN 622865-29-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-(diethoxyphosphinyl)phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-31-0 CAPLUS
 CN L-Alanine, N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-32-1 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-40-1 CAPLUS
 CN 3-Oxa-8,12-diaza-1-phosphatridecan-13-oic acid, 1,1,10-trihydroxy-8-[(4-methoxyphenyl)sulfonyl]-6,6-dimethyl-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (10R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-54-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-46-7 CAPLUS
 CN 3-Oxa-7,11-diaza-1-phosphadodecan-12-oic acid, 1,1,9-trihydroxy-7-[(4-methoxyphenyl)sulfonyl]-5,5-dimethyl-10-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (9R,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-51-4 CAPLUS
 CN 10,13-Dioxa-2,6-diaza-12-phosphapentadecanoic acid, 12-ethoxy-4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 12-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

— Ph


RN 622865-57-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[(2-dimethylamino)ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622865-56-9
 CMF C46 H60 N3 O12 P S

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


Ph

CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 622865-63-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl
1-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-75-2 CAPLUS
CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy]methyl]-2,6-dimethyl-7-oxo-, ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-88-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[1-formyl-4-piperidinyl)methyl] [(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-90-1 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl] [(1-methyl-4-
piperidinyl)methyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.

RN 622865-79-6 CAPLUS
CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, ethyl ester, 4-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-83-2 CAPLUS
CN Acetic acid,
[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-93-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methyl]phenyl]methylamino]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622865-99-0 CAPLUS
 CN L-Alanine, N,N'-[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]amino]phenyl)methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-02-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]-1-piperidinylmethyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-10-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]1-(2-methylpropyl)amino]-1-[[4-(dimethylamino)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-14-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-aminophenyl]methyl]-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


-Ph

RN 622866-16-4 CAPLUS
 CN L-Alanine, N,N'-[4-[[[(2R,3S)-4-[(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl]2-methylpropyl]amino]sulfonyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622866-17-5 CAPLUS
 CN L-Valine, N,N'-[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-18-6 CAPLUS
 CN L-Valine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-19-7 CAPLUS
 CN Glycine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-69-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxy-3-(phosphonomethoxy)phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-70-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-hydroxyphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-58-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-60-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[3-(phosphonomethoxy)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-68-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-72-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 622866-73-3 CAPLUS
 CN L-Alanine,
 N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 622866-74-4 CAPLUS
CN L-Alanine, N,N'-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-89-1 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[4-[[bis(ethylamino)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-90-4 CAPLUS
CN L-Alanine,
N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622866-82-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[4-[(ethoxyphenoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-88-0 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-94-8 CAPLUS
CN L-Alanine,
N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl] (phenylmethoxy)phosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-00-9 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




```

RN      622867-06-5 CAPLUS
CN      3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[4-[(2S,3R)-2-[[[(1R,3aS,6aR)-
        hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-
        methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy]methyl]-2,6,9-
        trimethyl-7-oxo-, 1-methylethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX
        NAME)

```

Absolute stereochemistry.



RN 622867-13-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3a,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methylpropylamino)-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
NAME)


RN 622867-17-8 CAPLUS
CN Carbamic acid, ({(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[{4-(4-morpholinylmethyl)phenyl}sulfonyl]amino}-1-[(4-(phosphonomethoxy)phenyl)methyl]propyl)-, C-[{(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

RN 622687-50-9 CAIUSU
 CN Propanoic acid, 2-[[[4-[[[2S,3R]-2-[[[1[3R,3aS,6aR]-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-3-[[triethylsilyl]oxy]butyl]methyl]amino]phenyl)methyl]phenoxyphosphinyl]oxy-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


RN 622867-16-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[[4-(hydroxymethyl)phenyl]sulfonyl](2-

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 622867-61-2 CAPLUS
 CN Propanoic acid, 2-[[[2-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinoliny]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

CO₂H

RN 622867-73-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[2-(diethoxyphosphinyl)ethyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-80-5 CAPLUS
 CN Propanoic acid, 2-[[[2,6-dimethylphenoxy][2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-79-2
 CMF C44 H62 N3 O13 P S

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-72-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinoliny]methyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 622867-85-0 CAPLUS
 CN Propanoic acid, 2-[[[2,6-dimethylphenoxy][2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, propyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-84-9
 CMF C45 H64 N3 O13 P S

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 622867-86-1 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622867-91-8 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](4-morpholinyl)oxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-92-9 CAPLUS
CN Propanoic acid, 2-[[[4-[(dimethylamino)oxy][4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-90-7 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 2-(1-methyl-4-piperidinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-03-5 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[1-(2-(dimethoxyphosphinyl)ethyl)-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-20-6 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[(dimethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-21-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(1-methylethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-22-8 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-26-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 2-(4-morpholinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-23-9 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-24-0 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622868-27-3 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-30-8 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxy]phosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-33-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-37-5 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-51-3 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-53-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-46-6 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-47-7 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-60-4 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-61-5 CAPLUS
 CN Carbamic acid, [[1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[(2-phosphonoethyl)amino]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-62-6 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-


methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-36-1

CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622868-71-7 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-72-8 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-63-7 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622868-66-0 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-73-9 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A


RN 622868-74-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(4-(1,1,3,3-tetramethylbutyl)phenoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 2-A




RN 622868-75-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(4-(1,1,3,3-tetramethylbutyl)phenoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

RN 622868-77-3 CAPLUS
 CN Benzoic acid, 3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(4-(1,1,3,3-tetramethylbutyl)phenoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-78-4 CAPLUS
 CN Propanoic acid, 2-[[[3-[(dimethylamino)methyl]phenoxy][(4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(4-(1,1,3,3-tetramethylbutyl)phenoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(1-methylethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622868-76-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(1-methyl-4-piperidinyl)oxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(3-[(4-methyl-1-piperazinyl)methyl]phenoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][(1-methyl-4-piperidinyl)oxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
piperidinylphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-83-1 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[6-[(diethoxyphosphinyl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-85-3 CAPLUS


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 622868-93-3 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

—OEt


RN 622869-08-3 CAPLUS
CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methylamino]methyl]phenyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-87-5 CAPLUS
CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-


methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-90-0 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(2-(phosphonomethoxy)ethoxy]phenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-10-7 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-14-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-1-(phenylmethyl)-2-(phosphonoxy)-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



● 2 Na

RN 622870-52-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[[4-[(methoxyphenoxyphosphinyl)methoxy]phenyl]methyl]-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-53-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622870-56-8 CAPLUS
 CN Acetic acid, [[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-57-9 CAPLUS
 CN L-Alanine, N-[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622870-54-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethylphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-55-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonophenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622870-58-0 CAPLUS
 CN L-Alanine, N-[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-59-1 CAPLUS
 CN D-Alanine, N-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-60-4 CAPLUS
 CN D-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-62-6 CAPLUS
 CN L-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-63-7 CAPLUS
 CN L-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-64-8 CAPLUS
 CN Butanoic acid, 2-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-65-9 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-66-0 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]amino]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-67-1 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]amino]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-68-2 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]amino]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-68-2 CAPLUS
 CN L-Alanine;
 N-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622870-69-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622870-71-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 3-(4-morpholinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622870-75-1 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-3-methyl-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-70-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



RN 622870-76-2 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-3-methyl-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-77-3 CAPLUS
 CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-2,2-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-78-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 3-(4-morpholinyl)propyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622870-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-81-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hosphinyl]oxy]-, 2-(1-piperidinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 622870-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622870-82-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-83-1 CAPLUS
 CN Propanoic acid, 2-[[[3-(aminomethyl)phenoxy][[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622870-84-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-[(1-piperidinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B



RN 622870-87-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[2-[(diethoxyphosphinyl)methoxy]ethoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-88-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622870-85-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-[(2-methoxyethyl)methylamino]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-86-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[5-oxido-10-phenyl-5-[2-(phenylmethoxy)ethoxy]-3,6,9-trioxo-5-phosphadec-1-yl]oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B

-CO2H

RN 622870-89-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[(diethoxyphosphinyl)ethyl]amino]methyl]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-90-0 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-92-2 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-93-3 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622870-96-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[(2-diethoxyphosphinyl)ethyl]-1-piperazinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-97-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]-1-[[[1,2,3,6-tetrahydro-1-(phosphonomethyl)-4-pyridinyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-94-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]-1-[[[4-[[[methyl(2-phosphonoethyl)amino]methyl]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-95-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[[diethoxyphosphinyl)methoxy]imino]methyl]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622870-98-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[1-[[[diethoxyphosphinyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-00-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-03-8 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-04-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]-1-[[1,2,3,6-tetrahydro-1-(2-phosphonoethyl)-4-pyridinyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-05-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-06-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-08-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]-1-[[[4-phosphonophenyl]methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A




RN 622871-07-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]amino]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 622871-09-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]amino]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-10-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[methyl[(4-phosphonomethoxy)methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-11-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[3,4-dihydro-6-(phosphonomethoxy)-2(1H)-isoquinolinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-14-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[[bis(phenylmethoxy)phosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-15-2 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyposphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-12-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[(phosphonomethyl)amino]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-13-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[[diethoxyphosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-16-3 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyposphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-17-4 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyposphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-18-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]hydrazoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-19-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl][2-methylpropyl]amino]-1-[[4-methylphenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-22-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl][2-(4-morpholinyl)ethyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-23-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl][2-(4-morpholinyl)ethyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-20-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)ethyl][4-methoxyphenyl]sulfonyl]amino]-2-hydroxy-1-[[4-(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-21-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)ethyl][4-methoxyphenyl]sulfonyl]amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-24-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)[4-methoxyphenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-45-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-1-[(4-(bromomethyl)phenyl)methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-56-2 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-86-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-70-3 CAPLUS
 CN Propanoic acid, 2-[[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[(triethylsilyl)oxy]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]phenoxyphosphinyloxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-06-8 CAPLUS
 CN Pyridinium, 1-[2-bis(phenylmethoxy)phosphinyloxy]ethyl]-4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 622868-05-7

CMF C43 H55 N3 O11 P S

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-43-0 CAPLUS

CN Carbamic acid, [(1S,2R)-1-[(4-ethenylphenyl)methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-47-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-48-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]-2-[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 37181-39-8


CMF C F3 O3 S



RN 622868-82-0 CAPLUS


CN Carbamic acid, [(1S,2R)-1-[[[6-[(diethoxyphosphinyloxy)methyl]-3,4-dihydro-2(1H)-isoquinolinyloxy]methyl]-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: BYP (Byproduct); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; prepn. of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622866-43-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxymethyl)phenyl)methyl]-3-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 253266-01-2P 605654-08-8P 605654-10-2P
 622865-05-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 253266-01-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605654-08-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 622865-53-6P 622865-86-5P 622866-12-0P
 622866-41-5P 622866-42-6P 622866-44-8P
 622866-56-2P 622866-86-8P 622867-43-0P
 622867-47-4P 622867-48-5P 622867-70-3P
 622868-06-8P 622868-82-0P 622869-12-9P
 622869-16-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622865-53-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)-3-[[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-86-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-12-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 605654-10-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-85-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxyphenyl)methyl)-3-[[[(4-methoxyphenyl)sulfonyl](4-piperidinylmethyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-41-5 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxycarbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-42-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-(formylphenyl)methyl)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-44-8 CAPLUS

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 865105-51-7 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-3-[[[(5-benzofuranylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




IT 664344-17-6P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of diamino-mono-ol dipeptide isostere core based resistance-repellent retroviral protease inhibitors)
 RN 664344-17-6 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:612479 CAPLUS
 DN 143:97530
 TI Preparation of phosphonate analogs of HIV protease inhibitors and methods for identifying anti-HIV therapeutic compounds
 IN Arimilli, Murty N.; Becker, Mark M.; Birkus, Gabriel; Bryant, Clifford; Chen, James M.; Chen, Xiaowu; Cihlar, Tomas; Dastgah, Azar; Eisenberg, Eugene J.; Fardis, Maria; Hatada, Marcos; He, Gong-Xin; Jin, Haolun; Kim, Choung U.; Lee, William A.; Lee, Christopher P.; Lin, Kuei-Ying; Liu, Hongtao; Mackman, Richard L.; McDermott, Martin J.; Mitchell, Michael L.; Nelson, Peter H.; Pyun, Hyung-Jung; Rowe, Tanisha D.; Sparacino, Mark; Swaminathan, Sundaramoorthi; Tario, James D.; Wang, Jianying; Williams, Matthew A.; Xu, Lianhong; Yang, Zheng-Yu; Yu, Richard H.; Zhang, Jiancun; Zhang, Lijun
 PA Gilead Sciences, Inc., USA
 SO PCT Int. Appl., 1723 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN: CNT 8


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005064008	A1	20050714	WO 2004-US42991	20041222
WO 2005064008	A9	20060928		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,				
SM RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005239054	A1	20051027	US 2003-740694	20031222
AU 2004309379	A1	20050714	AU 2004-309379	20041222
CA 2550730	A1	20050714	CA 2004-2550730	20041222
EP 1711617	A1	20061018	EP 2004-817046	20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRAI US 2003-740694	A	20031222		
US 2002-375622P	P	20020426		
US 2002-375665P	P	20020426		
US 2002-375779P	P	20020426		
US 2002-375834P	P	20020426		
US 2003-423496	A2	20030425		
US 2003-424130	A2	20030425		
US 2003-424186	A2	20030425		
US 2003-465721P	P	20030425		
US 2003-465810P	P	20030425		
US 2003-465824P	P	20030425		
WO 2003-US12901	A2	20030425		
WO 2003-US12926	A2	20030425		
WO 2003-US12943	A2	20030425		
WO 2004-US42991	W	20041222		

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE: CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention relates to phosphonate-substituted carbamates I and cyclic ureas II (wherein A = Al, A2, or W3 with the proviso that at least one of A = Al; A1 = {Y2(CR2R2)1-12}0-12Y2W6; A2 = {Y2(CR2R2)1-12}0-12Y2W3; W3 = substituted (hetero)cyclyl; R5, C(Y1)R5, C(Y1)W5, SO2R5, or SO2W5; W5 = substituted (hetero)cyclyl; W6 = triphosphono-substituted W3; Y1 = O, S, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), or N(N(Rx)2); Y2 = independently a bond, O, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), N(N(Rx)2), SOO-2, or SOO-2SOO-2; Rx = independently H, R1, W3, a protecting group, etc.; R1 = independently H or alkyl; R2 = independently H, R1, halo, CN, N3, NO2, Y1, Rx, N(Rx)2, SO-2Rx, substituted alkyl, alkenyl, alkynyl, etc.; R3 = halo, CN, N3, NO2, Y1, Rx, N(Rx)2, SRx, SO2Rx, SO2R5, OC(Y1)Rx, OC(Y1)ORx, C(Y1)Rx, etc. with provisos; R5 = substituted alkyl, alkenyl, or alkynyl; or pharmaceutically acceptable salts, hydrates, and formulations thereof] and other phosphonate-substituted analogs of HIV protease inhibitors for treating AIDS and other antiviral infections, as well as for use in assays for the detection of HIV protease. Comps. of the invention inhibit reverse transcriptase activity and have improved intracellular half-life compared to analogs not having the phosphonate or phosphonate prodrug. Libraries of such comps. were screened optionally using the novel enzyme GS-7340 ester hydrolase. Comps. and methods relating to GS-7340 ester hydrolase also are provided. Examples include preps. for non-nucleoside phosphonate protease inhibitors. In addition, extensive biol. data regarding PBMC uptake and metabolism, serum stability, and alkaline phosphatase inhibitor (ALPPI) activity of selected phosphonate-substituted prodrugs is presented. For instance, a 9-step reaction sequence starting from N-tert-butoxycarbonyl-O-benzyl-L-tyrosine provided III (Ki 510 pM for ALPPI activity). The synthesis involved multiple protection and deprotection steps along with coupling reactions using isobutylamine, (3R,3aR,6aR)-hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate, and dibenzyl hydroxymethylphosphonate.


IT 622866-43-7P

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-


methylpropyl]amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-
phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865105-44-8 CAPLUS
CN β-Alanine, N-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-

methylpropyl]amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-
phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 865105-48-2 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[(3Z)-3-[(ethoxycarbonyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 865105-45-9 CAPLUS
CN Glycine,
N-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-

methylpropyl]amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-
N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865105-47-1 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 865105-49-3 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[(3Z)-3-[(acetylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865105-50-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(cyclopropylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 865105-35-7 CAPLUS


CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[(2-quinolinylmethyl)amino]methylene]-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865105-36-8 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-3-[1-[(cyclohexylmethyl)amino]ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 865105-38-0 CAPLUS

CN L-Valine, N-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

OEt

Pr-i


RN 865105-39-1 CAPLUS

CN L-Phenylalanine, N-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 865105-37-9 CAPLUS

CN Glycine, N-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

Ph




RN 865105-40-4 CAPLUS


CN L-Phenylalanine, 4-chloro-N-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865105-42-6 CAPLUS

CN Glycine, N-[(2)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-


L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 865105-29-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(5-methylpyrazinyl)methyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A

PAGE 1-B




RN 865105-30-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(2,2,3,3,4,4,4-heptafluorobutyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 865105-32-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(2-(4-hydroxyphenyl)ethyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A

PAGE 1-B




RN 865105-33-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(3,5-dimethoxy-4-methyl-2-pyridinyl)methyl]amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 865105-31-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(2-(4-aminophenyl)ethyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 865105-34-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(2-methyl-4-thiazolyl)methyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A


PAGE 1-B



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


dimethylethoxy)carbonyl]amino]ethyl]amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A


PAGE 1-B



RN 865105-23-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(butylethylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 865105-26-6 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[(2-phenylamino)ethyl]amino]methylene]-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

PAGE 1-B



RN 865105-27-7 CAPLUS

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

—Bu-n

RN 865105-24-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[(2,2,3,3,3-pentafluoropropyl)amino]methylene]-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

PAGE 1-B



RN 865105-25-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(2-methyl-2-propenyl)amino]methylene]-2-oxo-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(1-methylpropyl)propylamino]methylene]-2-oxo-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

—Et

RN 865105-28-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[[(1H-benzimidazol-2-ylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 865105-16-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[methyl(2-methylpropyl)amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

-Bu-i

RN 865105-17-5 CAPLUS

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


-N(Bu-i)2

RN 865105-19-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(cyclobutylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865105-20-0 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[ethyl(1-methylethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[[6-ethyl-2-pyridinyl]amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865105-18-6 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[bis(2-methylpropyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


-Pr-i

RN 865105-21-1 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(cyclopentyl-2-propenylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865105-22-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[[2-[(1,1-

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

CHET2

RN 865105-09-5 CAPLUS


CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[[(1,3-dimethylbutyl)amino]methylene]-

2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



PAGE 1-A

PAGE 1-B

Bu-1

RN 865105-10-8 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[[(1,4-dimethylpentyl)amino]methylene]-

2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(cyclohexylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



PAGE 1-A

PAGE 1-B




RN 865105-13-1 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[(1-methylbutyl)amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.




PAGE 1-A

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 865105-11-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(ethylpropylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



PAGE 1-A

PAGE 1-B

Pr-n

RN 865105-12-0 CAPLUS

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


Pr-n

RN 865105-14-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(butylmethylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



PAGE 1-A

PAGE 1-B

Bu-n

RN 865105-15-3 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(cyclopentylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

Et

RN 865105-03-9 CAPLUS


CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[[(1,2-dimethylpropyl)amino]methylene]-

2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

CHET2

RN 865105-06-2 CAPLUS


CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[(cyclopropylmethyl)amino]methylene]-

2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


Pr-i

RN 865105-04-0 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(Z)-[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865105-05-1 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[[(1-ethylpropyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 865105-07-3 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[(cyclohexylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865105-08-4 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[[(2-ethylbutyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 865104-96-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methylene]-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 865104-99-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[[2-(ethylthio)ethyl]amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865105-00-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-(2-piperidinylidene)-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 865104-97-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[6-hydroxyhexyl]amino]methylene]-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 865104-98-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[[cyclohexyl(2-pyridinylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865105-01-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[2-(4-morpholinyl)ethyl]amino]methylene]-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865105-02-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[1-(2-methylpropyl)amino]methylene]-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 865104-90-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[bis(2-pyridinylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 865104-92-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-(3-pyridinyl)ethyl]amino]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865104-93-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-(hexahydro-2H-azepin-2-ylidene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 865104-91-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[ethyl(2-pyridinylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865104-94-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[[[3-ethoxypropyl]amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865104-95-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-(4-pyridinyl)ethyl]amino]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 865104-83-2 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[(4-phenylbutyl)amino]methylene]-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

PAGE 1-B




RN 865104-84-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[(nonylamino)methylene]-2-oxo-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 865104-87-6 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A


PAGE 1-B




RN 865104-88-7 CAPLUS

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 865104-85-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-(1-hydroxyethylidene)-2-oxo-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 865104-86-5 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-(2-phenoxyethyl)amino]methylene]-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-(2-pyridinyl)ethyl]amino]methylene]-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A


PAGE 1-B



RN 865104-89-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-(4-pyridinylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Ph

RN 865104-77-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(cyclohexylmethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Ph

RN 865104-80-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(2-cyclohexylethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 865104-78-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[4-pyridinylmethyl]amino]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865104-79-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-phenylethyl]amino]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 865104-81-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-(2-pyridinyl)ethyl]amino]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 865104-82-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[2-phenylpropyl]amino]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


CMe3

RN 865104-70-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[2-methylbutyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-A



RN 865104-71-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[3-methylbutyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-B

CHMe2


RN 865104-72-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[3,3-dimethylbutyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


CMe3

RN 865104-73-0 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[[[2-methyl-1-(1-methylethyl)propyl]amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


CH(Pr-1)2

RN 865104-74-1 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[1-(phenylamino)methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.




RN 865104-75-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[1-(phenylamino)methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


Ph

RN 865104-76-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[[1-(phenylamino)methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865104-60-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[(propylamino)methylene]-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-61-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[1-(propylamino)ethylidene]-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 865104-62-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-(2-pyrrolidinyldiene)-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-63-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(butylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-64-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[1-(butylamino)ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865104-65-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[(2-methylpropyl)amino)methylene]-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-66-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[1-[(2-methylpropyl)amino]ethylidene]-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-67-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(1,1-dimethylethyl)amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-


L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-68-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[1-[(1,1-dimethylethyl)amino]ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 865104-69-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[1-[(2,2-dimethylpropyl)amino]ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

OH

RN 865104-52-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[1-[(2-hydroxyethyl)amino]ethylidene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

OH

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

OMe

RN 865104-56-9 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-3-[[[2-(dimethylamino)ethyl]amino]methylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

NMe2

RN 865104-57-0 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-3-[1-[[2-(dimethylamino)ethyl]amino]ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 865104-54-7 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[1-[(2-methoxyethyl)amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

OMe

RN 865104-55-8 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[1-[(2-methoxyethyl)amino]ethylidene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

NMe2

RN 865104-58-1 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[1-[(1-methylethyl)amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-59-2 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[1-[(1-methylethyl)amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 865104-43-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3Z)-3-(aminomethylene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 865104-44-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3Z)-3-(1-aminomethylidene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865104-48-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3Z)-3-[1-(ethylamino)ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-49-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[2,2,2-trifluoroethyl]amino]ethylidene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 865104-45-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[(methylamino)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-46-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[1-(methylamino)ethylidene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-47-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3Z)-3-[1-(ethylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

CF₃

RN 865104-50-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[[2,2,2-trifluoroethyl]amino]ethylidene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


CF₃

RN 865104-51-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[(2-hydroxyethyl)amino]methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 865104-37-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(dipropylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

N(Pr-n)2

RN 865104-38-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-3-[(1-(dipropylamino)ethylidene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 865104-40-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[(1-(1-piperidinyl)ethylidene)-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 865104-41-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[(1-piperazinyl)methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) PAGE 1-A




PAGE 1-B

N(Pr-n)2

RN 865104-39-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-2-oxo-3-[(1-piperidinyl)methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 865104-42-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[(4-morpholinyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

865105-11-9P 865105-12-0P 865105-13-1P
 865105-14-2P 865105-15-3P 865105-16-4P
 865105-17-5P 865105-18-6P 865105-19-7P
 865105-20-0P 865105-21-1P 865105-22-2P
 865105-23-3P 865105-24-4P 865105-25-5P
 865105-26-6P 865105-27-7P 865105-28-8P
 865105-29-9P 865105-30-2P 865105-31-3P
 865105-32-4P 865105-33-5P 865105-34-6P
 865105-35-7P 865105-36-8P 865105-37-9P
 865105-38-0P 865105-39-1P 865105-40-4P
 865105-42-6P 865105-44-8P 865105-45-9P
 865105-47-1P 865105-48-2P 865105-49-3P
 865105-50-6P 865105-51-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diamino-mono-ol dipeptide isostere core based resistance-repellent retroviral protease inhibitors)


RN 865104-29-6 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[[2,2-dimethylpropyl]amino]methylene]-

2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A

PAGE 1-B


-CMe3

RN 865104-30-9 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[1-(dimethylamino)ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865104-33-2 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[(methylpropylamino)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A

PAGE 1-B

-Pr-n

RN 865104-34-3 CAPLUS

CN Carbamic acid,


[(1S,2R)-3-[[[(3Z)-2,3-dihydro-3-[(methylpropylamino)ethylidene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 865104-31-0 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[[2,2-dimethylpropyl]amino]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 865104-32-1 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[1-(ethylmethylamino)ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

-Pr-n


RN 865104-35-4 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[1-(diethylamino)ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


-Pr-n

RN 865104-36-5 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[1-(diethylamino)ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 865104-36-5 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3Z)-3-[[1-(diethylamino)ethylidene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 7 OF 51 CAPLUS[®] COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 623158-56-5 CAPLUS

CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-2,2-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1021739 CAPLUS

DN 143:326208

TI Preparation of diamino-mono-ol dipeptide isostere core based resistance-repellent retroviral protease inhibitors

IN Eissenstat, Michael; Guerassina, Tatiana

PA Sequoia Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 78 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005087728	A1	20050922	WO 2005-US8381	20050311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005222435	A1	20050922	AU 2005-222435	20050311
CA 2559328	A1	20050922	CA 2005-2559328	20050311
US 2005209301	A1	20050922	US 2005-77135	20050311
EP 1732891	A1	20061220	EP 2005-733249	20050311
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1953964	A	20070425	CN 2005-80014491	20050311
PRAI US 2004-552643P	P	20040311		
WO 2005-US8381	W	20050311		
OS MARPAT 143:326208				
GI				



II

AB Title compds. X-A-B-A'-X' [X = 5-7 membered non-aromatic heterocycle; A = 2CZNH, 2COCONH, 2SO2NH, etc.; 2 = amino, O, S, etc.; B = syn-CH(D)CH(OH)CH2; D = alk(en/yn)yl; aryl, cycloalkyl, etc.; A' =

ND'-E': D' = alk(en/yn)yl, aryl, cycloalkyl, etc.; E' = CO, SO, SO2; X' =

indolyl;

I] are prepared For instance, II is prepared in several steps from

L7 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

2-oxo-2,3-dihydro-1H-indol-5-sulfonyl chloride (prepn. given), [1-benzyl-2-hydroxy-4-phenylbutyl]isobutylcarbamate benzyl ester, carbonic acid 2,5-dioxopyrrolidin-1-yl ester hexahydrofuro[2,3-b]furan-3-yl ester and DMF di-Me acetal. II has an IC50 = 93 nM for a recombinant wild type HIV protease. I are useful for treating HIV infections.

IT 865104-28-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of diamino-mono-ol dipeptide isostere core based resistance-repellent retroviral protease inhibitors)


RN 865104-28-5 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[[(3Z)-3-[(dimethylamino)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 865104-29-6P 865104-30-9P 865104-31-0P
 865104-32-1P 865104-33-2P 865104-34-3P
 865104-35-4P 865104-36-5P 865104-37-6P
 865104-38-7P 865104-39-8P 865104-40-1P
 865104-41-2P 865104-42-3P 865104-43-4P
 865104-44-5P 865104-45-6P 865104-46-7P
 865104-47-8P 865104-48-9P 865104-49-0P
 865104-50-3P 865104-51-4P 865104-52-5P
 865104-54-7P 865104-55-8P 865104-56-9P
 865104-57-0P 865104-58-1P 865104-59-2P
 865104-60-5P 865104-61-6P 865104-62-7P
 865104-63-8P 865104-64-9P 865104-65-0P
 865104-66-1P 865104-67-2P 865104-68-3P
 865104-69-4P 865104-70-7P 865104-71-8P
 865104-72-9P 865104-73-0P 865104-74-1P
 865104-75-2P 865104-76-3P 865104-77-4P
 865104-78-5P 865104-79-6P 865104-80-9P
 865104-81-0P 865104-82-1P 865104-83-2P
 865104-84-3P 865104-85-4P 865104-86-5P
 865104-87-6P 865104-88-7P 865104-89-8P
 865104-90-1P 865104-91-2P 865104-92-3P
 865104-93-4P 865104-94-5P 865104-95-6P
 865104-96-7P 865104-97-8P 865104-98-9P
 865104-99-0P 865105-00-6P 865105-01-7P
 865105-02-8P 865105-03-9P 865105-04-0P
 865105-05-1P 865105-06-2P 865105-07-3P
 865105-08-4P 865105-09-5P 865105-10-8P

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 623158-45-2 CAPLUS

CN Pyridinium,

3-[[[(2R,3S)-4-[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl


1]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-74-3

CMF C42 H53 N3 O11 P S

Absolute stereochemistry.



CM 2

CRN 37181-39-8

CMF C F3 O3 S



RN 623158-46-3 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methyl-1-

piperazinyl)phenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phe

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 623158-49-6 CAPLUS


CN L-Valine, [4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 623158-48-5

CMF C45 H62 N3 O15 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 623158-51-0 CAPLUS

CN L-Valine, (1R,2S)-3-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]propyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 623158-50-9

CMF C45 H62 N3 O15 P S

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 623158-47-4 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-hydroxyethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OH

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 623158-55-4 CAPLUS

CN Propanoic acid, 2-[[[(2-ethoxyphenoxy)[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 623158-54-3

CMF C44 H62 N3 O14 P S

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622871-98-1 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[4-methoxyphenyl]sulfonyl](2-

methylpropyl)amino]-3-(phosphonoxy)butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-[1-methylethyl] ester, disodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 622871-99-2 CAPLUS

CN D-Valine, (1R,2S)-3-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino)methyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 623158-39-4 CAPLUS

CN L-Alanine, N-[[[4-[[[(2R,3S)-4-[4-(ethylamino)phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 623158-40-7 CAPLUS


CN Carbamic acid, [(1S,2R)-1-[4-[(diethoxyphosphinyl)methyl]phenyl]methyl]-2-

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622872-00-8 CAPLUS

CN D-Valine, [4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623158-38-3 CAPLUS


CN L-Alanine, N-[[[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623158-44-1 CAPLUS


CN Pyridinium, 3-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-75-4

CMF C39 H53 N3 O13 P S

Absolute stereochemistry.




CM 2

CRN 37181-39-8

CMF C F3 O3 S


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbanic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-93-6 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[(4-{2-(dimethylamino)ethoxy}phenyl)methyl]-2-hydroxy-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-94-7 CAPLUS
 CN L-Alanine, N-[(R)-{[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622871-96-9 CAPLUS
 CN L-Alanine, N-[(R)-{[4-[[[(2R,3S)-4-[4-(ethylamino)phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 622871-95-8 CAPLUS
 CN L-Alanine, N-[(S)-{[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622871-97-0 CAPLUS
 CN L-Alanine, N-[(S)-{[4-[[[(2R,3S)-4-[4-(ethylamino)phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622871-78-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(1-oxido-3-pyridinyl)sulfonyl]amino}butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-79-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(1-oxido-3-pyridinyl)sulfonyl]amino}butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-80-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(1-oxido-3-pyridinyl)sulfonyl]amino}butyl]phenoxy)methyl] (phenylmethoxy)phosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-87-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-


b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(1-oxido-3-pyridinyl)sulfonyl]amino}butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-89-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxy-4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 622871-85-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-(hydroxymethyl)phenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-86-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-(4-morpholinylmethyl)phenyl]sulfonyl]amino]butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622871-90-3 CAPLUS

CN L-Alanine, N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy)methyl]hydroxyphosphinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-CO₂H


RN 622871-91-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[(diphenoxyphosphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-92-5 CAPLUS

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-67-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[4-(1-piperidinyl)phenyl]sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyloxy], ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-68-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[4-(1-piperidinyl)methyl]phenyl]sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyloxy], ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-73-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[3-(pyridinylsulfonyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyloxy], (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-74-3 CAPLUS
 CN Pyridinium, 3-[[[4-[(2R,3S)-4-[[[4-[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyloxy]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl]amino]sulfonyl]-1-methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-70-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[3-(pyridinylsulfonyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-1[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-72-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[3-(pyridinylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyloxy], ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-75-4 CAPLUS
 CN Pyridinium, 3-[[[4-[(2R,3S)-4-[[[4-[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyloxy]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl]amino]sulfonyl]-1-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-77-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[1-oxido-3-pyridinylsulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-1[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-55-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(phenylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-57-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[(2-methylpropyl)(phenylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-61-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-(4-fluorophenyl)sulfonyl]-(2-methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-62-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-(4-fluorophenyl)sulfonyl]-(2-methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-58-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(phenylsulfonyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-59-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-63-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-1-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-66-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[4-(4-cyanophenyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-46-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
 3-[[[4-(ethylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-
 , (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 622871-47-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-
 1-[[4-[[bis(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-50-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[3-(aminophenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-51-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[3-(aminophenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-48-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
 C-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 622871-49-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-
 1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-52-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[3-(aminophenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-53-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
 2-hydroxy-3-[[[4-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-18-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]hydr oxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-19-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-methylphenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-22-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-(4-morpholinyl)ethyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-23-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-(4-morpholinyl)ethyl)amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-20-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)ethyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-21-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)ethyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-24-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-45-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-10-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]-1-[[methyl[(4-phosphonophenyl)methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-11-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[3,4-dihydro-6-(phosphonomethoxy)-2(1H)-isoquinolinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-14-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-15-2 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-12-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]-1-[[4-[(phosphonomethyl)amino]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-13-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[diethoxyphosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-16-3 CAPLUS
 CN L-Alanine, N-[(R)-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-17-4 CAPLUS
 CN L-Alanine, N-[(R)-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-04-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[1,2,3,6-tetrahydro-1-(2-phosphonoethyl)-4-pyridinyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-05-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 622871-07-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]amino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-06-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methylamino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-08-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[(4-phosphonophenyl)methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-09-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]methylamino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-92-2 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-93-3 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]methylamino]ethyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622870-96-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[2-(diethoxyphosphinyl)ethyl]-1-piperazinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-97-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[[1,2,3,6-tetrahydro-1-(phosphonomethyl)-4-pyridinyl]methyl]propyl]-, C-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-94-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[[methyl(2-phosphonoethyl)amino]methyl]phenyl]methyl]propyl]-, C-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622870-95-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[[diethoxyphosphinyl]methoxy]imino]methyl]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622870-98-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[1-[[[diethoxyphosphinyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-00-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-03-8 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-84-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-(1-piperidinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622870-85-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-[(2-methoxyethyl)methylamino]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-86-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[5-oxido-10-phenyl-5-(2-(phenylmethoxy)ethoxy]-3,6,9-trioxo-5-phosphadec-1-yl]oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B



RN 622870-87-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[(diethoxyphosphinyl)methoxy]ethoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-88-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B

CO₂H

RN 622870-89-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[(diethoxyphosphinyl)ethyl]amino]methyl]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-90-0 CAPLUS
 CN Butanoic acid, 2-[[[2-ethylphenoxy][2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-78-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 3-(4-morpholinyl)propyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622870-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

methoxyphenyl)sulfonyl (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-81-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hosphinyl]oxy]-, 2-(1-piperidinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 622870-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622870-82-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622870-83-1 CAPLUS
 CN Propanoic acid, 2-[[[3-(aminomethyl)phenoxy]4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



Absolute stereochemistry.




CM 1

CRN 622866-03-5
CMF C32 H49 N3 O11 P S

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 37181-39-8
CMF C F3 O3 S

RN 622867-34-9 CAPLUS
CN Carbamic acid, [(1R,2R)-1-formyl-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[(triethylsilyloxy)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 622867-35-0P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622867-35-0 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622870-91-1 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 622867-36-1P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622867-36-1 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

methylpropyl)amino]-1-[[4-[(2-phosphonoethyl)amino]methyl]phenyl]methyl]propyl]-, 2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 622867-04-3P 622870-49-9P 622870-91-1P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622867-04-3 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-49-9 CAPLUS
CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



IT 622865-08-1P 622866-91-5P 622866-97-1P
622868-28-4P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


Absolute stereochemistry.



RN 622866-91-5 CAPLUS
CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, ethyl ester (CA INDEX NAME)


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-28-4 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



IT 622865-70-7P 622865-71-8P 622866-92-6P
 622866-93-7P 622866-95-9P 622866-96-0P
 622866-98-2P 622866-99-3P 622868-52-4P
 622868-54-6P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN 622865-70-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-71-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 622868-58-0P 622868-59-1P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RCT (Reactant or reagent); USES (Uses)

(protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622868-58-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-59-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622866-92-6 CAPLUS
 CN D-Alanine, N-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-93-7 CAPLUS
 CN D-Alanine, N-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-95-9 CAPLUS

CN Propanoic acid,

2-[[[S]-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-96-0 CAPLUS


CN Propanoic acid,

2-[[[R]-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-98-2 CAPLUS

CN Propanoic acid,

2-[[[S]-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-99-3 CAPLUS


CN Propanoic acid,

2-[[[R]-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-52-4 CAPLUS

CN Propanoic acid, 2-[[[S]-[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-


methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-51-3

CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622868-54-6 CAPLUS

CN Propanoic acid, 2-[[[R]-[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-


methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-53-5

CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 622864-99-7P 622865-02-5P 622865-30-9P
 622865-39-8P 622865-45-6P 622865-55-8P
 622865-56-9P 622865-61-6P 622865-62-7P
 622865-87-6P 622865-89-8P 622865-92-3P
 622865-97-8P 622865-98-9P 622866-08-4P
 622866-09-5P 622866-13-1P 622866-15-3P
 622866-33-5P 622866-34-6P 622866-37-9P
 622866-38-0P 622866-39-1P 622866-40-4P
 622866-59-5P 622866-67-5P 622866-71-1P
 622866-76-6P 622866-79-9P 622866-80-2P
 622866-81-3P 622866-87-9P 622867-02-1P
 622867-03-2P 622867-22-5P 622867-23-6P
 622867-25-8P 622867-27-0P 622867-30-5P
 622867-31-6P 622867-32-7P 622867-33-8P
 622867-37-2P 622867-38-3P 622867-49-6P
 622867-71-4P 622867-79-2P 622867-84-9P

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622867-89-4P 622867-97-4P 622868-15-9P
 622868-16-0P 622868-17-1P 622868-29-5P
 622868-32-0P 622868-64-8P 622868-65-9P
 622868-68-2P 622868-69-3P 622868-70-6P
 622868-86-4P 622868-89-7P 622868-91-1P
 622868-92-2P 622868-94-4P 622868-97-7P
 622868-98-8P 622869-05-0P 622869-06-1P
 622869-07-2P 622869-11-8P 622869-13-0P
 622869-17-4P 622870-99-9P 622871-01-6P
 622871-02-7P 622871-54-9P 622871-56-1P
 622871-60-7P 622871-64-1P 622871-65-2P
 622871-69-6P 622871-71-0P 622871-76-5P
 622871-81-2P 622871-82-3P 622871-83-4P
 622871-84-5P 622871-88-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; prepn. of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622864-99-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1-methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-02-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-
 2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-45-6 CAPLUS
 CN 2,5-Dioxo-9,13-diaza-3-phosphatetradecan-14-oic acid, 11-hydroxy-9-[[[(4-
 methoxyphenyl)sulfonyl]-7,7-dimethyl-1-phenyl-3-(phenylmethoxy)-12-
 (phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester,
 3-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-55-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]
 (2-methylpropyl)amino]-1-[[4-
 hydroxyphenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-30-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]
 (phenylmethyl)-3-[[[(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-39-8 CAPLUS
 CN 2,5-Dioxo-10,14-diaza-3-phosphapentadecan-15-oic acid,
 12-hydroxy-10-[[[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-1-phenyl-3-
 (phenylmethoxy)-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester, 3-oxide, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—Ph

RN 622865-56-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]
 (2-methylpropyl)amino]-1-[[4-2-(dimethylamino)ethoxy]phenyl]methyl]-
 2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


Ph

RN 622865-61-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Ph

RN 622865-62-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-87-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-89-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[diethoxyphosphinyl]methoxy]phenyl]methyl]-3-[[[(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-92-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[diethoxyphosphinyl]methyl]phenyl]amino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-97-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methyl]phenyl]amino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-98-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(phosphonomethyl)phenyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-08-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-09-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminophenyl)methyl]-3-[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

— Ph


RN 622866-15-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminophenyl)methyl]-2-hydroxy-3-[[4-(2-methylpropyl)oxy]phenyl]sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-33-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-[(2-methylpropyl)oxy]phenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-13-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622866-34-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-1-[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-37-9 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)oxy]phenyl]sulfonyl]amino]butyl]phenyl]-, C-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-38-0 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-4-[[4-[(diphenoxyphosphinyl)methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-2-[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-39-1 CAPLUS
 CN Carbamic acid,
 [4-[[2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-[[hydroxyphenoxyposphinyl)methoxy]phenyl]sulfonyl]amino]butyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-40-4 CAPLUS
 CN L-Alanine,
 N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[[4-[[phenylmethoxy]carbonyl]amino]phenyl]butyl]amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Ph


RN 622866-67-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[bis(phenylmethoxy)phosphinyl]methoxy]-4-methoxyphenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-71-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[[4-[[hydroxyphenoxyposphinyl]methoxy]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-76-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[[diphenoxyposphinyl]methoxy]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622866-59-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622866-79-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[[hydroxy(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[4-methoxyphenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-80-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[ethoxy(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 622866-81-3 CAPLUS

CN Carbamic acid,
[(1S,2R)-1-[[4-[(ethoxyhydroxyphosphinyl)methoxy]phenyl]methyl]-
2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-
-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 622866-87-9 CAPLUS

CN Carbamic acid,
[(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
2-hydroxy-3-[[4-(4-nitrophenyl)sulfonyl]amino]propyl]-
-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 622867-02-1 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-03-2 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 622867-22-5 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-23-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

PAGE 1-A



PAGE 1-B

Ph

RN 622867-25-8 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 622867-24-7

CMF C43 H59 N4 O13 P 5

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 622867-27-0 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-(phenylmethoxy)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Ph


RN 622867-31-6 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl] (phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-32-7 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinyl)sulfonyl]amino]butyl]phenoxy]methyl] (phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-33-8 CAPLUS

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 622867-30-5 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-

methylpropyl] (phenyl)sulfonyl]amino]butyl]phenoxy]methyl] (phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622867-37-2 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[[[4-[(2R,3S)-4-[[[4-[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-37-2 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[[[4-[(2R,3S)-4-[[[4-[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


-OBu-t

RN 622867-38-3 CAPLUS

CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, (1R,2S)-3-[4-[[[(1S)-2-ethoxy-

1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-49-6 CAPLUS

CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


-OEt

RN 622867-79-2 CAPLUS

CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy)[2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-

hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-84-9 CAPLUS

CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy)[2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-

hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, propyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-71-4 CAPLUS


CN Propanoic acid, 2-[[[(2-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isquinolinyloxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-89-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2S)-2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-1-oxopropoxy]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-8



RN 622867-97-4 CAPLUS
 CN Carbamic acid, [1S,2R]-1-[[[1-[[bis(phenylmethoxy)phosphinyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-15-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[3-(acetyloxy)-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-29-5 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-32-0 CAPLUS
 CN Propanoic acid, 2-[[[3-formylphenoxy][4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-16-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[3-hydroxy-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-17-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[3-hydroxy-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-64-8 CAPLUS
 CN Carbamic acid, [1S,2R]-1-[[[4-[[bis(2,2,2-trifluoroethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-65-9 CAPLUS
 CN Carbamic acid, [1S,2R]-2-hydroxy-1-[[[4-[[hydroxy(2,2,2-trifluoroethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-68-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-69-3 CAPLUS
 CN Benzoic acid, 3-[[[1S]-2-ethoxy-1-methyl-2-oxoethoxy][4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 622868-86-4 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 622868-85-3
 CMF C43 H60 N3 O13 P 5

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 622868-70-6 CAPLUS
 CN Propanoic acid, 2-[[[1S]-[1,3-dimethylethoxy]carbonyl]amino]methyl]phenoxyl[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 622868-89-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[[bis(phenylmethoxy)phosphinyl]methoxy]ethoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-91-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[[diphenoxyphosphinyl]methoxy]ethoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 622868-92-2 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B


—OEt
RN 622868-94-4 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenylmethoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-98-8 CAPLUS
CN Carbanic acid, [(1S,2R)-1-[[5-[(diethoxyphosphinyl)methoxy]-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622869-05-0 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[(triethylsilyl)oxy]butyl]amino]methyl]phenyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




PAGE 1-A

—OEt
RN 622868-97-7 CAPLUS
CN Carbanic acid, [(1S,2R)-1-[[5-[(diethoxyphosphinyl)methoxy]-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622869-06-1 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]amino]methyl]phenyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-07-2 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methylamino]methyl]phenyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-11-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[2-[(hydroxyphenoxyphosphinyl)methoxy]ethoxy]phenyl]methyl]-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-13-0 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-01-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[1-[2-[bis(phenylmethoxy)phosphinyl]ethyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-02-7 CAPLUS
 CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-17-4 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-6-[[4-[[[(1S)-1-methyl-2-(1-methylethoxy)-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]methyl]-1-phenyl-3-(phenylmethoxy)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-99-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-54-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-56-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622871-60-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-3-[[4-(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-64-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl

1)methyl]-2-hydroxy-3-[(2-methylpropyl)[[4-(trifluoromethyl)phenyl]sulfonyl
 1)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-65-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl


1)methyl]-2-hydroxy-3-[(2-methylpropyl)[[4-(trifluoromethoxy)phenyl]sulfonyl

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-76-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-2-hydroxy-3-[(2-methylpropyl)[[4-(4-oxido-3-
 pyridinyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-81-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]-1-(4-pyridinylmethyl)propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-69-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-2-hydroxy-3-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]propyl]-
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 622871-71-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-
 pyridinylsulfonyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-,
 ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622871-82-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(4-formylphenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy)methyl]phenoxyphosphinyl]oxy
]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-83-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-3-[[4-(4-formylphenyl)sulfonyl](2-methylpropyl)amino]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-84-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 (hydroxymethyl)phenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]
 phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




```

RN      622871-88-9 CAPLUS
CN      Carbamic acid,
[[15,2R)-1-[[4-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
1-methyl]-2-hydroxy-3-[[[4-methyl-1-piperazinyl]sulfonyl](2-
methylpropyl)amino]propyl]- (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
ester (9CI)] CA INDEX NAME

```

Absolute stereochemistry.



IT	313679-71-9P	313682-97-2P	546085-61-6P
	546086-53-7P	546265-01-4P	546265-03-4P
	546265-05-8P	546265-06-9P	546265-07-0P
	546265-09-2P	546265-10-5P	546265-11-6P
	546265-12-7P	546265-13-8P	546265-14-9P
	546265-18-5P	546265-29-6P	546265-31-0P
	546265-32-1P	546265-40-1P	546265-46-7P
	546265-51-4P	546265-54-7P	546265-57-0P
	546265-63-8P	546265-75-2P	546265-79-6P
	546265-83-2P	546265-88-7P	546265-90-0P
	546265-93-4P	546266-19-0P	546266-02-8P
	546266-10-8P	546266-22-2P	546266-16-9P
	546266-17-5P	546266-33-0P	546266-19-7P
	546266-58-8P	546266-60-8P	546266-60-6P
	546266-69-7P	546266-70-0P	546266-72-2P

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622866-73-3P	622866-74-1P	622866-82-4P
622866-88-0P	622866-89-1P	622866-90-1P
622866-94-8P	622867-00-9P	622867-01-3P
622867-05-4P	622867-06-5P	622867-13-4P
622867-14-5P	622867-15-6P	622867-16-7P
622868-08-8P	622867-17-2P	622867-62-2P
622867-72-2P	622867-73-6P	622867-74-7P
622867-85-0P	622867-86-1P	622867-90-7P
622867-91-8P	622867-92-9P	622868-03-5P
622868-20-6P	622868-21-7P	622868-22-2P
622868-23-9P	622868-24-0P	622868-26-2P
622868-27-3P	622868-30-5P	622868-33-1P
622868-34-4P	622868-35-6P	622868-36-7P
622868-51-3P	622868-53-5P	622868-60-4P
622868-61-5P	622868-62-6P	622868-63-7P
622868-66-0P	622868-71-7P	622868-72-8P
622868-73-9P	622868-74-7P	622868-75-8P
622868-76-2P	622868-77-3P	622868-78-4P
622868-79-5P	622868-80-8P	622868-83-1P
622868-84-6P	622868-85-9P	622868-86-0P
622868-93-3P	622868-08-3P	622869-10-7P
622869-14-1P	622870-52-4P	622870-53-5P
622870-54-6P	622870-55-7P	622870-56-8P
622870-57-9P	622870-58-0P	622870-59-1P
622870-60-4P	622870-61-5P	622870-62-6P
622870-63-7P	622870-64-8P	622870-65-9P
622870-66-0P	622870-67-9P	622870-68-0P
622870-69-3P	622870-70-6P	622870-71-7P
622870-75-1P	622870-76-2P	622870-77-3P
622870-78-4P	622870-79-5P	622870-80-8P
622870-81-9P	622870-82-0P	622870-83-1P
622870-84-2P	622870-85-3P	622870-86-4P
622870-87-5P	622870-88-6P	622870-89-7P
622870-90-0P	622870-91-8P	622870-92-9P
622870-94-4P	622870-95-5P	622870-96-6P
622870-97-8P	622870-98-8P	622871-00-5P
622871-03-8P	622871-04-9P	622871-05-0P
622871-06-1P	622871-07-2P	622871-08-3P
622871-09-4P	622871-10-7P	622871-11-8P
622871-12-9P	622871-13-9P	622871-14-1P
622871-16-5P	622871-17-2P	622871-18-3P
622871-18-5P	622871-19-6P	622871-20-9P
622871-21-0P	622871-22-1P	622871-23-2P
622871-24-3P	622871-45-8P	622871-46-9P
622871-47-0P	622871-48-1P	622871-49-2P
622871-50-5P	622871-51-6P	622871-52-7P
622871-53-8P	622871-54-9P	622871-55-0P
622871-58-3P	622871-59-4P	622871-60-5P
622871-62-9P	622871-63-0P	622871-66-3P
622871-67-4P	622871-68-5P	622871-70-9P
622871-72-1P	622871-73-2P	622871-74-3P
622871-75-4P	622871-77-6P	622871-78-7P
622871-79-8P	622871-80-1P	622871-85-6P
622871-81-2P	622871-82-3P	622871-83-5P
622871-90-3P	622871-91-4P	622871-92-5P
622871-93-6P	622871-94-7P	622871-95-8P


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

ANSWER 9 OF 51 CARLOS COPYRIGHT 2007
622871-96-9P 622871-97-0P 622871-98-1P
622871-99-2P 622872-00-8P 623158-38-3P
623158-39-4P 623158-40-7P 623158-44-1P
623158-45-2P 623158-46-3P 623158-47-4P
623158-49-6P 623158-51-0P 623158-55-4P
623158-56-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protease inhibitor; prepn. of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN 313679-71-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313682-97-2 CAPLUS
CN Carbamic acid,
[[1S,2R]-3-[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
2-hydroxy-1-[[4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-61-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (SCI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-53-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](phenylmet
hy)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-01-4 CAPLUS
 CN Carbamic acid,
 N-[([1S,2R]-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl
]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-
 (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-03-6 CAPLUS
 CN 2,4,6,8-Tetraoxa-5-phosphonanedioic acid, 5-[[4-[(2S,3R)-2-
 [[[(4,3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-
 hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]
 methyl-1, bis(1-methylethyl) ester, 5-oxide (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 622865-05-8 CAPLUS
CN Glycine,
N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-06-9 CAPLUS
CN Glycine,
N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-10-5 CAPLUS
CN 8-Oxa-3,5-diaza-4-phosphadecanoic acid, 2,6-diethyl-4-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, butyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-11-6 CAPLUS
CN L-Leucine,
N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-07-0 CAPLUS
CN L-Alanine,
N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-09-2 CAPLUS
CN 8-Oxa-3,5-diaza-4-phosphadecanoic acid, 2,6-diethyl-4-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-12-7 CAPLUS
CN L-Leucine,
N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-13-8 CAPLUS
CN L-Phenylalanine, N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-14-9 CAPLUS
 CN L-Phenylalanine, N,N'-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-28-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-phosphonophenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-32-1 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-40-1 CAPLUS
 CN 3-Oxa-8,12-diaza-1-phosphatridecan-13-oic acid, 1,1,10-trihydroxy-8-[[4-methoxyphenyl)sulfonyl]-6,6-dimethyl-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (10R,11S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-29-6 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[[4-(diethoxyphosphinyl)phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-31-0 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-46-7 CAPLUS
 CN 3-Oxa-7,11-diaza-1-phosphadodecan-12-oic acid, 1,1,9-trihydroxy-7-[[4-methoxyphenyl)sulfonyl]-5,5-dimethyl-10-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (9R,10S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-51-4 CAPLUS
 CN 10,13-Dioxa-2,6-diaza-12-phosphapentadecanoic acid, 12-ethoxy-4-hydroxy-6-[[4-methoxyphenyl)sulfonyl]-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 12-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622865-54-7 CAPLUS


CN Carbamic acid,

[(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl

1)methyl]-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— Ph

RN 622865-57-0 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl

yl]sulfonyl] (2-methylpropyl)amino)-1-[[4-[2-(dimethylamino)ethoxy]phenyl]m

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-63-8 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[4-[[diethoxyphosphinyl]methoxy]phenyl]sulfonyl

1] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-75-2 CAPLUS

CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]-2,6-dimethyl-7-oxo-, ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-79-6 CAPLUS

CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-,

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ethyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 622865-56-9

CMF C46 H60 N3 O12 P S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— Ph


CM 2

CRN 75-75-2

CMF C H4 O3 S

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ethyl ester, 4-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-83-2 CAPLUS

CN Acetic acid,

[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-88-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[4-[(1-formyl-4-piperidinyl)methyl] [(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-90-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
 2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(1-methyl-4-
 piperidinyl)methyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-93-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methyl]phenyl]methylam-
 ino]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(2-
 methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-02-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]-1-
 piperidinyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(2-
 methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-10-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl
 1]-(2-methylpropyl)amino]-1-[[4-(dimethylamino)phenyl]methyl]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-A


PAGE 2-A



RN 622865-99-0 CAPLUS
 CN L-Alanine, N,N'-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]butyl]amino]phenyl]methyl]pho-
 sphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-14-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminophenyl)methyl]-3-[[4-
 [[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl]-(2-
 methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—Ph

RN 622866-16-4 CAPLUS
 CN L-Alanine, N,N'-[[[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenoxy)methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622866-17-5 CAPLUS
CN L-Valine,
N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-18-6 CAPLUS
CN L-Valine,
N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-19-7 CAPLUS
CN Glycine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-58-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-60-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-68-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-methoxyphenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-69-7 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxy-3-(phosphonomethoxy)phenyl]sulfonyl] (2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-70-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-hydroxyphenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-72-2 CAPLUS

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Propanoic acid, 2-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622866-73-3 CAPLUS
 CN L-Alanine,
 N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622866-74-4 CAPLUS
 CN L-Alanine, N,N'-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




RN 622866-82-4 CAPLUS

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid,
 [(1S,2R)-1-[[4-[[ethoxyphenoxyphosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-88-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[[diethoxyphosphinyl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-89-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(ethylamino)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-90-4 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-94-8 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-00-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-01-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-13-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenyl)sulfonyl]amino]-1-[[4-(trifluoromethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-14-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-05-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-06-5 CAPLUS
 CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-2,6,9-trimethyl-7-oxo-, 1-methylethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-15-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(formylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-16-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxymethyl)phenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-17-8 CAPLUS


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, {[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-(4-morpholinylmethyl)phenyl)sulfonyl]amino]-1-[(4-(phosphonomethoxy)phenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-50-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[(triethylsilyl)oxy]butyl]methylamino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


CO₂H

RN 622867-73-6 CAPLUS
 CN Carbamic acid, {[(1S,2R)-1-[(4-(2-(diethoxyphosphinyl)ethyl)-3,6-dihydro-1(2H)-pyridinyl)methyl]-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622867-61-2 CAPLUS
 CN Propanoic acid, 2-[[[2-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-72-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-80-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[(2,6-dimethylphenoxy)[2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-79-2
 CMF C44 H62 N3 O13 F S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-85-0 CAPLUS
 CN Propanoic acid, 2-[[[4-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, propyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-84-9
 CMF C45 H64 N3 O13 P S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622867-91-8 CAPLUS
 CN Propanoic acid, 2-[[[4-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-92-9 CAPLUS
 CN Propanoic acid, 2-[[[4-(dimethylamino)oxy][4-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622867-86-1 CAPLUS
 CN Propanoic acid, 2-[[[4-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]phosphinyl]oxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-90-7 CAPLUS
 CN Propanoic acid, 2-[[[4-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]phosphinyl]oxy]-, 2-(1-methyl-4-piperidinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-03-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[1-(2-(dimethoxyphosphinyl)ethyl)-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-20-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(dimethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-21-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(1-methylethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-22-8 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-26-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-(4-morpholinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-23-9 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-24-0 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622868-27-3 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-30-8 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-33-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-37-5 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-51-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-53-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-46-6 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-47-7 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-60-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl][3-(4-morpholinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-61-5 CAPLUS
 CN Carbamic acid, [[1S,2R]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[(2-phosphonoethyl)amino]phenyl]methyl]propyl]-C-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-62-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-36-1
 CMF C42 H58 N3 O13 P 8

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622868-71-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-72-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-63-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-66-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-73-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A




RN 622868-74-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 622868-75-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622868-77-3 CAPLUS
 CN Benzoic acid, 3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-78-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622868-76-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-(1-methyl-4-piperidinyl)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN piperidinyloxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-83-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[6-[(diethoxyphosphinyl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-85-3 CAPLUS

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 622868-93-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


—OEt

RN 622869-08-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methyl]amino]methyl]phenyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-87-5 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-90-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(2-(phosphonomethoxy)ethoxy]phenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-10-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-14-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-1-(phenylmethyl)-2-(phosphonoxy)-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 Na

RN 622870-52-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[(methoxyphenoxyphosphinyl)methoxy]
]phenyl]methyl]-3-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-53-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-
 methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
 C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-56-8 CAPLUS
 CN Acetic acid,
 [[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-,
 butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-57-9 CAPLUS
 CN L-Alanine, N-[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-,
 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-54-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethylphosphinyl)methoxy]phenyl]methyl]-2-
 hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-55-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
 C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-58-0 CAPLUS
 CN L-Alanine, N-[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-,
 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-59-1 CAPLUS
 CN D-Alanine,
 N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-,
 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-60-4 CAPLUS
 CN D-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-61-5 CAPLUS
 CN D-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-62-6 CAPLUS
 CN L-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-63-7 CAPLUS
 CN L-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-64-8 CAPLUS
 CN Butanoic acid, 2-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]amino-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-65-9 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]amino-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-66-0 CAPLUS
 CN Butanoic acid, 2-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]amino-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-67-1 CAPLUS
 CN Butanoic acid, 2-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]amino-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-68-2 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622870-69-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622870-71-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 3-(4-morpholinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



RN 622870-75-1 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-3-methyl-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-70-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



RN 622870-76-2 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-3-methyl-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-77-3 CAPLUS
 CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-2,2-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-78-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, 3-(4-morpholinyl)propyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622870-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-81-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 622870-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622870-82-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-83-1 CAPLUS
 CN Propanoic acid, 2-[[[3-(aminomethyl)phenoxy]4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy)methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-84-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-[(1-piperidinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622870-85-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-[(2-methoxyethyl)methylamino]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-86-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[5-oxido-10-phenyl-5-[2-(phenylmethoxy)ethoxy]-3,6,9-trioxo-5-phosphadec-1-yl]oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B



RN 622870-87-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-2-[(diethoxyphosphinyl)methoxy]ethoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-88-6 CAPLUS
 CN Propanoic acid, 2-[[[2-4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B

-CO₂H

RN 622870-89-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[(diethoxyphosphinyl)ethyl]amino]methyl]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-90-0 CAPLUS
 CN Butanoic acid, 2-[[[2-ethylphenoxy][2-[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-92-2 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-93-3 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]methylamino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622870-96-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[(diethoxyphosphinyl)ethyl]-1-piperazinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-97-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[1,2,3,6-tetrahydro-1-(phosphonomethyl)-4-pyridinyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-94-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[methyl(2-phosphonoethyl)amino]methyl]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-95-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[[(diethoxyphosphinyl)methoxy]imino]methyl]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622870-98-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[1-[(diethoxyphosphinyl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-00-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-03-8 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-04-9 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[1,2,3,6-tetrahydro-1-(2-phosphonoethyl)-4-pyridinyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-05-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 622871-07-2 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]amino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-06-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methylamino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-08-3 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[4-(phosphonophenyl)methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-09-4 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]methylamino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-10-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]-1-[[methyl(4-phosphonophenyl)methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-11-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[3,4-dihydro-6-(phosphonomethoxy)-2(1H)-isoquinoliny]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-14-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-15-2 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-12-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]-1-[[4-[(phosphonomethyl)amino]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-13-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[[diethoxyphosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-16-3 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-17-4 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-18-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[4-((2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl]amino]butyl]phenyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-19-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]amino]-1-[[4-methylphenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-22-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-23-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-20-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)ethyl]amino]-2-hydroxy-1-[[4-(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-21-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)ethyl]amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-24-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[3-hydroxy-2,2-dimethylpropyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-45-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622871-46-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
 3-[[4-[(ethylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-
 , (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 622871-47-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622871-48-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
 C-1[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 622871-49-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-,
 C-1[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622871-50-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[4-[(3-aminophenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-51-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[4-[(3-aminophenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622871-52-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[4-[(3-aminophenyl)sulfonyl](2-
 methylpropyl)amino]-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-53-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
 2-hydroxy-3-[[4-[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-55-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]-2-[(phenylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-57-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]-2-[(phenylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-61-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-fluorophenyl]sulfonyl]-(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-62-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-fluorophenyl]sulfonyl]-(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-58-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]-2-[(phenylsulfonyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-59-4 CAPLUS
 CN Carbamic acid, 1-[(1S,2R)-3-[[[4-fluorophenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-63-0 CAPLUS
 CN Carbamic acid, 1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-66-3 CAPLUS
 CN Carbamic acid, 1-[(1S,2R)-1-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[4-cyanophenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-67-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(4-(1-piperidinyl)phenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-68-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(4-(1-piperidinyl)methyl]phenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-73-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinyl)sulfonyl]amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-74-3 CAPLUS
 CN Pyridinium, 3-[[[4-[(2R,3S)-4-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]1-3-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-70-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(3-pyridinyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-72-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-75-4 CAPLUS
 CN Pyridinium, 3-[[[4-[(2R,3S)-4-[[4-[[[1S]-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[4-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-77-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(3-pyridinyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-77-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(3-pyridinyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622871-78-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(1-oxido-3-pyridinyl)sulfonyl]amino]butyl]phenoxy[methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-79-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(1-oxido-3-pyridinyl)sulfonyl]amino]butyl]phenoxy[methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-80-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(1-oxido-3-pyridinyl)sulfonyl]amino]butyl]phenoxy[methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-87-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-


b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(4-(4-morpholinyl)methyl)phenyl)sulfonyl]amino]butyl]phenoxy[methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-89-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-hydroxy-4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 622871-85-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-(hydroxymethyl)phenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy[methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-86-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[(4-(4-morpholinyl)methyl)phenyl)sulfonyl]amino]butyl]phenoxy[methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622871-90-3 CAPLUS
 CN L-Alanine,

N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl][2-methylpropyl]amino]sulfonyl]phenoxy[methyl]hydroxyphosphinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CO₂H

RN 622871-91-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[(diphenoxyposphinyl)methoxy]phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-92-5 CAPLUS


L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbanic acid, [(1S,2R)-1-[(4-(2-hydroxyphenyl)methyl)-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-93-6 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[(4-(2-(dimethylamino)ethoxy)phenyl)methyl]-2-hydroxy-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-94-7 CAPLUS
 CN L-Alanine, N-[(R)-[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622871-96-9 CAPLUS
 CN L-Alanine, N-[(R)-[4-[[[(2R,3S)-4-(4-(ethylamino)phenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



(Continued)

PAGE 1-A

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-B



RN 622871-95-8 CAPLUS
 CN L-Alanine, N-[(S)-[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622871-97-0 CAPLUS
 CN L-Alanine, N-[(S)-[4-[[[(2R,3S)-4-(4-(ethylamino)phenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622871-98-1 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-(phosphonoxy)butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-(1-methylethyl) ester, disodium salt, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 622871-99-2 CAPLUS

CN D-Valine, (1R,2S)-3-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 623158-39-4 CAPLUS

CN L-Alanine, N-[[[4-[[[(2R,3S)-4-[4-(ethylamino)phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 623158-40-7 CAPLUS


CN Carbamic acid, 1-[[[(1S,2R)-1-[4-[(diethoxyphosphinyl)methyl]phenyl]methyl]-2-

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622872-00-8 CAPLUS

CN D-Valine, [4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623158-38-3 CAPLUS

CN L-Alanine, N-[[[4-[[[(2R,3S)-4-[4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623158-44-1 CAPLUS


CN Pyridinium, 3-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-75-4

CMF C39 H53 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 37181-39-8

CMF C F3 O3 S

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 623158-45-2 CAPLUS

CN Pyridinium,

3-[[[(2R,3S)-4-[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl


1]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-74-3

CMF C42 H53 N3 O11 P S

Absolute stereochemistry.



CM 2

CRN 37181-39-8

CMF C F3 O3 S



RN 623158-46-3 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methyl-1-

piperazinyl]phenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phe

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 623158-49-6 CAPLUS


CN L-Valine, [4-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 623158-48-5

CMF C45 H62 N3 O15 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 623158-51-0 CAPLUS

CN L-Valine, (1R,2S)-3-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]propyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 623158-50-9


CMF C45 H62 N3 O15 P S

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

noxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623158-47-4 CAPLUS

CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-, 2-hydroxyethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

OH

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 623158-55-4 CAPLUS

CN Propanoic acid, 2-[[[2-ethoxyphenoxy](2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 623158-55-4 CAPLUS

CN Propanoic acid, 2-[[[2-ethoxyphenoxy](2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 623158-54-3

CMF C44 H62 N3 O14 P S

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 623158-56-5 CAPLUS
CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyloxy]-2,2-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:612062 CAPLUS
DN 143:139156
TI Self-microemulsifying drug delivery systems of a HIV protease inhibitor
IN Vootsopoulos, Jody Firmin Marceline
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 47 pp.
CODEN: P1XXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005063209	A1	20050714	WO 2004-EP53700	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004308712	A1	20050714	AU 2004-308712	20041223
CA 2549462	A1	20050714	CA 2004-2549462	20041223
EP 1715847	A1	20061102	EP 2004-805027	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
PRAI EP 2003-104959	A	20031223		
US 2004-565451P	P	20040426		
WO 2004-EP53700	W	20041223		

AB The present invention relates to pharmaceutical formulations of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[[4-(aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]carbamate (I), salts, esters, polymorphic and pseudopolymorphic forms thereof, which are self-microemulsifying drug delivery systems and comprise as carrier a lipophilic phase, one or more surfactants, a hydrophilic solvent and a nucleation inhibitor. A self-microencapsulating system for hard gelatin capsules comprised I ethanolate, Cremophor RH40, FVP, and diethylene glycol monoethyl ether.

IT 635728-39-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study);


USES
(Uses)
(self-microemulsifying drug delivery systems of a HIV protease inhibitor)

RN 635728-39-1 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, compd. with ethanol (9CI) (CA INDEX NAME)

CM 1

CRN 206361-99-1
CMF C27 H37 N3 O7 S

L7 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




CM 2

CRN 64-17-5
CMF C2 H6 O

H3C-CH2-OH


RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:589363 CAPLUS
 DN 143:248118
 TI Synthesis and antiviral activities of novel
 N-alkoxy-arylsulfonamide-based
 HIV protease inhibitors
 AU Sherrill, Ronald G.; Furfine, Eric S.; Hazen, Richard J.; Miller, John
 F.:
 Reynolds, David J.; Sammond, Douglas M.; Spaltenstein, Andrew; Whealan,
 Pat; Wright, Lois L.
 CS GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(15), 3560-3564
 CODEN: BMCL68; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 143:248118
 GI




AB A series of N-alkoxy-arylsulfonamide HIV protease inhibitors, e.g., I, with low picomolar enzyme activity and single digit nanomolar antiviral activity is disclosed.
 IT 252871-23-1P 252871-64-0P 252871-84-4P
 252872-15-4P 252872-16-5P 252872-30-3P
 252872-31-4P 252872-32-5P 252872-33-6P
 252872-38-1P 252872-48-3P 252872-53-0P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 and (preparation, antiviral activity, HIV protease inhibitory activity, structure-activity relationship of N-alkoxy arylsulfonamide derivs. starting from alkoxyamines, phenylalanine-epoxide, and arylsulfonfyl chlorides)
 RN 252871-23-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(4-hydroxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252872-15-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](cyclopentylloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-16-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-30-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](cyclohexyloxy)amino]-

L7 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 252871-64-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252871-84-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-31-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](cyclohexyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-32-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](cyclohexyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252872-33-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(cyclohexyloxy)[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-38-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyloxy)[(4-hydroxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252872-46-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-aminophenyl)sulfonyl](cyclohexyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-53-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-aminophenyl)sulfonyl](cyclohexyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:589326 CAPLUS
 DN 143:267225
 TI Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles
 AU Miller, John F.; Brieger, Michael; Furfine, Eric S.; Hazen, Richard J.; Kaldor, Istvan; Reynolds, David; Sherrill, Ronald G.; Spaltenstein, Andrew
 CS GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(15), 3496-3500
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 143:267225
 AB A novel series of tyrosine-derived HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and two protease inhibitor-resistant viruses. All of the compds. had wild-type antiviral activities that were similar to or greater than several currently marketed HIV protease inhibitors. In addition, a number of compds. in this series were more potent against the drug-resistant mutant viruses than they were against wild-type virus.
 IT 313680-07-8P 313680-24-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles)
 RN 313680-07-8 CAPLUS
 CN Carbamic acid, [2-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-24-9 CAPLUS
 CN Carbamic acid, [3-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]propyl]-, methyl ester (9CI)

L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.




IT 313680-01-2P 313680-03-4P 313680-05-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of P1 chain-extended HIV protease inhibitors possessing

potent anti-HIV activity and remarkable inverse antiviral resistance profiles)

RN 313680-01-2 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-(2-aminoethoxy)phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-03-4 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-(3-aminopropoxy)phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-08-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-[(methylsulfonyl)amino]ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-10-3 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[3-(acetylamino)propoxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-11-4 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[4-(acetylamino)butoxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-05-6 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminobutoxy)phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 313680-06-7P 313680-08-9P 313680-10-3P
313680-11-4P 313680-25-0P 313680-32-9P
313680-33-0P 313680-34-1P 313680-35-2P
313680-36-3P 313680-38-5P 313680-40-9P
313681-90-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of P1 chain-extended HIV protease inhibitors possessing


potent anti-HIV activity and remarkable inverse antiviral resistance profiles)

RN 313680-06-7 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-(2-(acetylamino)ethoxy)phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-25-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-[(methylsulfonyl)amino]ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-32-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(methylsulfonyl)amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 313680-33-0 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(methylsulfonyl)amino]butoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-34-1 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-1-[[4-[2-[(dimethylamino)carbonyl]amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-35-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-1-[[4-[3-[(dimethylamino)carbonyl]amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-40-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-2-hydroxy-1-[[4-[(methylamino)carbonyl]amino]butoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-90-2 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-2-hydroxy-1-[[4-[2-[(methylamino)carbonyl]amino]ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-36-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-1-[[4-[(dimethylamino)carbonyl]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-38-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(methylamino)carbonyl]amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 313679-55-9P 313679-57-1P 313680-00-1P

313680-02-3P 313680-04-5P

RL: RCT (Reactant); SPH (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of PI chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles)

RN 313679-55-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313679-57-1 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-2-hydroxy-1-[[4-(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-00-1 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

methylpropyl)amino]-1-[[4-[2-[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-02-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-04-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:527407 CAPLUS

DN 143:59982

TI Preparation of HIV protease inhibitors, in particular imidazolidine derivatives

IN Flentge, Charles A.; Chen, Hui-Ju; DeGoey, David A.; Flosi, William J.; Gramovnik, David J.; Huang, Peggy P.; Kempf, Dale J.; Klein, Larry L.; Krueger, Allan C.; Madigan, Darold L.; Randolph, John T.; Sun, Minghua; Yeung, Ming C.; Zhao, Chen

FA USA

SO U.S. Pat. Appl. Publ., 287 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005131042	A1	20050616	US 2003-733915	20031211
CA 2549389	A1	20050707	CA 2004-2549389	20041110
WO 2005061450	A2	20050707	WO 2004-US37745	20041110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1709037	A2	20061011	EP 2004-810802	20041110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRAI US 2003-733915	A	20031211		
WO 2004-US37745	W	20041110		
OS MARPAT 143:59982				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. of formula ANH(CHR)(CHR1)(CHR2)NR3S(O2)R4 (I) [wherein A = alkylcarbonyl, arylsulfonyl, 1,3-substituted 2-oxoimidazolidinyl, 2,4-dioxoimidazolidinyl, etc.; X, Y = independently O, S, NH; R = (un)substituted alk(en)yl, cycloalk(en)yl, hetero/arylalkyl, etc.; R1 = and derivs., OPO3H and derivs., OSO2H and derivs., etc.; R2 = H; R3 = halo/alkyl, halo/alkenyl, (un)substituted cycloalk(en)yl, aryl; R4 = (un)substituted cycloalk(en)yl, heterocyclyl, hetero/aryl] were prepared

as HIV protease inhibitors. For example, II was prepared, in 62% yield, by coupling acid III (preparation given) with amine IV (preparation given). I showed antiviral activity against Wild-Type HIV with EC50 in the range of 1 nM to 100 nM.

IT 854742-01-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L7 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Antiviral agent; prepn. of HIV protease inhibitors, in particular imidazolidine derivs.)

RN 854742-01-1 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L7 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AN 2005-451646 CAPLUS
 DN 143:1225
 TI Methods and enzymes including hydrolase GS-7340 involved in prodrug activation for identifying anti-AIDS agents and other therapeutic compounds
 IN McDermott, Martin
 PA Gilead Sciences, Inc., USA
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005047898	A2	20050526	WO 2004-US35083	20041022
WO 2005047898	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004290298	A1	20050526	AU 2004-290298	20041022
CA 2543294	A1	20050526	CA 2004-2543294	20041022
US 2005136397	A1	20050623	US 2004-970389	20041022
EP 1678322	A2	20060712	EP 2004-816931	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007508843	T	20070412	JP 2006-536834	20041022
PRAI US 2003-513532P	P	20031024		
US 2003-513542P	P	20031024		
US 2003-514241P	P	20031024		
US 2003-514299P	P	20031024		
US 2003-514894P	P	20031029		
US 2003-514925P	P	20031029		
WO 2003-US312943	A2	20030425		
WO 2004-US35083	W	20041022		

AB The present invention includes identification of enzymes responsible for prodrug activation and their utilization in the identification of candidate compds. as prodrugs. Methods for identifying a candidate compound


as a suitable prodrug as well as methods of screening candidate compds. for suitability as therapeutic agents are presented. The methods are especially

useful for screening inhibitors of e.g. GS-9005 ester hydrolase A, hydrolase GS-7340, HIV protease, HIV integrase or HIV reverse transcriptase to screen for HIV, inflammation and cancer therapeutics.

IT 622866-97-1 851456-06-9 851456-08-1
 852238-87-0
 RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

L7 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AN 2005-451646 CAPLUS
 DN 142:462296
 TI Enzymes involving in prodrug activation for identifying therapeutic or anti-HIV agents
 IN McDermott, Martin
 PA Gilead Sciences, Inc., USA
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 8

Absolute stereochemistry.




PAGE 1-B

—OPr-i

RN 852238-87-0 CAPLUS
 CN 2-Propenoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (methods and enzymes including hydrolase GS-7340 involved in prodrug activation for identifying anti-AIDS agents and other therapeutic compounds.)


RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851456-06-9 CAPLUS
 CN L-Alanine, N-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851456-08-1 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005-409699 CAPLUS
 DN 142:462296
 TI Enzymes involving in prodrug activation for identifying therapeutic or anti-HIV agents
 IN McDermott, Martin
 PA Gilead Sciences, Inc., USA
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 8

Absolute stereochemistry.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005042772	A1	20050512	WO 2004-US35084	20041022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004286238	A1	20050512	AU 2004-286238	20041022
CA 2543142	A1	20050512	CA 2004-2543142	20041022
US 2005136396	A1	20050623	US 2004-970388	20041022
EP 1680512	A1	20060719	EP 2004-796134	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007508844	T	20070412	JP 2006-536835	20041022
PRAI US 2003-513532P	P	20031024		
US 2003-513542P	P	20031024		
US 2003-514241P	P	20031024		
US 2003-514299P	P	20031024		
US 2003-514894P	P	20031029		
US 2003-514925P	P	20031029		
WO 2004-US35084	W	20041022		

AB By the present invention, enzymes responsible for prodrug activation are identified and utilized for the identification of candidate compds. as prodrugs. The present invention includes methods for identifying a candidate compound as a suitable prodrug as well as methods of screening candidate compds. for suitability as therapeutic agents. The methods are especially useful for screening inhibitors of e.g. GS-9005 ester

hydrolase A, prolylcarboxypeptidase, HIV protease, HIV integrase or HIV reverse transcriptase.

IT 622866-97-1 622867-36-1 851456-06-9
 851456-07-0 851456-08-1

RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(enzymes involving in prodrug activation for identifying therapeutic or anti-HIV agents)

RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

or anti-HIV agents

RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

or anti-HIV agents


RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

or anti-HIV agents

L7 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-36-1 CAPLUS

CN Propanoic acid,
2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851456-06-9 CAPLUS


CN L-Alanine, N-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
NAME)

Absolute stereochemistry.



PAGE 1-B

—OPR-i

IT 622870-91-1P 851456-01-4P 851456-02-5P
851456-03-6P

RI: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation);
BSU (Biological study, unclassified); ANST (Analytical study); BIOL
(Biological study); PREP (Preparation)
(enzymes involving in prodrug activation for identifying therapeutic

or


anti-HIV agents)

RN 622870-91-1 CAPLUS


CN Propanoic acid,
2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851456-07-0 CAPLUS

CN L-Alanine, N-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—OPR-i

RN 851456-08-1 CAPLUS

CN Propanoic acid,
2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 851456-01-4 CAPLUS

CN Propanoic acid,
2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851456-02-5 CAPLUS

CN Carbamic acid, [[1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[[[2-[[[4S)-4-methyl-2-oxido-5-oxo-1,3,2-dioxaphospholan-2-yl]ethyl]amino]methyl]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851456-03-6 CAPLUS

CN Carbamic acid, [[1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[[[4-[[[7S)-tetrahydro-2-hydroxy-7-methyl-2-oxido-6-oxo-1,5,2-oxazaphosphepin-5(2H)-yl]methyl]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:300421 CAPLUS
DN 142:373819
TI Methods for the preparation of aminohydroxypropyl
benzoxazolesulfonamides
as intermediates in the preparation of HIV protease inhibitors
IN De Kock, Herman Augustinus; Filliers, Walter Ferdinand Maria; Aelterman,
Wim Albert Alex
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005030739	A1	20050407	WO 2004-EP52382	20040930
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004276017	A1	20050407	AU 2004-276017	20040930
CA 2537877	A1	20050407	CA 2004-2537877	20040930
EP 1670773	A1	20060621	EP 2004-766869	20040930
EP 1670773	B1	20070207		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
HR BR 2004014916	A	20061107	BR 2004-14916	20040930
CN 1860107	A	20061108	CN 2004-80028097	20040930
AT 353323	T	20070215	AT 2004-766869	20040930
JP 2007507468	T	20070329	JP 2006-530265	20040930
NO 2006001951	A	20060502	NO 2006-1951	20060502
PRAI EP 2003-103630	A	20030930		
US 2003-507996P	P	20031002		
WO 2004-EP52382	W	20040930		
OS CASREACT 142:373819; MARPAT 142:373819				
GI				

L7 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Aminohydroxypropyl benzoxazolesulfonamides I [E = electrophilic moiety;
PG = protecting group; R2 = H, alkyl; R3 = (un)substituted cycloalkyl, aryl, heteroaryl, alkyl; R4 = H, HO2C, (un)substituted alkyl, alkoxy, carbonyl, aminocarbonyl, cycloalkyl, alkenyl, alkynyl] such as II (R5 = MeS; R6 = Me3C) are prepared as intermediates in the synthesis of HIV protease inhibitors such as II (R5 = H2N; R6 = 5-thiazolylmethyl). S-alkylation of 2-benzoxazolethione followed by regioselective sulfonylation yields an benzoxazolesulfonic acid derivative which sulfonylates an amino alc. (derived from ring opening of an epoxide with an amine) to provide I. For example, 2-mercaptobenzoxazole is methylated and the product regioselectively sulfonylated with chlorosulfonic acid and converted to the sulfonyl chloride with thionyl chloride to yield 2-(methylthio)-6-benzoxazolesulfonyl chloride. Ring opening of (1-(Boc-amino)-2-phenylethyl)oxirane (Boc = Me3COCO) with isobutylamine yields the amine PhCH2CH(NHBoc)CH(OH)CH2NHCH2CHMe2 (III). Sulfonylation of III with 2-(methylthio)-6-benzoxazolesulfonyl chloride provides II (R5 = MeS; R6 = Me3C). Heating of II (R5 = MeS; R6 = Me3C) with ammonia under pressure, cleavage of the Boc group with hydrogen chloride in isopropanol, and treatment with mono(N-hydroxysuccinimidyl) mono(5-thiazolylmethyl) carbonate yields II (R5 = H2N; R6 = 5-thiazolylmethyl).
849611-72-9P
IT RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; methods for the preparation of aminohydroxypropyl benzoxazolesulfonamides as intermediates in the preparation of HIV protease inhibitors)
RN 849611-72-9 CAPLUS
CN Carbamic acid,
[2-hydroxy-3-((2-(methylamino)-6-benzoxazolyl)sulfonyl)(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-,
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:166504 CAPLUS
 DW 142:397894
 TI Development of a capillary electrophoretic method for the separation of diastereoisomers of a new human immunodeficiency virus protease inhibitor.
 AU Leonard, Stefanie; Van Schepdael, Ann; Ivanyi, Times; Lazar, Istvan; Rosler, Jan; Vanstockem, Marc; Vermeersch, Hans; Hoogmartens, Jos
 CS Laboratorium voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Faculteit Farmaceutische Wetenschappen, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
 SO Electrophoresis (2005), 26(3), 627-632
 CODEN: ELCTDM; ISSN: 0173-0835
 PB Wiley-VCH Verlag GmbH & Co. KGaA
 DT Journal
 LA English
 AB A capillary electrophoretic (CE) method was developed for the separation of

diastereoisomers of a new human immunodeficiency virus (HIV) protease inhibitor TMC114. In total 16 isomers of this drug were synthesized (8 pairs of enantiomers). The authors succeeded in the separation of the 8 diastereoisomers, but no enantiomers could be separated. Because of the

high similarity and water-insolubility of these isomers, the separation is a real challenge. Different CE modes were tried out: capillary zone electrophoresis (CZE), nonaqueous capillary electrophoresis (NACE), micellar electrokinetic capillary chromatography (MEKC), and microemulsion electrokinetic capillary chromatography (MEEKC). Only MEEKC offered resolution of these compounds.

IT 799241-73-9, TMC 87344 799241-74-0, TMC 181568

799241-75-1, TMC 181596 850141-19-4, TMC 96606

850141-20-7, TMC 96608 850141-21-8, TMC 181603

850141-22-9, TMC 181595

RI: ANT (Analyte); PRP (Properties); ANST (Analytical study)

(capillary electrophoretic method for separation of diastereoisomers

of a new HIV protease inhibitor)

RN 799241-73-9 CAPLUS

CN Carbamic acid,


[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-

2-hydroxy-1-(phenylmethyl)propyl]-,


(3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-

3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850141-20-7 CAPLUS

CN Carbamic acid,


[(1S,2S)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-

2-hydroxy-1-(phenylmethyl)propyl]-,

(3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-

3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850141-21-8 CAPLUS

CN Carbamic acid,


[(1S,2S)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-

2-hydroxy-1-(phenylmethyl)propyl]-,

(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-

3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850141-22-9 CAPLUS

CN Carbamic acid,

[(1S,2S)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-

2-hydroxy-1-(phenylmethyl)propyl]-,

(3R,3aR,6aS)-hexahydrofuro[2,3-b]furan-

3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 799241-74-0 CAPLUS

CN Carbamic acid,


[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-

2-hydroxy-1-(phenylmethyl)propyl]-,

(3R,3aR,6aS)-hexahydrofuro[2,3-b]furan-

3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 799241-75-1 CAPLUS

CN Carbamic acid,


[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-

2-hydroxy-1-(phenylmethyl)propyl]-,

(3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-

3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850141-19-4 CAPLUS

CN Carbamic acid,

[(1S,2S)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-

2-hydroxy-1-(phenylmethyl)propyl]-,


(3R,3aR,6aR)-hexahydrofuro[2,3-b]furan-

3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:67041 CAPLUS
DI 142:309248
TI Design of HIV-1 Protease Inhibitors Active on Multidrug-Resistant Virus
AU Surleraux, Dominique L. N. G.; De Kock, Herman A.; Verschuuren, Wim G.;
Pille, Geert M. E.; Maes, Louis J. R.; Peeters, Anik; Vendeville,
Sandrine; De Meyer, Sandra; Azijn, Hilde; Pauwels, Rudi; De Bethune,
Marie-Pierre; King, Nancy M.; Prabu-Jeyabalan, Moses; Schiffer, Celia A.;
Wigerinck, Piet B. T. P.
CS Tibotec BVBA, Mechelen, B-2800, Belg.
SO Journal of Medicinal Chemistry (2005), 48(6), 1965-1973
CODEN: JMCMAH; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:309248
AB On the basis of structural data gathered during our ongoing HIV-1
protease inhibitors program, from which our clin. candidate TMC114 9 was selected,
we have discovered new series of fused heteroarom. sulfonamides. The
further extension into the P2' region was aimed at identifying new
classes of comds. with an improved broad spectrum activity and acceptable
pharmacokinetic properties. Several of these comds. display an
exceptional broad spectrum activity against a panel of highly
cross-resistant mutants. Certain members of these series exhibit
favorable pharmacokinetic profiles in rat and dog. Crystal structures
and mol. modeling were used to rationalize the broad spectrum profile
resulting from the extension into the P2' pocket of the HIV-1 protease.
IT 470704-42-8P 470704-47-3P 470704-54-2P
470704-55-3P 473737-26-7P 473737-31-4P
473737-35-8P 473737-37-0P 473737-99-4P
473738-12-4P 473738-14-6P 475487-74-2P
475487-76-4P 660410-46-8P 848253-09-8P
848253-10-1P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(design of HIV-1 protease inhibitors active on multidrug-resistant
virus)
RN 470704-42-8 CAPLUS
CN Carbanic acid, ((1S,2R)-3-[[[2-[[2-(dimethylamino)ethyl]amino]-6-
benzoxazolyl]sulfonyl]-2-methylpropyl]amino]-2-hydroxy-1-
[phenylmethyl]propyl]-, (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

 NMe_2


```

RN  470704-47-3  CAPLUS
CN  Carbanic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[[2-(1-
    pyrrolidinyl)ethyl]amino]-6-benzoxazolyl]sulfonyl]amino]-1-
    (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
    (9CI)  (CA INDEX NAME)

```

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 470704-54-2 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-methyl[3-(1-pyrrolidinyl)propyl]amino)-6-benzoxazolyl]sulfonyl]amino)-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470704-55-3 CAPLUS
 CN Carbacic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-{methyl[2-(1-pyrrolidinyl)ethyl]amino}-6-benzoxazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester

L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473737-26-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(2-dimethylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl (2-methylpropyl)amino]-2-hydroxy-1-phenylmethyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

NMe₂

RN 473737-31-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[[2-(1-pyrrolidinyl)ethyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B



RN 473737-35-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[3-(dimethylamino)propyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

NHMe

RN 473737-99-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[3-(dimethylamino)propyl]methylamino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


(CH₂)₃NMe₂

RN 473738-12-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[methyl[3-(1-pyrrolidinyl)propyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

(CH₂)₃NMe₂

RN 473737-37-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[2-(methylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

RN 473738-14-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[methyl[2-(1-pyrrolidinyl)propyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 475487-74-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475487-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[2-(methylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 660410-46-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[2-(methylamino)-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-67-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 848253-11-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (design of HIV-1 protease inhibitors active on multidrug-resistant virus)


RN 848253-11-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-methylsulfinyl)-6-benzothiazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD

L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 848253-09-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 848253-10-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 473739-17-2 546085-67-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (design of HIV-1 protease inhibitors active on multidrug-resistant virus)
 RN 473739-17-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-amino-6-benzothiazolyl)sulfonyl](2-

L7 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:996120 CAPLUS
 DN 141:411225
 TI Preparation of peptidyl HIV prodrugs which are cleavable by CD26
 IN De Kock, Herman Augustinus; Wigerinck, Piet Tom Bert Paul; Balzarini, Jan
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004099135	A2	20041118	WO 2004-EP50753	20040510
WO 2004099135	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004235988	A1	20041118	AU 2004-235988	20040510
CA 2517338	A1	20041118	CA 2004-2517338	20040510
EP 1624897	A2	20060215	EP 2004-741542	20040510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
HR				
BR 2004010158	A	20060516	BR 2004-10158	20040510
CN 1784244	A	20060607	CN 2004-80012260	20040510
NO 2005005826	A	20060208	NO 2005-5826	20051208
PRAI GB 2003-10593	A	20030508		
WO 2004-EP50753	W	20040510		
OS MARPAT 141:411225				
GI				

L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The invention provides new prodrugs which are conjugates of a therapeutic compound and a peptide which are cleavable by dipeptidyl-peptidases, preferably by CD26, also known as DPP-IV (dipeptidyl aminopeptidase IV). Prodrugs I [n is 1-5; Y is proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioprolin), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine or threonine; X is a D- or L-amino acid; X and Y in each repeat of [Y-X] are chosen independently from one another and independently from other repeats; Z is a direct bond or a bivalent straight or branched saturated hydrocarbon group having from 1 to 4 carbon atoms; R1 is aryl, heteroaryl, heteroalkoxy, aryloxyalkyl, heterocycloalkoxy, heterocycloalkylalkoxy, heteroalkylalkoxy, heteroalkylalkoxy; R2 is arylalkyl; R3 is alkyl, alkenyl or cycloalkylalkyl; R4 is H or alkyl and their stereoisomeric forms and salts are claimed. Thus, peptide conjugate II (Val-Pro-PI 1) was prepared via peptide coupling reaction and studied biol., e.g., its conversion to the parent drug PI 1 in human or bovine serum.

IT 791071-78-8P 791071-82-4P 791071-83-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 791071-78-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[[[(2S)-1-[(2S)-2-amino-3-methyl-1-oxobutyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



PAGE 1-B




RN 791071-82-4 CAPLUS
 CN L-Prolineamide, L-α-aspartyl-L-prolyl-L-lysyl-N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 791071-83-5 CAPLUS
 CN L-Prolineamide, L-α-aspartyl-L-prolyl-L-lysyl-N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




IT 253266-00-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of peptidyl prodrugs which are cleavable by CD26)
 RN 253266-00-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminomethyl)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 791071-79-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 791071-77-7P 791071-79-9P 791071-80-2P
 791071-81-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of peptidyl prodrugs which are cleavable by CD26)
 RN 791071-77-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[[[(2S)-1-[(2S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 791071-80-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-[[[(2S)-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 791071-81-3 CAPLUS
 CN L-Prolineamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-N-[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



L7 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of peptidyl prodrugs which are cleavable by CD26)
 RN 791071-78-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[[[(2S)-1-[(2S)-2-amino-3-methyl-1-oxobutyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 253266-00-1P
 RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of peptidyl prodrugs which are cleavable by CD26)
 RN 253266-00-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[(aminomethyl)phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 RN 2004:996009 CAPLUS
 DN 141:411224
 TI Preparation of peptidyl prodrugs which are cleavable by CD26
 IN Balzarini, Jan
 PA K.U. Leuven Research & Development, Belg.
 SO PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN: CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004098644	A1	20041118	WO 2004-BE69	20040510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004236371	A1	20041118	AU 2004-236371	20040510
CA 2525191	A1	20041118	CA 2004-2525191	20040510
EP 1620130	A1	20060201	EP 2004-731856	20040510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				
HR CN 1784244	A	20060607	CN 2004-80012260	20040510
JP 2006525235	T	20061109	JP 2006-504046	20040510
PRAI GB 2003-10593	A	20030508		
WO 2004-BE69	W	20040510		
OS MARPAT 141:411224				

AB The invention provides new prodrug technol. and prodrugs in order to increase solubility, modulate plasma protein binding or enhance the bioavailability of a drug. The prodrugs are conjugates of a therapeutic compound and a peptide (e.g., a tetra- or hexapeptide) which are cleavable by dipeptidyl-peptidases, preferably by CD26, also known as DPP-IV (dipeptidyl aminopeptidase IV). Claimed prodrugs comprise a compound linked via an amide bond to an oligopeptide H-(X-Y)_n, where X is an amino acid, n is 1-5, and Y is an amino acid selected from the group consisting of proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipercolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine. Thus, Val-Pro-NAP-TSAO, the dipeptide conjugate of the antiviral prodrug NAP-TSAO, was prepared and studied biol., e.g., its conversion to the parent drug in human or bovine serum.
 IT 791071-78-8P
 RL: BSU (Biological study, unclassified); PUR (Purification or recovery);


L7 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 791071-77-7P 791071-79-9P 791071-80-2P
 791071-81-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of peptidyl prodrugs which are cleavable by CD26)
 RN 791071-77-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[[[(2S)-1-[(2S)-2-[[[1,1-dimethylethoxy]carbonyl]amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 791071-79-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN	791071-80-2	CAPLUS
CN	Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[(4-[[[(2S)-2-pyrrolidinylcarbonyl]amino]methyl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



```

RN      791071-81-3    CAPLUS
CN      L-Prolineamide, N-[[[1,1-dimethylethoxy)carbonyl]-L- $\alpha$ -aspartyl-N-[[4-
      [[[ (2R, 3S) -3-[[[[( (3R, 3aS, 6aR) -hexahydrofuro[2,3-b]furan-3-
      yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-
      methylpropyl)amino]sulfonyl]phenyl)methyl]-, 1,1-dimethyl ethyl ester
(9CI)
      (CA INDEX NAME)


```

Absolute stereochemistry.


17 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2004:885959 CAPLUS
 DN 142:51214
 TI Inhibition of Wild-Type and Mutant Human Immunodeficiency Virus Type 1
 AU Hanlon, Mary H.; Porter, David J. T.; Furfine, Eric S.; Spaltenstein, Andrew; Carter, H. Luke; Danger, Dana; Shu, Arthur Y. L.; Kaldor, Istvan W.; Miller, John F.; Samano, Vicente A.
 SO GlaxoSmithKline, Research Triangle Park, PA, 19405, USA
 CS Biochemistry (2004), 43(45), 14500-14507
 PB American Chemical Society
 DT Journal
 LA English
 AB The Arylsulfonamide deriva. described herein were such potent inhibitors of human immunodeficiency virus type 1 (HIV-1) protease (enzyme, E) that values for the inhibition constants (K_i) could not be determined by conventional steady-state kinetic techniques (i.e., the minimal enzyme concentration usable for the activity assay was much greater than the value of the dissociation constant). Consequently, two alternative methods were developed for estimation of K_i values. The first method employed kinetic detns. of values for k₁ and k₋₁, from which K_i was determined (k₋₁/k₁). The second method was a competitive displacement assay used to determine binding affinities of other inhibitors relative to that of GW0385. In these assays, the inhibitor of unknown affinity was used to displace [3H]GW0385 from E·[3H]GW0385. From the concentration of E·[3H]GW0385 at equilibrium, the concns. of enzyme-bound and free inhibitors were calculated, and the ratio of the K_i value of the unknown to that of GW0385 was determined (K_i, unknown/K_i, GW0385). The values of k_i were calculated from data in which changes in the intrinsic protein fluorescence of the enzyme associated with inhibitor binding were directly or indirectly monitored. In the case of saquinavir, the fluorescence changes associated with complex formation were large enough to monitor directly. The value of k₁ for saquinavir was 62±2 μM⁻¹ s⁻¹. In the case of GW0385, the fluorescence changes associated with complex formation were too small to monitor directly. Consequently, the value of k₁ was estimated from a competition experiment in which the effect of GW0385 on the binding of E to saquinavir was determined. The value of k₁ for GW0385 was estimated from these expts. to be 137±4 μM⁻¹ s⁻¹. Because E·[3H]GW0385 was stable in the standard buffer at room temperature for greater than 33 days, the value of the first-order rate constant for dissociation of E·[3H]GW0385 (k₋₁) could be estimated from the time-course for exchange of E·[3H]GW0385 with excess unlabeled GW0385. The value of k₋₁ calculated from these data was (2.1±0.1) × 10⁻⁶ s⁻¹ (t_{1/2} = 91 h). The K_i value of wild-type HIV-1 protease for GW0385, calculated from these values for k₁ and k₋₁, was 15±1 fM. Three multidrug resistant enzymes had K_i values for GW0385 that were less than 5 pM.
 IT 810687-58-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (as reactant in preparation of [3H]GW0385; inhibition of wild-type and

L7 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 drug-resistant mutant human immunodeficiency virus type 1 proteases by
 GW0385 and other arylsulfonamides monitored by fluorescence)
 RN 810687-58-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[(3-bromo-4-[(2-methyl-4-thiazolyl)methoxy]phenyl)methyl]-2-hydroxypropyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



PAGE 2-A


IT 810687-57-1P
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhibition of wild-type and drug-resistant mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides monitored by fluorescence)
 RN 810687-57-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[(4-[(2-methyl-4-thiazolyl)methoxy]phenyl)-3-t)methylpropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-51-3 CAPLUS
 CN 15-Oxa-2,6,13-triazapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 313679-77-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[(4-[(2-pyridinylmethoxy)phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

IT 288292-27-3 288292-51-3 313679-77-5
 313679-90-2
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
 (inhibition of wild-type and drug-resistant mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides monitored by fluorescence)
 RN 288292-27-3 CAPLUS
 CN 4-Oxa-2,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313679-90-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[(4-[(2-thienyl)ethoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:807698 CAPLUS
 DN 142:211389
 TI Discovery and Selection of TMC114, a Next Generation HIV-1 Protease Inhibitor
 AU Surleaux, Dominique L. N. G.; Tahri, Abdellah; Verschuere, Wim G.; Pille, Geert M. E.; de Kock, Herman A.; Jonckers, Tim H. M.; Peeters, Anik; De Meyer, Sandra; Azijn, Hilde; Pauwels, Rudi; de Bethune, Marie-Pierre; King, Nancy M.; Prabu-Jeyabalan, Moses; Schiffer, Celia A.; Wigerinck, Piet B. T. P.
 CS Tibotec BVBA Generaal de Wittelaan 11B 3, Mechelen, B-2800, Belg.
 SO Journal of Medicinal Chemistry (2005), 48(6), 1813-1822
 CODEN: JMCMAJ; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:211389
 AB The screening of known HIV-1 protease inhibitors against a panel of multidrug-resistant viruses revealed the potent activity of TMC126 on drug-resistant mutants. In comparison to amprenavir, the improved affinity of TMC126 is largely the result of one extra hydrogen bond to the backbone of the protein in the P2 pocket. Modification of the substitution pattern on the phenylsulfonamide P2' substituent of TMC126 created an interesting SAR, with the close analog TMC114 being found to have a similar antiviral activity against the mutant and the wild-type viruses. X-ray and thermodynamic studies on both wild-type and mutant enzymes showed an extremely high enthalpy driven affinity of TMC114 for HIV-1 protease. In vitro selection of mutants resistant to TMC114 starting from wild-type virus proved to be extremely difficult; this was not the case for other close analogs. Therefore, the extra H-bond to the backbone in the P2 pocket cannot be the only explanation for the interesting antiviral profile of TMC114. Absorption studies in animals indicated that TMC114 has pharmacokinetic properties comparable to currently approved HIV-1 protease inhibitors.
 IT 546085-00-1P 333798-27-9P 546085-59-0P
 546085-60-3P 553645-10-6P 799241-73-9P
 799241-74-0P 799241-75-1P 799241-76-2P
 799241-77-3P 799241-78-4P 799269-47-9P
 799269-48-0P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (discovery and selection of TMC114, a next generation HIV-1 protease inhibitor)
 RN 253266-00-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminomethyl)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L7 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553645-10-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(cyanophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 799241-73-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 799241-74-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L7 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 333798-27-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 546085-59-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 546085-60-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L7 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 799241-75-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 799241-76-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(nitrophenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 799241-77-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(iodophenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 799241-78-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-acetylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 799269-47-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methylphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 799269-48-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 RN 2004:760314 CAPLUS
 DN 141:384410
 TI A screening strategy for the development of enantiomeric separation methods in capillary electrophoresis
 AU Jimidar, M. Ilias; van Ael, Willy; van Nyen, Patrick; Peeters, Margot; Redlich, Dirk; de Smet, Maurits
 CS Pharmaceutical Research & Development (J&J-PRD) A division of Janssen Pharmaceutica n.v., Global Analytical Development, Johnson and Johnson, Beerse, Belg.
 SO Electrophoresis (2004), 25(16), 2772-2785
 CODEN: ELCTDN; ISSN: 0173-0835
 PB Wiley-VCH Verlag GmbH & Co. KGaA
 DT Journal
 LA English
 AB Method development of enantiomeric sepns. in capillary electrophoresis (CE) is a time-consuming task, since finding the appropriate chiral selector is usually a "trial and error" process. It is impossible to predict the selectivity of a selector towards a certain enantiomer. Therefore, the affinity of all selectors has to be examined one at a time.
 In order to speed up this process, a strategy is proposed based on simple exptl. design methodol. The approach includes first a screening in function of the pH to determine the optimal migration conditions followed by a selection of the right chiral selector by means of Taguchi designs. In the approach several variables, such as the type and concentration of cyclodextrin, the concentration of buffer electrolyte, and the percentage of organic modifier, are varied simultaneously to find initial separation conditions rapidly. The resulting initial separation conditions can be optimized in further steps to be more reproducible. We discuss the results of the approach when applied on a number of selected compds. that are recently in development at Johnson & Johnson - Pharmaceutical Research and Development. Parameters, such as quality of the separation and anal. time, are evaluated to determine initial separation conditions for each compound
 IT 783370-60-5
 RL: ANT (Analyte); ANST (Analytical study)
 (screening strategy for development of enantiomeric separation methods in capillary electrophoresis)
 RN 783370-60-5 CAPLUS
 CN Carbamic acid, [(1R,2S)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:162694 CAPLUS
 DN 140:210820
 TI Broad spectrum substituted oxindole sulfonamide HIV protease inhibitors
 IN Tahri, Abdellah; Wigerinck, Piet Tom Bert Paul
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CMT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004016619	A1	20040226	WO 2003-EP50379	20030814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493940	A1	20040226	CA 2003-2493940	20030814
AU 2003262574	A1	20040303	AU 2003-262574	20030814
BR 2003005771	A	20041005	BR 2003-5771	20030814
EP 1546153	A1	20050629	EP 2003-787818	20030814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688586	A	20051026	CN 2003-824095	20030814
JP 2005537305	T	20051208	JP 2004-528524	20030814
NZ 538714	A	20070330	NZ 2003-538714	20030814
US 2006058368	A1	20060316	US 2005-524451	20050210
US 7199148	B2	20070403		
NO 2005001291	A	20050518	NO 2005-1291	20050314
PRAI EP 2002-78384	A	20020814		
WO 2003-EP50379	W	20030814		
OS MARPAT 140:210820				
GI				

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The present invention concerns the compds. having the formula (I) N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters, and metabolites thereof [wherein R1, R8 = H, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, aryl, Het1, Het1-C1-6 alkyl, etc.; or R1 = (un)substituted H2N-CH2CH2-; t is 0, 1 or 2; R2 = H, C1-6 alkyl; L = CO, O-CO, NR8CO, O-C1-6 alkanediyl-CO, NR8-C1-6 alkanediyl-CO, SO2, O-SO2, NR8-SO2; R3 = (un)substituted C1-6 alkyl, aryl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, aryl-C1-4alkyl; R4 = H, C1-4 alkyl-O-CO, carboxyl, CONH2, mono- or di(C1-4alkyl)carbamoyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl; R6 = H, (un)substituted C1-6 alkyl; Het1 is a 5 to 10 ring membered mono- or bicyclic heterocycle containing 21 heteroatoms selected from N, O, and S]. It further relates to their use as broad spectrum HIV protease inhibitors, pharmaceutical compns., and a method

for treating or combating infection or disease associated with multi-drug resistant retrovirus infection in a mammal. It also may concern combinations thereof with another anti-retroviral agent, and to their use in assays as reference compds. or as reagents. These compds. I exhibited potent anti-HIV activity against a wild type laboratory HIV strain (HIV-1 strain

L-AI), e.g. sec50 of 8.5 for the compound (II), and also were effective

in inhibiting a broad range of mutant strains which show various degrees of phenotypic cross-resistance to the currently com. available drugs such as for instance saquinavir, ritonavir, nelfinavir, indinavir and amprenavir.

IT 664344-03-OP
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(substituted oxindolesulfonamide derivs. for use as broad spectrum HIV protease inhibitors)


RN 664344-03-0 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(3E)-3-(2-furanylmethylene)-2,3-dihydro-2-oxo-

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 664343-98-0 664343-99-1 664344-00-7
 664344-01-8 664344-02-9 664344-04-1
 664344-05-2 664344-06-3 664344-07-4
 664344-08-5 664344-09-6 664344-10-9
 664344-11-0 664344-12-1 664344-13-2
 664344-14-3 664344-15-4 664344-16-5
 664344-18-7 664344-19-8 664344-20-1
 664344-21-2 664344-22-3 664344-23-4
 664344-24-5 664344-25-6 664344-26-7
 664344-27-8 664344-28-9 664344-29-0
 664344-30-3 664344-31-4 664344-32-5
 664344-33-6 664344-35-8 664344-37-0
 664344-45-0 664344-46-1


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (substituted oxindolesulfonamide derivs. for use as broad spectrum HIV protease inhibitors)

RN 664343-98-0 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 664343-99-1 CAPLUS

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbamic acid,


[(1S,2R)-3-[[[(2,3-dihydro-3-[[5-methyl-2-furanylmethylene]-2-oxo-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



PAGE 1-A

PAGE 1-B




RN 664344-00-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-3-[[[(2,3-dihydro-3-[[5-methyl-2-furanylmethylene]-2-oxo-1H-indol-5-yl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



PAGE 1-A


L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 664344-01-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 664344-02-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(2-ethylbutylidene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.




RN 664344-04-1 CAPLUS

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 664344-06-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-[(4-hydroxy-3,5-dimethylphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-[(4-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 664344-05-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-2-oxo-3-[[4-(2-pyridinyl)phenyl]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 664344-07-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(dimethylamino)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 664344-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-[(1H-indol-2-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 664344-09-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[5-(acetyloxy)methyl]-2-furanyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A



L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 664344-12-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-[(2-hydroxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 664344-13-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-[(2-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 664344-10-9 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-2-oxo-3-(phenylmethylene)-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 664344-11-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[4-(diethylamino)-3-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A



L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 664344-14-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-[(4-hydroxy-3-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 664344-15-4 CAPLUS
 CN Carbamic acid, 4-[[5-[[[2,3-dihydro-3-[(5-methyl-2-furanyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




PAGE 1-A




RN 664344-16-5 CAPLUS
 CN Benzoic acid, 4-[[5-[[[2,3-dihydro-3-[(5-methyl-2-furanyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 664344-20-1 CAPLUS
 CN Carbamic acid, 3-[[[2,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 664344-21-2 CAPLUS
 CN Carbamic acid, 3-[[[2,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 664344-22-3 CAPLUS
 CN Carbamic acid, 3-[[[3-(2-ethylbutylidene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 664344-23-4 CAPLUS
 CN Carbamic acid, 3-[[[3-(2-furanylmethylene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
 Double bond geometry unknown.


PAGE 1-A



PAGE 1-B




RN 664344-18-7 CAPLUS
 CN Carbamic acid, 3-[[[2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 664344-19-8 CAPLUS
 CN Carbamic acid, 3-[[[2,3-dihydro-3-[(5-methyl-2-furanyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 664344-24-5 CAPLUS
 CN Carbamic acid, 3-[[[2,3-dihydro-3-[(4-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




PAGE 1-A



RN 664344-25-6 CAPLUS
 CN Carbamic acid, 3-[[[2,3-dihydro-2-oxo-3-[[4-(2-pyridinyl)phenyl]methylene]-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 664344-26-7 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-3-[(4-hydroxy-3,5-dimethylphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 664344-27-8 CAPLUS
 CN Carbamic acid, [3-[[[3-[[[4-(dimethylamino)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 1-B

-NMe2

RN 664344-28-9 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A




PAGE 1-B

-NEt2

RN 664344-31-4 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-3-[(2-hydroxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 664344-32-5 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-3-[(2-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 664344-33-6 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-3-[(4-hydroxy-3-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



RN 664344-29-0 CAPLUS
 CN Carbamic acid, [3-[[[3-[[[5-[(acetyloxy)methyl]-2-furanyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


-CH2-OAc

RN 664344-30-3 CAPLUS
 CN Carbamic acid, [3-[[[3-[[[4-(diethylamino)-3-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 664344-35-8 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-3-[(5-methyl-2-furanyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)-2-phosphonopropyl]-, C-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 664344-37-0 CAPLUS
 CN Benzoic acid, 4-[[[5-[[[3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


-CO2H

RN 664344-45-0 CAPLUS
 CN Carbamic acid, [3-[[[2,3-dihydro-3-[(2-methylpropylidene)-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry unknown.




RN 664344-46-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



IT 664344-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(substituted oxindolesulfonamide derivs. for use as broad spectrum HIV protease inhibitors)

RN 664344-17-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
AN 2004:142955 CAPLUS
DN 140:193033
TI Broad-spectrum 2-aminobenzothiazole sulfonamide HIV protease inhibitors
IN Surlieriaux, Dominique Louis Nestor Ghislain; Wigerinck, Piet Tom Bert Paul;
Getman, Daniel P.
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 44 pp.
CODEN: PIIKXD
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014371	A1	20040219	WO 2003-EP50359	20030804
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VM, YU, ZA, ZM, ZW			
RN:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2492832	A1	20040219	CA 2003-2492832	20030804
AU 2003262561	A1	20040225	AU 2003-262561	20030804
BR 2003005717	A	20040928	BR 2003-5717	20030804
EP 1545518	A1	20050629	EP 2003-784205	20030804
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1671380	A	20050921	CN 2003-818404	20030804
JP 2006503815	T	20060202	JP 2004-526916	20030804
IN 2005DN00259	A	20060721	IN 2005-DN259	20050124
US 2005267156	A1	20051201	US 2005-523445	20050131
NO 2005001089	A	20050502	NO 2005-1089	20050301
PRAI EP 2002-78231	A	20020802		
US 2002-427862P	P	20021120		
WO 2003-EP50359	W	20030804		
OS MARPAT 140:193033				
GI				




AB The invention discloses the use of 2-amino-benzothiazole sulfonamides I
[R1 = (un)substituted Ph, hexahydrofuro[2,3-b]furan-yl, tetrahydrofuran-yl, oxazol-yl, thiazol-yl, pyridin-yl; R2 = H, C1-6 alkyl; L = bond, O, C1-6 alkanediyl-O-, -O-C1-6 alkanediyl; R3 = Ph C1-4 alkyl; R4 = C1-6 alkyl; R5, R6 = H, C1-6 alkyl] in the manufacture of a medicament useful for inhibiting mutant HIV protease in a mammal infected with the mutant HIV

L7 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L7 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
protease. The invention also discloses novel compds. I.
IT 473739-17-2P 662138-74-1P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(2-aminobenzothiazole sulfonamide HIV protease inhibitors)
RN 473739-17-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-6-benzothiazol-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 662138-74-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(2-(methylamino)-6-benzothiazol-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 662138-75-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(2-aminobenzothiazole sulfonamide HIV protease inhibitors)

RN 662138-75-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2-(dimethylamino)-6-benzothiazol-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 473775-04-1 660410-08-2 660410-10-6
 660410-11-7 660410-46-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (2-aminobenzothiazole sulfonamide HIV protease inhibitors)
 RN 473775-04-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(2-amino-6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 660410-08-2 CAPLUS
 CN Carbamic acid, [3-[[[2-(2-amino-6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 660410-10-6 CAPLUS
 CN Carbamic acid, [2-hydroxy-3-[[[2-(methylamino)-6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 660410-11-7 CAPLUS
 CN Carbamic acid, [3-[[[2-(dimethylamino)-6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



RN 660410-46-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(methylamino)-6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:142902 CAPLUS

DN 140:187404

TI Electrospun amorphous pharmaceutical compositions

IN Ignatious, Francis; Sun, Linghong

FA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014304	A2	20040219	WO 2003-US24641	20030807
WO 2004014304	A3	20040624		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GE, GM, KE, LS, MG, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494865	A1	20040219	CA 2003-2494865	20030807
AU 2003258120	A1	20040225	AU 2003-258120	20030807
EP 1534250	A2	20050601	EP 2003-784959	20030807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013222	A	20050614	BR 2003-13222	20030807
CN 1684673	A	20051019	CN 2003-823237	20030807
JP 2005534716	T	20051117	JP 2004-527797	20030807
US 2006013869	A1	20060119	US 2005-523835	20050207
US 2006083784	A1	20060420	US 2005-64890	20050224
NO 2005001123	A	20050506	NO 2005-1123	20050302
PRAI US 2002-401726P	P	20020807		
WO 2003-US24641	W	20030807		
US 2005-523835	A2	20050207		

AB The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under elec. forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers. Thus, carvedilol-HBr monohydrate was dissolved in THF and water. The solution was added to Polyox WSR1105 in MeCN solution

This solution was spun to give nanofibers, and the morphol. of the drug was shown to be amorphous.

IT 659727-44-3

RL: PEP (Physical, engineering or chemical process); PRP (Properties);

PYP

(Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (electrospun amorphous pharmaceutical compns.)

RN 659727-44-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[2-methyl-4-thiazolyl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)


L7 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 313682-08-5

CMF C33 H41 N3 O10 S2


Absolute stereochemistry.




CM 2

CRN 104-15-4

CMF C7 H8 O3 S




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-46-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
 3-[[4-(ethylamino)phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxypropyl]-
 , (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 622871-47-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-(4-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-50-5 CAPLUS
 CN Propanoic acid, 2-[[[(S)-4-[(3-aminophenyl)sulfonyl]-(2-
 methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-51-6 CAPLUS
 CN Propanoic acid, 2-[[[(S)-4-[(3-aminophenyl)sulfonyl]-(2-
 methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-48-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-,
 C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 622871-49-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-52-7 CAPLUS
 CN Propanoic acid, 2-[[[(R)-4-[(3-aminophenyl)sulfonyl]-(2-
 methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy
]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-53-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-
 2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-55-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-57-2 CAPLUS
 CN Carbamic acid, [[1S,2R)-3-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-61-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-(4-fluorophenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-62-9 CAPLUS
 CN Carbamic acid, 2-[[[4-[(2S,3R)-4-[[[4-(4-fluorophenyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-58-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-59-4 CAPLUS
 CN Carbamic acid, [[1S,2R)-3-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-63-0 CAPLUS
 CN Carbamic acid, [[1S,2R)-2-hydroxy-3-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-66-3 CAPLUS
 CN Carbamic acid, [[1S,2R)-1-[[[4-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-67-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)][4-(1-piperidinyl)phenyl]sulfonyl]amino]butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-68-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)][4-(1-piperidinyl)methyl]phenyl]sulfonyl]amino]butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-73-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)](3-pyridinylsulfonyl]amino]butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-74-3 CAPLUS
 CN Pyridinium, 3-[[[(2R,3S)-4-[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]-1-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-70-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)](3-pyridinylsulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-72-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)](3-pyridinylsulfonyl]amino]butyl]phenoxy)methyl]phenylmethoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-75-4 CAPLUS
 CN Pyridinium, 3-[[[(2R,3S)-4-[4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-77-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)](1-oxido-3-pyridinylsulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622871-78-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(1-oxido-3-pyridinyl)sulfonyl]amino]butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-79-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(1-oxido-3-pyridinyl)sulfonyl]amino]butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-80-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-

b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(1-oxido-3-pyridinyl)sulfonyl]amino]butyl]phenoxy)methyl] (phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-87-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(4-(4-


morpholinyl)methyl]phenyl]sulfonyl]amino]butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-89-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxy-4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 622871-85-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

(hydroxymethyl)phenyl]sulfonyl] (2-methylpropyl)amino]butyl]phenoxy)methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-86-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl){(4-(4-

morpholinyl)methyl]phenyl]sulfonyl]amino]butyl]phenoxy)methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622871-90-3 CAPLUS
 CN L-Alanine, N-[[[4-[(2R,3S)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] (2-methylpropyl)amino]sulfonyl]phenoxy)methyl]hydroxyphosphinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CO2H

RN 622871-91-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxy-4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-92-5 CAPLUS


L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbanic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-93-6 CAPLUS
 CN Carbanic acid, [(1S,2R)-1-[(4-[2-(dimethylamino)ethoxy]phenyl)methyl]-2-hydroxy-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-94-7 CAPLUS
 CN L-Alanine, N-[(R)-[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622871-96-9 CAPLUS
 CN L-Alanine, N-[(S)-[4-[[[(2R,3S)-4-(4-(ethylamino)phenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 622871-95-8 CAPLUS
 CN L-Alanine, N-[(S)-[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622871-97-0 CAPLUS
 CN L-Alanine, N-[(S)-[4-[[[(2R,3S)-4-(4-(ethylamino)phenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622871-99-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-3-(phosphonoxy)butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-[1-methylethyl] ester, disodium salt, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 Na

RN 622871-99-2 CAPLUS
 CN D-Valine, (1R,2S)-3-[4-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]methyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 623158-39-4 CAPLUS
 CN L-Alanine, N-[[[4-[[[[(2R,3S)-4-[4-(ethylamino)phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 623158-40-7 CAPLUS
 CN Carbamic acid, 1-[[[4-[(diethoxyphosphinyl)methyl]phenyl]methyl]-2-

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622872-00-8 CAPLUS
 CN D-Valine, [4-[[[[(2R,3S)-4-[4-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623158-38-3 CAPLUS
 CN L-Alanine, N-[[[4-[[[[(2R,3S)-4-[4-(aminophenyl)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623158-44-1 CAPLUS
 CN Pyridinium, 3-[[[4-[[[[(2R,3S)-4-[4-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-75-4
 CMF C39 H53 N3 O13 P S

Absolute stereochemistry.



CM 2

CRN 37181-39-8
 CMF C F3 O3 S

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 623158-45-2 CAPLUS

CN Pyridinium,
3-[[[(2R,3S)-4-{4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl


1]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-74-3

CMF C42 H53 N3 O11 P S

Absolute stereochemistry.



CM 2

CRN 37181-39-8

CMF C F3 O3 S



RN 623158-46-3 CAPLUS

CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methyl-1-piperazinyl)phenyl]sulfonyl](2-methylpropyl)amino)butyl]phenoxy)methyl]phenoxy

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 623158-49-6 CAPLUS


CN L-Valine, [4-[[[(2R,3S)-4-{4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]phenyl]methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 623158-48-5

CMF C45 H62 N3 O15 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 623158-51-0 CAPLUS

CN L-Valine, [(1R,2S)-3-{4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino)methyl]propyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 623158-50-9

CMF C45 H62 N3 O15 P S

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
noxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623158-47-4 CAPLUS

CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino)butyl]phenoxy)methyl]phenoxy]phosphinyl]oxy]-, 2-hydroxyethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OH

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 623158-55-4 CAPLUS

CN Propanoic acid, 2-[[[(2-ethoxyphenoxy)[2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino)butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 623158-54-3

CMF C44 H62 N3 O14 P S

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 623158-56-5 CAPLUS
CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]butyl]phenoxy]methyl]phenoxy]methyl]phosphinoyloxy]-2,2-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

methoxyphenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]methyl]phosphinoyloxy]-2,2-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:875071 CAPLUS
DN 139:381609
TI Preparation of phosphonate analogs of HIV protease inhibitors with improved cellular accumulation properties
IN Arimilli, Murty N.; Becker, Mark M.; Bryant, Clifford; Chen, James M.; Chen, Xiaowu; Dastgah, Azar; Fardis, Maria; He, Gong-Xin; Jin, Haolun; Kim, Chung U.; Lee, William A.; Lee, Christopher P.; Lin, Kuei-Ying;

Liu, Hongtao; Mackman, Richard L.; Mitchell, Michael L.; Nelson, Peter H.; Pyun, Hyung-Jung; Rowe, Tanisha D.; Sparacino, Mark; Swaminathan, Sundaramoorthi; Tario, James D.; Wang, Jianying; Williams, Matthew A.;

Xu, Lianhong; Yang, Zheng-Yu; Yu, Richard H.; Zhang, Jiansun; Zhang, Lijun

PA Gilead Sciences, Inc., USA
SO PCT Int. Appl., 1727 pp.

CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003090690	A2	20031106	WO 2003-US12901	20030425
WO 2003090690	A3	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2481261 A1 20031106 CA 2003-2481261 20030425

AU 2003231765 A1 20031110 AU 2003-231765 20030425

BR 2003009573 A 20050201 BR 2003-9573 20030425

EP 1509537 A2 20050302 EP 2003-747326 20030425

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1649885 A 20050803 CN 2003-814963 20030425

JP 2005523912 T 20050811 JP 2003-587329 20030425

CN 1656109 A 20050817 CN 2003-812478 20030425

WO 2004096818 A2 20041111 WO 2003-EP12423 20031106

WO 2004096818 A3 20050407

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

TA 2003291998 A1 20041123 AU 2003-291998 20031106

EP 1620445 A2 20060201 EP 2003-767521 20031106

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK

JP 2006524487 T 20061102 JP 2004-571244 20031106

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US	2005239054	A1	20051027	US	2003-740694	20031222
ZA	2004009376	A	20050914	ZA	2004-9376	20041122
NO	2004005150	A	20050126	NO	2004-5150	20041125
US	2007010489	A1	20070111	US	2005-511998	20050725

PRAI US 2002-375622P F 20020426

US 2002-375665P F 20020426

US 2002-375779P F 20020426

US 2002-375834P F 20020426

US 2003-423496 A2 20030425

US 2003-424130 A2 20030425

US 2003-424186 A2 20030425

US 2003-465721P F 20030425

US 2003-465810P F 20030425

US 2003-465824P F 20030425

WO 2003-US12901 W 20030425

WO 2003-US12926 A 20030425

WO 2003-US12943 A 20030425

WO 2003-EPI2423 W 20031106

OS MARPAT 139:381609

GI

III

AB The invention relates to phosphonate-substituted carbamates I and cyclic ureas II [wherein A = Al, A2, or W3 with the proviso that at least one of A = Al, A1 = [Y2(CR2R2)1-12]0-12Y2W6; A2 = [Y2(CR2R2)1-12]0-12Y2W3; W3 = substituted (hetero)cyclyl; R5, C(Y1)R5, C(Y1)W5, SO2R5, or SO2W5; W5 = substituted (hetero)cyclyl; W6 = triphosphono-substituted W3; Y1 = O, S, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), or N(N(Rx)2); Y2 = independently a bond, O, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), N(N(Rx)2), SOO-2, or SOO-2SOO-2; Rx = independently H, R1, W3, a protecting group, etc.; R1 = independently H or alkyl; R2 = independently H, R1, halo, CN, N3, NO2,

Y1, Rx, N(Rx)2, SO-2Rx, substituted alkyl, alkenyl, alkynyl, etc.; R3 = halo, CN, N3, NO2, Y1, Rx, N(Rx)2, SRx, SO2Rx, OC(Y1)Rx, OC(Y1)ORx, C(Y1)Rx, etc. with provisos; R5 = substituted alkyl, alkenyl, or alkynyl; or pharmaceutically acceptable salts, hydrates, and formulations thereof] and other phosphonate-substituted analogs of HIV protease inhibitors for

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
treating AIDS and other antiviral infections, as well as for use in assays

for the detection of HIV protease. Comps. of the invention inhibit reverse transcriptase activity and have improved intracellular half-life compared to analogs not having the phosphonate or phosphonate prodrug. Examples include preps. for non-nucleoside saquinavir-like, lopinavir-like, ritonavir-like, indinavir-like, atazanavir-like, nelfinavir-like, tipranavir-like, amprenavir-like, KNI-like, and cyclic carbonyl-like phosphonate protease inhibitors. In addn., extensive biol. data regarding PMSC uptake and metab., serum stability, and alk. phosphatase protease inhibitor (ALPPI) activity of selected phosphonate-substituted prodrugs is presented. For instance, a 9-step reaction sequence starting from N-tert-butoxycarbonyl-O-benzyl-L-tyrosine provided III (Ki ≤ 10 pM for ALPPI activity). The synthesis involved multiple protection and deprotection steps along with coupling reactions using isobutylamine,

(3R,3aR,6aS)-hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate, and dibenzyl hydroxymethylphosphonate.


IT 622866-43-7P

RL: BYP (Byproduct); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622866-43-7 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-(hydroxymethyl)phenyl)methyl]-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 253266-01-2P 605654-08-8P 605654-10-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 253266-01-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 622865-53-6P 622865-86-5P 622866-12-0P

622866-41-5P 622866-42-6P 622866-44-8P

622866-56-2P 622866-86-8P 622867-43-0P

622867-47-4P 622867-48-5P 622867-70-3P

622868-06-8P 622868-82-0P 622869-12-9P


622869-16-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622865-53-6 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-86-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 605654-08-8 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-(phenylmethoxy)phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 605654-10-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-85-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(4-methoxyphenyl)sulfonyl](4-piperidinylmethyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-12-0 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-41-5 CAPLUS


CN Methanesulfonic acid, trifluoro-, 4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622866-42-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-formylphenyl)methyl]-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-44-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-(bromomethyl)phenyl)methyl]-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-56-2 CAPLUS
 CN L-Alanine, N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622867-47-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-48-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[(phenylmethoxy)methyl]-2-[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-70-3 CAPLUS
 CN Propanoic acid, 2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[(triethylsilyl)oxy]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]oxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-86-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-43-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-ethenylphenyl)methyl]-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-06-8 CAPLUS
 CN Pyridinium, 1-[2-[bis(phenylmethoxy)phosphinyl]ethyl]-4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-05-7

CMF C43 H55 N3 O11 P S

Absolute stereochemistry.



CM 2

CRN 37181-39-8


CMF C F3 O3 S

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-82-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[6-[(diethoxyphosphinyl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]methyl]-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[(triethylsilyloxy)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622869-12-9 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



IT 546085-60-3P 622867-36-1P 622869-15-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 546085-60-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-36-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-16-3 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-6-[[4-[(1S)-1-methyl-2-(1-methylethoxy)-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]methyl]-1-phenyl-3-(phenylmethoxy)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 622868-31-9P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN 622868-31-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyp

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-15-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[4-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 622868-57-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622868-57-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-aminophenyl)methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 622865-84-3P 622866-84-6P 622867-34-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622865-84-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[(4-methoxyphenyl)sulfonyl]butyl][(4-methoxyphenyl)sulfonyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-84-6 CAPLUS
 CN Pyridinium, 1-[[[(diethoxyphosphinyl)methyl]-4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl]butyl]phenoxy]methyl]hydroxyphosphinyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 622866-83-5
 CMF C32 H49 N3 O11 P S

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622865-00-3 CAPLUS
 CN Carbamic acid, N-[[[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]butyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl]butyl]phenoxy]methyl]hydroxyphosphinyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)


Absolute stereochemistry.



IT 622870-49-9P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)


RN 622870-49-9 CAPLUS
 CN L-Alanine, N-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl]butyl]amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 622865-08-1P 622866-91-5P 622868-28-4P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622865-08-1 CAPLUS

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.




CM 2

CRN 37181-39-B
 CMF C F3 O3 S



RN 622867-34-9 CAPLUS
 CN Carbamic acid, [(1R,2R)-1-formyl-3-[[[(4-methoxyphenyl)sulfonyl]butyl]amino]-2-[[[(triethylsilyl)oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 622865-00-3P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622866-91-5 CAPLUS
 CN L-Alanine, N-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl]butyl]amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-91-5 CAPLUS
 CN L-Alanine, N-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl]butyl]amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-28-4 CAPLUS
 CN Butanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl]butyl]amino]butyl]phenoxy]methyl]hydroxyphosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




IT 622868-58-0P 622868-59-1P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622868-58-0 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[2-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-59-1 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[2-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

Absolute stereochemistry.



RN 622866-92-6 CAPLUS
 CN D-Alanine, N-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-93-7 CAPLUS
 CN D-Alanine, N-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



IT 622865-70-7P 622865-71-8P 622866-92-6P
 622866-93-7P 622866-95-9P 622866-96-0P
 622866-98-2P 622866-99-3P 622868-52-4P
 622868-54-6P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protease inhibitor; preparation of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)

RN 622865-70-7 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-


methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-71-8 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622866-95-9 CAPLUS
 CN Propanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-96-0 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-98-2 CAPLUS

CN Propanoic acid, 2-[[[S]-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinoyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-99-3 CAPLUS

CN Propanoic acid, 2-[[[R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-

methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinoyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-54-6 CAPLUS

CN Propanoic acid, 2-[[[R)-[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-


methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]amino]ethyl]phenoxyphosphinoyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-53-5

CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



IT 622864-99-7P 622865-02-5P 622865-30-9P
 622865-39-8P 622865-45-6P 622865-55-8P
 622865-56-9P 622865-61-6P 622865-62-7P
 622865-87-6P 622865-89-8P 622865-92-3P
 622865-97-8P 622865-98-9P 622866-08-4P
 622866-09-5P 622866-13-1P 622866-15-3P
 622866-33-5P 622866-34-6P 622866-37-9P
 622866-38-0P 622866-39-1P 622866-40-4P

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-52-4 CAPLUS

CN Propanoic acid, 2-[[[S)-[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-


methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinoyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622868-51-3

CMF C42 H58 N3 O13 P S

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622866-59-5P 622866-67-5P 622866-71-1P
 622866-76-6P 622866-79-9P 622866-80-2P
 622866-81-3P 622866-87-9P 622866-97-1P
 622867-02-1P 622867-03-2P 622867-22-5P
 622867-23-6P 622867-25-8P 622867-27-0P
 622867-30-5P 622867-31-6P 622867-32-7P
 622867-33-8P 622867-35-0P 622867-37-2P
 622867-38-3P 622867-49-6P 622867-71-4P
 622867-79-2P 622867-84-9P 622867-89-4P
 622867-97-4P 622868-15-9P 622868-16-0P
 622868-17-1P 622868-29-5P 622868-32-0P
 622868-64-8P 622868-65-9P 622868-68-2P
 622868-69-3P 622868-70-6P 622868-86-4P
 622868-89-7P 622868-91-1P 622868-92-2P
 622868-94-4P 622868-97-7P 622868-98-8P
 622869-05-0P 622869-06-1P 622869-07-2P
 622869-11-8P 622869-13-0P 622869-17-4P
 622870-99-9P, GS 193786 622871-01-6P, GS 173848
 622871-02-7P, GS 277856 622871-54-9P, GS 273847
 622871-56-1P, GS 191477 622871-60-7P, GS 191482
 622871-64-1P, GS 191479 622871-65-2P, GS 191508
 622871-69-6P, GS 273805 622871-71-0P, GS 273806
 622871-76-5P, GS 277774 622871-81-2P, GS 7921
 622871-82-3P, GS 278052 622871-83-4P, GS 278114
 622871-84-5P, GS 278053 622871-88-9P, GS 273835
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; prepn. of phosphonate-substituted HIV protease inhibitors for treatment of AIDS and other viral infections)
 RN 622864-99-7 CAPLUS
 CN Carbamic acid, [[(1S,2R)-1-[[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-02-5 CAPLUS

CN Carbamic acid, [[(1S,2R)-1-[[[4-[(diphenoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 622865-30-9 CAPLUS

CN Carbanic acid,

[(1S,2R)-2-hydroxy-1-[[4-[(hydroxyphenoxyphosphinyl)methoxy]phenyl]methyl]-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-39-8 CAPLUS


CN Carbanic acid,

2,5-Dioxo-10,14-diaza-3-phosphapentadecan-15-oic acid, 12-hydroxy-10-[[4-methoxyphenyl)sulfonyl]-8,8-dimethyl-1-phenyl-3-(phenylmethoxy)-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

— Ph


RN 622865-56-9 CAPLUS

CN Carbanic acid,

[(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl)methoxy]phenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-45-6 CAPLUS

CN

2,5-Dioxo-9,13-diaza-3-phosphatetradecan-14-oic acid, 11-hydroxy-9-[[4-methoxyphenyl)sulfonyl]-7,7-dimethyl-1-phenyl-3-(phenylmethoxy)-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-55-8 CAPLUS


CN Carbanic acid,

[(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl)methoxy]phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

— Ph


RN 622865-61-6 CAPLUS

CN Carbanic acid,

[(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl)methoxy]phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Ph


RN 622865-62-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-(phosphonomethoxy)phenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-87-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-3-[[1-(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-89-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-3-[[1-(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-92-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methyl]phenyl]amino]methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622865-97-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(bis(phenylmethoxy)phosphinyl)methyl]phenyl]amino]methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-98-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]-1-[[4-(phosphonomethyl)phenyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622866-08-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-09-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-aminophenyl)methyl]-3-[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-13-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-nitrophenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

—Ph

RN 622866-15-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-aminophenyl]methyl]-2-hydroxy-3-[[2-methylpropyl] [4-(phosphonomethoxy)phenyl]sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-33-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[2-methylpropyl] [(3-nitrophenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-34-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-aminophenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-37-9 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl) [4-(phosphonomethoxy)phenyl]sulfonyl]amino]butyl]phenyl]-, C-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-38-0 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-4-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-39-1 CAPLUS
 CN Carbamic acid,
 [4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-[(hydroxyphenoxyposphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-40-4 CAPLUS
 CN L-Alanine,
 N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-[[[(phenylmethoxy)carbonyl]amino]phenyl]butyl](2-methylpropyl)amino)sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-71-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[[4-[(hydroxyphenoxyphosphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-76-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[4-[(diphenoxyphosphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-79-9 CAPLUS

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 622866-59-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Ph


RN 622866-67-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[bis(phenylmethoxy)phosphinyl]methoxy]-4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[[4-[[[hydroxy(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-80-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[[ethoxy(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-81-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[[ethoxyhydroxyphosphinyl]methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622866-87-9 CAPLUS
 CN Carbamic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp


Absolute stereochemistry.



RN 622866-97-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyp


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622867-22-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]([4-(phenylmethoxy)phenyl]sulfonyl)amino]butyl]phenoxy]methyl]phenoxyp


Absolute stereochemistry.



RN 622867-23-6 CAPLUS
 CN 1-Piperazincarboxylic acid, 4-[[[4-[(2R,3S)-4-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxy]phosphinyl]methoxy]phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl]([2-methylpropyl]amino)sulfonyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 622867-02-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenylm

Absolute stereochemistry.




RN 622867-03-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenylm

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

PAGE 1-A



PAGE 1-B

Ph


RN 622867-25-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[2-methylpropyl]([4-(1-piperazinyl)phenyl]sulfonyl)amino]butyl]phenoxy]methyl]phenoxyp

CM 1

CRN 622867-24-7
 CMF C43 H59 N4 O13 P S

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 622867-27-0 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 2-(phenylmethoxy)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

-Ph


RN 622867-31-6 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-32-7 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinyl)sulfonyl]amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-33-8 CAPLUS

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622867-30-5 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(phenyl)sulfonyl]amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(4-(phenylmethoxy)phenyl)sulfonyl]amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-35-0 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(2-phosphonoethyl)amino]methyl]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-37-2 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[[[[(2R,3S)-4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxy]phosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

-OBU-t

RN 622867-38-3 CAPLUS

CN L-Valine, N-[[[1,1-dimethylethoxy]carbonyl]-, (1R,2S)-3-[4-[[[(1S)-2-ethoxy-


1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-OEt


RN 622867-79-2 CAPLUS

CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy)[2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-

hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-49-6 CAPLUS

CN Propanoic acid, 2-[[[(4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[(4-methoxyphenyl)sulfonyl](2-

methylpropyl)amino]-3-[[triethylsilyl]oxy]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-71-4 CAPLUS

CN Propanoic acid, 2-[[[(2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI)


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-84-9 CAPLUS

CN Propanoic acid, 2-[[[(2,6-dimethylphenoxy)[2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, propyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-89-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[[(2S)-2-[[[(4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-1-oxopropoxy]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622867-97-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[1-[[bis(phenylmethoxy)phosphinyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-15-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[3-(acetyloxy)-4-methoxyphenyl)sulfonyl]amino]-2-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl] (phenylmethoxy)phosphinoyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-16-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[3-hydroxy-4-methoxyphenyl)sulfonyl]amino]butyl]phenoxy]methyl] (phenylmethoxy)phosphinoyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-17-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[3-hydroxy-4-methoxyphenyl)sulfonyl]amino]butyl]phenoxy]methyl] (phenylmethoxy)phosphinoyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-29-5 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl]amino]butyl]phenoxy]methyl] (phenylmethoxy)phosphinoyl]oxy]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-32-0 CAPLUS
 CN Propanoic acid, 2-[[[3-formylphenoxy] [4-[(2S,3R)-2-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl]amino]butyl]phenoxy]methyl] phosphinoyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622868-64-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[bis(2,2,2-trifluoroethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



PAGE 1-A

11

Absolute stereochemistry.




PAGE 1-A

PAGE 2-A

CM 1

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2




Absolute stereochemistry.



RN 622868-91-1 CAPLUS
CN Carbamic acid,
[(1S,2R)-1-[[4-[2-[(diphenoxyphosphinyl)methoxy]ethoxy]phen


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl)methyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-92-2 CAPLUS
CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OEt


RN 622868-94-4 CAPLUS
CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-98-8 CAPLUS
CN Carbamic acid, 1-[[[5-[(diethoxyphosphinyl)methoxy]-1,3-dihydro-2H-isindol-2-yl)methyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-05-0 CAPLUS
CN Propanoic acid, 2-[[[4-[[[[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[[[triethylsilyl]oxy]butyl]amino]methyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


OEt

RN 622868-97-7 CAPLUS
CN Carbamic acid, 1-[[[5-[(diethoxyphosphinyl)methoxy]-1,3-dihydro-2H-isindol-2-yl)methyl]-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-[[[triethylsilyl]oxy]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622869-06-1 CAPLUS
CN Propanoic acid, 2-[[[4-[[[[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]amino]methyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-07-2 CAPLUS
CN Propanoic acid, 2-[[[4-[[[[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methylamino]methyl]phenyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622869-11-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-1-[[4-[2-[(hydroxyphenoxyphosphinyl)methoxy]ethoxy]phenyl]methyl]-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622869-13-0 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-01-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[1-[2-(bis(phenylmethoxy)phosphinyl)ethyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-02-7 CAPLUS
 CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622869-17-4 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]methyl]-6-[[4-[[[(1S)-1-methyl-2-(1-methylethoxy)-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]methyl]-1-phenyl-3-(phenylmethoxy)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-99-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-54-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-56-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622871-60-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-3-[[4-fluorophenyl)sulfonyl(2-methylpropyl)amino]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-64-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl

1)methyl]-2-hydroxy-3-[[2-methylpropyl]([4-(trifluoromethyl)phenyl)sulfonyl
 amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-65-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl


1)methyl]-2-hydroxy-3-[[2-methylpropyl]([4-(trifluoromethoxy)phenyl)sulfonyl

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-76-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-2-hydroxy-3-[[2-methylpropyl]([1-oxido-3-
 pyridinyl)sulfonyl amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-81-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl(2-
 methylpropyl)amino]-1-(4-pyridinylmethyl)propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-69-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-2-hydroxy-3-[[2-methylpropyl]([3-pyridinyl)sulfonyl amino]propyl]-
 , (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 622871-71-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-
 pyridinyl)sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-,
 ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622871-82-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(4-formylphenyl)sulfonyl(2-
 methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]
]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-83-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-3-[[4-formylphenyl)sulfonyl(2-methylpropyl)amino]-2-
 hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-84-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-
 (hydroxymethyl)phenyl)sulfonyl(2-methylpropyl)amino]butyl]phenoxy]methyl]
 phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-88-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 methyl]-2-hydroxy-3-[[[(4-methyl-1-piperazinyl)sulfonyl](2-
 methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 313679-71-9P 313682-97-2P 546085-61-4P
 546086-53-7P 622865-01-4P 622865-03-6P
 622865-05-8P 622865-06-9P 622865-07-0P
 622865-09-2P 622865-10-5P 622865-11-6P
 622865-12-7P 622865-13-8P 622865-14-9P
 622865-28-5P 622865-29-6P 622865-31-0P
 622865-32-1P 622865-40-1P 622865-46-7P
 622865-51-4P 622865-54-7P 622865-57-0P
 622865-63-8P 622865-75-2P 622865-79-6P
 622865-83-2P 622865-88-7P 622865-90-1P
 622865-93-4P 622865-99-0P 622866-02-8P
 622866-10-8P 622866-14-2P 622866-16-4P
 622866-17-5P, GS 17389 622866-18-6P 622866-19-7P
 622866-58-4P 622866-60-8P 622866-68-6P
 622866-69-7P 622866-70-0P 622866-72-2P

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622871-72-1P 622871-73-2P, GS 273834
 622871-74-3P 622871-75-4P 622871-77-6P, GS
 277775 622871-78-7P, GS 273851 622871-79-8P, GS 277777
 622871-80-1P 622871-85-6P, GS 278764
 622871-86-7P, GS 278115 622871-87-8P, GS 278116
 622871-89-0P 622871-90-3P 622871-91-4P
 622871-92-5P 622871-93-6P 622871-94-7P
 622871-95-8P 622871-96-9P 622871-97-0P
 622871-98-1P, GS 273811 622871-99-2P
 622872-00-8P 623158-38-3P, GS 77369 623158-39-4P
 , GS 77425 623158-40-7P, GS 191338 623158-44-1P, GS
 273813 623158-45-2P, GS 273812 623158-46-3P, GS 277937
 623158-47-4P, GS 278809 623158-49-6P, GS 278635
 623158-51-0P, GS 278785 623158-55-4P, MF 1912-68
 623158-56-5P, GS 191484


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(protease inhibitor; prepn. of phosphonate-substituted HIV protease
 inhibitors for treatment of AIDS and other viral infections)

RN 313679-71-9 CAPLUS

CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-97-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

622866-73-3P 622866-74-4P 622866-82-4P
 622866-88-0P 622866-89-1P 622866-90-4P
 622866-94-8P 622867-00-9P 622867-01-0P
 622867-04-3P 622867-05-4P 622867-06-5P
 622867-13-4P, GS 191478 622867-14-5P, GS 192041
 622867-15-6P 622867-16-7P, GS 278118
 622867-17-8P, GS 278117 622867-50-9P
 622867-61-2P 622867-72-5P 622867-73-6P
 622867-80-5P 622867-85-0P 622867-86-1P
 622867-90-7P 622867-91-8P 622867-92-9P
 622868-03-5P 622868-20-6P 622868-21-7P
 622868-22-8P 622868-23-9P 622868-24-0P
 622868-26-2P 622868-27-3P 622868-30-8P
 622868-33-1P 622868-37-5P 622868-46-6P
 622868-47-7P 622868-51-3P 622868-53-5P
 622868-60-4P 622868-61-5P 622868-62-6P
 622868-63-7P 622868-66-0P 622868-71-7P
 622868-72-8P 622868-73-9P 622868-74-0P
 622868-75-1P 622868-76-2P 622868-77-3P
 622868-78-4P 622868-79-5P 622868-80-8P
 622868-83-1P 622868-85-3P 622868-87-5P
 622868-90-0P 622868-93-3P 622869-08-3P
 622869-10-7P 622869-14-1P 622870-52-4P
 622870-53-5P 622870-54-6P 622870-55-7P
 622870-56-8P 622870-57-9P 622870-58-0P
 622870-59-1P 622870-60-4P 622870-61-5P
 622870-62-6P 622870-63-7P 622870-64-8P
 622870-65-9P 622870-66-0P 622870-67-1P
 622870-68-2P 622870-69-3P 622870-70-6P
 622870-71-7P 622870-75-1P, GS 192771
 622870-76-2P, GS 192772 622870-77-3P
 622870-78-4P, GS 192781 622870-79-5P
 622870-80-8P 622870-81-9P 622870-82-0P
 622870-83-1P 622870-84-2P 622870-85-3P
 622870-86-4P 622870-87-5P 622870-88-6P
 622870-89-7P 622870-90-0P 622870-91-1P, GS
 273842 622870-92-2P 622870-93-3P 622870-94-4P
 , GS 277957 622870-95-5P, GS 277771 622870-96-6P
 622870-97-7P, GS 192711 622870-98-8P, GS 192710
 622871-00-5P, GS 193816 622871-03-8P, GS 277930
 622871-04-9P, GS 173850 622871-05-0P
 622871-06-1P 622871-07-2P 622871-08-3P, GS
 277929 622871-09-4P 622871-10-7P, GS 277935
 622871-11-8P 622871-12-9P 622871-13-0P
 622871-14-1P 622871-15-2P 622871-16-3P
 622871-17-4P 622871-18-5P 622871-19-6P
 622871-20-9P 622871-21-0P 622871-22-1P
 622871-23-2P 622871-24-3P 622871-45-8P
 622871-46-9P 622871-47-0P 622871-48-1P, GS
 17424 622871-49-2P 622871-50-5P 622871-51-6P
 622871-52-7P 622871-53-8P 622871-55-0P, GS
 273838 622871-57-2P, GS 192779 622871-58-3P, GS 224342
 622871-59-4P, GS 191483 622871-61-8P, GS 192776
 622871-62-9P, GS 224343 622871-63-0P, GS 191480
 622871-66-3P, GS 191717 622871-67-4P
 622871-68-5P 622871-70-9P, GS 273845


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546085-61-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](2-
 methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-53-7 CAPLUS

CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](phenylmet
 hyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-01-4 CAPLUS

CN Carbamic acid,
 N-[[[(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl
]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-03-6 CAPLUS
 CN 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-, bis(1-methylethyl) ester, 5-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-05-8 CAPLUS
 CN Glycine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-06-9 CAPLUS
 CN Glycine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-07-0 CAPLUS
 CN L-Alanine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-09-2 CAPLUS
 CN 8-Oxa-3,5-diaza-4-phosphadecanoic acid, 2,6-diethyl-4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-10-5 CAPLUS
 CN 8-Oxa-3,5-diaza-4-phosphadecanoic acid, 2,6-diethyl-4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-, butyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-11-6 CAPLUS
 CN L-Leucine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-12-7 CAPLUS
 CN L-Leucine,
 N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-13-8 CAPLUS
 CN L-Phenylalanine, N,N'-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phosphinoylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute, stereochemistry.



RN 622865-14-9 CAPLUS
 CN L-Phenylalanine, N,N'-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phosphinoylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-31-0 CAPLUS
 CN L-Alanine,
 N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-32-1 CAPLUS
 CN L-Alanine,
 N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy)methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-28-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]-1-[[4-phosphonophenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 622865-29-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-(diethoxyphosphinyl)phenyl)methyl]-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-40-1 CAPLUS
 CN 3-Oxa-8,12-diaza-1-phosphatridecan-13-oic acid, 1,1,10-trihydroxy-8-[[4-methoxyphenyl)sulfonyl]-6,6-dimethyl-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (10R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-46-7 CAPLUS
 CN 3-Oxa-7,11-diaza-1-phosphadodecan-12-oic acid, 1,1,9-trihydroxy-7-[[4-methoxyphenyl)sulfonyl]-5,5-dimethyl-10-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 1-oxide, (9R,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 622865-51-4 CAPLUS
 CN 10,13-Dioxo-2,6-diaza-12-phosphapentadecanoic acid,
 12-ethoxy-4-hydroxy-6-
 [(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-3-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 12-oxide (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 622865-54-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl
 1)methyl]-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]sulfonyl](2-
 methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


Ph

CM 2
 CRN 75-75-2
 CNF C H4 O3 S



RN 622865-63-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[diethoxyphosphinyl]methoxy]phenyl]sulfonyl
 1](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622865-75-2 CAPLUS
 CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-,
 ethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Ph


RN 622865-57-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phen
 yl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[2-(dimethylamino)ethoxy]phenyl]m
 ethyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 622865-56-9
 CNF C46 H60 N3 O12 P S

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-79-6 CAPLUS
 CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-
 methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-7-oxo-,
 ethyl ester, 4-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622865-83-2 CAPLUS
 CN Acetic acid,
 [[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-
 methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622865-88-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(1-formyl-4-piperidinyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622865-90-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl][(1-methyl-4-piperidinyl)methyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 622865-99-0 CAPLUS
 CN L-Alanine, N,N'-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]amino]phenyl]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-02-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]-1-piperidinyl]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622865-93-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methyl]phenyl]methyl]amino]methyl]-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-10-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]amino]-1-[[4-[(dimethylamino)phenyl]methyl]-2-hydroxypropyl]amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-14-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-aminophenyl)methyl]-3-[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—Ph

RN 622866-16-4 CAPLUS
 CN L-Alanine, N,N'-[[[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622866-17-5 CAPLUS
 CN L-Valine,
 N,N'-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-18-6 CAPLUS
 CN L-Valine,
 N,N'-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-19-7 CAPLUS
 CN Glycine, N-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622866-58-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[3-[[[(diethoxyphosphinyl)methoxy]phenyl]sulfonyl]1-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-60-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[(diethoxyphosphinyl)methoxy]-4-methoxyphenyl]sulfonyl]1-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-68-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-[[[(diethoxyphosphinyl)methoxy]-4-methoxyphenyl]sulfonyl]1-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 622866-69-7 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxy-3-(phosphonomethoxy)phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622866-70-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[(diethoxyphosphinyl)methoxy]-4-hydroxyphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




PAGE 1-A

PAGE 1-B




RN 622866-74-4 CAPLUS
CN L-Alanine, N,N'-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phosphinylidene]bis-, dibutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622866-72-2 CAPLUS
CN Propanoic acid, 2-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 622866-73-3 CAPLUS
CN L-Alanine, N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 622866-82-4 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[(ethoxyphenoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622866-88-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-aminophenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622866-89-1 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-1-[[4-[[bis(ethylamino)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-90-4 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622866-94-8 CAPLUS
 CN L-Alanine,
 N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl] (phenylmethoxy)phosphinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-04-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-05-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 622867-00-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-01-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-06-5 CAPLUS
 CN 3,5,8-Trioxa-4-phosphadecanoic acid, 4-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]-2,6,9-trimethyl-7-oxo-, 1-methylethyl ester, 4-oxide, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622867-13-4 CAPLUS
 CN Carbamic acid,
 [[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622867-14-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-(trifluoromethoxy)phenyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-15-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(formylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622867-50-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-3-[[triethylsilyl]oxy]butyl]methylamino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 622867-61-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-16-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxymethyl)phenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-17-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxymethyl)phenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622867-72-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

-CO₂H

RN 622867-73-6 CAPLUS
 CN Carbamic acid, 2-[[[4-[[2-(diethoxyphosphinyl)ethyl]-3,6-dihydro-1(2H)-pyridinylmethyl]-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622867-80-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[[2-(6-dimethylphenoxy)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 622867-79-2
 CMF C44 H62 N3 O13 P S

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 622867-86-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[[2-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622867-90-7 CAPLUS

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 622867-85-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[[2-(6-dimethylphenoxy)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, propyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 622867-84-9
 CMF C45 H64 N3 O13 P S

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Propanoic acid, 2-[[[4-[[2-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, 2-(1-methyl-4-piperidinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622867-91-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[[2-(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxymethyl]phenoxyposphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622867-92-9 CAPLUS
CN Propanoic acid, 2-[[[4-[(dimethylamino)oxy][4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-03-5 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[1-[2-(dimethoxyphosphinyl)ethyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-22-8 CAPLUS
CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-23-9 CAPLUS
CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622868-20-6 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[(dimethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-21-7 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(1-methylethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-24-0 CAPLUS
CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-26-2 CAPLUS
CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 2-(4-morpholinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622868-27-3 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-30-8 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxy]phosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-33-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-(4-morpholinyl)methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-37-5 CAPLUS
 CN Butanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-46-6 CAPLUS
 CN Butanoic acid, 2-[[[5]-[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-47-7 CAPLUS
 CN Butanoic acid, 2-[[[5]-[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-51-3 CAPLUS
 CN Propanoic acid, 2-[[[5]-[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-53-5 CAPLUS
 CN Propanoic acid, 2-[[[(R)-[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-60-4 CAPLUS
 CN Propanoic acid, 2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 622868-63-7 CAPLUS
 CN Propanoic acid, 2-[[ethoxy[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622868-66-0 CAPLUS
 CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-61-5 CAPLUS
 CN Carbamic acid, [[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(2-phosphonoethyl)amino]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622868-62-6 CAPLUS
 CN Propanoic acid, 2-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 622867-36-1
 CMF C42 H58 N3 O13 P 5

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 622868-71-7 CAPLUS
 CN Propanoic acid, 2-[[[(2-ethoxyphenoxy)[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-72-8 CAPLUS
 CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-73-9 CAPLUS
 CN Propanoic acid, 2-[[[4-(4-butylphenoxy)[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 622868-74-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 622868-75-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 622868-77-3 CAPLUS
 CN Benzoic acid, 3-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy][[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-78-4 CAPLUS
 CN Propanoic acid, 2-[[[3-[(dimethylamino)methyl]phenoxy][4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622868-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-83-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[6-[(diethoxyphosphinyl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-85-3 CAPLUS
 CN Butanoic acid, 2-[[[2-[[4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622868-87-5 CAPLUS
 CN Butanoic acid, 2-[[[2-[[4-[(2S,3R)-2-[[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phenoxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622868-90-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[[2-(phosphonomethoxy)ethoxy]phenyl]methyl]propyl]-, C-[[3-(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622868-93-3 CAPLUS

CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-

methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OEt


RN 622869-08-3 CAPLUS

CN Propanoic acid, 2-[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-

methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methylamino]methyl]phenyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 2 Na

RN 622870-52-4 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-1-[[[4-[(methoxyphenoxyphosphinyl)methoxy]phenyl]methyl]-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 622870-53-5 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622869-10-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622869-14-1 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-1-(phenylmethyl)-2-(phosphonoxy)-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622870-54-6 CAPLUS

CN Carbamic acid,

[(1S,2R)-1-[[[4-[(diethylphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-55-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-56-8 CAPLUS

CN Acetic acid,

[[[4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]phosphinyl]oxy]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-57-9 CAPLUS
 CN L-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-58-0 CAPLUS
 CN L-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-59-1 CAPLUS
 CN D-Alanine, N-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-60-4 CAPLUS
 CN D-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-61-5 CAPLUS
 CN D-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-62-6 CAPLUS
 CN L-Alanine, N-[(R)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-63-7 CAPLUS
 CN L-Alanine, N-[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-64-8 CAPLUS
 CN Butanoic acid, 2-[[[(S)-[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-65-9 CAPLUS
 CN Butanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]amino]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-66-0 CAPLUS
 CN Butanoic acid, 2-[[[(S)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]amino]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-67-1 CAPLUS
 CN Butanoic acid, 2-[[[(R)-[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]amino]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-68-2 CAPLUS
 CN L-Alanine, N-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-69-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-70-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-71-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 3-(4-morpholinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622870-75-1 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-3-methyl-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-76-2 CAPLUS
 CN Butanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-3-methyl-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 622870-79-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-2-(1-piperidinyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 phosphinyl]oxy]-3-methyl-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622870-77-3 CAPLUS
 CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-2,2-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622870-78-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-3-(4-morpholinyl)propyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 622870-80-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-81-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 622870-82-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-(hydroxymethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-83-1 CAPLUS
 CN Propanoic acid, 2-[[[3-(aminomethyl)phenoxy][4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622870-84-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-(1-piperidinylmethyl)phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-85-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]methyl][3-[(2-methoxyethyl)methylamino]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-86-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[[5-oxido-10-phenyl-5-[[2-(phenylmethoxy)ethoxy]-3,6,9-trioxo-5-phosphadec-1-yl]oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



RN 622870-87-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-[(diethoxyphosphinyl)methoxy]ethoxy]phenyl


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1-methyl-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622870-88-6 CAPLUS
 CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

CO₂H

RN 622870-89-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[2-(diethoxyphosphinyl)ethyl]amino]methyl]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-92-2 CAPLUS
 CN Butanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-93-3 CAPLUS
 CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenoxy]ethoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-90-0 CAPLUS
 CN Butanoic acid, 2-[[[2-(2-ethylphenoxy)[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-91-1 CAPLUS
 CN Propanoic acid, 2-[[[2-[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-94-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[[methyl(2-phosphonoethyl)amino]methyl]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622870-95-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[[4-(diethoxyphosphinyl)methoxy]imino]methyl]phenyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622870-96-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[2-(diethoxyphosphinyl)ethyl]-1-piperazinyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622870-97-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[1,2,3,6-tetrahydro-1-(phosphonomethyl)-4-pyridinyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622871-03-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]ethyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-04-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[1,2,3,6-tetrahydro-1-(2-phosphonoethyl)-4-pyridinyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-05-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]amino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622870-98-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[1-[(diethoxyphosphinyl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]methyl]-2-hydroxy-3-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-00-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]-3,6-dihydro-1(2H)-pyridinyl]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 622871-06-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[4-(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]butyl]methylamino]phenyl]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

RN 622871-07-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]amino]methyl]-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-08-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[4-(phosphonophenyl)methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-11-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[3,4-dihydro-6-(phosphonomethoxy)-2(1H)-isoquinolinyl]methyl]-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-12-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[4-(phosphonomethyl)amino]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-09-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-(diethoxyphosphinyl)phenyl]methyl]methylamino]methyl]-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-10-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-[[[4-(phosphonophenyl)methyl]amino]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-13-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[[diethoxyphosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-14-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-1-[[[4-[[[bis(phenylmethoxy)phosphinyl]methyl]amino]phenyl]methyl]-2-hydroxy-3-[[[4-(methoxyphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-15-2 CAPLUS
 CN L-Alanine, N-[(R)-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-16-3 CAPLUS
 CN L-Alanine, N-[(S)-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-19-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-[(4-methylphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-20-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(dimethylamino)ethyl]((4-methoxyphenyl)sulfonyl)amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-21-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(dimethylamino)ethyl]((4-methoxyphenyl)sulfonyl)amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-17-4 CAPLUS
 CN L-Alanine, N-[(R)-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-18-5 CAPLUS
 CN Propanoic acid, 2-[[[2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]amino]ethyl]hydroyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-[[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-22-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-(4-morpholinyl)ethyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-1-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-23-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-(4-morpholinyl)ethyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-24-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-45-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]propyl]-, 2-hydroxy-1-[[4-[(phosphonmethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-48-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(phosphonmethoxy)phenyl]methyl]propyl]-, 2-hydroxy-1-[[4-[(phosphonmethoxy)phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-49-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-46-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-3-[[[4-(ethylamino)phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-47-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-50-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-51-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-52-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, butyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-53-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[(diethoxyphosphinyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[(4-hydroxyphenyl)sulfonyl]-(2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-58-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(phenylsulfonyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-59-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-fluorophenyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-[[[(4-(phosphonomethoxy)phenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-61-8 CAPLUS

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-55-0 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-hydroxyphenyl)sulfonyl]-(2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-57-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(phenylsulfonyl)amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622871-58-3 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-62-9 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-4-[[[(4-fluorophenyl)sulfonyl]-(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-63-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-1-[[[(4-(phosphonomethoxy)phenyl)methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-66-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]methyl]-3-[[4-(cyanophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-67-4 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[4-(1-piperidinyl)phenyl]sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-72-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]butyl]phenoxy]methyl](phenylmethoxy)phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-73-2 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-68-5 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)[4-(1-piperidinylmethyl)phenyl]sulfonyl]amino]butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622871-70-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(3-pyridinylsulfonyl)amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-1[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 622871-74-3 CAPLUS
 CN Pyridinium, 3-[[[(2R,3S)-4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]1]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-75-4 CAPLUS
 CN Pyridinium, 3-[[[(2R,3S)-4-[[bis(phenylmethoxy)phosphinyl]methoxy]phenyl]1]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino]sulfonyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-77-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(1-oxido-3-pyridinyl)sulfonyl]amino]-1-[[4-(phosphonomethoxy)phenyl]methyl]propyl]-, C-1[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-78-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-79-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-86-7 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-87-8 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 622871-80-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-85-6 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 622871-89-0 CAPLUS
 CN Carbamic acid, [[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[(2-methylpropyl)amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-90-3 CAPLUS
 CN L-Alanine, N-[[[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]butyl]phenoxy]methyl]hydroxyphosphinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PAGE 1-B

CO₂H


RN 622871-91-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[4-[(diphenoxyphosphinyl)methoxy]phenyl]sulfonyl]amino]propyl]-, (2-methylpropyl)amino]-2-hydroxy-1-[(4-nitrophenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622871-92-5 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(2-methylpropyl)amino]sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PAGE 1-B



RN 622871-95-8 CAPLUS
CN L-Alanine, N-[(S)-[[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 622871-96-9 CAPLUS
CN L-Alanine, N-[(R)-[[4-[[[(2R,3S)-4-(4-(ethylamino)phenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 622871-93-6 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)amino]sulfonyl]amino]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622871-94-7 CAPLUS
CN L-Alanine, N-[(R)-[[4-[[[(2R,3S)-4-(4-aminophenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 622871-97-0 CAPLUS
CN L-Alanine, N-[(S)-[[4-[[[(2R,3S)-4-(4-(ethylamino)phenyl)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]phenoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 622871-98-1 CAPLUS
 CN Propanoic acid, 2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-3-(phosphonooxy)butyl]phenoxy]methyl]phenoxyphosphinyl]oxy]-, 1-[1-methylethyl] ester, disodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 Na

RN 622871-99-2 CAPLUS
 CN D-Valine, [(1R,2S)-3-[4-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]methyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622872-00-8 CAPLUS
 CN D-Valine, [4-[[[[(2R,3S)-4-[4-[[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 623158-38-3 CAPLUS
 CN L-Alanine, N-[[[4-[[[[(2R,3S)-4-(4-aminophenyl)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]phenoxymethyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 623158-39-4 CAPLUS
 CN L-Alanine, N-[[[4-[[[[(2R,3S)-4-[4-(ethylamino)phenyl]-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl](2-methylpropyl)amino)sulfonyl]phenoxymethyl]phenoxyphosphinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 623158-40-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[[diethoxyphosphinyl]methyl]phenyl]methyl]-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 623158-44-1 CAPLUS


CN Pyridinium, 3-[[[(2R,3S)-4-{4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-75-4

CMF C39 H53 N3 O13 P S

Absolute stereochemistry.




CM 2

CRN 37181-39-8

CMF C F3 O3 S

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 623158-47-4 CAPLUS

CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phenoxy]phosphinyl]oxy]-, 2-hydroxyethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

OH

RN 623158-49-6 CAPLUS

CN L-Valine, [4-[[[(2R,3S)-4-{4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 623158-45-2 CAPLUS


CN Pyridinium, 3-[[[(2R,3S)-4-{4-[[[(bis(phenylmethoxy)phosphinyl)methoxy]phenyl]-1-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxybutyl] (2-methylpropyl)amino]sulfonyl]-1-methyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 622871-74-3

CMF C42 H53 N3 O11 P S

Absolute stereochemistry.



CM 2

CRN 37181-39-8

CMF C F3 O3 S



RN 623158-46-3 CAPLUS

CN Propanoic acid, 2-[[[(4-[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[(4-methyl-1-piperazinyl)phenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phe

piperazinyl]phenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl]phe

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


methoxyphenyl)sulfonyl] (2-methylpropyl)amino]butyl]phenoxy]methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 623158-48-5

CMF C45 H62 N3 O15 P S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 623158-51-0 CAPLUS

CN L-Valine, (1R,2S)-3-{4-[[[(1S)-2-ethoxy-1-methyl-2-oxoethoxy]phenoxyphosphinyl]methoxy]phenyl]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-1-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]methyl]propyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 623158-50-9

CMF C45 H62 N3 O15 P S

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 623158-55-4 CAPLUS
CN Propanoic acid, 2-[[[(2-ethoxyphenoxy)[2-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-, ethyl ester, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 623158-54-3
CMF C44 H62 N3 O14 P S

Absolute stereochemistry.

L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 623158-56-5 CAPLUS
CN Propanoic acid, 3-[[[4-[(2S,3R)-2-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl]methyl]amino]ethyl]phosphinyl]oxy]-2,2-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:757713 CAPLUS
DN 139:276880
TI Preparation of carbamates as HIV protease inhibitors
IN Ghosh, Arun K.; Bilcer, Geoffrey M.; Devasamudram, Thippeswamy
PA The Board of Trustees of the University of Illinois, USA
SO PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003078438	A1	20030925	WO 2003-US7032	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004039016	A1	20040226	US 2003-382435	20030306
US 7157489	B2	20070102		
CA 2478731	A1	20030925	CA 2003-2478731	20030307
AU 2003213776	A1	20030929	AU 2003-213776	20030307
EP 1485387	A1	20041215	EP 2003-711467	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504621	T	20060209	JP 2003-576443	20030307
US 2007082883	A1	20070412	US 2006-593665	20061107
PRAI US 2002-363628P	P	20020312		
US 2002-433627P	P	20021213		
US 2003-382435	A3	20030306		
WO 2003-US7032	W	20030307		
OS HARPAT 139:276880				
GI				




I

AB R102CNHCH(CH2Ph)CH(OH)CHR4NR2R3 [R1 = alkyl, aryl, heterocyclic; R2 = H, (un)substituted alkyl, NH2, heterocyclic, cycloalkyl; R3 = (un)substituted cyclohexadienylsulfonyl, arylsulfonyl, aryl, aralkylsulfonyl, heterocyclylsulfonyl, aralkanoyl, heterocyclic, acrylamino, arylsulfonylamino; NR2R3 = heterocyclic; R4 = H, (un)substituted heterocyclylalkyl] were prepared for use as HIV protease inhibitors in


L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
treating wild-type HIV and of multidrug-resistant strains of HIV. Thus, the carbamate I was prepd. in a multi-step synthesis and has K_i 2.1 nM for inhibition of HIV protease.
IT 253266-00-1P 605653-36-9P 605654-11-3P 605654-58-8P 605654-59-9P 605655-24-1P
RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (Preparation of carbamates as HIV protease inhibitors)
RN 253266-00-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-(aminomethyl)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605653-36-9 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-[[[4-methylphenyl]sulfonyl]oxy]methyl]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A


L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 605654-59-9 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(nitrophenyl)sulfonyl][(2R)-5-oxo-2-pyrrolidinyl]methyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605655-24-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[5-hexenyloxy]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 253266-03-4P 605653-37-0P 605653-38-1P 605653-39-2P 605653-59-6P 605653-62-1P 605653-64-3P 605653-67-6P 605653-69-8P 605653-71-2P 605653-77-8P 605653-92-7P 605653-94-9P 605653-95-0P 605653-97-2P 605653-98-3P 605653-99-4P 605654-07-7P 605654-08-8P 605654-10-2P 605654-15-7P 605654-18-0P 605654-57-7P 605654-60-2P 605654-67-9P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Preparation of carbamates as HIV protease inhibitors)
RN 253266-03-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(hydroxymethyl)phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-


hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PAGE 1-B




RN 605654-11-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[5-hexenyloxy]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605654-58-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(nitrophenyl)sulfonyl][(2R)-5-oxo-2-pyrrolidinyl]methyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605653-37-0 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-[(methylamino)methyl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605653-38-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-[(hydroxymethyl)imino]methyl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 605653-39-2 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(3-hydroxy-1-propenyl)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry unknown.




RN 605653-59-6 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(1-benzoyl-4-piperidinyl)methyl]-2-hydroxy-3-[(4-methylphenyl)sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605653-62-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-methylphenyl)sulfonyl](2-methylpropyl)amino]-1-[(1-(phenylmethyl)-4-piperidinyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605653-64-3 CAPLUS

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 605653-71-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[2-(dimethylamino)ethyl][3-(hydroxymethyl)-4-methylphenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605653-77-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(5-nitro-3-pyridinyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 605653-92-7 CAPLUS
CN Hydrazinecarboxylic acid, 2-[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]-2-[(4-


L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Carbamic acid, [(1S,2R)-3-[[[(4-chloro-3-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605653-67-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(4-chloro-3-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605653-69-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(hydroxymethyl)-4-methylphenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605653-94-9 CAPLUS
CN Benzenesulfonic acid, 4-methoxy-, 1-[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]hydrazide, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 605653-93-8
CMF C24 H31 N3 O8 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 605653-95-0 CAPLUS
CN Hydrazinecarboxylic acid, 2-[(3-amino-4-fluorophenyl)sulfonyl]-2-[(2R,3S)-


L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605653-97-2 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl] [(4-methoxyphenyl)sulfonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605653-98-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (1-methyl-3-azetidinyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 605654-08-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605654-10-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-[[[(4-hydroxyphenyl)methyl]-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605654-15-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(5-hexenyl)[2-(2-propenyloxy)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 605653-99-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (1-methyl-3-azetidinyl)amino]-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605654-07-7 CAPLUS
 CN Carbamic acid, [(1S,2S)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 605654-18-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-(3-butenyloxy)phenyl)sulfonyl] (5-hexenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605654-57-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl] [(2R)-5-oxo-2-pyrrolidinyl]methyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 605654-60-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3-aminophenyl)sulfonyl] [(2R)-5-oxo-2-pyrrolidinyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 605654-67-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-((4-methoxyphenyl)sulfonyl)-1-((2S)-5-oxo-2-pyrrolidinylmethyl)amino)-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 605655-10-5P 605655-11-6P 605655-12-7P
 605655-13-8P 605655-14-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of carbamates as HIV protease inhibitors)
 RN 605655-10-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-(azidomethyl)phenyl)sulfonyl)-2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry unknown.

RN 605655-14-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-((4-(2-(hydroxyamino)ethenyl)phenyl)sulfonyl)-1-((2S)-5-oxo-2-pyrrolidinylmethyl)amino)-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


IT 333798-27-9P 605654-48-6P 605654-50-0P
 605654-88-4P 605654-89-5P 605654-90-8P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of carbamates as HIV protease inhibitors)
 RN 333798-27-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)-2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605654-48-6 CAPLUS

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 605655-11-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-(4-azidophenyl)sulfonyl)-1-((2S)-5-oxo-2-pyrrolidinylmethyl)amino)-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 605655-12-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-((4-(4-(hydroxyimino)methyl)phenyl)sulfonyl)-1-((2S)-5-oxo-2-pyrrolidinylmethyl)amino)-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 605655-13-8 CAPLUS
 CN 2-Propenoic acid, 3-[4-(((2R,3S)-3-(((3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl)oxy)carbonyl)amino)-2-hydroxy-4-phenylbutyl]-2-methylpropyl)amino]sulfonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry unknown.

RN 605654-50-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-(4-aminophenyl)sulfonyl)-1-((2R)-5-oxo-2-pyrrolidinylmethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 605654-88-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-(4-aminophenyl)sulfonyl)-1-((2R)-5-oxo-2-pyrrolidinylmethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 605654-69-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[[3-methoxy-4-(methylamino)phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 605654-90-8 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[4-(ethylamino)-3-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:737734 CAPLUS
 DN 139:261299
 TI Preparation of broad spectrum substituted benzimidazolesulfonamide HIV protease inhibitors
 IN Surleaux, Dominique Louis Nestor Ghislain; Wigerinck, Piet Tom Bert Paul;
 Voets, Marieke Christiane Johanna; Vendeveille, Sandrine Marie Helene; De Kock, Herman Augustinus; Vergouwen, Bernhard Joanna Bernard
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003076413	A1	20030918	WO 2003-EP50057	20030312
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2479012	A1	20030918	CA 2003-2479012	20030312
AU 2003219159	A1	20030922	AU 2003-219159	20030312
BR 2003003373	A	20040323	BR 2003-3373	20030312
EP 1485358	A1	20041215	EP 2003-714954	20030312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005519952	T	20050707	JP 2003-574633	20030312
US 2005171175	A1	20050804	US 2003-508561	20030312
CN 1653053	A	20050810	CN 2003-810472	20030312
ZA 2004007242	A	20051004	ZA 2004-7242	20040909
PRAI EP 2002-75999	A	20020312		
WO 2003-EP50057	W	20030312		
OS MARPAT 139:261299				
GI				

L7 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I (R1 = H, alkyl, alkenyl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, heterocyclylalkyl, aminoalkyl; R2 = H, alkyl; R3 = (un)substituted alkyl, aryl, cycloalkyl; R4 = H, (un)substituted CO2H, CONH2, cycloalkyl, alkenyl, alkynyl, OH, NH2; R5 = H, (un)substituted alkyl; R6 = H, (un)substituted alkyl, NH2; L = CO, CO2, (un)substituted NHCO, OXCO, NHXCO, SO2, SO3, NHSO2, NHXSO2, where either or SO12 is attached to NR2; X = alkanediyl were prepared. Thus, Me 2-benzimidazolecarbamate was chlorosulfonylated, treated with (1S,2R)-PhCH2CH(NHBoc)CH(OH)CH2NHCH2CHMe2, deblocked, and treated with 2,6-Me2C6H3OCH2CO2H to give the title compound II which had pIC50 against HIV-1 strain LAI of 8.5.

IT 602310-43-OP
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of broad spectrum substituted benzimidazolesulfonamide HIV protease inhibitors)

RN 602310-43-0 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[[[1-methyl-1H-benzimidazol-6-yl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 602310-05-4P 602310-07-6P 602310-10-1P
 602310-14-5P 602310-23-6P 602310-49-6P
 602310-58-7P 602310-63-4P 602310-82-7P
 602310-84-9P 602310-90-7P 602311-00-2P
 602311-05-7P 602311-13-7P 602311-15-9P
 602311-21-7P 602311-29-5P 603066-61-1P
 603066-62-2P 603066-63-3P 603066-64-4P
 603066-65-5P 603066-66-6P 603066-67-7P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BLOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of broad spectrum substituted benzimidazolesulfonamide


HIV protease inhibitors)

RN 602310-05-4 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(1-(phenylmethyl)-1H-benzimidazol-6-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 602310-07-6 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methyl-1-(phenylmethyl)-1H-benzimidazol-6-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 602310-10-1 CAPLUS


CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(1-(2-methylpropyl)-

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(1-[2-(1-pyrrolidinyl)ethyl]-1H-benzimidazol-6-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 602310-58-7 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-methyl-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 602310-63-4 CAPLUS


CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(1-(4-pyridinylmethyl)-1H-benzimidazol-6-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

1H-benzimidazol-6-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 602310-14-5 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(1-(2-phenylethyl)-1H-benzimidazol-6-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 602310-23-6 CAPLUS

CN Carbamic acid,

[5-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 602310-49-6 CAPLUS

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 602310-82-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(1-(2-phenylethyl)-2-[[2-(1-pyrrolidinyl)ethyl]amino]-1H-benzimidazol-6-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 602310-84-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-1-methyl-1H-benzimidazol-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 602310-90-7 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[1-(2-hydroxyethyl)-1H-benzimidazol-6-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 602311-00-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[2-[[3-(dimethylamino)-1-oxopropyl]amino]-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 602311-15-9 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(hydroxymethyl)-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 602311-21-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[1-(2-(dimethylamino)ethyl)-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 602311-05-7 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[1-(1-methyl-1H-imidazol-5-yl)methyl]-1H-benzimidazol-6-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 602311-13-7 CAPLUS

CN Carbamic acid, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [5-[[[[(2R,3S)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-1H-benzimidazol-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 602311-29-5 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[1-(1-methyl-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 603066-61-1 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl){[1-(phenylmethyl)-1H-benzimidazol-6-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 603066-62-2 CAPLUS
 CN Carbamic acid, [5-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603066-63-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[1-[2-(2-pyridinyl)ethyl]-1H-benzimidazol-6-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 603066-67-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 602312-19-6P 602312-22-1P 602312-25-4P
 602312-28-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of broad spectrum substituted benzimidazolesulfonamide)

HIV protease inhibitors)

RN 602312-19-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-1-(2-phenylethyl)-1H-benzimidazol-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 603066-64-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-(acetylamino)-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603066-65-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603066-66-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-[(dimethylamino)ethyl]amino)carbonyl]amino]-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 602312-22-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-3-(2-phenylethyl)-2-thioxo-1H-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 602312-25-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-(methylthio)-1-(2-phenylethyl)-1H-benzimidazol-6-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 602312-28-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-(methylsulfinyl)-1-(2-phenylethyl)-1H-benzimidazol-6-yl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:511143 CAPLUS

DN 139:85387

TI Preparation of heterocyclic substituted phenylsulfonamides as broad-spectrum HIV protease inhibitors

IN Vendeville, Sandrine Marie Helene; Verschueren, Wim Gaston; Tahri, Abdellah; Moore, Samuel Leo Christiaan; Erra Sola, Montserrat

PA Tibotec Pharmaceuticals Ltd., Ire.

SO PCT Int. Appl., 74 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CHT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003053435	A1	20030703	WO 2002-EP14839	20021220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2470964	A1	20030703	CA 2002-2470964	20021220
AU 2002361235	A1	20030709	AU 2002-361235	20021220
EP 1463502	A1	20041006	EP 2002-796754	20021220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002015260	A	20041207	BR 2002-15260	20021220
JP 2005513102	T	20050512	JP 2003-554192	20021220
CN 1620292	A	20050525	CN 2002-828166	20021220
HU 200500164	A2	20050530	HU 2005-164	20021220
NZ 533665	A	20051028	NZ 2004-533665	20040621
IN 2004DN01777	A	20050401	IN 2004-DN1777	20040622
NO 2004003114	A	20040920	NO 2004-3114	20040720
ZA 2004005784	A	20050831	ZA 2004-5784	20040720
US 2005222215	A1	20051006	US 2005-499221	20050412
PRAI EP 2001-205115	A	20011221		
WO 2002-EP14839	W	20021220		
OS MARPAT 139:85387				
GI				



AB R11N(R2)CHR3CH(OH)CH2N(R4)SO2C6H4R5 [R1 = H, alkyl, alkenyl, aralkyl,

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, heterocyclylalkyl, (un)substituted CH2CH2NH2; L = CO, O2C, (un)substituted NHCO, oxalkylcarbonyl, aminoalkylcarbonyl, SO2, O3S, (un)substituted NHSO2; R2 = H, alkyl; R3 = alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl; R4 = H, (un)substituted CO2H, CONH2, cycloalkyl, alkenyl, alkynyl, alkyl; R5 = (un)substituted heteroaryl were prepd. for use as broad-spectrum HIV protease inhibitors. Thus, (1S,2R)-Me3CO2CNHCH(CH2Ph)CH(OH)CH2NHCH2CHMe2 was treated with 4-NCC6H4SO2Cl to give (1S,2R)-Me3CO2CNHCH(CH2Ph)CH(OH)CH2N(CH2CHMe2)SO2C6H4CN-4 which was deblocked and treated with the hexahydrofurofuran-2-yl carbonyloxypyrrolidinedione to give the carbamate I [R6 = CN]. Treatment of I [R6 = CN] with NH2OH.HCl gave I [R6 = C(NH2).NOH] which was cyclized with 2-furoyl chloride to

give I [R6 = 5-(2-furyl)-1,2,4-oxadiazol-3-yl] which had pEC50 = 8.4 for inhibition of HIV-1.

IT 553643-70-2P 553643-72-4P 553643-75-7P
553643-79-1P 553643-83-7P 553643-87-1P
553643-91-7P 553644-41-0P 553644-43-2P
553644-45-4P 553644-48-7P 553644-50-1P
553644-52-3P 553644-54-5P 553644-55-6P
553644-57-8P 553644-59-0P 553644-61-4P
553644-64-7P 553644-66-9P 553644-68-1P
553644-70-5P 553644-71-6P 553644-72-7P
553644-73-8P 553644-74-9P 553644-75-0P
553644-76-1P 553644-77-2P 553644-78-3P
553644-79-4P 553644-80-7P 553644-81-8P
553644-82-9P 553644-83-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic substituted phenylsulfonamides as broad-spectrum HIV protease inhibitors)

RN 553643-70-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-[2-(methylamino)-4-thiazolyl]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 553643-72-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-[2-amino-4-thiazolyl]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553643-75-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-[2-(acetilamino)-4-thiazolyl]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 553643-79-1 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-[2-[(1-pyrrolidinyl)ethyl]amino]-4-thiazolyl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 553643-83-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-[2-(4-pyridinylamino)-4-thiazolyl]phenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 553644-41-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-(2-methyl-1H-imidazol-4-yl)phenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553644-43-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-[2-(acetyl-amino)-1H-imidazol-4-yl]phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 553644-45-4 CAPLUS
 CN Carbamic acid, [4-[4-[(2R,3S)-3-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 553643-87-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-[2-[(3-(dimethylamino)propyl]amino]-4-thiazolyl]phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 553643-91-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-(2-amino-5-methyl-4-thiazolyl)phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylpropyl]amino]sulfonyl]phenyl]-1H-imidazol-2-yl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 553644-48-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-(2-amino-1H-imidazol-4-yl)phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 553644-50-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(2-methyl-4-oxazolyl)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553644-52-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-[2-(5-thiazolylmethoxy)-4-oxazolyl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B




L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 553644-54-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(2-amino-4-oxazolyl)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553644-55-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[5-(2-furanyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 553644-57-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-[5-(phenylmethoxy)methyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 553644-59-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-[5-propyl-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 553644-61-4 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 553644-64-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[4-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 553644-66-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[4-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 553644-68-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 553644-71-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-[5-(3-isoxazolyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 553644-72-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-[5-(4-iodophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 553644-70-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 553644-73-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[5-(acetyloxyphenylmethyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 553644-74-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553644-75-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[4-[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 553644-76-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-(4-bromophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 553644-77-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-(4-cyanophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 553644-80-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-(1,3-benzodioxol-5-yl)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553644-81-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-pyrazinyl)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 553644-82-9 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-pyridinyl)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 553644-78-3 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(4-imidazo[2,1-b]thiazol-6-yl)phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 553644-79-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-(1H-tetrazol-5-yl)phenyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 553644-83-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 553645-10-6P 553645-11-7P 553645-14-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic substituted phenylsulfonamides as broad-spectrum HIV protease inhibitors)

RN 553645-10-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-(4-cyanophenyl)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 553645-11-7 CAPLUS
 CN Carbanic acid,
 ((1S,2R)-2-hydroxy-3-[[4-[(hydroxyamino)iminomethyl]phenyl
 sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553645-14-0 CAPLUS
 CN Carbanic acid,
 ((1S,2R)-3-[[4-bromophenyl)sulfonyl](2-methylpropyl)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:472395 CAPLUS
 DI 139:47200
 TI Combination of cytochrome P 450 inhibitors and HIV protease inhibitors to
 treat retrovirus infections
 IN Van Der Geest, Ronald; Stoffels, Paul; Groen, Cornelis; Jochmans, Dirk
 Edward Desire
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 63 pp.
 CODEN: PIIKXD
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049746	A2	20030619	WO 2002-EP14277	20021212
WO 2003049746	A3	20031231		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2469343	A1	20030619	CA 2002-2469343	20021212
AU 2002358713	A1	20030623	AU 2002-358713	20021212
EP 1458447	A2	20040922	EP 2002-793018	20021212
R:	AE, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002015043	A	20041103	BR 2002-15043	20021212
CN 1604803	A	20050406	CN 2002-824911	20021212
JP 200511723	T	20050428	JP 2003-550795	20021212
US 2005119338	A1	20050602	US 2003-498024	20021212
NZ 533826	A	20060428	NZ 2002-533826	20021212
ZA 2004004633	A	20050901	ZA 2004-4633	20040610
NO 2004002666	A	20040909	NO 2004-2666	20040624
EP 2001-204841	A	20011212		
WO 2002-EP14277	W	20021212		

OS MARPAT 139:47200
 AB The present invention relates to a method for improving the pharmacokinetics of hexahydrofuro[2,3-b]furan-3-yl containing HIV protease inhibitors comprising administering to a human in need thereof a combination of a therapeutically effective amount of a hexahydrofuro[2,3-b]furan-3-yl containing HIV protease inhibitor, and a therapeutically effective amount of a cytochrome P450 inhibitor.

IT 253266-01-2 253266-01-2D, esters 333798-27-9
 333798-27-9D, esters 470704-39-3 470704-39-3D,
 esters 470704-42-8 470704-42-8D, esters
 470704-44-0 470704-44-0D, esters 470704-47-3
 470704-47-3D, esters 470704-54-2 470704-54-2D,
 esters 470704-55-3 470704-55-3D, esters
 473737-28-0 473737-28-0D, esters 473737-30-3
 473737-30-3D, esters 473737-31-4 473737-31-4D,
 esters 473737-33-6 473737-33-6D, esters
 473737-35-8 473737-35-8D, esters 473737-37-0
 473737-37-0D, esters 473737-39-2 473737-39-2D,
 esters 473737-41-6 473737-41-6D, esters

L7 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

473737-42-7 473737-42-7D, esters 473737-43-8
 473737-43-8D, esters 473737-44-9 473737-44-9D,
 esters 473774-92-4 473774-92-4D, esters
 473774-93-5 473774-93-5D, esters 473774-94-6
 473774-94-6D, esters 473774-95-7 473774-95-7D,
 esters 473774-96-8 473774-96-8D, esters
 473774-97-9 473774-97-9D, esters 473774-98-0
 473774-98-0D, esters 473774-99-1 473774-99-1D,
 esters 473775-00-7 473775-00-7D, esters 473775-01
 -8 473775-01-8D, esters 473775-04-1
 473775-04-1D, esters 475487-76-4 475487-76-4D,
 esters 475488-79-0 475488-79-0D, esters
 475976-40-0 475976-40-0D, esters 546085-57-8
 546085-57-8D, esters 546085-58-9 546085-58-9D,
 esters 546085-59-0 546085-59-0D, esters
 546085-60-3 546085-60-3D, esters 546085-61-4
 546085-61-4D, esters 546085-62-5 546085-62-5D,
 esters 546085-63-6 546085-63-6D, esters
 546085-64-7 546085-64-7D, esters 546085-65-8
 546085-65-8D, esters 546085-66-9 546085-66-9D,
 esters 546085-67-0 546085-67-0D, esters
 546085-68-1 546085-68-1D, esters 546085-69-2
 546085-69-2D, esters 546085-70-5 546085-70-5D,
 esters 546085-71-6 546085-71-6D, esters
 546085-72-7 546085-72-7D, esters 546085-73-8
 546085-73-8D, esters 546085-74-9 546085-74-9D,
 esters 546085-75-0 546085-75-0D, esters
 546085-76-1 546085-76-1D, esters 546085-77-2
 546085-77-2D, esters 546085-78-3 546085-78-3D,
 esters 546085-79-4 546085-79-4D, esters
 546085-80-7 546085-80-7D, esters 546085-81-8
 546085-81-8D, esters 546085-82-9 546085-82-9D,
 esters 546085-83-0 546085-83-0D, esters
 546085-84-1 546085-84-1D, esters 546085-85-2
 546085-85-2D, esters 546085-86-3 546085-86-3D,
 esters 546085-87-4 546085-87-4D, esters
 546085-88-5 546085-88-5D, esters 546085-89-6
 546085-89-6D, esters 546085-90-9 546085-90-9D,
 esters 546085-91-0 546085-91-0D, esters
 546085-92-1 546085-92-1D, esters 546085-93-2
 546085-93-2D, esters 546085-94-3 546085-94-3D,
 esters 546085-95-4 546085-95-4D, esters
 546085-96-5 546085-96-5D, esters 546085-97-6
 546085-97-6D, esters 546085-98-7 546085-98-7D,
 esters 546085-99-8D, esters 546086-01-5
 546086-01-5D, esters 546086-02-6 546086-02-6D,
 esters 546086-03-7 546086-03-7D, esters
 546086-04-8 546086-04-8D, esters 546086-05-9
 546086-05-9D, esters 546086-06-0 546086-06-0D,
 esters 546086-07-1 546086-07-1D, esters
 546086-08-2 546086-08-2D, esters 546086-09-3
 546086-09-3D, esters 546086-10-6 546086-10-6D,
 esters 546086-11-7 546086-11-7D, esters
 546086-12-8 546086-12-8D, esters 546086-13-9
 546086-13-9D, esters 546086-14-0 546086-14-0D,
 esters 546086-15-1 546086-15-1D, esters
 546086-16-2 546086-16-2D, esters 546086-17-3
 546086-17-3D, esters 546086-18-4 546086-18-4D,
 esters 546086-19-5 546086-19-5D, esters
 546086-20-8 546086-20-8D, esters 546086-21-9

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

546086-21-9D, esters 546086-22-0 546086-22-0D, esters 546086-23-1 546086-23-1D, esters 546086-24-2 546086-24-2D, esters 546086-25-3 546086-25-3D, esters 546086-26-4 546086-26-4D, esters 546086-27-5 546086-27-5D, esters 546086-28-6 546086-28-6D, esters 546086-29-7 546086-29-7D, esters 546086-30-0 546086-30-0D, esters 546086-31-1 546086-31-1D, esters 546086-32-2 546086-32-2D, esters 546086-33-3 546086-33-3D, esters 546086-34-4 546086-34-4D, esters 546086-35-5 546086-35-5D, esters 546086-36-6 546086-36-6D, esters 546086-37-7 546086-37-7D, esters 546086-38-8 546086-38-8D, esters 546086-39-9 546086-39-9D, esters 546086-40-2 546086-40-2D, esters 546086-41-3 546086-41-3D, esters 546086-42-4 546086-42-4D, esters


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of cytochrome P 450 inhibitors and HIV protease

inhibitors to treat retrovirus infections and increase pharmacokinetics of HIV protease inhibitors in relation to resistance)

RN 253266-01-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253266-01-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 470704-39-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 470704-42-8 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[[[2-[(2-(dimethylamino)ethyl)amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 333798-27-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333798-27-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 470704-39-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

-NMe2

RN 470704-42-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[2-[(2-(dimethylamino)ethyl)amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


-NMe2

RN 470704-44-0 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[2-[(ethoxycarbonyl)amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 470704-44-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(ethoxycarbonyl)amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 470704-47-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(pyrrolidinyl)ethylamino]-6-benzoxazolylsulfonylamino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 470704-54-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(pyrrolidinyl)ethylamino]-6-benzoxazolylsulfonylamino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 470704-47-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(pyrrolidinyl)ethylamino]-6-benzoxazolylsulfonylamino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470704-54-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(pyrrolidinyl)propylamino]-6-benzoxazolylsulfonylamino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 470704-55-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(pyrrolidinyl)ethylamino]-6-benzoxazolylsulfonylamino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 470704-55-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(pyrrolidinyl)ethylamino]-6-benzoxazolylsulfonylamino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473737-29-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[3-(dimethylamino)propyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473737-30-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[2-(1-pyrrolidinyl)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 473737-29-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[3-(dimethylamino)propyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473737-30-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[2-(1-pyrrolidinyl)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 473737-31-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[[2-(1-pyrrolidinyl)ethyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 473737-31-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[[2-(1-pyrrolidinyl)ethyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 473737-33-6 CAPLUS
 CN Carbamic acid, [2-[[[6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-2-benzothiazolyl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 473737-33-6 CAPLUS
 CN Carbamic acid, [2-[[[6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-2-benzothiazolyl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 473737-35-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[3-(dimethylamino)propyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473737-35-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[3-(dimethylamino)propyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 473737-37-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[[2-(methylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 473737-37-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[[2-(methylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—NHMe

RN 473737-39-2 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-3-oxo-1-piperazinyl)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

—Me


RN 473737-41-6 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[2-(3-methyl-2-oxo-1-imidazolidinyl)-

6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

—Me

RN 473737-41-6 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[2-(3-methyl-2-oxo-1-imidazolidinyl)-

6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

—Me


RN 473737-39-2 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-3-oxo-1-piperazinyl)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Me


RN 473737-42-7 CAPLUS

CN Carbamic acid,

[(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-3-oxo-1-piperazinyl)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 473737-42-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-2-oxo-1-piperazinyl)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-A



RN 473737-43-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[2-(dimethyloxidoamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-B



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473737-44-9 CAPLUS
 CN Carbamic acid, [2-(dimethylamino)ethyl][6-[[[2-(2R,3S)-3-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-2-benzothiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 473737-44-9 CAPLUS
 CN Carbamic acid, [2-(dimethylamino)ethyl][6-[[[2-(2R,3S)-3-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino)sulfonyl]-2-benzothiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473774-92-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 473774-92-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473774-93-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(ethoxycarbonyl)amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473774-93-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(ethoxycarbonyl)amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

NMe2

RN 473774-95-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(dimethylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

NMe2

RN 473774-95-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(dimethylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 473774-94-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(dimethylamino)acetyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NMe2


RN 473774-94-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(dimethylamino)acetyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NMe2

RN 473774-96-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(1-piperazinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 473774-96-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(1-

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 piperazinylacetyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-
 (phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473774-97-9 CAPLUS
 CN Glycine, N-[6-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473774-98-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473774-99-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-(acetylmethylamino)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

—OMe

RN 473774-97-9 CAPLUS
 CN Glycine, N-[6-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OMe

RN 473774-98-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 473774-98-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473774-99-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-(acetylmethylamino)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 473774-99-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-(acetylmethylamino)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473775-00-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(4-morpholinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 473775-00-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(4-morpholinylacetyl)amino]-6-benzothiazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



RN 473775-01-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-(acetyl)amino)-6-benzothiazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 473775-04-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475487-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-(methylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475487-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-(methylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 473775-01-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-(acetyl)amino)-6-benzothiazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473775-04-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 475488-79-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475488-79-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475976-40-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 475976-40-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-57-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-57-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-59-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-60-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-60-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-58-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-58-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-59-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-61-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-61-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-62-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-ethoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-62-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-ethoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-63-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-ethoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-63-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-ethoxyphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-65-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(1H-pyrrol-2-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-66-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-66-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-64-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-thienylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-64-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-thienylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-65-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(1H-pyrrol-2-yl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-67-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-67-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-68-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-68-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-69-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-69-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-71-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-72-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-72-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 546085-70-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-70-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-71-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl](2-

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-73-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-73-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-74-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-74-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-75-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-75-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-77-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-78-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) Absolute stereochemistry.




RN 546085-76-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-76-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-77-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](3-methylbutyl)amino]-

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546085-78-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-79-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-hydroxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-79-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-hydroxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-80-7 CAPLUS


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-hydroxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-80-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-hydroxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-81-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546085-83-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-ethoxyphenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-83-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(4-ethoxyphenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-84-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3-ethoxyphenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 546085-81-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-82-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-82-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546085-84-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3-ethoxyphenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-84-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(3-ethoxyphenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-85-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methylbutyl)(2-thienylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-86-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(1H-pyrrol-2-ylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-86-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(1H-pyrrol-2-ylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-87-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546085-88-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-89-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-89-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 546085-87-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-88-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546085-90-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-90-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546085-91-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-91-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-92-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546085-94-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-94-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546085-95-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-95-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl](3-

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl ester (9CI) (CA INDEX NAME)


RN 546085-92-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-93-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-93-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-96-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-96-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-97-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546085-97-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-98-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546085-98-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-01-5 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-02-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546085-99-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(methylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-01-5 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-02-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-03-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-03-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-aminophenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-04-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-hydroxyphenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-04-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-hydroxyphenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-05-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-hydroxyphenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-05-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-hydroxyphenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-06-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-06-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-07-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-methoxyphenyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-07-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-08-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-ethoxyphenyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-08-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-ethoxyphenyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-09-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-ethoxyphenyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-09-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-(2-pyridinylamino)ethyl)(2-thienylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-10-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-(2-pyridinylamino)ethyl)(2-thienylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-10-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-(2-pyridinylamino)ethyl)(2-thienylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-11-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-(2-pyridinylamino)ethyl)(1H-pyrrol-2-ylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-11-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-(pyridinylamino)ethyl](1H-pyrrrol-2-yl)sulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-12-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-12-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-13-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-13-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-14-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-14-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-15-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-15-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-16-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-16-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-17-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-17-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-18-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-18-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-19-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-19-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-6-benzoxazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-20-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-5-benzoxazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-20-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-5-benzoxazolyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-21-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-6-benzofuranyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-21-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-22-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-6-benzofuranyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-22-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-23-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[(1,3-benzodioxol-5-yl)sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-23-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((1,3-benzodioxol-5-ylsulfonyl)[2-(2-pyridinylamino)ethylamino]-2-hydroxy-1-(phenylmethyl)propyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-24-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((cyclohexyl(methylsulfonyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-26-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-aminophenyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-26-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-aminophenyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-24-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((cyclohexyl(methylsulfonyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-25-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-(((3-aminophenyl)sulfonyl)cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-25-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-(((3-aminophenyl)sulfonyl)cyclohexylamino)-2-

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-27-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-hydroxyphenyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-27-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-((4-hydroxyphenyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-28-6 CAPLUS


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(3-hydroxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-28-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(4-hydroxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-29-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(4-methoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-29-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(4-methoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-30-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(3-methoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-30-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(3-methoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-31-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(4-ethoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-31-1 CAPLUS


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(4-ethoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-32-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(3-ethoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-32-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(3-ethoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-33-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl(2-thienylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-33-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl(2-thienylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-34-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl(1H-pyrrol-2-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-34-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl(1H-pyrrol-2-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-35-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl(2-furanylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-35-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl(2-furanylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-36-6 CAPLUS


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-36-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-37-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-37-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-38-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-38-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-39-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-39-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-40-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-40-2 CAPLUS

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-41-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-41-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-42-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl]cyclohexylami
 no]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-42-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(2-amino-6-benzoxazolyl)sulfonyl]cyclohexylami
 no]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

esters 546087-00-7 546087-00-7D, esters
 546087-01-8 546087-01-8D, esters 546087-02-9
 546087-02-9D, esters 546087-03-0 546087-03-0D,
 esters 546087-04-1 546087-04-1D, esters
 546087-05-2 546087-05-2D, esters 546087-06-3
 546087-06-3D, esters 546087-07-4 546087-07-4D,
 esters 546087-08-5 546087-08-5D, esters
 546087-09-6 546087-09-6D, esters 546087-10-9
 546087-10-9D, esters 546087-11-0 546087-11-0D,
 esters 546087-12-1 546087-12-1D, esters
 RI: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of cytochrome P 450 inhibitors and HIV protease
 inhibitors
 to treat retrovirus infections and increase pharmacokinetics of HIV
 protease inhibitors in relation to resistance)


RN 546086-43-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl]cyclohexylami
 no]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-43-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl]cyclohexylami
 no]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 546086-43-5 546086-43-5D, esters 546086-44-6
 546086-44-6D, esters 546086-45-7 546086-45-7D,
 esters 546086-46-8 546086-46-8D, esters
 546086-47-9 546086-47-9D, esters 546086-48-0
 546086-48-0D, esters 546086-49-1 546086-49-1D,
 esters 546086-50-4 546086-50-4D, esters
 546086-51-5 546086-51-5D, esters 546086-52-6
 546086-52-6D, esters 546086-53-7 546086-53-7D,
 esters 546086-54-8 546086-54-8D, esters
 546086-55-9 546086-55-9D, esters 546086-56-0
 546086-56-0D, esters 546086-57-1 546086-57-1D,
 esters 546086-58-2 546086-58-2D, esters
 546086-59-3 546086-59-3D, esters 546086-60-6
 546086-60-6D, esters 546086-61-7 546086-61-7D,
 esters 546086-62-8 546086-62-8D, esters
 546086-63-9 546086-63-9D, esters 546086-64-0
 546086-64-0D, esters 546086-66-2 546086-66-2D,
 esters 546086-67-3 546086-67-3D, esters
 546086-68-4 546086-68-4D, esters 546086-69-5
 546086-69-5D, esters 546086-70-8 546086-70-8D,
 esters 546086-71-9 546086-71-9D, esters
 546086-72-0 546086-72-0D, esters 546086-73-1
 546086-73-1D, esters 546086-74-2 546086-74-2D,
 esters 546086-75-3 546086-75-3D, esters
 546086-76-4 546086-76-4D, esters 546086-77-5
 546086-77-5D, esters 546086-78-6 546086-78-6D,
 esters 546086-79-7 546086-79-7D, esters
 546086-80-0 546086-80-0D, esters 546086-81-1
 546086-81-1D, esters 546086-82-2 546086-82-2D,
 esters 546086-83-3 546086-83-3D, esters
 546086-84-4 546086-84-4D, esters 546086-85-5
 546086-85-5D, esters 546086-86-6 546086-86-6D,
 esters 546086-87-7 546086-87-7D, esters
 546086-88-8 546086-88-8D, esters 546086-89-9
 546086-89-9D, esters 546086-90-2 546086-90-2D,
 esters 546086-91-3 546086-91-3D, esters
 546086-92-4 546086-92-4D, esters 546086-93-5
 546086-93-5D, esters 546086-94-6 546086-94-6D,
 esters 546086-96-8 546086-96-8D, esters
 546086-97-9 546086-97-9D, esters 546086-98-0
 546086-98-0D, esters 546086-99-1 546086-99-1D,

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-44-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl[(2,3-dihydro-6-
 benzofuran-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-44-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl[(2,3-dihydro-6-
 benzofuran-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-45-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[cyclohexyl[(2,3-dihydro-5-
 benzofuran-4-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-45-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyl[(2,3-dihydro-5-benzofuranyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-46-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546086-46-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)cyclohexylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-47-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(methylsulfonyl)(phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-47-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(methylsulfonyl)(phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-48-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(phenylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-48-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(phenylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-49-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-49-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-50-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546086-50-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[4-aminophenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-51-5 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[4-hydroxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-51-5 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546086-53-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-54-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[4-ethoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-54-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546086-52-6 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[3-hydroxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-52-6 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[3-ethoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-53-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546086-55-9 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[4-ethoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-55-9 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[3-ethoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-56-0 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[3-ethoxyphenyl)sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546086-56-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(3-ethoxyphenyl)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-57-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(2-thienylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-57-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(2-furanylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 546086-59-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-60-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-60-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546086-58-2 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(1H-pyrrol-2-ylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-58-2 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(1H-pyrrol-2-ylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-59-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 546086-61-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-61-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-62-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 546086-62-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(6-benzoxazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-63-9 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(5-benzoxazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-63-9 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(5-benzoxazolylsulfonyl)(phenylmethyl)amino]-2-


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-5-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-66-2 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-5-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-67-3 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-6-benzoxazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-67-3 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-6-benzoxazolylsulfonyl)(phenylmethyl)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-64-0 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-6-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-64-0 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-6-benzothiazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-66-2 CAPLUS


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-68-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-5-benzoxazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-68-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2-amino-5-benzoxazolylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-69-5 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl](phenylmethyl)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
thyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-69-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl]-(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-70-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-70-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 546086-72-0 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(methylsulfonyl)(2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-73-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)(2-pyridinylmethyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-73-1 CAPLUS


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
thyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-71-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-71-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-72-0 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(methylsulfonyl)(2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)(2-pyridinylmethyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-74-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-74-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-75-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-aminophenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-75-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-aminophenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-77-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-hydroxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-78-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-78-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-hydroxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-hydroxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-77-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-hydroxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-79-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-79-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 546086-80-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-ethoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-80-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-ethoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-81-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-ethoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-82-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-pyridinylmethyl)(2-thienylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-83-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-pyridinylmethyl)(1H-pyrrol-2-ylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-83-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-pyridinylmethyl)(1H-pyrrol-2-ylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-81-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-ethoxyphenyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-82-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-pyridinylmethyl)(2-thienylsulfonyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-84-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-84-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-furanylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-85-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-85-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-86-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-87-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-88-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-88-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzoxazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-86-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-benzothiazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-87-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-benzoxazolylsulfonyl)(2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-89-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-89-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-89-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546086-90-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-90-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzothiazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-91-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 546086-92-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-93-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-93-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-91-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-amino-5-benzoxazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-92-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 546086-94-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546086-94-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546086-96-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(2-[(dimethylamino)acetyl]amino]-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NMe2

RN 546086-96-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-[[[dimethylamino]acetyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 546086-98-0 CAPLUS
CN Glycine, N-[6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzoxazolyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OMe

RN 546086-98-0 CAPLUS

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

—NMe2

RN 546086-97-9 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-piperazinylacetyl)amino]-6-benzoxazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 546086-97-9 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-piperazinylacetyl)amino]-6-benzoxazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Glycine, N-[6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzoxazolyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OMe

RN 546086-99-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinylacetyl)amino]-6-benzoxazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 546086-99-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(1-pyrrolidinylacetyl)amino]-6-benzoxazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 546087-00-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylmethylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 546087-01-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(4-morpholinylacetyl)amino]-6-benzoxazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 546087-02-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[acetyl[3-(dimethylamino)propyl]amino]-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 546087-00-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylmethylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 546087-01-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(4-morpholinylacetyl)amino]-6-benzoxazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 546087-02-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[acetyl[3-(dimethylamino)propyl]amino]-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 546087-03-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[2-(1-pyrrolidinyl)ethyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 546087-03-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[2-(1-pyrrolidinyl)ethyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 546087-04-1 CAPLUS
 CN Carbamic acid, [2-[[[6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzoxazolyl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 546087-05-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[3-(dimethylamino)propyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 546087-04-1 CAPLUS
 CN Carbamic acid, [2-[[[6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzoxazolyl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 546087-05-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[3-(dimethylamino)propyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 546087-06-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[2-(methylamino)ethyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 546087-06-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[2-(methylamino)ethyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 546087-07-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-3-oxo-1-piperazinyl)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 546087-07-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-3-oxo-1-piperazinyl)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 546087-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(3-methyl-2-oxo-1-imidazolidinyl)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 546087-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(3-methyl-2-oxo-1-imidazolidinyl)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

— Me

RN 546087-09-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-2-oxo-1-piperazinyl)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Me

RN 546087-09-6 CAPLUS

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 546087-10-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[2-(dimethyloxidoamino)ethyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-2-oxo-1-piperazinyl)-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— Me

RN 546087-10-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[2-(dimethyloxidoamino)ethyl]amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 546087-11-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[2-(hydroxyethyl)amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


— OH

RN 546087-11-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[2-(hydroxyethyl)amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

OH

RN 546087-12-1 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzoxazolyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546087-12-1 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzoxazolyl]sulfonyl][2-(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:944563 CAPLUS
 DN 138:11384
 TI Methods for determining plasma free drug concentration
 IN Xie, Dong; Cao, Wei; Erickson, John W.
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO Eur. Pat. Appl., 16 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1265073	A2	20021211	EP 2002-77275	20020605
EP 1265073	A3	20031126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003113748	A1	20030619	US 2002-161613	20020605
US 7087373	B2	20060808		
US 2006205002	A1	20060914	US 2006-429481	20060505
PRAI US 2001-29557P	P	20010605		
US 2002-161613	A3	20020605		

AB The present invention relates to methods for isothermal titration calorimetry
 anal. of the binding affinity of protease inhibitors to plasma proteins.
 IT 333798-27-9
 RL: ANT (Analyte); ANST (Analytical study)
 (methods for determining plasma free drug concentration)
 RN 333798-27-9 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl][2-methylpropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 546085-99-8
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nation of cytochrome P 450 inhibitors and HIV protease inhibitors to treat retrovirus infections and increase pharmacokinetics of HIV protease inhibitors in relation to resistance)
 RN 546085-99-8 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[(methylsulfonyl)[2-(2-pyridinylamino)ethyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L7 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:888736 CAPLUS
 DN 137:384805
 TI Preparation of 2-amino-benzoxazole sulfonamide as broad-spectrum HIV protease inhibitors
 IN Surleraux, Dominique Louis Nestor Ghislain; Vendeville, Sandrine Marie Helene; Verschueren, Wim Gaston; De Bethune, Marie-Pierre T. M. M. G.; De Kock, Herman Augustinus; Tahri, Abdellah
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002092595	A1	20021121	WO 2002-EP5212	20020510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444895	A1	20021121	CA 2002-2444895	20020510
AU 2002310818	A1	20021125	AU 2002-310818	20020510
EP 1387842	A1	20040211	EP 2002-735354	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300547	A	20040216	EE 2003-547	20020510
BR 2002009594	A	20040330	BR 2002-9594	20020510
CN 1507446	A	20040623	CN 2002-809741	20020510
HU 200400438	A2	20040830	HU 2004-438	20020510
JP 2004534757	T	20041118	JP 2002-589479	20020510
NZ 529250	A	20050527	NZ 2002-529250	20020510
ZA 2003007799	A	20050106	ZA 2003-7799	20031006
IN 2003DN01588	A	20070112	IN 2003-DN1588	20031006
US 2004106661	A1	20040603	US 2003-474485	20031009
BG 108309	A	20041230	BG 2003-108309	20031103
PRAI EP 2001-201732	A	20010511		
WO 2002-EP5212	W	20020510		
OS MARPAT 137:384835				
GI				

L7 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [R1, R8 = H, alkyl, alkenyl, arylalkyl, cycloalkyl, aryl, heterocyclyl, etc.; R2 = H, alkyl; L = CO, OCO, NR8CO, etc.; R3 = alkyl, cycloalkyl, aryl, etc.; R4 = H, alkoxy, carbonyl, carboxy, aminocarbonyl, cycloalkyl, etc.; R5-6 = H, alkyl], N-oxides, stereoisomers, metabolites and prodrugs thereof were prepared. For instance, II was prepared from

the corresponding diamine (preparation described), N,N'-disuccinimidylcarbonate and 5-hydroxymethylthiazole (CH2Cl2, 6 h). Compds. of the invention are effective in inhibiting a broad range of mutant HIV strains; II had pEC50 = 8.18 against HIV-1 (Lai strain).

IT 475487-74-2P 475487-76-4P 475488-36-9P
475488-38-1P 475488-41-6P 475488-79-0P
475976-40-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-amino-benzoxazole sulfonamide as broad-spectrum HIV protease inhibitors)

RN 475487-74-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CRN 75-75-2
CMF C H4 O3 S



RN 475488-38-1 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(2-methylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 475488-41-6 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(2-methylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 475487-76-4
CMF C29 H38 N4 O8 S

Absolute stereochemistry.




L7 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 475487-76-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(2-methylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475488-36-9 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(2-methylamino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 475487-76-4
CMF C29 H38 N4 O8 S

Absolute stereochemistry.




CM 2

L7 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 475488-79-0 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-6-benzoxazolyl)sulfonyl](2-pyridinylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475976-40-0 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AM 2002:81417 CAPLUS
 DN 137:325410
 TI Broad-spectrum 2-(substituted-amino)-benzothiazolesulfonamide HIV
 protease
 inhibitors
 IN Surlieriaux, Dominique Louis Nestor Ghislain; Wigerinck, Piet Tom Bert
 Paul;
 Getman, Daniel; Verschueren, Wim Gaston; Vendeville, Sandrine; De
 Bethune,
 Marie-Pierre; De Kerpel, Jan Octaaf Antoon; Moors, Samuel Leo Christiaan;
 De Kock, Herman Augustinus; Voets, Marieke Christiane Johanna
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002083657	A2	20021024	WO 2002-EP1788	20020214
WO 2002083657	A3	20030213		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2438304	A1	20021024	CA 2002-2438304	20020214
AU 2002302363	A1	20021028	AU 2002-302363	20020214
EE 200300381	A	20031215	EE 2003-381	20020214
EP 1370543	A2	20031217	EP 2002-729930	20020214
EP 1370543	B1	20061025		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
HU 200303257	A2	20040128	HU 2003-3257	20020214
BR 2002007862	A	20040622	BR 2002-7862	20020214
JP 2004518767	T	20040624	JP 2002-581413	20020214
CN 1525962	A	20040901	CN 2002-804982	20020214
NZ 527391	A	20050429	NZ 2002-527391	20020214
AP 1504	A	20060228	AP 2003-2856	20020214
W:	GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW			
AT 343567	T	20061115	AT 2002-729930	20020214
ZA 2003006086	T	20041108	ZA 2003-6086	20030806
US 2004116485	A1	20040617	US 2003-467609	20030807
IN 2003DN01269	A	20050527	IN 2003-DN1269	20030811
NO 2003003584	A	20031014	NO 2003-3584	20030813
BG 108143	A	20040730	BG 2003-108143	20030901
PRAI EP 2001-200529	A	20010214		
US 2001-287758P	P	20010502		
WO 2002-EP1788	W	20020214		
OS MARPAT 137:325410				
GI				


L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I (R1, R6 = H, (un)substituted alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl; R2 = H, alkyl; L = CO, O2C, (un)substituted NHCO, oxoalkylcarbonyl, aminoalkylcarbonyl, SO2, O3S, NHSO2; R3 = alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl; R4 = H, alkoxycarbonyl, carboxy, (un)substituted CONH2, cycloalkyl, alkenyl, alkynyl (un)substituted alkyl; A = alkanediyl, CO, CS, SO2, oxoalkanediyl, thioalkanediyl, alkanediylsulfonyl; R5 = H, OH, alkyl, heterocyclylalkyl, (un)substituted aminoalkyl; R6 = alkoxy, heterocyclyl, heterocyclyloxy, aryl, aryloxy, alkoxy, carbonylamino, amino; and when A is other than alkanediyl then R6 may also be alkyl, heterocyclylalkyl, heterocyclyloxyalkyl, aralkyl, aryloxyalkyl, (un)substituted aminoalkyl; R5NAR6 = heterocyclic their N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters and metabolites were prepared I are useful as broad-spectrum HIV protease inhibitors, and may be formulated in diagnostic kits. Thus, the sulfonamide II, prepared in several steps from the benzothiazolecarbamate, showed activity against a number of resistant mutants of HIV-1 strain LAI.
 IT 473737-31-4P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (broad-spectrum 2-aminobenzothiazolesulfonamide HIV protease inhibitors)
 RN 473737-31-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-[[2-(2-methylpropyl)amino]-6-benzothiazolyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 473737-99-4P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (broad-spectrum 2-aminobenzothiazolesulfonamide HIV protease inhibitors)
 RN 473737-99-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-[[3-(dimethylamino)propyl]methylamino]-6-benzothiazolyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



IT 473737-26-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (broad-spectrum 2-aminobenzothiazolesulfonamide HIV protease inhibitors)
 RN 473737-26-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2-[[2-(dimethylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 473737-16-5P 473737-18-7P 473737-20-1P
 473737-22-3P 473737-24-5P 473737-28-9P
 473737-29-0P 473737-30-3P 473737-33-6P
 473737-35-8P 473737-37-0P 473737-39-2P
 473737-41-6P 473737-42-7P 473737-43-8P
 473737-44-9P 473738-00-0P 473738-01-1P

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

473738-03-3P 473738-04-4P 473738-05-5P
 473738-10-2P 473738-11-3P 473738-12-4P
 473738-14-6P 473738-46-4P 473738-94-2P
 473738-95-3P 473739-01-4P 473774-92-4P
 473774-93-5P 473774-94-6P 473774-95-7P
 473774-96-8P 473774-97-9P 473774-98-0P
 473774-99-1P 473775-00-7P 473775-01-8P
 473775-02-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(broad-spectrum 2-aminobenzothiazolesulfonamide HIV protease inhibitors)

RN 473737-16-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[2-[(dimethylamino)acetyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-NMe2

RN 473737-18-7 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 473737-22-3 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B




RN 473737-24-5 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 473737-20-1 CAPLUS


CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473737-18-7
 CMF C34 H45 N5 O8 S2

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 pyrrolidinylacetyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473737-18-7
 CMF C34 H45 N5 O8 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 473737-28-9 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-piperazinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 473737-29-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[3-(dimethylamino)propyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 473737-30-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetyl[2-(1-pyrrolidinyl)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




RN 473737-33-6 CAPLUS
 CN Carbamic acid, [2-[[[6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 473737-35-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[3-(dimethylamino)propyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 473737-37-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[[2-(methylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 473737-39-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[[[4-methyl-3-oxo-1-piperazinyl]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 473737-41-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[[2-(3-methyl-2-oxo-1-imidazolidinyl)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

RN 473737-43-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[2-(dimethyloxidoamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

RN 473737-44-9 CAPLUS
 CN Carbamic acid, [2-(dimethylamino)ethyl][6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—Me

RN 473737-42-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-2-oxo-1-piperazinyl)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—NMe2

RN 473738-00-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[[[1-ethyl-2-pyrrolidinyl]methyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 473738-01-1 CAPLUS
 CN Carbamic acid, [3-[[[2-[(2-dimethylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

-NMe2

RN 473738-03-3 CAPLUS
 CN Carbamic acid, [2-hydroxy-3-[(2-methylpropyl)[2-[(1-pyrrolidinyl)ethyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



PAGE 1-A


L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 473738-10-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-(2-oxo-1-imidazolidinyl)-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473738-11-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-(4-methyl-1-piperazinyl)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 473738-04-4 CAPLUS
 CN Carbamic acid, [3-[[[2-[[[3-(dimethylamino)propyl]methylamino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

-NMe2

RN 473738-05-5 CAPLUS
 CN Carbamic acid, [3-[[[2-[[[1-ethyl-2-pyrrolidinyl]methyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



PAGE 1-A


L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

-Me

RN 473738-12-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[methyl[3-(1-pyrrolidinyl)propyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 473738-14-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(methyl(2-(1-pyrrolidinyl)ethyl)amino]-6-benzothiazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473738-46-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(2-pyridinylcarbonyl)amino]-6-benzothiazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylpropyl)amino)sulfonyl]-2-benzothiazolyl][2-(1-pyrrolidinyl)ethyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473739-01-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(2-aminoethyl)amino]-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 473738-94-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(2-[(5-thiazolylcarbonyl)amino]-6-benzothiazolyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473738-95-3 CAPLUS
 CN Carbamic acid, [6-[[[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-


L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

-NH2


RN 473774-92-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473774-93-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(ethoxycarbonyl)amino]-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473774-94-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(dimethylamino)acetyl]amino]-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—NMe₂

RN 473774-95-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(2-dimethylamino)ethyl]amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NMe₂

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

—OMe

RN 473774-98-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(1-pyrrolidinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473774-99-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetymethylamino)-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 473774-96-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(1-piperazinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 473774-97-9 CAPLUS
 CN Glycine, N-[6-[[[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl][2-methylpropyl]amino]sulfonyl]-2-benzothiazolyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 473775-00-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[2-[(4-morpholinylacetyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 473775-01-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetylamino)-6-benzothiazolyl]sulfonyl][2-[(2-pyridinylamino)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473775-02-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-(acetymethylamino)-6-benzothiazolyl]sulfonyl][2-pyridinylmethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



IT 473775-04-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(broad-spectrum 2-aminobenzothiazolesulfonamide HIV protease inhibitors)
RN 473775-04-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 473739-17-2P 473739-18-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(broad-spectrum 2-aminobenzothiazolesulfonamide HIV protease inhibitors)
RN 473739-17-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 473739-18-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2-[(chloroacetyl)amino]-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CH₂Cl

L7 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:793630 CAPLUS
DN 137:310904
TI Preparation of 2-(substituted-amino)benzoxazole sulfonamides as broad-spectrum HIV protease inhibitors
IN Surleraux, Dominique Louis Nestor Ghislain; Vendeville, Sandrine Marie Helene; Verschueren, Wim Gaston; De Bethune, Marie-Pierre T. M. M. G.; De Kock, Herman Augustinus; Tahri, Abdellah; Erra Sola, Montserrat
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002081478	A2	20021017	WO 2002-EP4012	20020409
WO 2002081478	A3	20030501		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2442870	A1	20021017	CA 2002-2442870	20020409
AU 2002257774	A1	20021021	AU 2002-257774	20020409
EE 200300494	A	20031215	EE 2003-494	20020409
HU 200303744	A2	20040301	HU 2003-3744	20020409
BR 2002008796	A	20040309	BR 2002-8796	20020409
EP 1397367	A2	20040317	EP 2002-727554	20020409
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004529144	T	20040924	JP 2002-579466	20020409
NZ 528954	A	20050429	NZ 2002-528954	20020409
CN 1636006	A	20050706	CN 2002-811480	20020409
AP 1544	A	20060228	AP 2003-2882	20020409
W:	GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW			
BG 108218	A	20040930	BG 2003-108218	20031001
ZA 2003007683	A	20050103	ZA 2003-7683	20031001
IN 2003DN01589	A	20070223	IN 2003-DN1589	20031006
US 2004132791	A1	20040708	US 2003-474162	20031007
NO 2003004505	A	20031208	NO 2003-4505	20031008
PRAI EP 2001-201308	A	20010409		
EP 2001-287704P	P	20010502		
WO 2002-EP4012	W	20020409		
OS MARPAT 137:310904				
GI				

L7 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Benzoxazole sulfonamides of formula I (R₁ = H, alkyl, alkenyl, arylalkyl, aryl, etc.; R₂ = H, alkyl; R₃ = alkyl, aryl, cycloalkyl, cycloalkyl-alkyl, arylalkyl; R₄ = H, alkyl, alkenyl, aryl, cycloalkyl, etc.; R₅ = H, OH, alkyl, etc.; R₆ = alkyl, aryl, cycloalkyl, etc.; L = CO, O-CO, NHCO, O-alkyl-CO, SO₂, etc.; A = alkylene, CO, CS, SO₂, etc.) are prepared as broad-spectrum HIV protease inhibitors. The compds. can also be combined with another anti-retroviral agent, and be used in assays as reference compds. or as reagents. Thus, II was prepared, and was effective in inhibiting a broad range of mutant strains in a cellular assay.

IT 470704-39-3P 470704-42-8P 470704-44-OP 470704-47-3P 470704-54-2P 470704-55-3P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminobenzoxazole sulfonamides as broad-spectrum HIV protease inhibitors)

RN 470704-39-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2-(acetamido)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 470704-42-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2-[(dimethylamino)ethyl]amino)-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NMe2

RN 470704-44-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-[(ethoxycarbonyl)amino]-6-benzoxazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 470704-47-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinyl)ethyl]amino]-6-benzoxazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



RN 470704-55-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinyl)ethyl]amino]-6-benzoxazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L7 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 470704-54-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1-pyrrolidinyl)propyl]amino]-6-benzoxazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:516927 CAPLUS
 DN 135:313143
 TI Structure-based design of non-peptide HIV protease inhibitors
 AU Ghosh, Arun K.; Shin, Dongwoo; Swanson, Lisa; Krishnan, K.; Cho, Hanna; Hussain, Khaja Azhar; Walters, D. Eric; Holland, Louis; Buthod, Jim
 CS Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA
 SO Farmaco (2001), 56(1-2), 29-32
 CODEN: FRMCEB; ISSN: 0014-827X
 PB Elsevier Science S.A.
 DT Journal
 LA English
 AB A number of structurally novel P2-ligands have been designed and synthesized.
 Incorporation of these ligands in the (R)-(hydroxyethyl)sulfonamide isostere provided a series of potent non-peptidyl HIV protease inhibitors.
 IT 253265-95-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure-based design of non-peptide HIV protease inhibitors)

RN 253265-95-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:265423 CAPLUS
 DN 134:295811
 TI Preparation of hexahydrofuro[2,3-b]furan-3-yl-N-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as retroviral protease inhibitor
 IN Wigerinck, Piet Tom Bert Paul; Wang, Guangyang; Eissenstat, Michael; Erickson, John W.
 PA Tibotec N.V., Belg.; United States Dept. of Health and Human Services
 SO PCT Int. Appl., 29 pp.
 CODEN: PIIKXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001025240	A1	20010412	WO 2000-EP9917	20001006
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2386850	A1	20010412	CA 2000-2386850	20001006
AU 200076638	A	20010510	AU 2000-76638	20001006
AU 781656	B2	20050602		
BR 2000014602	A	20020611	BR 2000-14602	20001006
EP 1222192	A1	20020717	EP 2000-966144	20001006
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
HU 200203130	A2	20030128	HU 2002-3130	20001006
JP 2003511383	T	20030325	JP 2001-528184	20001006
NZ 518580	A	20040130	NZ 2000-518580	20001006
RU 2247123	C2	20050227	RU 2002-111657	20001006
AP 1459	A	20050930	AP 2002-2472	20001006
W:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, ZA, ZW			
NO 2002001598	A	20020529	NO 2002-1598	20020404
ZA 2002002655	A	20030704	ZA 2002-2655	20020404
IN 2002MN00452	A	20050318	IN 2002-MN452	20020411
US 6649651	B1	20031118	US 2002-89991	20021223
US 2005261364	A1	20051124	US 2003-606342	20030625
US 7157495	B2	20070102		
HK 1054746	A1	20051209	HK 2003-107022	20030929
PRAI US 1999-157850P	P	19991006		
WO 2000-EP9917	W	20001006		
US 2002-89991	A1	20021223		



L7 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The present invention relates to novel bis-tetrahydrofuran benzodioxolyl sulfonamide compds. (I) and its stereoisomers which are surprisingly effective protease inhibitors. The invention also relates to pharmaceutical compns., methods of inhibiting retrovirus proteases, in particular multidrug resistant retrovirus proteases, methods of treating or combating infection or disease associated with retrovirus infection

in a mammal, and methods of inhibiting viral replication. I and its stereoisomer (II) were tested against 17 HIV-1 strains and showed IC50 of 0.0014 and 0.0008 μM, resp., against HIV-1 LAI strain in MT4 cells.

IT 333798-26-8P 333798-27-9P
 AL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

hexahydrofuro[2,3-b]furan-3-yl-N-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as retroviral protease inhibitor
 RN 333798-26-8 CAPLUS
 CN Carbamic acid, (3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl)-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)




RN 333798-27-9 CAPLUS

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:306007 CAPLUS
 DN 134:56676
 TI Preparation of arylsulfonamides as inhibitors of aspartyl protease
 IN Hale, Michael Robin; Tung, Roger; Price, Stephen; Wilkes, Robin David; Schairer, Wayne Carl; Jarvis, Ashley Nicholas; Spaltenstein, Andrew; Furfine, Eric Steven; Samano, Vicente; Kaldor, Istvan; Miller, John Franklin; Brieger, Michael Stephen
 PA Vertex Pharmaceuticals Inc., USA; et al.
 SO PCT Int. Appl., 396 pp.
 CODEN: PIIKXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000076961	A1	20001221	WO 2000-US15781	20000608
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2380858	A1	20001221	CA 2000-2380858	20000608
BR 2000011745	A	20020319	BR 2000-11745	20000608
EP 1194404	A1	20020410	EP 2000-941279	20000608
EP 1194404	B1	20060503		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
TR 200200407	T2	20020821	TR 2002-407	20000608
JP 2003502309	T	20030121	JP 2001-503821	20000608
TR 200202528	T2	20030221	TR 2002-2528	20000608
HU 200300385	A2	20030728	HU 2003-385	20000608
NZ 516003	A	20040227	NZ 2000-516003	20000608
TW 593248	B	20040621	TW 2000-89111145	20000608
AU 779594	B2	20050224	AU 2000-56006	20000608
IN 2000CA00336	A	20050311	IN 2000-CA336	20000608
AT 325091	T	20060615	AT 2000-941279	20000608
EP 1686113	A1	20060802	EP 2006-9072	20000608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
PT 1194404	T	20060831	PT 2000-941279	20000608
ES 2263478	T3	20061216	ES 2000-941279	20000608
TR 200603871	T2	20070122	TR 2006-3871	20000608
US 6878728	B1	20050412	US 2000-591464	20000608
IN 2001KN01289	A	20050311	IN 2001-KN1289	20011206
NO 2001006034	A	20020118	NO 2001-6034	20011210
ZA 2001010177	A	20030113	ZA 2001-10177	20011211
HK 1046899	A1	20070302	HK 2002-106939	20020923
US 2004122000	A1	20040624	US 2003-691333	20031021
PRAI US 1999-139070P	P	19990611		
US 2000-190211P	P	20000317		
EP 2000-941279	A3	20000608		
WO 2000-US15781	W	20000608		
US 2000-591464	A3	20000609		

OS MARPAT 134:56676
 GI

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title arylsulfonamides, namely (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 3-arylsulfonamino-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate derivs. (e.g. 1) are prepared. These compds. are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. They are useful for treating with a patient diagnosed with

AIDS, AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, or AIDS-related neuropathies such as AIDS dementia complex, multiple sclerosis or tropical paraparesis, etc. Thus, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl

3-[N-(1,3-benzodioxol-5-ylsulfonyl)-N-isobutylamino]-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate underwent Mitsunobu reaction with phenethyl alc. using Ph3P and di-tert-Bu azodicarbonate in CH₂Cl₂ at room temperature for 1.5 h to give 72% I. I showed IC₅₀ of <0.001, <0.001, and 0.01-0.001 μM against drug-resistant HIV strains, i.e. wild type, mutant HIV-1 EP13, and

mutant D545701-14 HIV strains, resp., in MT-4 cells.

IT 313679-55-9P 313679-57-1P 313680-00-1P 313680-01-2P 313680-02-3P 313680-03-4P 313680-04-5P 313680-05-6P 313680-50-1P 313680-51-2P 313681-35-5P 313681-41-3P 313681-46-8P 313681-47-9P 313681-69-5P 313681-70-8P 313681-74-2P 313681-76-4P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of arylsulfonamides as inhibitors of HIV aspartyl

protease and antiviral agents)

RN 313679-55-9 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-01-2 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-(2-aminoethoxy)phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-02-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(1,1-dimethylethoxy)carbonyl]amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-03-4 CAPLUS


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313679-57-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-00-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[2-[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Carbamic acid, [(1S,2R)-1-[[4-(3-aminopropoxy)phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-04-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-[(1,1-dimethylethoxy)carbonyl]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-05-6 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-(4-aminobutoxy)phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-50-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(cyanoamino)phenoxy]methylene]amino]propoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-51-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(cyanoamino)phenoxy]methylene]amino]butoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313681-46-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(4-hydroxybutoxy)phenyl)methyl]amino]propoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-47-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(4-ethoxybutoxy)phenyl)methyl]amino]propoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-69-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(4-carboxybutoxy)phenyl)methyl]amino]propoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-35-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(4-hydroxybutoxy)phenyl)methyl]amino]propoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-41-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(4-hydroxybutoxy)phenyl)methyl]amino]propoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


methylpropyl)amino]-2-hydroxy-1-[[4-[(phenylmethoxy)phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313681-70-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(4-hydroxybutoxy)phenyl)methyl]amino]propoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-74-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-[(acetyloxy)-3-methylphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-[(phenylmethoxy)phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[(4-acetoxyphenyl)sulfonyl]methyl]propyl]amino]-2-hydroxy-1-[(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 313679-72-0P 313679-73-1P 313679-75-3P
 313679-76-4P 313679-77-5P 313679-78-6P
 313679-79-7P 313679-80-0P 313679-81-1P
 313679-82-2P 313679-83-3P 313679-84-4P
 313679-85-5P 313679-86-6P 313679-87-7P
 313679-88-8P 313679-89-9P 313679-90-2P
 313679-91-3P 313679-92-4P 313679-93-5P
 313679-94-6P 313679-95-7P 313679-96-8P
 313679-97-9P 313679-98-0P 313679-99-1P
 313680-06-7P 313680-07-8P 313680-08-9P
 313680-10-3P 313680-11-4P 313680-12-5P
 313680-13-6P 313680-14-7P 313680-15-8P
 313680-16-9P 313680-17-0P 313680-18-1P
 313680-19-2P 313680-20-5P 313680-21-6P
 313680-22-7P 313680-23-8P 313680-24-9P
 313680-25-0P 313680-26-1P 313680-27-2P
 313680-28-3P 313680-29-4P 313680-30-7P
 313680-31-8P 313680-32-9P 313680-33-0P


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 [propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313679-73-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-[(4-[(4-morpholinyl)propoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313679-75-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-[(4-(phenylmethoxy)phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


313680-34-1P 313680-35-2P 313680-36-3P
 313680-38-5P 313680-40-9P 313680-42-1P
 313680-44-3P 313680-46-5P 313680-48-7P
 313680-52-3P 313680-53-4P 313680-54-5P
 313680-55-6P 313680-56-7P 313680-57-8P
 313680-58-9P 313680-59-0P 313680-60-3P
 313680-61-4P 313680-62-5P 313680-63-6P
 313680-64-7P 313680-65-8P 313680-66-9P
 313680-67-0P 313680-68-1P 313680-69-2P
 313680-70-5P 313680-71-6P 313680-72-7P
 313680-73-8P 313680-75-0P 313680-76-1P
 313680-77-2P 313680-78-3P 313680-81-8P
 313680-83-0P 313680-89-6P 313680-90-9P
 313681-02-6P 313681-03-7P 313681-04-8P
 313681-05-9P 313681-10-6P 313681-13-9P
 313681-16-2P 313681-22-0P 313681-23-1P
 313681-25-3P 313681-26-4P 313681-27-5P
 313681-28-6P 313681-29-7P 313681-30-0P
 313681-33-3P 313681-37-7P 313681-38-8P
 313681-42-4P 313681-44-6P 313681-53-7P
 313681-55-9P 313681-56-0P 313681-57-1P
 313681-58-2P 313681-59-3P 313681-60-6P
 313681-63-9P 313681-64-0P 313681-65-1P
 313681-71-9P 313681-75-3P 313681-77-5P
 313681-79-7P 313681-80-0P 313681-82-2P
 313681-90-2P 313681-91-3P 313681-98-0P
 313682-02-9P 313682-04-1P 313682-06-3P
 313682-10-9P 313682-12-1P 313682-14-3P
 313682-16-5P 313682-18-7P 313682-20-1P
 313682-22-3P 313682-24-5P 313682-26-7P
 313682-28-9P 313682-30-3P 313682-33-6P
 313682-35-8P 313682-37-0P 313682-39-2P
 313682-41-6P 313682-43-8P 313682-45-0P
 313682-47-2P 313682-49-4P 313682-51-8P
 313682-53-0P 313682-55-2P 313682-57-4P
 313682-59-6P 313682-61-0P 313682-63-2P
 313682-70-1P 313682-72-3P 313682-74-5P
 313682-91-6P 313682-92-7P 313682-93-8P
 313682-94-9P 313682-95-0P 313682-96-1P
 313682-97-2P 313682-98-3P 313682-99-4P
 313683-00-0P 313683-01-1P 313683-02-2P
 313683-03-3P 313683-04-4P 313683-05-5P
 313683-06-6P 313683-07-7P 313683-09-9P
 313683-10-2P 313683-11-3P 313683-16-8P
 313683-17-9P 313683-18-0P 313683-19-1P
 313683-20-4P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of arylsulfonamides as inhibitors of HIV aspartyl protease and antiviral agents)


RN 313679-72-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-[(4-[2-(4-morpholinyl)ethoxy]phenyl)methyl]

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 313679-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-[(4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-77-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-[(4-(2-pyridinylmethoxy)phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313679-78-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(3-pyridinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-79-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-pyridinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313679-82-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-(1H-pyrazol-1-yl)ethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-83-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-phenylethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313679-80-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(5-methyl-3-isoxazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-81-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 313679-84-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(3-phenylpropoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313679-85-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(4,4,4-trifluorobutoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 313679-86-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(4-fluorophenyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-87-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(4-methoxyphenyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313679-88-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(3-thienylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-89-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(3-thienyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 NAME)

Absolute stereochemistry.



RN 313679-90-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(2-thienyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-91-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(4-pyridinyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313679-92-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(4-pyridinyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-93-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(2-pyridinyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313679-94-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(4-methyl-5-thiazolyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-95-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(3-pyridinyl)propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313679-98-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(3,3,3-trifluoropropoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313679-99-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(4-aminophenyl)methoxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313679-96-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[2-(4-cyanophenyl)ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313679-97-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(4,4,4-trifluorobutoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-06-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[2-(acetylamino)ethoxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-07-8 CAPLUS
 CN Carbamic acid, [2-[[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-08-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-[(methylsulfonyl)amino]ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-10-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[3-(acetylamino)propoxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(2,2-dimethyl-1-oxopropyl)amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-14-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(benzoylamino)propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-15-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[2-[(2-furanylcarbonyl)amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-11-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[4-(acetylamino)butoxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-12-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(3-methyl-1-oxobutyl)amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-13-6 CAPLUS

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-16-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(2-furanylcarbonyl)amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-17-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-[(2-furanylcarbonyl)amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-18-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-[(2-thienylcarbonyl)amino]ethoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-19-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(2-thienylcarbonyl)amino]propoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313680-22-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(methoxyacetyl)amino]propoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-23-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[4-[(methoxyacetyl)amino]butoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-20-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[4-[(2-thienylcarbonyl)amino]butoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-21-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-[(methoxyacetyl)amino]ethoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-24-9 CAPLUS
 CN Carbamic acid, [3-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-25-0 CAPLUS
 CN Carbamic acid, [4-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]butyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-26-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[2-[(ethoxycarbonyl)amino]ethoxy]phenyl]methyl]-

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 313680-27-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(ethoxycarbonyl)amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 313680-28-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(ethoxycarbonyl)amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-31-8 CAPLUS
CN Carbamic acid, [4-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]butyl]-, 1-methylethyl ester
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 313680-32-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(methylsulfonyl)amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)


(CA INDEX NAME)

Absolute stereochemistry.



RN 313680-33-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-29-4 CAPLUS
CN Carbamic acid, [2-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]ethyl]-, 1-methylethyl ester
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 313680-30-7 CAPLUS
CN Carbamic acid, [3-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]propyl]-, 1-methylethyl ester
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

methylpropyl)amino]-2-hydroxy-1-[[4-[4-[(methylsulfonyl)amino]butoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 313680-34-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[2-[[[(dimethylamino)carbonyl]amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 313680-35-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[[[(dimethylamino)carbonyl]amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-36-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(dimethylamino)carbonyl]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-38-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[[(methylamino)carbonyl]amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-44-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[[(methylamino)thioxomethyl]amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-46-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[[(methylamino)thioxomethyl]amino]butoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-40-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[[(methylamino)carbonyl]amino]butoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-42-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[[(methylamino)thioxomethyl]amino]ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 313680-48-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(3-furanylcarbonyl)amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-52-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(2-[[[(cyanoamino)iminomethyl]amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-53-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[[(2-[[[(cyanoamino)iminomethyl]amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313680-54-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[2-[(cyanoamino)-4-morpholinylmethylene]amino]ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-55-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-[(cyanoamino)iminomethyl]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-58-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(5-cyano-2-pyridinyl)amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-59-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-(2-pyrimidinylamino)propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-56-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-[(cyanoamino)(methylamino)methylene]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-57-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-[(cyanoamino)(dimethylamino)methylene]amino]butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-60-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[3-[(5-(trifluoromethyl)-2-pyridinyl)amino]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-61-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 313680-62-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-63-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(dimethylamino)butoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

Absolute stereochemistry.



RN 313680-67-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(1H-1,2,3-triazol-1-yl)propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-68-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(2H-1,2,3-triazol-2-yl)propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


RN 313680-64-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(iodopropoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313680-65-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(3-thiazolidinyl)propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-66-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(1H-imidazol-1-yl)propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

Absolute stereochemistry.



RN 313680-69-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(1-pyrrolidinyl)propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-70-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(1H-pyrazol-3-yl)amino]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-71-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-72-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(2-methoxyethyl)amino]propoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-76-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[4-(methyldamino)-4-oxobutoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-77-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-(dimethylamino)-4-oxobutoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313680-73-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(1H-pyrazol-1-yl)propoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-75-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-(4-amino-4-oxobutoxy)phenyl)methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-78-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-(butylamino)-4-oxobutoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-81-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[4-(3-cyanophenyl)methoxy]phenyl)methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-83-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(4-aminobutoxy)phenyl]methyl]-3-[[[3-aminophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313680-82-9
 CMF C31 H46 N4 O8 S


Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-02-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(4-aminobutoxy)phenyl]methyl]-3-[[[3-aminophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313681-03-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(4-aminobutoxy)phenyl]methyl]-3-[[[3-aminophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-89-6 CAPLUS
 CN Benzenesulfonic acid, 4-nitro-, 4-[[[2S,3R)-2-[[[[(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[2-methylpropyl]amino]-2-[[[[(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-90-9 CAPLUS
 CN Benzenesulfonic acid, 4-aminobutoxy-, 4-[[[2S,3R)-2-[[[[(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[2-methylpropyl]amino]-2-[[[[(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-04-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(4-aminobutoxy)phenyl]methyl]-3-[[[3-aminophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-05-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-(4-aminobutoxy)phenyl]methyl]-3-[[[3-aminophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-10-6 CAPLUS
 CN Butanoic acid, 4-[[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonfyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-13-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313681-23-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(1-methylethyl)amino]carbonyl]oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-25-3 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonfyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-26-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(aminocarbonyl)oxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonfyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-16-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)(5-cyano-2,2-dimethylpentyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-22-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(methylamino)carbonyl]oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-27-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[[2-(1H-imidazol-1-yl)ethyl]amino]carbonyl]oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




RN 313681-28-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-29-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(methylamino)-2-oxoethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313681-30-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[3-[(aminocarbonyl)oxy]propoxy]phenyl]methyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-42-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-[(methylamino)carbonyl]oxy]ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 313681-30-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-(sulfoxy)propoxy]phenyl]methyl]propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, monopotassium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● K


RN 313681-33-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[4-[(methylamino)carbonyl]oxy]butoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-37-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[3-[(methylamino)carbonyl]oxy]propoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-44-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[2-(3-thiazolidinyl)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-53-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(1-ethylpropoxy)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-55-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(1-ethylpropoxy)amino]-1-[[4-[(dimethylamino)iminomethoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-56-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(3,4,5,6-tetrafluoro-2-pyridinyl)oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313681-59-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(5-cyano-2-pyridinyl)oxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-60-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-(2,4-dinitrophenoxy)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313681-57-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(5-nitro-2-pyridinyl)oxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313681-58-2 CAPLUS
 CN Benzoic acid, 2-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]-3,5-dinitro- (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-63-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-64-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(3-cyanophenyl)methoxy]phenyl]methyl]-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-65-1 CAPLUS
 CN Propanoic acid, 3-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-71-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(3-cyanophenyl)methoxy]phenyl]methyl]-3-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-79-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(acetoxy)-3-methylphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-80-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxy-3-methylphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-75-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxy-3-methylphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-77-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(3-cyanophenyl)methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-(hydroxy-3-methylphenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-82-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(acetoxy)-3-methylphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-90-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(acetoxy)-3-methylphenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-91-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(1H-imidazol-1-ylcarbonyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-98-0 CAPLUS
 CN 4-Oxa-2,10,14-triazapentadecan-15-oic acid, 10-(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-13-[[4-(phenylmethoxy)phenyl]methyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-02-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl][2-methylpropyl]amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-04-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-(3-(4-fluorophenyl)propoxy)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-06-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[3-cyanophenyl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-10-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[4-(methylthio)phenyl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-12-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-14-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[4-(4-fluorophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313682-16-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(trifluoromethyl)phenyl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-18-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(trifluoromethyl)phenyl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-24-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-naphthalenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-26-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(3-methylphenyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313682-20-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(1,2,3-thiadiazol-4-yl)phenyl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-22-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(5-phenyl-1,2,4-thiadiazol-3-yl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-28-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-30-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(3,4-difluorophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-33-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(3,5-difluorophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-35-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(4-cyanophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 313682-41-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(3-nitrophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-43-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313682-37-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(2-cyanophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-39-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(4-nitrophenyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-45-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(5-chloro-1,2,3-thiadiazol-4-yl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-47-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(benzo[b]thien-3-ylmethoxy)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-49-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[2-[(phenylsulfonyl)methyl]phenyl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-51-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 3-yl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313682-57-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[2'-cyano[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-59-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[(cyanomethoxy)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 313682-53-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313682-55-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[5-(4-methoxyphenyl)-1,2,4-oxadiazol-

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-61-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[1-(phenylmethyl)-1H-imidazol-2-yl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-63-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(cyclopentylmethyl)amino]-2-hydroxy-1-[[4-[(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-70-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](cyclopentylmethyl)amino]-1-[[4-[(3-cyanophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-72-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](cyclopentylmethyl)amino]-1-[[4-[(4-cyanomethoxy)phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-92-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-1-[[4-[(bis(2-methoxyethyl)amino)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-93-8 CAPLUS
 CN 4-Morpholinecarboxylic acid, 4-[(2S,3R)-4-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-74-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](cyclopentylmethyl)amino]-2-hydroxy-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-91-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-94-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-morpholinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-95-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-(4-morpholinyl)ethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-96-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(4-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-97-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(4-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(2-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-00-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 2-hydroxy-1-[[4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]methyl]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-01-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 2-hydroxy-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313682-98-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(4-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 2-hydroxy-1-[[4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]methyl]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313682-99-4 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 1-[[4-[[bis(2-methoxyethyl)amino]methoxy]phenyl]methyl]-2-hydroxypropyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-02-2 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(2-methylpropyl)amino]-
 2-hydroxy-1-[[4-[(4-morpholinyl)methoxy]phenyl]methyl]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-03-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-hydroxy-3-
 methylphenyl)sulfonyl]-(2-methylpropyl)amino]-1-[[4-
 hydroxyphenyl]methyl]propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-04-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-hydroxy-3-methylphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-(2-(4-morpholinyl)ethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-05-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[[4-[[bis(2-methoxyethyl)amino]methoxy]phenyl]methyl]-2-hydroxy-3-[[[4-hydroxy-3-methylphenyl]sulfonyl](2-methylpropyl)amino]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-09-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-amino-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-10-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-amino-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-[[5-methyl-3-isoxazolyl]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-06-6 CAPLUS
 CN 4-Morpholinecarboxylic acid, 4-[[[(2S,3R)-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxy-4-[[[4-hydroxy-3-methylphenyl]sulfonyl](2-methylpropyl)amino]butyl]phenyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-07-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-hydroxy-3-methylphenyl]sulfonyl](2-methylpropyl)amino]-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-11-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2-amino-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-[[4-[[bis(2-methoxyethyl)amino]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-16-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-aminophenyl]sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-17-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-18-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-[[4-[[bis(2-methoxyethyl)amino]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 288291-99-6 313680-09-0 313680-74-9
 313681-39-9 313681-66-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylsulfonamides as inhibitors of HIV aspartyl protease and antiviral agents)
 RN 288291-99-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)(1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313680-09-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[2-(2-methylhydrazino)ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313683-19-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-1-[[4-[[bis(2-methoxyethyl)amino]methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-20-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[bis(2-methoxyethyl)amino]methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313680-74-9 CAPLUS
 CN Butanoic acid, 4-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313681-39-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-66-2 CAPLUS


L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Propanoic acid, 3-[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313679-69-5P 313679-70-8P 313679-71-9P
 313680-87-4P 313680-99-8P 313681-00-4P
 313681-01-5P 313681-24-2P 313681-31-1P
 313681-32-2P 313681-34-4P 313681-36-6P
 313681-43-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of arylsulfonamides as inhibitors of HIV aspartyl protease and antiviral agents)
 RN 313679-69-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(3-nitrophenyl)sulfonyl]amino]-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313679-70-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313680-99-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-[[4-(2-pyridinylmethoxy)phenyl]methyl]propyl]-, (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-00-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.




RN 313679-71-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-(4-hydroxyphenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313680-87-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-[[4-[(3-cyanophenyl)methoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313681-01-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[(3-cyanophenyl)methoxy]phenyl]methyl]-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]propyl]-, (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-24-2 CAPLUS
 CN Carbamic acid, 4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-31-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[4-[(1,1-dimethylethyl)dimethylsilyl]oxy]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313681-32-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[4-[(1,1-dimethylethyl)dimethylsilyl]oxy]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 313681-43-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[4-[(1,1-dimethylethyl)dimethylsilyl]oxy]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 313681-34-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-1-[[4-[[4-[(1,1-dimethylethyl)dimethylsilyl]oxy]propoxy]phenyl]methyl]-2-hydroxypropyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313681-36-6 CAPLUS
 CN Carbamic acid, 3-[[4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-3-hydroxybutyl]phenoxy]propyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:699185 CAPLUS
 DN 133:267150
 TI Preparation of amino acid sulfonamide derivatives as inhibitors of aspartyl protease
 IN Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Murcko, Mark Andrew; Novak, Perry Michael; Bhisetti, Govinda Rao
 PA Vertex Pharmaceuticals, Incorporated, USA
 SO U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 207,580, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6127372	A	20001003	US 1996-424372	19960401
WO 9524385	A1	19950914	WO 1995-US2420	19950224
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI US 1994-207580	B2	19940307		
WO 1995-US2420	W	19950224		

OS MARPAT 133:267150
 AB Sulfonamides 2-(CH-D)pC(:G)(CX'')mC(:G')N(D')SO₂-E' [Z = N(D), SO₂E, NH-A,
 N(D)-A, NH-E, NHC(O)N(D)(E), NH-Ht, N(D)-Ht or phthalimidyl (A = Ht or -R1-Ht, where Ht is a heterocycle which may be substituted, R1 = CO, SO₂, COCO, O₂C, OSO₂, NHSO₂, NHCOC, which may be substituted; D, D' = aryl, carbocycle, Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl, etc.; m = 1-3; p = 0 or 1; G, G' = H₂ or O; X' = H, OH, NH₂, SH, D, halo or XX'


O] were prepared as aspartyl protease inhibitors. Thus, t-BuNHCON(CH₂Ph)CH₂CH(OH)N(CH₂-cyclopentyl)SO₂C₆H₄OMe-p, prepared by sequential reactions of cyclopentylmethylamine, p-methoxybenzenesulfonyl chloride, epibromohydrin, benzylamine, and t-Bu isocyanate, showed K_i = 2,400 for inhibition of HIV-1 protease.

IT 298205-63-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) [preparation of amino acid sulfonamide derivs. as inhibitors of aspartyl protease]

RN 298205-63-7 CAPLUS
 CN Carbamic acid, [(2S)-3-[(3-aminophenyl)sulfonyl](cyclopentylmethyl)amino]-2-hydroxypropyl]-, (3S)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 298205-74-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


aspartyl protease)

RN 298205-74-0 CAPLUS

CN Carbamic acid,

[(2S)-3-((cyclopentylmethyl)((3-nitrophenyl)sulfonyl)amino)-2-hydroxypropyl (2-phenylethyl)-, (3S)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:573770 CAPLUS

DN 133:177157

TI Preparation of (1-benzyl-2-hydroxy-3-(arylsulfonamido)propyl)carbamates

as

HIV aspartyl protease inhibitors

IN Hale, Michael R.; Baker, Christopher T.; Stammers, Timothy A.; Sherrill, Ronald G.; Spaltenstein, Andrew; Furfine, Eric S.; Maltais, Francois; Andrews, Clarence Webster, III; Miller, John F.; Samano, Vicente

Vertex Pharmaceuticals Incorporated, USA

PA FCT Int. Appl., 369 pp.

SO CODEM: P1XXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000047551	A2	20000817	WO 2000-US3288	20000209
WO 2000047551	A3	20010816		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6319946	B1	20011120	US 2000-500781	20000209
EP 1159278	A2	20011205	EP 2000-913402	20000209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536430	T	20021029	JP 2000-598472	20000209
AT 311391	T	20051215	AT 2000-913402	20000209
EP 1637518	A2	20060322	EP 2005-25977	20000209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ES 2254156	T3	20060616	ES 2000-913402	20000209
PT 1159278	T	20060630	PT 2000-913402	20000209
TW 260322	B	20060821	TW 2000-89102108	20000209
US 2002198388	A1	20021226	US 2001-927271	20010809
US 6617350	B2	20030909		
US 2004127488	A1	20040701	US 2003-613650	20030702
PRAI US 1999-120047P	P	19990212		
SY 2000-1090	A	20000207		
EP 2000-913402	A3	20000209		
US 2000-500781	A3	20000209		
WO 2000-US3288	W	20000209		
US 2001-927271	A3	20010809		
OS MARPAT 133:177157				
GI				

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB ABxN(GX)CH(D)CH(OR7)CH2ND'E'E [wherein A = H, or (un)substituted Ht,

or R1Ak; Ak = alkyl; Ht = cycloalkyl, cycloalkenyl, or (un)substituted aryl or heterocyclyl; R1 = CO(CO), (O)SO2, O2C, or (un)substituted NHSO2 or NHSO2(CO); B = (un)substituted NHCH2CO; x = 0 or 1; G = H, R7, alkyl,

or

G may be bound to R7 to form a heterocyclic ring; R7 = H, (CH2O)xY(ZM) (:X)Z(M)x; etc.; M = H, Li, Na, K, Mg, Ca, Ba, alkyl, alkenyl, etc.; X = O or S; Y = P or S; Z = H, O, S, or (un)substituted NH2; D = independently Q or (un)substituted (cyclo)alkyl or (cyclo)alkenyl; Q = (un)substituted carbocyclyl or heterocyclyl; D' = (un)substituted alkyl, alkenyl, alkynyl; E = Ht, OH, HtHt, alkoxy, (un)substituted NH2, alkyl, or carbocyclyl; E' = CO or SO2] were prepared as antiviral agents against HIV-1 and HIV-2 viruses. Thus, 3-NO2C6H4SO2Cl was added to tert-Bu (1S,2R)-N-[(1-benzyl-3-[(4-cyano-2,2-dimethylbutyl)amino]-2-hydroxypropyl)carbamate (preparation given) to form the 3-nitrophenylsulfonamide (55%). Reduction to the 3-aminophenylsulfonamide (85%), followed by transesterification with [(3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl][(4-nitrophenyl)carbonate (65%), gave 1.

In

an antiviral activity assay, 1 inhibited HIV-1 protease in the MT4 cell line with Ki < 1 nM and IC50 < 0.1 μM.

IT 288291-42-9P 288291-55-4P 288291-61-2P
288291-66-7P 288291-87-2P 288291-99-6P
288292-00-2P 288292-12-6P 288292-37-5P
288292-38-6P 288304-71-2P 288304-72-3P
288304-76-7P 288304-77-8P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(HIV inhibitor; preparation of heterocyclyl


arylsulfonamidopropylcarbamate

HIV protease inhibitors by reductive alkylation of amines and

subsequent addition of arylsulfonamide chlorides)
RN 288291-42-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(3-methylamino)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288291-55-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288291-61-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(4-phenylmethoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288291-66-7 CAPLUS

CN Carbamic acid, [3-[(4-cyano-2,2-dimethylbutyl)[(2R,3S)-3-[[[(3R,3aS,6aR)-


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hexahydrofuro[2,3-b]furan-3-yl]oxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino)sulfonyl]phenyl]ethyl-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 288291-87-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,2-dimethyl-5-oxohexyl)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288291-99-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)(1,3-benzodioxol-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-37-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-amino-2,2-dimethylbutyl)(1,3-benzodioxol-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-38-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(7-amino-2,2-dimethylheptyl)(1,3-benzodioxol-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288304-71-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-azido-2,2-dimethylpentyl)(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-00-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-12-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-amino-2,2-dimethylpentyl)(1,3-benzodioxol-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288304-72-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-amino-2,2-dimethylpentyl)(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288304-76-7 CAPLUS
 CN 2,6,12,14-Tetraazahexadecanedioic acid, 4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]amino]-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, 16-ethyl 1-(hexahydrofuro[2,3-b]furan-3-yl) ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288304-77-8 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(4-amino-2,2-dimethylbutyl)](4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 288291-40-7P 288291-41-8P 288291-43-0P
 288291-46-3P 288291-50-9P 288291-51-0P
 288291-53-2P 288291-58-7P 288291-59-8P
 288291-60-1P 288291-63-4P 288291-67-8P
 288291-68-9P 288291-69-0P 288291-70-3P
 288291-76-9P 288291-91-8P 288291-93-0P
 288291-94-1P 288291-96-3P 288291-97-4P
 288291-98-5P 288292-01-3P 288292-02-4P
 288292-03-5P 288292-04-6P 288292-05-7P
 288292-06-8P 288292-07-9P 288292-08-0P
 288292-09-1P 288292-10-4P 288292-11-5P
 288292-13-7P 288292-14-8P 288292-15-9P
 288292-16-0P 288292-17-1P 288292-18-2P
 288292-19-3P 288292-20-6P 288292-21-7P
 288292-22-8P 288292-23-9P 288292-24-0P
 288292-25-1P 288292-26-2P 288292-27-3P
 288292-35-3P 288292-39-7P 288292-40-0P
 288292-41-1P 288292-42-2P 288292-43-3P
 288292-44-4P 288292-45-5P 288292-46-6P
 288292-47-7P 288292-51-3P 288292-52-4P
 288292-53-5P 288292-54-6P 288292-55-7P
 288292-56-8P 288292-57-9P 288292-58-0P
 288292-59-1P 288292-60-4P 288292-61-5P
 288292-62-6P 288292-63-7P 288292-64-8P
 288292-65-9P 288292-66-0P 288292-67-1P
 288292-68-2P 288292-69-3P 288292-70-6P
 288292-71-7P 288292-72-8P 288292-73-9P
 288292-74-0P 288292-75-1P 288292-76-2P
 288292-77-3P 288292-78-4P 288292-79-5P
 288292-80-8P 288292-81-9P 288292-82-0P
 288292-83-1P 288292-84-2P 288292-85-3P
 288292-86-4P 288292-87-5P 288292-88-6P
 288292-89-7P 288292-90-0P 288292-91-1P
 288292-92-2P 288292-93-3P 288292-94-4P
 288292-95-5P 288292-96-6P 288292-97-7P
 288292-98-8P 288292-99-9P 288293-00-5P
 288293-01-6P 288293-02-7P 288293-03-8P

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

288293-04-9P 288293-05-0P 288293-06-1P
 288293-07-2P 288293-08-3P 288293-09-4P
 288293-10-7P 288293-11-8P 288293-12-9P
 288293-13-0P 288293-14-1P 288293-25-4P
 288293-26-5P 288293-27-6P 288293-28-7P
 288293-29-8P 288293-30-1P 288293-31-2P
 288293-32-3P 288293-33-4P 288293-34-5P
 288293-35-6P 288293-36-7P 288293-37-8P
 288293-38-9P 288293-39-0P 288293-40-3P
 288293-41-4P 288293-42-5P 288293-43-6P
 288293-44-7P 288293-45-8P 288293-46-9P
 288293-47-0P 288293-48-1P 288293-49-2P
 288293-50-5P 288293-51-6P 288293-52-7P
 288293-53-8P 288293-54-9P 288293-55-0P
 288293-56-1P 288293-57-2P 288293-58-3P
 288293-59-4P 288293-60-7P 288293-61-8P
 288293-62-9P 288293-63-0P 288293-64-1P
 288293-65-2P 288293-66-3P 288293-67-4P
 288293-68-5P 288293-69-6P 288293-70-9P
 288293-71-0P 288293-72-1P 288293-73-2P
 288293-74-3P 288293-75-4P 288293-76-5P
 288293-77-6P 288293-78-7P 288293-79-8P
 288293-80-1P 288293-81-2P 288293-82-3P
 288293-83-4P 288293-84-5P 288293-85-6P
 288293-86-7P 288293-87-8P 288293-88-9P
 288293-89-0P 288293-90-3P 288293-91-4P
 288293-92-5P 288293-93-6P 288293-94-7P
 288293-95-8P 288293-96-9P 288293-97-0P
 288293-98-1P 288293-99-2P 288294-00-8P
 288294-01-9P 288294-02-0P 288294-03-1P
 288294-04-2P 288294-05-3P 288294-06-4P
 288294-07-5P 288294-08-6P 288294-09-7P
 288294-10-0P 288294-11-1P 288294-12-2P
 288294-13-3P 288294-14-4P 288294-15-5P
 288294-16-6P 288294-17-7P 288294-18-8P
 288294-19-9P 288294-20-2P 288294-21-3P
 288294-22-4P 288294-23-5P 288294-24-6P
 288294-25-7P 288294-26-8P 288294-27-9P
 288294-28-0P 288294-29-1P 288294-30-4P
 288294-31-5P 288294-32-6P 288294-33-7P
 288294-34-8P 288294-35-9P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (HIV inhibitor; prep. of heterocyclized arylsulfonamidopropylcarbamate HIV protease inhibitors by reductive alkylation of amines and subsequent addn. of arylsulfonyl chlorides)

RN 288291-40-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288291-41-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)](4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288291-43-0 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)](4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288291-46-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288291-50-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)](4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288291-51-0 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)](4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 288291-53-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(3-(dimethylamino)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288291-58-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-(acetylamino)phenyl)sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288291-59-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-(acetylamino)-4-fluorophenyl)sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288291-67-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(3-(ethylamino)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288291-68-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl](4-cyano-2,2-dimethylbutyl)amino)-1-(phenylmethyl)-2-(phosphonoxy)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 288291-69-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(3-(methylamino)phenyl)sulfonyl]amino)-1-(phenylmethyl)-2-(phosphonoxy)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, diammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288291-60-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-(acetylamino)phenyl)sulfonyl](4-cyano-2,2-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288291-63-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(4-hydroxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 NH3

RN 288291-70-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(4-methoxyphenyl)sulfonyl]amino)-1-(phenylmethyl)-2-(phosphonoxy)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, diammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 NH3

RN 288291-76-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2-cyanoethyl)[(4-methoxyphenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 288291-91-8 CAPLUS
 CN 4-Oxa-2,9,13-triazatetradecan-14-oic acid, 11-hydroxy-9-[(4-methoxyphenyl)sulfonyl]-7,7-dimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288291-93-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,2-dimethyl-5-oxohexyl)[3-(methylamino)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 288291-98-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)[3-(methylamino)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-01-3 CAPLUS
 CN 2-Oxa-4,11,15-Tetraazahexadecan-16-oic acid, 13-hydroxy-9,9-dimethyl-11-[(3-(methylamino)phenyl)sulfonyl]-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-02-4 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


RN 288291-94-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(5-(hydroxyimino)-2,2-dimethylhexyl)[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 288291-96-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-[(aminocarbonyl)oxy]-2,2-dimethylbutyl)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288291-97-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2,2-dimethyl-5-oxohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


CN 2,4,11,15-Tetraazahexadecan-16-oic acid, 13-hydroxy-2,9,9-trimethyl-11-[(3-(methylamino)phenyl)sulfonyl]-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-03-5 CAPLUS
 CN 2-Oxa-4,11,15-Tetraazahexadecan-16-oic acid, 11-(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-04-6 CAPLUS
 CN 2,4,11,15-Tetraazahexadecan-16-oic acid, 11-(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-2,9,9-trimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-05-7 CAPLUS
 CN 2-Oxa-4,11,15-Triazahexadecan-16-oic acid, 11-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-13-hydroxy-9,9-dimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-06-8 CAPLUS
 CN 2,4,11,15-Tetraazahexadecan-16-oic acid, 11-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-13-hydroxy-2,9,9-trimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-09-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-(dimethylamino)phenyl]sulfonyl](2,2-dimethyl-5-oxohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-10-4 CAPLUS
 CN 2-Thia-3,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-yl)sulfonyl]-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-11-5 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-07-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2,2-dimethyl-5-oxohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-08-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[[3-aminophenyl)sulfonyl](2,2-dimethyl-5-oxohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 2-Thia-3,10,14-triazapentadecan-15-oic acid, 10-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-13-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-amino-2,2-dimethylpentyl)[[3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-14-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(2,2-dimethyl-6-oxoheptyl)[[4-methoxyphenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-15-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-(hydroxyimino)-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 288292-16-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-(methoxyimino)-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-19-3 CAPLUS
 CN 2-Oxa-4,10,14-Triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-10-[(3-[(methylamino)phenyl]sulfonyl)-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-20-6 CAPLUS
 CN 2-Oxa-4,10,14-Triazapentadecan-15-oic acid, 10-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-17-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-amino-2,2-dimethylpentyl)[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-18-2 CAPLUS
 CN 2-Oxa-4,10,14-Triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-21-7 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-2,8,8-trimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-22-8 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 12-hydroxy-2,8,8-trimethyl-10-[(3-[(methylamino)phenyl]sulfonyl)-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-23-9 CAPLUS


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid,
 10-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-12-hydroxy-2,8,8-trimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-24-0 CAPLUS
 CN 2-Thia-3,9,13-triazatetradecan-14-oic acid, 9-[(1,3-benzodioxol-5-yl)sulfonyl]-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-25-1 CAPLUS
 CN 2-Thia-3,9,13-triazatetradecan-14-oic acid, 11-hydroxy-7,7-dimethyl-9-[[3-(methylamino)phenyl]sulfonyl]-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-35-3 CAPLUS
 CN Carbanic acid, [(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl]-(3-oxobutyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-39-7 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(4-amino-2,2-dimethylbutyl)[(3-(methylamino)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-40-0 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(4-amino-2,2-dimethylbutyl)[(3-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-26-2 CAPLUS
 CN 2-Thia-3,9,13-triazatetradecan-14-oic acid, 9-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-27-3 CAPLUS
 CN 4-Oxa-2,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-yl)sulfonyl]-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-41-1 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(4-amino-2,2-dimethylbutyl)[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-42-2 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(5-amino-2,2-dimethylpentyl)[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 288292-43-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-amino-2,2-dimethylpentyl)[(3-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-44-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-45-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)[(3-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288292-51-3 CAPLUS
 CN 15-Oxa-2,6,13-triazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-52-4 CAPLUS
 CN 15-Oxa-2,6,13-triazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,16-trimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-53-5 CAPLUS
 CN 2,4,11,15-Tetraazahexadecan-16-oic acid, 11-(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-46-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-47-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(6-amino-2,2-dimethylhexyl)[(1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288292-54-6 CAPLUS
 CN 14-Oxa-2,6,12-triazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-55-7 CAPLUS
 CN 14-Oxa-2,6,12-triazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,15-trimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-56-8 CAPLUS


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2-Thia-4,10,14-triazapentadecan-15-oic acid, 10-(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-57-9 CAPLUS
 CN 14-Thia-2,6,12-triazahexadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-58-0 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 10-(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-61-5 CAPLUS
 CN 13-Oxa-2,6,11-triazapentadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-62-6 CAPLUS
 CN 2-Thia-3,8,12-triazatridecan-13-oic acid, 8-(1,3-benzodioxol-5-ylsulfonyl)-10-hydroxy-6,6-dimethyl-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (10R,11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-59-1 CAPLUS
 CN 2-Oxa-4,9,13-triazatetradecan-14-oic acid, 9-(1,3-benzodioxol-5-ylsulfonyl)-11-hydroxy-7,7-dimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-60-4 CAPLUS
 CN 13-Oxa-2,6,11-triazapentadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,14-trimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-63-7 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid, 9-(1,3-benzodioxol-5-ylsulfonyl)-11-hydroxy-2,7,7-trimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-64-8 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid, 9-(1,3-benzodioxol-5-ylsulfonyl)-11-hydroxy-7,7-dimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288292-65-9 CAPLUS
 CN 2-Oxa-4,12,16-triazaheptadecan-17-oic acid, 12-[(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-3-oxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-66-0 CAPLUS
 CN 16-Oxa-2,6,14-triazaoctadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-15-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-67-1 CAPLUS
 CN 16-Oxa-2,6,14-triazaoctadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,17-trimethyl-15-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-70-6 CAPLUS
 CN 2-Thia-3,8,12-triazatridecan-13-oic acid, 10-hydroxy-6,6-dimethyl-8-[(3-(methylamino)phenyl)sulfonyl]-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (10R,11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-71-7 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid, 11-hydroxy-2,7,7-trimethyl-9-[(3-(methylamino)phenyl)sulfonyl]-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-68-2 CAPLUS
 CN 2-Thia-3,11,15-triazahexadecan-16-oic acid, 11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-69-3 CAPLUS
 CN 2-Oxa-4,9,13-triazatetradecan-14-oic acid, 11-hydroxy-7,7-dimethyl-9-[(3-(methylamino)phenyl)sulfonyl]-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-72-8 CAPLUS
 CN 2-Oxa-4,9,13-triazatetradecan-14-oic acid, 9-[(3-aminophenyl)sulfonyl]-11-hydroxy-7,7-dimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-73-9 CAPLUS
 CN 13-Oxa-2,6,11-triazapentadecanoic acid, 6-[(3-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288292-74-0 CAPLUS
 CN 13-Oxa-2,6,11-triazapentadecanoic acid, 6-[(3-aminophenyl)sulfonyl]-4-hydroxy-8,8,14-trimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-75-1 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid, 9-[(3-aminophenyl)sulfonyl]-11-hydroxy-2,7,7-trimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-76-2 CAPLUS
 CN 2-Thia-3,8,12-triazatridecan-13-oic acid, 8-[(3-aminophenyl)sulfonyl]-10-hydroxy-6,6-dimethyl-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (10R,11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-79-5 CAPLUS
 CN 2-Thia-3,8,12-triazatridecan-13-oic acid, 8-[(4-aminophenyl)sulfonyl]-10-hydroxy-6,6-dimethyl-11-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (10R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-80-8 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid, 9-[(4-aminophenyl)sulfonyl]-11-hydroxy-2,7,7-trimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-81-9 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-77-3 CAPLUS
 CN 2-Oxa-4,9,13-triazatetradecan-14-oic acid, 9-[(4-aminophenyl)sulfonyl]-11-hydroxy-7,7-dimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-78-4 CAPLUS
 CN 13-Oxa-2,6,11-triazapentadecanoic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 13-Oxa-2,6,11-triazapentadecanoic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,8,14-trimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-82-0 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 10-[(4-aminophenyl)sulfonyl]-12-hydroxy-2,8,8-trimethyl-3-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288292-83-1 CAPLUS
 CN 2-Thia-3,9,13-triazatetradecan-14-oic acid, 9-[(4-aminophenyl)sulfonyl]-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-84-2 CAPLUS
 CN 2-Oxa-4,10,14-triazapentadecan-15-oic acid, 10-[(4-aminophenyl)sulfonyl]-12-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-85-3 CAPLUS
 CN 14-Oxa-2,6,12-triazahexadecanoic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288292-89-7 CAPLUS
 CN 2-Thia-3,9,13-triazatetradecan-14-oic acid, 9-[(3-aminophenyl)sulfonyl]-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-90-0 CAPLUS
 CN 14-Oxa-2,6,12-triazahexadecanoic acid, 6-[(3-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-91-1 CAPLUS
 CN 14-Oxa-2,6,12-triazahexadecanoic acid, 6-[(3-aminophenyl)sulfonyl]-4-

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288292-86-4 CAPLUS
 CN 14-Oxa-2,6,12-triazahexadecanoic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,8,15-trimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-87-5 CAPLUS
 CN 2-Oxa-4,10,14-triazapentadecan-15-oic acid, 10-[(3-aminophenyl)sulfonyl]-12-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-88-6 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 10-[(3-aminophenyl)sulfonyl]-12-hydroxy-2,8,8-trimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hydroxy-8,8,15-trimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-92-2 CAPLUS
 CN 2-Thia-3,10,14-triazapentadecan-15-oic acid, 12-hydroxy-8,8-dimethyl-10-[(3-methylamino)phenyl)sulfonyl]-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288292-93-3 CAPLUS
 CN 15-Oxa-2,6,13-triazahexadecanoic acid, 4-hydroxy-8,8-dimethyl-6-[(3-methylamino)phenyl)sulfonyl]-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288292-96-6 CAPLUS
 CN 15-Oxa-2,6,13-triazaseptadecanoic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288292-97-7 CAPLUS
 CN 15-Oxa-2,6,13-triazaheptadecanoic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,16-trimethyl-14-oxo-3-(phenylmethyl)-, (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester. (3S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 288293-01-6 CAPLUS
 CN 15-Oxa-2,6,13-triazaheptadecanoic acid, 6-[(3-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

The diagram illustrates the absolute stereochemistry of a complex molecule. The structure includes a bicyclic system with a bridgehead oxygen atom. A side chain contains a chiral center with a phenyl group (Ph) and a hydroxyl group (OH). Another side chain contains a sulfonamide group (SO₂NH₂) and a chiral center with a methyl group (Me) and a hydrogen atom (H). The stereochemistry is indicated by wedged and dashed bonds.

RN 288293-02-7 CAPLUS
 CN 15-Oxa-2,6,13-triazaheptadecanoic acid, 6-([3-aminophenyl)sulfonyl]-4-hydroxy-8,16-trimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)-(9CI) (CA INDEX NAME)




RN 288293-03-8 CAPLUS
CN 2,4,11,15-Tetraazahexadecan-16-oic acid, 11-[(3-aminophenyl)sulfonyl]-13-hydroxy-2,9,9-trimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-04-9 CAPLUS
CN 2-Thia-3,10,14-triazapentadecan-15-oic acid, 10-[(3-aminophenyl)sulfonyl]-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-05-0 CAPLUS
CN 2-Thia-4,11,15-triazahexadecan-16-oic acid, 11-[(3-aminophenyl)sulfonyl]-13-hydroxy-9,9-dimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288293-08-3 CAPLUS
CN 15-Oxa-2,6,13-triazahexadecan-16-oic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-09-4 CAPLUS
CN 15-Oxa-2,6,13-triazahexadecan-16-oic acid, 6-[(4-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-10-7 CAPLUS
CN 2-Thia-3,10,14-triazapentadecan-15-oic acid, 10-[(4-aminophenyl)sulfonyl]-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-06-1 CAPLUS
CN 15-Thia-2,6,13-triazahexadecan-16-oic acid, 6-[(3-aminophenyl)sulfonyl]-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-07-2 CAPLUS
CN 2-Oxa-4,11,15-triazahexadecan-16-oic acid, 11-[(4-aminophenyl)sulfonyl]-13-hydroxy-9,9-dimethyl-3-oxo-14-(phenylmethyl)-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-11-8 CAPLUS
CN 2-Oxa-4,11,15-triazahexadecan-16-oic acid, 11-[(1,3-benzodioxol-5-yl)sulfonyl]-13-hydroxy-9,9-dimethyl-3-oxo-14-(phenylmethyl)-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-12-9 CAPLUS
CN 15-Oxa-2,6,13-triazahexadecan-16-oic acid, 6-[(1,3-benzodioxol-5-yl)sulfonyl]-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-13-0 CAPLUS
 CN 15-Oxa-2,6,13-triazaheptadecanoic acid,
 6-(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,16-trimethyl-14-oxo-3-(phenylmethyl)-, (3S,3aR,6aS)-
 hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-14-1 CAPLUS
 CN 2-Thia-3,10,14-triazapentadecan-15-oic acid, 10-(1,3-benzodioxol-5-
 ylsulfonyl)-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-,
 (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide,
 (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-25-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-(acetamino)-2,2-dimethylbutyl](1,3-
 benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-26-5 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(2,2-dimethyl-
 1-oxopropyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-27-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-
 [(cyclobutylcarbonyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-28-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2,2-dimethyl-4-
 [(3-methyl-1-oxobutyl)amino]butyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-29-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-(benzoylamino)-
 2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-30-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(2-
 furanylcarbonyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-31-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-4-((2-thienylcarbonyl)amino)butyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-32-3 CAPLUS
 CN 13-Oxa-2,6,11-triazahexadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-33-4 CAPLUS
 CN 13-Oxa-2,6,11-triazahexadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-34-5 CAPLUS
 CN 13-Oxa-2,6,11-triazahexadec-15-ynoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-35-6 CAPLUS
 CN 13-Oxa-2,6,11-triazapentadec-14-enoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,14-trimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-36-7 CAPLUS
 CN 13-Oxa-2,6,11-triazahexadec-16-enoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-37-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(4-fluorophenoxy)carbonyl]amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-38-9 CAPLUS
 CN 2,6,11,13-Tetraazapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-13-ethyl-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-39-0 CAPLUS
 CN 2,6,11,13-Tetraazapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,14-trimethyl-13-(1-methylethyl)-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-40-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-4-[(4-morpholinylcarbonyl)amino]butyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-41-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-4-[(1-pyrrolidinylcarbonyl)amino]butyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-42-5 CAPLUS
 CN 12-Thia-2,6,11-triazatetradecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 12,12-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288293-43-6 CAPLUS
 CN 12-Thia-2,6,11-triazapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 12,12-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-44-7 CAPLUS
 CN 12-Thia-2,6,11-triazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 12,12-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-45-8 CAPLUS


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-4-[(phenylsulfonyl)amino]butyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-46-9 CAPLUS
 CN 2,5-Dioxo-7,12,16-triazaheptadecan-17-oic acid, 12-[(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-6-oxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-47-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(4-fluorobenzoyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-48-1 CAPLUS
 CN Carbamic acid, 4-[(1,3-benzodioxol-5-ylsulfonyl)](2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-2,3-dimethylbutyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-49-2 CAPLUS
 CN 2-Oxa-5,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-4-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-52-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)]4-[(cyclopropylcarbonyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-53-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)]4-[(cyclopentylcarbonyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-50-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)](2,2-dimethyl-4-[(2-methyl-1-oxopropyl)amino]butyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-51-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)]4-[(3,3-dimethyl-1-oxobutyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-54-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)]4-[(3-cyclopentyl-1-oxopropyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-55-0 CAPLUS
 CN 16-Oxa-2,6,11-triazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12,15-dioxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-56-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(3,5-difluorobenzoyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-57-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[(1,3-benzodioxol-5-ylcarbonyl)amino]-2,2-dimethylbutyl][(1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-60-7 CAPLUS
 CN 2,4,9,13-Tetraazapentadecan-14-oic acid, 9-[(1,3-benzodioxol-5-ylsulfonyl)-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-3-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-61-8 CAPLUS
 CN 2,6,11,13-Tetraazahexadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-12-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-58-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(4-fluorophenyl)sulfonyl]amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-59-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(4-methoxyphenyl)sulfonyl]amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288293-62-9 CAPLUS
 CN 2,6,11,13-Tetraazapentadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,14-trimethyl-3-(phenylmethyl)-12-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-63-0 CAPLUS
 CN 2,6,11,13-Tetraazapentadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,14,14-tetramethyl-3-(phenylmethyl)-12-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288293-64-1 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid,
 9-[(1,3-benzodioxol-5-ylsulfonyl)-
 1-(2-furanyl)-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-3-thio-
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 288293-65-2 CAPLUS
 CN 2,6,11,13-Tetraazahexadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-66-3 CAPLUS
 CN 2,6,11,13-Tetraazapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8,14,14-tetramethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA
 INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288293-69-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-5-[(2,2-dimethyl-
 1-oxopropyl)amino]-2,2-dimethylpentyl)amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-70-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-5-
 [(cyclobutylcarbonyl)amino]-2,2-dimethylpentyl)amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 288293-67-4 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid,
 9-[(1,3-benzodioxol-5-ylsulfonyl)-
 11-hydroxy-7,7-dimethyl-3-oxo-1-phenyl-12-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 288293-68-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-(acetamino)-2,2-dimethylpentyl)(1,3-
 benzodioxol-5-ylsulfonyl)amino]pentyl)amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288293-71-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2,2-dimethyl-5-
 [(3-methyl-1-oxobutyl)amino]pentyl)amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-72-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-5-(benzoylamino)-
 2,2-dimethylpentyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-73-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-5-[(2-
 furanylcarbonyl)amino]-2,2-dimethylpentyl)amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-74-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-5-[(2-thienylcarbonyl)amino]pentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-75-4 CAPLUS
 CN 14-Oxa-2,6,12-triazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-76-5 CAPLUS
 CN 14-Oxa-2,6,12-triazaoctadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-77-6 CAPLUS
 CN 14-Oxa-2,6,12-triazaheptadec-16-ynoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288293-78-7 CAPLUS
 CN 14-Oxa-2,6,12-triazaheptadec-15-enoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,15-trimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-79-8 CAPLUS
 CN 14-Oxa-2,6,12-triazaoctadec-17-enoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-80-1 CAPLUS


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[[4-(4-fluorophenoxy)carbonyl]amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-81-2 CAPLUS
 CN 2,6,12,14-Tetraazahexadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-14-ethyl-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-82-3 CAPLUS
 CN 2,6,12,14-Tetraazahexadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,15-trimethyl-14-(1-methylethyl)-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-83-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-5-[(4-morpholinylcarbonyl)amino]pentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-84-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-5-[(1-pyrrolidinylcarbonyl)amino]pentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288293-87-8 CAPLUS
 CN 13-Thia-2,6,12-triazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 13,13-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-88-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-5-[(phenylsulfonyl)amino]pentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-89-0 CAPLUS
 CN 2,5-Dioxo-7,13,17-triazaoctadecan-18-oic acid, 13-[(1,3-benzodioxol-5-

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288293-85-6 CAPLUS
 CN 13-Thia-2,6,12-triazapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 13,13-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-86-7 CAPLUS
 CN 13-Thia-2,6,12-triazahexadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 13,13-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 13-Thia-2,6,12-triazahexadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-15-hydroxy-11,11-dimethyl-6-oxo-16-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (15R,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-90-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(4-fluorobenzoyl)amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-91-4 CAPLUS
 CN Carbamic acid, [5-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-4,4-dimethylpentyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B


OMe

RN 288293-92-5 CAPLUS
 CN 2-Oxa-5,11,15-triazahexadecan-16-oic acid, 11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-4-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288293-96-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(cyclopentylcarbonyl)amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288293-97-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(3-cyclopentyl-1-oxopropyl)amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288293-98-1 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 288293-93-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-5-[(2-methyl-1-oxopropyl)amino]pentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-94-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(3,3-dimethyl-1-oxobutyl)amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-95-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(cyclopropylcarbonyl)amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 17-Oxa-2,6,12-triazaoctadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13,16-dioxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288293-99-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(3,5-difluorobenzoyl)amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-00-8 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(5-[(1,3-benzodioxol-5-ylcarbonyl)amino]-2,2-dimethylpentyl)(1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-01-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(4-fluorophenyl)sulfonyl]amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-02-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(4-methoxyphenyl)sulfonyl]amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-05-3 CAPLUS
 CN 2,6,12,14-Tetraazahexadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,15-trimethyl-3-(phenylmethyl)-13-thio-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-06-4 CAPLUS
 CN 2,6,12,14-Tetraazahexadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,15,15-tetramethyl-3-(phenylmethyl)-13-thio-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-07-5 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 10-(1,3-benzodioxol-5-

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-03-1 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 10-(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-3-thio-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-04-2 CAPLUS
 CN 2,6,12,14-Tetraazapentadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-13-thio-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 sulfonfyl)-1-(2-furyl)-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-3-thio-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-08-6 CAPLUS
 CN 2,6,12,14-Tetraazapentadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-09-7 CAPLUS
 CN 2,6,12,14-Tetraazapentadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,15,15-tetramethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-10-0 CAPLUS
 CN 2,4,10,14-Tetraoxapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-3-oxo-1-phenyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-11-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(2,2-dimethyl-1-oxopropyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-12-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(2,2-dimethyl-1-oxopropyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-13-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(cyclobutylcarbonyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-14-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-6-[(3-methyl-1-oxobutyl)amino]hexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-15-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-(benzoylamino)-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288294-16-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(2-furanylcarbonyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-17-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-6-[(2-thienylcarbonyl)amino]hexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-18-8 CAPLUS
 CN 15-Oxa-2,6,13-triazaoctadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-19-9 CAPLUS
 CN 15-Oxa-2,6,13-triazanonadecanoic acid,
 6-(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-20-2 CAPLUS
 CN 15-Oxa-2,6,13-triazanonadecanoic acid,
 6-(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-23-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[[[(4-fluorophenoxy)carbonyl]amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-24-6 CAPLUS
 CN 2,6,13,15-Tetraazaseptadecanoic acid,
 6-(1,3-benzodioxol-5-ylsulfonyl)-15-
 ethyl-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-21-3 CAPLUS
 CN 15-Oxa-2,6,13-triazaseptadec-16-enoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,16-trimethyl-14-oxo-3-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-22-4 CAPLUS
 CN 15-Oxa-2,6,13-triazanonadec-18-enoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-25-7 CAPLUS
 CN 2,6,13,15-Tetraazaseptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8,16-trimethyl-15-(1-methylethyl)-14-oxo-3-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-26-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-6-[(4-morpholinyl)carbonyl]amino]hexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 288294-27-9 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-6-
 [(1-pyrrolidinylcarbonyl)amino]hexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-28-0 CAPLUS
 CN 14-Thia-2,6,13-triazahexadecanoic acid,
 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester, 14,14-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-29-1 CAPLUS
 CN 14-Thia-2,6,13-triazaheptadecanoic acid,
 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester, 14,14-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-32-6 CAPLUS
 CN 2,5-Dioxo-7,14,18-triazanonadecan-19-oic acid, 14-[(1,3-benzodioxol-5-
 ylsulfonyl)-16-hydroxy-12,12-dimethyl-6-oxo-17-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (16R,17S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 288294-33-7 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(4-
 fluorobenzoyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-30-4 CAPLUS
 CN 14-Thia-2,6,13-triazaoctadecanoic acid,
 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester, 14,14-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-31-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-6-
 [(phenylsulfonyl)amino]hexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 288294-34-8 CAPLUS
 CN Carbanic acid, [6-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-
 [(1,3-benzodioxol-5-ylsulfonyl)amino]hexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 14,14-dioxide, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

RN 288294-35-9 CAPLUS
 CN 2-Oxa-5,12,16-triazaheptadecan-17-oic acid, 12-[(1,3-benzodioxol-5-
 ylsulfonyl)-14-hydroxy-10,10-dimethyl-4-oxo-15-(phenylmethyl)-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




IT 288294-36-0P 288294-37-1P 288294-38-2P
 288294-39-3P 288294-40-6P 288294-41-7P
 288294-42-8P 288294-43-9P 288294-44-0P
 288294-45-1P 288294-46-2P 288294-47-3P
 288294-48-4P 288294-49-5P 288294-50-8P
 288294-51-9P 288294-52-0P 288294-53-1P
 288294-54-2P 288294-55-3P 288294-56-4P
 288294-57-5P 288294-58-6P 288294-59-7P
 288294-60-0P 288294-61-1P 288294-62-2P
 288294-63-3P 288294-64-4P 288294-65-5P
 288294-66-6P 288294-67-7P 288294-68-8P
 288294-69-9P 288294-70-2P 288294-71-3P
 288294-72-4P 288294-73-5P 288294-74-6P
 288294-75-7P 288294-76-8P 288294-77-9P
 288294-78-0P 288294-79-1P 288294-80-4P
 288294-81-5P 288294-82-6P 288294-83-7P
 288294-84-8P 288294-85-9P 288294-86-0P
 288294-87-1P 288294-88-2P 288294-89-3P
 288294-90-6P 288294-91-7P 288294-92-8P
 288294-93-9P 288294-94-0P 288294-95-1P
 288294-96-2P 288294-97-3P 288294-98-4P
 288294-99-5P 288295-00-1P 288295-01-2P
 288295-02-3P 288295-03-4P 288295-04-5P
 288295-05-6P 288295-06-7P 288295-07-8P
 288295-08-9P 288295-09-0P 288295-10-3P
 288295-11-4P 288295-12-5P 288295-13-6P
 288295-14-7P 288295-15-8P 288295-16-9P
 288295-17-0P 288295-18-1P 288295-19-2P
 288295-20-5P 288295-21-6P 288295-22-7P
 288295-23-8P 288295-24-9P 288295-25-0P
 288295-26-1P 288295-27-2P 288295-28-3P
 288295-29-4P 288295-30-7P 288295-31-8P
 288295-32-9P 288295-33-0P 288295-34-1P
 288295-35-2P 288295-36-3P 288295-37-4P
 288295-38-5P 288295-39-6P 288295-40-9P
 288295-41-0P 288295-42-1P 288295-43-2P
 288295-44-3P 288295-45-4P 288295-46-5P
 288295-47-6P 288295-48-7P 288295-49-8P
 288295-50-1P 288295-51-2P 288295-52-3P
 288295-53-4P 288295-54-5P 288295-55-6P
 288295-56-7P 288295-57-8P 288295-58-9P

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

288295-59-0P 288295-60-3P 288295-61-4P
 288295-62-5P 288295-63-6P 288295-64-7P
 288295-65-8P 288295-66-9P 288295-67-0P
 288295-68-1P 288304-73-4P 288304-74-5P
 288304-75-6P 288304-78-9P 288304-79-0P
 288304-80-3P 288304-81-4P 288304-82-5P
 288304-83-6P 288304-84-7P 288304-85-8P
 288304-86-9P 288304-87-0P 288304-88-1P
 288304-89-2P 288304-90-5P 288304-91-6P
 288305-96-4P 288305-97-5P 288305-98-6P
 288306-40-1P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (HIV inhibitor; prepn. of heterocycl arylsulfonamidopropylcarbamate
 HIV protease inhibitors by reductive alkylation of amines and
 subsequent addn. of arylsulfonamide chlorides)
 RN 288294-36-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-6-
 [(2-methyl-1-oxopropyl)amino]hexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-37-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(3,3-dimethyl-1-oxobutyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 288294-38-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-
 [(cyclopropylcarbonyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-39-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-
 [(cyclopentylcarbonyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-40-6 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(3-
 cyclopentyl-1-oxopropyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-41-7 CAPLUS
 CN 18-Oxa-2,6,13-triazanonadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-
 hydroxy-8,8-dimethyl-14,17-dioxo-3-(phenylmethyl)-, (3R,3aS,6aR)-
 hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-42-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(3,5-
 difluorobenzoyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-43-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[6-[(1,3-benzodioxol-5-ylcarbonyl)amino]-2,2-dimethylhexyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-44-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[6-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(4-fluorophenyl)sulfonyl]amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-47-3 CAPLUS
 CN 2,6,13,15-Tetraazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-14-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-48-4 CAPLUS
 CN 2,6,13,15-Tetraazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,16-trimethyl-3-(phenylmethyl)-14-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-49-5 CAPLUS
 CN 2,6,13,15-Tetraazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,16-tetramethyl-3-(phenylmethyl)-14-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-45-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[6-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(4-methoxyphenyl)sulfonyl]amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-46-2 CAPLUS
 CN 2,4,11,15-Tetraazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-14-(phenylmethyl)-3-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-50-8 CAPLUS
 CN 2,4,11,15-Tetraazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-14-(phenylmethyl)-3-thioxo-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-51-9 CAPLUS
 CN 2,6,13,15-Tetraazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-52-0 CAPLUS
 CN 2,6,13,15-Tetraazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,16,16-tetramethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-53-1 CAPLUS
 CN 2,4,11,15-Tetraazahexadecan-16-ic acid, 11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-3-oxo-1-phenyl-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-56-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-7-[(cyclobutylcarbonyl)amino]-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-57-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-7-[(cyclopropylcarbonyl)amino]-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-58-6 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-54-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-2,2-dimethylheptyl]-1,3-benzodioxol-5-ylsulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-55-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-2,2-dimethyl-7-[(3-methyl-1-oxobutyl)amino]heptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-7-(benzoylamino)-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-59-7 CAPLUS
 CN 2-Oxa-5,13,17-triazaoctadecan-18-ic acid, 13-(1,3-benzodioxol-5-ylsulfonyl)-15-hydroxy-11,11-dimethyl-4-oxo-16-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (15R,16S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-60-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-7-[(2-furanylcabonyl)amino]-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-61-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-7-[(2-thienylcarbonyl)amino]heptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-62-2 CAPLUS
CN 16-Oxa-2,6,14-triazanadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-15-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-65-5 CAPLUS
CN 16-Oxa-2,6,14-triazadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-15-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-66-6 CAPLUS
CN 16-Oxa-2,6,14-triazanadec-18-ynoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-15-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-67-7 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-63-3 CAPLUS
CN 16-Oxa-2,6,14-triazadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-15-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-64-4 CAPLUS
CN 16-Oxa-2,6,14-triazadec-17-enoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-15-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2,5-Dioxo-7,15,17-triazadecanoic acid, 15-[(1,3-benzodioxol-5-ylsulfonyl)-17-hydroxy-13,13-dimethyl-6-oxo-18-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (17R,18S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-68-8 CAPLUS
CN 2,4,12,16-Tetrazaheptadecan-17-oic acid, 12-[(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-2,10,10-trimethyl-3-oxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-69-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-7-[(1-pyrrolidinylcarbonyl)amino]heptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-70-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-7-[(4-morpholinylcarbonyl)amino]heptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-71-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-7-[(phenylsulfonyl)amino]heptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-72-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[(aminoacetyl)amino]-2,2-dimethylbutyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-73-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[5-[(aminoacetyl)amino]-2,2-dimethylpentyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-74-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[6-[(aminoacetyl)amino]-2,2-dimethylhexyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-75-7 CAPLUS
 CN 2,6,11,14-Tetraazahexadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12,15-dioxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-76-8 CAPLUS


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2-Oxa-4,7,12,16-tetraazapentadecan-17-oic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-3,6-dioxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288294-77-9 CAPLUS
 CN 2,5,10,14-Tetraazapentadecanedioic acid, 10-(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-4-oxo-13-(phenylmethyl)-, 1-ethyl 15-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-78-0 CAPLUS
 CN 2,4,7,12,16-Pentazapentadecan-17-oic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-2,10,10-trimethyl-3,6-dioxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-79-1 CAPLUS
CN 2-Oxa-5,8,13,17-tetraazaheptadecan-18-oic acid, 13-(1,3-benzodioxol-5-ylsulfonyl)-15-hydroxy-11,11-dimethyl-4,7-dioxo-16-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (15R,16S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-80-4 CAPLUS
CN 2-Thia-3,6,11,15-tetraazahexadecan-16-oic acid, 11-(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-5-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxido, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-83-7 CAPLUS
CN 2,5,11,15-Tetraazahexadecanedioic acid, 11-(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-4-oxo-14-(phenylmethyl)-, 16-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] 1-methyl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-84-8 CAPLUS
CN 2,5,11,15-Tetraazahexadecanedioic acid, 11-(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-4-oxo-14-(phenylmethyl)-, 1-ethyl 16-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-81-5 CAPLUS
CN 2,4,7,12,16-Pentaazaheptadecan-17-oic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-3,6-dioxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-82-6 CAPLUS
CN 2,6,12,15-Tetraazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13,16-dioxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-85-9 CAPLUS
CN 2,4,7,13,17-Pentaazaheptadecan-18-oic acid, 13-(1,3-benzodioxol-5-ylsulfonyl)-15-hydroxy-2,11,11-trimethyl-3,6-dioxo-16-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (15R,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-86-0 CAPLUS
CN 2-Oxa-5,8,14,18-tetraazanonadecan-19-oic acid, 14-(1,3-benzodioxol-5-ylsulfonyl)-16-hydroxy-12,12-dimethyl-4,7-dioxo-17-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (16R,17S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 288294-87-1 CAPLUS

CN 2-Thia-3,6,12,16-tetraazaheptadecan-17-oic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-5-oxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (14R,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-88-2 CAPLUS

CN 2,4,7,13,17-Pentazaheptadecan-18-oic acid, 13-(1,3-benzodioxol-5-ylsulfonyl)-15-hydroxy-11,11-dimethyl-3,6-dioxo-16-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (15R,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 288294-89-3 CAPLUS

CN 2,6,13,16-Tetraazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13,17-dioxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-90-6 CAPLUS

CN 2,5,12,16-Tetraazaheptadecanedioic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-4-oxo-15-(phenylmethyl)-, 17-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] 1-methyl ester, (14R,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 288294-91-7 CAPLUS

CN 2,5,12,16-Tetraazaheptadecanedioic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-4-oxo-15-(phenylmethyl)-, 1-ethyl 16-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester, (14R,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-92-8 CAPLUS

CN 2,4,7,14,18-Pentazaheptadecan-19-oic acid, 14-(1,3-benzodioxol-5-ylsulfonyl)-16-hydroxy-2,12,12-trimethyl-3,6-dioxo-17-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (16R,17S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 288294-93-9 CAPLUS

CN 2-Oxa-5,8,15,19-tetraazaeicosan-20-oic acid, 15-(1,3-benzodioxol-5-ylsulfonyl)-17-hydroxy-13,13-dimethyl-4,7-dioxo-18-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (17R,18S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288294-94-0 CAPLUS

CN 2-Thia-3,6,13,17-tetraazaheptadecan-18-oic acid, 13-(1,3-benzodioxol-5-ylsulfonyl)-15-hydroxy-11,11-dimethyl-5-oxo-16-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (15R,16S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-95-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(hydroxyacetyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288294-96-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(hydroxyacetyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288294-99-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[7-[(hydroxyacetyl)amino]-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-00-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-4-[[[(3R)-tetrahydro-3-furanyl]oxy]carbonyl]amino]butyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288294-97-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(hydroxyacetyl)amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 288294-98-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[(hydroxyacetyl)amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




Absolute stereochemistry.



RN 288295-02-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-5-[[[(3R)-tetrahydro-3-furanyl]oxy]carbonyl]amino]pentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-03-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(1,3-dioxan-5-yloxy)carbonyl]amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-04-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-6-[[[(3R)-tetrahydro-3-furanyl]oxy]carbonyl]amino]hexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-05-6 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[[[(1,3-dioxan-5-yloxy)carbonyl]amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-08-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[[[(cyanoamino)phenoxy]methylene]amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-09-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[[[(cyanoamino)phenoxy]methylene]amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 288295-06-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[2,2-dimethyl-7-[[[(3R)-tetrahydro-3-furanyl]oxy]carbonyl]amino]heptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-07-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[7-[[[(1,3-dioxan-5-yloxy)carbonyl]amino]-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-10-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[[[(cyanoamino)phenoxy]methylene]amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-11-4 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[7-[[[(cyanoamino)phenoxy]methylene]amino]-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288295-12-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)[4-[(cyanoamino)iminomethyl]amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-13-6 CAPLUS
 CN 2,4,9,13-Tetraazatetradec-2-en-14-oic acid, 9-(1,3-benzodioxol-5-ylsulfonfyl)-3-(cyanoamino)-11-hydroxy-7,7-dimethyl-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-14-7 CAPLUS
 CN 2,6,11,13-Tetraazahexadec-11-enoic acid, 6-(1,3-benzodioxol-5-ylsulfonfyl)-12-(cyanoamino)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288295-17-0 CAPLUS
 CN 2,4,10,14-Tetraazapentadec-2-en-15-oic acid, 10-(1,3-benzodioxol-5-ylsulfonfyl)-3-(cyanoamino)-12-hydroxy-8,8-dimethyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-18-1 CAPLUS
 CN 2,6,12,14-Tetrazaheptadec-12-enoic acid, 6-(1,3-benzodioxol-5-ylsulfonfyl)-13-(cyanoamino)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-15-8 CAPLUS
 CN 2,4,9,13-Tetraazatetradec-3-en-14-oic acid, 9-(1,3-benzodioxol-5-ylsulfonfyl)-3-(cyanoamino)-11-hydroxy-2,7,7-trimethyl-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-16-9 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)[5-[(cyanoamino)iminomethyl]amino]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288295-19-2 CAPLUS
 CN 2,4,10,15-Tetraazapentadec-3-en-15-oic acid, 10-(1,3-benzodioxol-5-ylsulfonfyl)-3-(cyanoamino)-12-hydroxy-2,8,8-trimethyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-20-5 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)[6-[(cyanoamino)iminomethyl]amino]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-21-6 CAPLUS
 CN 2,4,11,15-Tetraazahexadec-2-en-16-oic acid, 11-(1,3-benzodioxol-5-ylsulfonfyl)-3-(cyanoamino)-13-hydroxy-9,9-dimethyl-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-22-7 CAPLUS
 CN 2,6,13,15-Tetraazaoctadec-13-enoic acid, 6-((1,3-benzodioxol-5-ylsulfonyl)-14-(cyanoamino)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-23-8 CAPLUS
 CN 2,4,11,15-Tetraazahexadec-3-en-16-oic acid, 11-((1,3-benzodioxol-5-ylsulfonyl)-3-(cyanoamino)-13-hydroxy-2,9,9-trimethyl-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-26-1 CAPLUS
 CN 2,6,14,16-Tetraazanonadec-14-enoic acid, 6-((1,3-benzodioxol-5-ylsulfonyl)-15-(cyanoamino)-4-hydroxy-8,8-dimethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-27-2 CAPLUS
 CN 2,4,12,16-Tetraazaheptadec-3-en-17-oic acid, 12-((1,3-benzodioxol-5-ylsulfonyl)-3-(cyanoamino)-14-hydroxy-2,10,10-trimethyl-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-24-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[7-[[[(cyanoamino)iminomethyl]amino]-2,2-dimethylheptyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-25-0 CAPLUS
 CN 2,4,12,16-Tetraazaheptadec-2-en-17-oic acid, 12-((1,3-benzodioxol-5-ylsulfonyl)-3-(cyanoamino)-14-hydroxy-10,10-dimethyl-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-28-3 CAPLUS
 CN Carbonic acid, 4-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-3,3-dimethylbutyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-29-4 CAPLUS
 CN Carbonic acid, 5-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-4,4-dimethylpentyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—NO₂

RN 288295-30-7 CAPLUS
 CN Carbonic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-5,5-dimethylhexyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—NO₂

RN 288295-31-8 CAPLUS
 CN 4-Oxa-2,9,13-triazatetradecan-14-oic acid, 9-[(1,3-benzodioxol-5-ylsulfonyl)-11-hydroxy-2,7,7-trimethyl-3-oxo-12-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288295-32-9 CAPLUS
 CN Carbanic acid,
 [(1S,2R)-3-[[[4-[(aminocarbonyl)oxy]-2,2-dimethylbutyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-33-0 CAPLUS
 CN 11-Oxa-2,6,13-triazapentadecanoic acid,
 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-34-1 CAPLUS
 CN 11-Oxa-2,6,13-triazahexadecanoic acid,
 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-35-2 CAPLUS
 CN 11-Oxa-2,6,13-triazapentadecanoic acid,
 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,14-trimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-36-3 CAPLUS
 CN 11-Oxa-2,6,13-triazahexadecanoic acid,
 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-37-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[(cyclopropylamino)carbonyl]oxy]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-38-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 4-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-3,3-dimethylbutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288295-41-0 CAPLUS
 CN 12-Oxa-2,6,14-triazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-42-1 CAPLUS
 CN 12-Oxa-2,6,14-triazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-39-6 CAPLUS
 CN 4-Morpholinecarboxylic acid, 4-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-3,3-dimethylbutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-40-9 CAPLUS
 CN Hydrazinecarboxylic acid, 4-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-3,3-dimethylbutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288295-43-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[(cyclopropylamino)carbonyl]oxy]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-44-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 5-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-4,4-dimethylpentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-45-4 CAPLUS
 CN 4-Morpholinecarboxylic acid, 5-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-4,4-dimethylpentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-46-5 CAPLUS
 CN Hydrazinecarboxylic acid, 5-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(1,3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-4,4-dimethylpentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-47-6 CAPLUS
 CN 4-Oxa-2,11,15-triazahexadecan-16-oic acid, 11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-2,9,9-trimethyl-3-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288295-50-1 CAPLUS
 CN 13-Oxa-2,6,15-triazaoctadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-51-2 CAPLUS
 CN 13-Oxa-2,6,15-triazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,16-trimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-52-3 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-48-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[6-[(aminocarbonyl)oxy]-2,2-dimethylhexyl](1,3-benzodioxol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,3aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-49-8 CAPLUS
 CN 13-Oxa-2,6,15-triazaheptadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 13-Oxa-2,6,15-triazaonadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-53-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[6-[[[(cyclopropylamino)carbonyl]oxy]-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-54-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(1,3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-5,5-dimethylhexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-55-6 CAPLUS
 CN 4-Morpholinecarboxylic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(1,3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-5,5-dimethylhexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-56-7 CAPLUS
 CN Hydrazinecarboxylic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)[(2R,3S)-3-[[[(1,3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]-5,5-dimethylhexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-57-8 CAPLUS
 CN Carbamic acid, [(1,3R,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[4-[[[(hydroxyamino)carbonyl]oxy]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-58-9 CAPLUS
 CN 2,5-Dioxo-3,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-4-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288295-59-0 CAPLUS
 CN 2,5-Dioxo-3,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-3,8,8-trimethyl-4-oxo-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-60-3 CAPLUS
 CN 11-Oxa-2,6,13-triazapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4,15-dihydroxy-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288295-61-4 CAPLUS
 CN Carbamic acid, [(1,3R,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)[5-[[[(hydroxyamino)carbonyl]oxy]-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288295-62-5 CAPLUS
 CN 2,5-Dioxo-3,11,15-triazahexadecan-16-oic acid, 11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-9,9-dimethyl-4-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-63-6 CAPLUS
 CN 2,5-Dioxo-3,11,15-triazahexadecan-16-oic acid, 11-[(1,3-benzodioxol-5-ylsulfonyl)-13-hydroxy-3,9,9-trimethyl-4-oxo-14-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (13R,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-64-7 CAPLUS
 CN 12-Oxa-2,6,14-triazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4,16-dihydroxy-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-65-8 CAPLUS
 CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-6-[(hydroxyamino)carbonyl]oxy]-2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288295-66-9 CAPLUS
 CN 2,5-Dioxo-3,12,16-triazaheptadecan-17-oic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-4-oxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288295-67-0 CAPLUS
 CN 2,5-Dioxo-3,12,16-triazaheptadecan-17-oic acid, 12-(1,3-benzodioxol-5-ylsulfonyl)-14-hydroxy-10,10-dimethyl-4-oxo-15-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288295-68-1 CAPLUS
 CN 13-Oxa-2,6,15-triazaheptadecanoic acid, 6-(1,3-benzodioxol-5-ylsulfonyl)-4,17-dihydroxy-8,8-dimethyl-14-oxo-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288304-73-4 CAPLUS
 CN 2-Oxa-4,10,14-tetraazapentadecan-15-oic acid, 12-hydroxy-10-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288304-74-5 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 12-hydroxy-10-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-3-oxo-13-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288304-75-6 CAPLUS
 CN 2-Thia-3,9,13-triazatetradecan-14-oic acid, 11-hydroxy-9-[(4-methoxyphenyl)sulfonyl]-7,7-dimethyl-12-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288304-78-9 CAPLUS
 CN 2-Oxa-4,9,13-triazatetradecan-14-oic acid, 11-hydroxy-9-[(4-methoxyphenyl)sulfonyl]-7,7-dimethyl-12-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288304-79-0 CAPLUS


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid, 11-hydroxy-9-[(4-methoxyphenyl)sulfonyl]-7,7-dimethyl-3-oxo-12-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288304-80-3 CAPLUS
 CN 2-Thia-3,8,12-triazatridecan-13-oic acid, 10-hydroxy-8-[(4-methoxyphenyl)sulfonyl]-6,6-dimethyl-11-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, 2,2-dioxide, (10R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288304-81-4 CAPLUS
 CN 2,6,11,13-Tetraazapentadecanoic acid, 15-amino-4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-12,15-dioxo-3-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288304-84-7 CAPLUS
 CN 2,5,7,12,16-Pentazapentadecan-17-oic acid, 14-hydroxy-12-[(4-methoxyphenyl)sulfonyl]-10,10-dimethyl-3,6-dioxo-15-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (14R,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288304-85-8 CAPLUS
 CN 2,4,9,13-Tetraazatetradecan-14-oic acid, 11-hydroxy-9-[(4-methoxyphenyl)sulfonyl]-2,7,7-trimethyl-3-oxo-12-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (11R,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288304-86-9 CAPLUS
 CN 14-Oxa-2,6,12-triazahexadecanoic acid, 4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-13-oxo-3-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288304-82-5 CAPLUS
 CN 2,5,7,13,17-Pentazaoctadecan-18-oic acid, 15-hydroxy-13-[(4-methoxyphenyl)sulfonyl]-11,11-dimethyl-3,6-dioxo-16-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (15R,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288304-83-6 CAPLUS
 CN 13-Oxa-2,6,11-triazapentadecanoic acid, 4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 288304-87-0 CAPLUS
 CN 2,4,10,14-Tetraazapentadecan-15-oic acid, 12-hydroxy-10-[(4-methoxyphenyl)sulfonyl]-2,8,8-trimethyl-3-oxo-13-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288304-88-1 CAPLUS
 CN 2,6,12,14-Tetraazahexadecanoic acid, 16-amino-4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-13,16-dioxo-3-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288304-89-2 CAPLUS
 CN 2-Oxa-4,10,14-triazapentadecan-15-oic acid, 12-hydroxy-10-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-13-(nitroimino)-13-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (3S,12R,13S)- (9CI) (CA INDEX NAME)


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.

RN 288304-90-5 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[[2,2-dimethyl-5-[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288304-91-6 CAPLUS


CN Carbanic acid, [(1S,2R)-3-[[5-(dimethylamino)-2,2-dimethylpentyl] [(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 14-Oxa-2,6,12-triazahexadecanoic acid, 4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8,15-trimethyl-13-oxo-3-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288306-40-1 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[[2,2-dimethyl-4-[(4-morpholinylcarbonyl)amino]butyl] [(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 288295-85-2P 288295-87-4P 288295-88-5P

288295-89-6P 288296-17-3P 288296-25-3P

288296-28-6P 288296-29-7P 288296-33-3P

288296-37-7P 288296-38-8P 288296-39-9P

288296-40-2P 288296-41-3P 288296-42-4P

288296-43-5P 288296-45-7P 288296-46-8P

288296-47-9P 288296-48-0P 288296-52-6P

288296-58-2P 288296-60-6P 288296-61-7P

288296-63-9P 288305-99-7P 288306-00-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocycl)

arylsulfonamidopropylcarbamate


HIV protease inhibitors by reductive alkylation of amines and

subsequent addition of arylsulfonyl chlorides)

RN 288295-85-2 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[[1,3-benzodioxol-5-ylsulfonyl] (4-cyano-2,2-dimethylbutyl)amino]-1-(phenylmethyl)-2-(phosphonoxy)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288305-96-4 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[[4-(dimethylamino)-2,2-dimethylbutyl] [(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288305-97-5 CAPLUS

CN 13-Oxa-2,6,11-triazapentadecanoic acid, 4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8,14-trimethyl-12-oxo-3-(phenylmethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288305-98-6 CAPLUS

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 288295-87-4 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[[4-cyano-2,2-dimethylbutyl] [(3-methyl(trifluoroacetyl)amino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288295-88-5 CAPLUS

CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(4-cyano-2,2-dimethylbutyl) [(4-methoxyphenyl)sulfonyl]amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 288295-89-6 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[4-cyano-2,2-dimethylbutyl] [(4-methoxyphenyl)sulfonyl]amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288296-28-6 CAPLUS
 CN 12-Oxa-2,6-diaza-13-silapentadecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,8,13,13,14,14-hexamethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288296-29-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (5-hydroxy-2,2-dimethylpentyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288296-33-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (4-


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 288296-17-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(5-cyano-2,2-dimethylpentyl) [(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288296-25-3 CAPLUS
 CN Carbamic acid, [3-[[[(4-cyano-2,2-dimethylbutyl) [(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 [bis(phenylmethyl)amino]-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288296-37-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (6-cyano-2,2-dimethylhexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288296-38-8 CAPLUS
 CN Carbamic acid, [3-[[[(4-[bis(phenylmethyl)amino]-2,2-dimethylbutyl) [(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288296-39-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288296-40-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-nitrophenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 288296-43-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-nitrophenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288296-45-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288296-46-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 288296-41-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288296-42-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288296-47-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288296-48-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[[4-[[bis(phenylmethyl)amino]-2,2-dimethylbutyl][3-(methylamino)phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 288296-52-6 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(5-cyano-2,2-dimethylpentyl)[(4-nitrophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288296-58-2 CAPLUS

CN 2-Oxa-5,10,14-triazapentadecan-15-oic acid, 10-[(1,3-benzodioxol-5-ylsulfonyl)-12-hydroxy-8,8-dimethyl-4-oxo-1-phenyl-13-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (12R,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288296-60-6 CAPLUS

CN 11-Oxa-2,6-diaza-12-silatetradecanoic acid, 6-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-8,12,12,13,13-hexamethyl-3-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 288305-99-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(4-bis(phenylmethyl)amino)-2,2-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288306-00-3 CAPLUS

CN 2,6,11,13-Tetraazapentadecanedioic acid, 4-hydroxy-6-[(4-methoxyphenyl)sulfonyl]-8,8-dimethyl-12-oxo-3-(phenylmethyl)-, 15-ethyl 1-(hexahydrofuro[2,3-b]furan-3-yl) ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 288296-70-8 288296-75-3 288296-76-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of heterocyclized arylsulfonamidopropylcarbamate HIV protease inhibitors by reductive alkylation of amines and subsequent addition of arylsulfonyl chlorides)

RN 288296-70-8 CAPLUS

CN 2,4-Dioxa-7-aza-3-phosphaoctan-8-oic acid, 5-[(1,3-benzodioxol-5-ylsulfonyl)-4-cyano-2,2-dimethylbutyl]amino]methyl-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 288296-61-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-4-hydroxy-2,2-dimethylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288296-63-9 CAPLUS


CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-6-hydroxy-2,2-dimethylhexyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 288296-75-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-5-cyano-2,2-dimethylpentyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288296-76-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(4-cyano-2,2-dimethylbutyl)[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L7 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pharmaceutically acceptable salt, a prodrug, a compn., or an ester thereof.

IT 253265-95-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (fitness assay and associated methods, and applications to drug resistance and HIV protease inhibitors and other drugs with reduced resistance)

RN 253265-95-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl]sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 206362-01-8 253266-00-1 253266-01-2

253266-02-3 253266-03-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (fitness assay and associated methods, and applications to drug resistance and HIV protease inhibitors and other drugs with reduced resistance)

RN 206362-01-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-methylphenyl]sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253266-00-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[4-(aminomethyl)phenyl]sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:819523 CAPLUS

DN 132:59135

TI Fitness assay and associated methods, and applications to drug resistance and HIV protease inhibitors and other drugs with reduced resistance

IN Erickson, John W.; Gulnik, Sergei V.

PA United States of America, Represented by the Secretary, Department of Health and Human Services, USA

SO PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN: CHT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9967417	A2	19991229	WO 1999-US14119	19990623
WO 9967417	A3	20000928		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336160	A1	19991229	CA 1999-2336160	19990623
AU 9948280	A	20000110	AU 1999-48280	19990623
AU 771780	B2	20040401		
EP 1088098	A2	20010404	EP 1999-931861	19990623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518063	T	20020625	JP 2000-556057	19990623
AU 2004200629	A1	20040311	AU 2004-200629	20040218
US 2005158713	A1	20050721	US 2005-30632	20050106
US 1998-90393P	P	19980623		
AU 1999-48280	A3	19990623		
WO 1999-US14119	W	19990623		
US 2001-720276	A1	20010307		

OS MARPAT 132:59135


GI For diagram(s), see printed CA Issue.

AB The invention provides an assay for determining the biochem. fitness of a biochem. species in a mutant replicating biol. entity relative to its predecessor. The invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy.

The invention also provides a compound
 AXQN(R2)CH[(CH2)mR3]CH(R4)CH2N(R5)NR
 6) [A = Q1, Q2, Q3, Q4; R1, R2, R3, R5, R6 = H, (substituted and/or heteroatom-bearing) alkyl, alkenyl, alkynyl, or cyclic group; Y, Z = CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivs. thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n = 1-5; X = bond, (substituted) methylene or ethylene, amino, O, S; Q = C(O), C(S), SO2; m = 0-6; R4 = OH, =O (keto), NH2, alkylamino, including esters, amides, and salts thereof; W = C(O), C(S), S(O), SO2; Optionally, R5 and R6, together with the NW bond comprise a macrocyclic ring, or a

L7 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 253266-01-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[3-hydroxyphenyl]sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253266-02-3 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[4-(hydroxymethyl)phenyl]sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253266-03-4 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(hydroxymethyl)phenyl]sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



L7 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Nonpeptidic, retroviral protease-inhibiting compds. AZ2N2CH(CH2)mR3CHR4CH2NR5Z2R6 [I: A = heterocyclyl (structures specified); R2 = H, Cl-6 alk(en)yl, Cl-6 alkynyl; R3 = (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl; R4 = OH, O, NH2, NMe; R5 = H, Cl-6 alk(en)yl, etc.; R6 = (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl; R5R6 together with N22 bond can form a 12-18-membered ring containing 21 addnl. heteroatom; Z = bond, CHR10, O, S, NR10, etc.; R10 = (un)substituted alk(en)yl or alkynyl; Z1, Z2 = C(O), S(O), SO2; m = 0-6] or their pharmaceutically acceptable salts, prodrugs, or esters, were prepared. Also provided are pharmaceutical

comps. for, and therapeutic methods of treating a multidrug-resistant retroviral infection in a mammal. For example, azidoepoxybutane II (4-step

preparation from butadiene monooxide and PhMgBr given) was subjected to ring cleavage/amination with Me2CHCH2NH2, the amine amidated with p-MeOC6H4SO2Cl and the azide function of the resulting amide reduced by Pd-catalyzed hydrogenation to give aminosulfonamide III. Transamidation of the latter with (3R,3aS,6aR)-3-hydroxyhexahydrofuro[2,3-b]furyl succinimidyl carbonate (5-step preparation from dihydrofuran and propargyl alc.

given) gave a title inhibitor IV which showed nanomolar and sub-nanomolar potency against several multidrug-resistant HIV-1.


IT 253265-95-1P

RL: BAC (Biological activity or effector, except adverse); BSU study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Preparation of multidrug-resistant retroviral protease inhibitors and associated methods)

RN 253265-95-1 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 206362-01-8 253266-00-1 253266-01-2

253266-02-3 253266-03-4

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES

(Uses) (preparation of multidrug-resistant retroviral protease inhibitors and associated methods)

RN 206362-01-8 CAPLUS

CN Carbamic acid, [(2S,3R)-2-hydroxy-3-[[[4-methylphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-

L7 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:819380 CAPLUS

DN 132:64254

TI Multidrug-resistant retroviral protease inhibitors and associated methods

IN Erickson, John W.; Gulnik, Sergei V.; Ghosh, Arun K.; Hussain, Khaja A.

PA United States Dept. of Health and Human Services, USA; Board of Trustees of the University of Illinois

SO PCT Int. Appl., 85 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9967254	A2	19991229	WO 1999-US14120	19990623
WO 9967254	A3	20000210		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9948281	A	20000110	AU 1999-48281	19990623
AU 2004200629	A1	20040311	AU 2004-200629	20040218
PRAI US 1998-90393P	P	19980623		
AU 1999-48280	A3	19990623		
WO 1999-US14120	W	19990623		
OS MARPAT 132:64254				
GI				



L7 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253266-00-1 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-(aminomethyl)phenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253266-01-2 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253266-02-3 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[4-(hydroxymethyl)phenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 253266-03-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[3-(hydroxymethyl)phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


to R7; D = (substituted) Q, alkyl, alkenyl; Q = (substituted) carbocyclyl, heterocyclyl; D' = OR10, N(R10)R1R3; E = Ht, OHT, OR3, NR2R3, (substituted) alkyl, alkenyl, etc.; R7 = H, (CH2O)xY(2M)(X)2(M)x, etc.;

M = null, H, Li, Na, K, Mg, Ca, Ba, alkyl, alkenyl, etc.; X = O, S; Y = P, S; Z = O, S, N(R2)2, H], were prep. as inhibitors of HIV aspartyl protease (no data). Thus, 3-H2NC6H4SO2NHOCHMe2 (prepn. given), tert-Bu N-(1S)-1-[(2S)-oxiran-2-yl]-2-phenylethylcarbamate, and phosphazene base P4 tert-Bu were stirred in 8 h in THF to give 95% tert-Bu N-(1S,2R)-3-[[[3-(aminophenyl)sulfonyl](isopropoxy)amino]-1-benzyl-2-hydroxypropyl]carbamate.

IT 252871-23-1P 252871-26-4P 252872-06-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compounds as inhibitors of HIV aspartyl protease)

RN 252871-23-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(4-hydroxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-26-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(3-hydroxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

1999-811207 CAPLUS

DN 132:49801

TI Preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compounds as inhibitors of HIV aspartyl protease.

IN Sherrill, Ronald George; Hale, Michael R.; Spaltenstein, Andrew; Furfine, Eric Steven; Andrews, Clarence Webster, III; Lowen, Gregory Thomas

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 344 pp.

CODEN: PIXX22

DT Patent

LA English

FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9965870	A2	19991223	WO 1999-US13744	19990617
WO 9965870	A3	20010315		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2335477 A1 19991223 CA 1999-2335477 19990617
 AU 9945760 A 20000105 AU 1999-45760 19990617
 AU 767729 B2 20031120
 EP 1086076 A1 20010328
 EP 1086076 B1 20041222 EP 1999-928769 19990617

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI


BR 9912169 A 20010410 BR 1999-12169 19990617
 NZ 508855 A 20031031 NZ 1999-508855 19990617
 AT 285396 T 20050115 AT 1999-928769 19990617
 PT 1086076 T 20050531 PT 1999-928769 19990617
 ES 2235492 T3 20050701 ES 1999-928769 19990617
 US 2002049201 A1 20020425 US 2000-731129 20001206
 US 6613743 B2 20030902
 NO 2000006405 A 20010219 NO 2000-6405 20001215
 HK 1037605 A1 20051007 HK 2001-106764 20010925
 US 2004097594 A 20040520 US 2003-600937 20030620
 NZ 528074 A 20041126 NZ 2003-528074 20030908
 AU 2004200636 A1 20040311 AU 2004-200636 20040219
 US 2006172936 A1 20060803 US 2005-212045 20050825

PRAT US 1998-90094P P 19980619
 WO 1999-US13744 W 19990617
 US 2000-731129 A3 20001206
 US 2003-600937 B3 20030620

OS MARPAT 132:49801
 AB ABXN(GX)CHDCHOR'CH2ND'SO2E [A = H, (substituted) Ht, R1Ht, R1Ak; Ak = alkyl; Ht = cycloalkyl, cycloalkenyl, (substituted) aryl, heterocyclyl;

R1 = CO, SO2, COCO, O2C, NR2CO, NR2SO2, etc.; B = null, NR2C(R3)2CO; x = 0, 1; R2 = H, (substituted) Ht, alkyl; R3 = H, (substituted) Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl; G = null, H, R7, alkyl; G may be bound


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252872-06-3 CAPLUS

CN Carbamic acid, [3-[[[(cyclopentylloxy)[(2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 252871-16-2P 252871-17-3P 252871-18-4P
 252871-20-8P 252871-21-9P 252871-22-0P
 252871-24-2P 252871-25-3P 252871-27-5P
 252871-29-7P 252871-38-8P 252871-41-3P
 252871-43-5P 252871-54-8P 252871-60-6P
 252871-64-0P 252871-68-4P 252871-70-8P
 252871-72-0P 252871-76-4P 252871-77-5P
 252871-78-6P 252871-79-7P 252871-80-0P
 252871-81-1P 252871-83-3P 252871-84-4P
 252871-85-9P 252871-97-9P 252871-98-0P
 252871-99-1P 252872-02-9P 252872-04-1P
 252872-05-2P 252872-12-1P 252872-13-2P
 252872-14-3P 252872-15-4P 252872-16-5P
 252872-17-6P 252872-18-7P 252872-19-8P
 252872-20-1P 252872-21-2P 252872-22-3P
 252872-23-4P 252872-25-6P 252872-26-7P
 252872-27-8P 252872-28-9P 252872-29-0P
 252872-30-3P 252872-31-4P 252872-32-5P
 252872-33-6P 252872-34-7P 252872-35-8P
 252872-36-9P 252872-38-1P 252872-40-5P
 252872-41-6P 252872-42-7P 252872-44-9P
 252872-46-1P 252872-48-3P 252872-49-4P
 252872-51-8P 252872-52-9P 252872-53-0P

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

252872-55-2P 252872-57-4P 252873-80-6P
 252873-82-8P 252879-33-7P 252879-34-8P
 252879-35-9P 252879-36-0P 252879-37-1P
 252879-38-2P 252879-40-6P 252879-41-7P
 252879-42-8P 252879-43-9P 252879-44-0P
 252879-45-1P 252879-46-2P 252879-47-3P
 252879-48-4P 252879-49-5P 252879-50-8P
 252879-51-9P 252879-52-0P 252879-53-1P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-
 hydroxypropanes and related compds. as inhibitors of HIV aspartyl
 protease)

RN 252871-16-2 CAPLUS

CN Carbamic acid,
 [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(cyclopentyl)oxy]amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-17-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy]([3-[(2-
 (dimethylamino)ethyl)amino]phenyl)sulfonyl]amino)-2-hydroxy-1-
 (phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 252871-21-9 CAPLUS

CN Carbamic acid,
 [(1S,2R)-3-[(cyclopentyl)oxy]([2-[(methylsulfonyl)amino]-1H-
 benzimidazol-5-yl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-22-0 CAPLUS

CN Carbamic acid,
 [(1S,2R)-3-[(cyclopentyl)oxy]([2-[(methylsulfonyl)amino]-1H-
 benzimidazol-5-yl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252871-24-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy]([4-(2-
 hydroxyethoxy)phenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252871-16-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy]([3-(3-methyl-1-
 imidazolidinyl)phenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252871-20-8 CAPLUS

CN Carbamic acid,
 [(1S,2R)-3-[(3-aminophenyl)sulfonyl]-(1-methylethoxy)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252871-25-3 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy]([3-
 (dimethylamino)phenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-27-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy]([3-
 (dimethylamino)phenyl)sulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252871-29-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(1H-benzimidazol-5-
 ylsulfonyl]-(cyclopentyl)oxy]amino)-2-hydroxy-1-(phenylmethyl)propyl]-,


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-38-8 CAPLUS
CN Carbamic acid, [5-[[[(cyclopentyl)oxy] [(2R,3S)-3-[[[(3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-41-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy] (1H-indazol-5-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252871-43-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy] (1H-indazol-6-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-54-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (1-methylpropoxy)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252871-60-6 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] [(tetrahydro-2H-pyran-4-yl)oxy]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-64-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(cyclohexyloxy) [(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-68-4 CAPLUS


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Carbamic acid, [(1S,2R)-3-[[[(2-amino-2-oxoethyl)amino]phenyl]sulfonyl] (cyclopentyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-70-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(cyclopentyl)oxy] [(3-nitrophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-72-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1H-benzotriazol-5-yl)sulfonyl] (cyclopentyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252871-76-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(4-(phenylmethoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-77-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(3-(phenylmethoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 252871-80-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(3-(2-(4-morpholinyl)ethoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 252871-81-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](cyclopentylloxy)amino]-1-(phenylmethyl)-2-(phosphonoxy)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 252871-76-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(3-(2-hydroxyethoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252871-79-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(4-[2-(4-morpholinyl)ethoxy]phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252871-83-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)-2-(phosphonoxy)propyl]-, C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-84-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252871-89-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-amino-1H-indazol-5-yl)sulfonyl](cyclopentylloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 252871-97-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252871-98-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 252872-04-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-05-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-12-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252871-99-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-02-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 252872-13-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-14-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-15-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6AR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-16-5 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(cyclopentylthio)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-17-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(cyclopentylthio)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
dimethoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 252872-20-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-


yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-21-2 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(cyclopentylthio)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
C-[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-22-3 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252872-18-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(cyclopentylthio)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
methylthoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-19-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[(cyclopentylthio)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
methylthoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252872-23-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-25-6 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[(3-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-26-7 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[(3-hydroxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-27-8 CAPLUS
CN Carbamic acid,
[(1S,2R)-2-hydroxy-3-[[[(4-hydroxyphenyl)sulfonyl][(tetrahydro-2H-pyran-4-yl)oxy]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-28-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl][(tetrahydro-2H-pyran-4-yl)oxy]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252872-31-4 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[(3-aminophenyl)sulfonyl](cyclohexyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-32-5 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](cyclohexyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-33-6 CAPLUS

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252872-29-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(1,3-benzodioxol-5-yl)sulfonyl][(tetrahydro-2H-pyran-4-yl)oxy]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-30-3 CAPLUS
CN Carbamic acid,
[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](cyclohexyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Carbamic acid,
[(1S,2R)-3-[[[(cyclohexyloxy)[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-34-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(cyclohexyloxy)[(4-phenylmethoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-35-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(cyclohexyloxy)[(3-phenylmethoxy)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252872-36-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyloxy)[(3-hydroxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-38-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclohexyloxy)[(4-hydroxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252872-44-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1-ethylpropoxy)[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-46-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1-ethylpropoxy)[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-48-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 252872-40-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-41-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-42-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252872-49-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252872-51-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminocarbonyl)phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 RN 252872-52-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[3-[(2-(dimethylamino)ethyl]amino)phenyl]sulfonylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-53-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-aminophenyl)sulfonyl](cyclopentylloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252872-55-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[3-[(2-(methoxymethylamino)-2-oxoethyl]amino)phenyl]sulfonylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 252873-82-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(3-[(2-amino-2-oxoethyl)amino]phenyl)sulfonyl](cyclopentylloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252879-33-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[4-(methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252879-34-8 CAPLUS
 CN Glycine, N-[3-[(cyclopentylloxy)[(2R,3S)-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]-, (9CI) (CA INDEX NAME)


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 252872-57-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[3-[(2-(dimethylamino)ethyl]amino)phenyl]sulfonylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

RN 252873-80-6 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[3-[(3-methyl-1-imidazolidinyl)phenyl]sulfonylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252879-35-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[3-[(2-(methoxymethylamino)-2-oxoethyl]amino)phenyl]sulfonylamino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252879-36-0 CAPLUS
 CN Glycine, N-[3-[(cyclopentylloxy)[(2R,3S)-3-[[[hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252879-37-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)[3-[(2-


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued).
hydroxyethyl)amino]phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252879-38-2 CAPLUS
CN Carbamic acid, [3-[[[(cyclopentyl)oxy][(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl][2-[(2-hydroxyethyl)amino]-2-oxoethyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B




RN 252879-40-6 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[(2-aminoethyl)amino]phenyl)sulfonyl](cyclopentyl)oxy]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252879-43-9 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(cyclopentyl)oxy][(3-[[2-(4-morpholinyl)-2-oxoethyl]amino]phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 252879-44-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(cyclopentyl)oxy][(3-[[2-(methoxymethylamino)-2-oxoethyl]amino]phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 252879-41-7 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[[2-(acetylamino)ethyl]amino]phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252879-42-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[3-[[2-(cyanomethyl)amino]phenyl)sulfonyl](cyclopentyl)oxy]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252879-45-1 CAPLUS
CN Glycine, N-[[[2-[[[3-[[[(cyclopentyl)oxy][(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]amino]ethyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 252879-46-2 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[(cyclopentyl)oxy][(3-[[2-[(methylamino)carbonyl]amino]ethyl]amino]phenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

NHMe

RN 252879-47-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)]{3-[[2-[(methylsulfonyl)amino]ethyl]amino]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Me

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 252879-50-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)]{3-[[2-[[2-(methylamino)-2-oxoethyl]amino]carbonyl]amino]ethyl]amino]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 252879-51-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)]{3-[[2-(methoxyamino)-2-oxoethyl]amino]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 252879-48-4 CAPLUS
 CN Carbamic acid, [2-[[3-[[[(cyclopentylloxy)]{(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-yl)oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OMe


RN 252879-49-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)]{3-[[2-[[methoxy(nitroimino)methyl]amino]ethyl]amino]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252879-52-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)]{3-[[2-(dimethylamino)-2-oxoethyl]amino]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252879-53-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentylloxy)]{3-[[2-(ethylmethylamino)-2-oxoethyl]amino]phenyl]sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 252873-47-5 252879-55-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compds. as inhibitors of HIV aspartyl protease)
 RN 252873-47-5 CAPLUS


L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Indazole-1-carboxylic acid, 3-amino-5-[[[(cyclopentylloxy)((2R,3S)-3-[[[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252879-55-3 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3-aminophenyl)sulfonyl](cyclopentylloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252872-84-7P 252872-96-1P 252873-09-9P
 252873-10-2P 252873-11-3P 252873-12-4P
 252873-15-7P 252873-16-8P 252873-17-9P
 252873-25-9P 252873-26-0P 252873-30-6P
 252873-31-7P 252873-32-8P 252873-42-0P
 252879-54-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compds. as inhibitors of HIV aspartyl protease)
 RN 252872-84-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(1-methylethoxy)((3-nitrophenyl)sulfonyl]amino)-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252873-10-2 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(1,3-benzodioxol-5-yl)sulfonyl](cyclopentylloxy)amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252873-11-3 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(cyclopentylloxy)((2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252872-96-1 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[[[(3-nitrophenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252873-09-9 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(1,3-benzodioxol-5-yl)sulfonyl](cyclopentylloxy)amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (5R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 252873-12-4 CAPLUS
 CN 2,4-Dioxo-7-aza-3-phosphaoctan-8-oic acid, 5-[[[(cyclopentylloxy)((2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, 3-oxide, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252873-15-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[[(4-nitrophenyl)sulfonyl]amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252873-16-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[[(3-nitrophenyl)sulfonyl]amino]methyl]-1-phenyl-3-(phenylmethoxy)-6-(phenylmethyl)-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252873-17-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-2-hydroxy-3-[[4-(phenylmethoxy)phenyl]sulfonyl]amino]-
 tetrahydro-2H-pyran-4-yl oxy]amino]-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252873-25-9 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(cyclohexyloxy)[(4-nitrophenyl)sulfonyl]amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252873-26-0 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(cyclohexyloxy)[(3-nitrophenyl)sulfonyl]amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252873-30-6 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(1-ethylpropoxy)[(4-nitrophenyl)sulfonyl]amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252873-31-7 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(1-ethylpropoxy)[(3-nitrophenyl)sulfonyl]amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252873-32-8 CAPLUS
 CN Carbamic acid,
 [(1S,2R)-3-[(3-cyanophenyl)sulfonyl](cyclopentyloxy)amino]-
 2-hydroxy-1-(phenylmethyl)propyl]-,
 (3R,3aR,6aR)-hexahydrofuro[2,3-b]furan-
 3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252873-42-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(cyclopentyloxy)[(1-(triphenylmethyl)-1H-
 indazol-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-,
 (3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 252879-54-2 CAPLUS
 CN Glycine,
 N-[3-[[[(cyclopentyloxy)[(2R,3S)-3-[[[(hexahydrofuro[2,3-b]furan-3-
 yl]oxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]phenyl]-,
 methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:50679 CAPLUS
 DN 130:233899
 TI Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors
 AU Baker, Christopher T.; Salituro, Francesco G.; Court, John J.; Deininger, David D.; Kim, Eunice E.; Li, Biquin; Novak, Perry M.; Rao, Bhisetti G.; Pazhanisamy, S.; Schairer, Wayne C.; Tung, Roger D.
 CS Vertex Pharmaceuticals Incorporated, Cambridge, MA, 02139, USA
 SO Bioorganic & Medicinal Chemistry Letters (1998), 8(24), 3631-3636
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB A combination of structure-based design and both solution, and solid-phase synthesis were utilized to derive a potent (nanomolar) series of HIV-1 protease inhibitors bearing a structurally novel backbone. Detailed structural anal. of several inhibitors prepared in this series has suggested that rigidification of the P1/P2 region of this class of mols. may result in compds. with improved potency.
 IT 221312-56-7P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (design, synthesis, and conformational anal. of a novel series of HIV protease inhibitors)
 RN 221312-56-7 CAPLUS
 CN Carbanic acid, [(2S,3R)-3-[(cyclopentylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl](2-phenylethyl)-, (3S,3aS,6aS)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:220237 CAPLUS
 DN 129:16069
 TI Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere
 AU Ghosh, Arun K.; Kincaid, John F.; Cho, Wonhwa; Walters, D. Eric; Krishnan, K.; Hussain, Khaja Azhar; Koo, Yumee; Cho, Hanna; Rudall, Clare; Holland, Louis; Buthod, Jim
 CS Department of Chemistry, Univ. of Illinois at Chicago, Chicago, IL, 60607, USA
 SO Bioorganic & Medicinal Chemistry Letters (1998), 8(6), 687-690
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 GI




AB The preparation of the title protease inhibitors, e.g., I, is described.
 IT 206362-01-8P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere)
 RN 206362-01-8 CAPLUS
 CN Carbanic acid, [(2S,3R)-2-hydroxy-3-[[[(4-methylphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1995:994876 CAPLUS
 DN 124:116874
 TI Preparation of sulfonamide derivatives as aspartyl protease inhibitors
 IN Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Murcko, Mark Andrew; Novak, Perry Michael; Bhisetti, Govinda Rao
 PA Vertex Pharmaceuticals Inc., USA
 SO PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524385	A1	19950914	WO 1995-US2420	19950224
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2183653	A1	19950914	CA 1995-2183653	19950224
AU 9519332	A	19950925	AU 1995-19332	19950224
AU 699483	B2	19981203		
EP 749421	A1	19961227	EP 1995-911960	19950224
EP 749421	B1	19990915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1146201	A	19970326	CN 1995-192473	19950224
JP 10500938	T	19980127	JP 1995-523497	19950224
AT 184594	T	19991015	AT 1995-911960	19950224
ES 2139195	T3	20000201	ES 1995-911960	19950224
ZA 9501688	A	19951211	ZA 1995-1688	19950301
IN 1995CA00242	A	20050304	IN 1995-CA242	19950306
US 6127372	A	20001003	US 1996-424372	19960401
HK 1012622	A1	20000922	HK 1998-113972	19981217
GR 3032151	T3	20000427	GR 1999-403237	19991215
FRAT US 1994-207580	A	19940307		
WO 1995-US2420	W	19950224		
OS MARPAT 124:116874				
GI				



AB 2[(CHD)pC(:G)(CX'')mC(:G')ND'SO2E' [D,D' = aryl, heterocyclyl, NH2, alkyl, etc.; E,E' = OH, NH2, aryl, heterocyclyl, etc.; G,G' = H2, O; X,X' = H, OH, NH2, halo, etc.; XX' = O; Z = NDSO2E, NHA, NHE, heterocyclyl, etc.; A = H, (cyclo)alkyl, Ph, heterocyclyl, etc.; m = 1-3; p = 0 or 1] were

L7 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
prepd. Title compd. I had Ki of 7nM against HIV-1 protease.
IT 172738-15-7P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide derivs. as aspartyl protease inhibitors)
RN 172738-15-7 CAPLUS
CN Carbamic acid, [3-[[[(3-aminophenyl)sulfonyl](cyclopentylmethyl)amino]-2-
hydroxypropyl](2-phenylethyl)-, hexahydrofuro[2,3-b]furan-3-yl ester
(9CI)
(CA INDEX NAME)



=> fil reg

FILE 'REGISTRY' ENTERED AT 09:49:13 ON 04 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2007 HIGHEST RN 934264-62-7

DICTIONARY FILE UPDATES: 3 MAY 2007 HIGHEST RN 934264-62-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


=> d 15 1-3

L5 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 313682-08-5 REGISTRY
 ED Entered STN: 12 Jan 2001
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Brecanavir
 CN GW 0385
 CN GW 64085X
 FS STEREOSEARCH
 MF C33 H41 N3 O10 S2
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, PROSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1907 TO DATE)
 18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 206361-99-1 REGISTRY
 ED Entered STN: 04 Jun 1998
 CN Carbamic acid, N-[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester, [3R-[3 α [(1S*,2R*),3 $\alpha\beta$,6 $\alpha\beta$]]-]

OTHER NAMES:

CN Darunavir
 CN TMC 114
 CN UIC 94017
 FS STEREOSEARCH
 DR 618109-00-5
 MF C27 H37 N3 O7 S
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, CBNS, EMBASE, IMSDRUGNEWS, IMPATENTS, IMSRESEARCH, IPA, PHAR, PROSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

75 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 75 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 206362-00-7 REGISTRY
 ED Entered STN: 04 Jun 1998
 CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI)
 CN Carbamic acid, [2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester, [3R-[3 α [(1S*,2R*),3 $\alpha\beta$,6 $\alpha\beta$]]-]

OTHER NAMES:

CN TMC 126
 CN UIC 94003
 FS STEREOSEARCH
 MF C28 H38 N2 O8 S
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH, PROSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

25 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 25 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 206362-00-7/rn
L8 1 206362-00-7/RN

=> fil capl
FILE 'CAPLUS' ENTERED AT 09:52:04 ON 04 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 4 May 2007 VOL 146 ISS 20
FILE LAST UPDATED: 3 May 2007 (20070503/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>
'FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

L9 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:181652 CAPLUS
 DN 137:179417
 TI Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease
 AU Ghosh, Arun K.; Pretzer, Elizabeth; Cho, Hanna; Hussein, Khaja Azhar; Duzgunes, Nejat
 CS Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA
 SO Antiviral Research (2002), 54(1), 29-36
 CODEN: ARSRDR; ISSN: 0166-3542
 PB Elsevier Science B.V.
 DT Journal
 LA English
 GI

L9 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



I


AB The human immunodeficiency virus type 1 (HIV-1) protease inhibitor UIC-PI (I) was developed via structure-based design and incorporated a novel bis-tetrahydrofuran (bis-THF) ligand in the (R)-(hydroxyethyl)sulfonamide based isostere. The EC50 and EC90 of the compound in acutely-infected H9 cells were <1 and .apprx.1 nM, resp. In chronically infected H9/HIV-1IIIB cells, the EC50 and EC90 were 20 and 50 nM, resp. In parallel studies comparing UIC-PI and saquinavir in H9/HIV-1IIIB cells, viral p24 levels in culture supernatants were an order of magnitude lower with UIC-PI than with saquinavir.
 IT 206362-00-7P, TMC-126
 RI: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease)
 RN 206362-00-7 CAPLUS
 CN Carbanic acid, N-[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:79486 CAPLUS
 DN 136:363282
 TI A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003
 AU Yoshimura, Kazuhisa; Kato, Ryohei; Kavlick, Mark F.; Nguyen, Aline; Maroun, Victor; Maeda, Kenji; Hussain, Khaja A.; Ghosh, Arun K.; Gulnik, Sergei V.; Erickson, John W.; Mitsuya, Hiroaki
 CS Experimental Retrovirology Section, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
 SO Journal of Virology (2002), 76(3), 1349-1358
 CODEN: JOVIAM; ISSN: 0022-538X
 PB American Society for Microbiology
 DT Journal
 LA English
 AB We identified UIC-94003, a nonpeptidic human immunodeficiency virus (HIV) protease inhibitor (PI), containing 3(R), 3a(S), 6a(R)-bis-tetrahydrofuran-yl urethane (bis-THF) and a sulfonamide isostere, which is extremely potent against a wide spectrum of HIV (50% inhibitory concentration, 0.0003 to 0.0005 μM). UIC-94003 was also potent against multi-PI-resistant HIV-1 strains isolated from patients who had no response to any existing antiviral regimens after having received a variety of antiviral agents (50% inhibitory concentration, 0.0005 to 0.0055 μM). Upon selection of HIV-1 in the presence of UIC-94003, mutants carrying a novel active-site mutation, A28S, in the presence of L10F, M46I, I50V, A71V, and N88D appeared. Modeling anal. revealed that the close contact of UIC-94003 with the main chains of the protease active-site amino acids (Asp29 and Asp30) differed from that of other PIs and may be important for its potency and wide-spectrum activity against a variety of drug-resistant HIV-1 variants. Thus, introduction of inhibitor interactions with the main chains of key amino acids and seeking a unique inhibitor-enzyme contact profile should provide a framework for developing novel PIs for treating patients harboring multi-PI-resistant HIV-1.
 IT 206362-00-7, UIC 94003
 RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (TMC 126, UIC 94003; potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in protease active site)
 RN 206362-00-7 CAPLUS
 CN Carbanic acid, N-[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]-(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:516927 CAPLUS
 DN 135:313143
 TI Structure-based design of non-peptide HIV protease inhibitors
 AU Ghosh, Arun K.; Shin, Dongwoo; Swanson, Lisa; Krishnan, K.; Cho, Hanna; Hussain, Khaja Azhar; Walters, D. Eric; Holland, Louis; Roth, Jim
 CS Department of Chemistry, University of Illinois at Chicago, Chicago, IL, 60607, USA
 SO Farmaco (2001), 56(1-2), 29-32
 CODEN: FRMCE8; ISSN: 0014-827X
 PB Elsevier Science S.A.
 DT Journal
 LA English
 AB A number of structurally novel P2-ligands have been designed and synthesized. Incorporation of these ligands in the (R)-(hydroxyethyl)sulfonamide isostere provided a series of potent non-peptidyl HIV protease inhibitors.
 IT 206362-00-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure-based design of non-peptide HIV protease inhibitors)
 RN 206362-00-7 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)


Absolute stereochemistry.




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AN 1999:819523 CAPLUS
 DN 132:59135
 TI Fitness assay and associated methods, and applications to drug resistance and HIV protease inhibitors and other drugs with reduced resistance
 IN Erickson, John W.; Gulnik, Sergei V.; Ghosh, Arun K.; Hussain, Khaja A.
 PA United States of America, Represented by the Secretary, Department of Health and Human Services, USA
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 9967417 A2 19991229 WO 1999-US14119 19990623
 WO 9967417 A3 20000928
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2336160 A1 19991229 CA 1999-2336160 19990623
 AU 9948280 A 20000110 AU 1999-48280 19990623
 AU 771780 B2 20040401
 EP 1088098 A2 20010404 EP 1999-931861 19990623
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, TE, FI
 JP 2002518063 T 20020625 JP 2000-556057 19990623
 AU 2004200629 A1 20040311 AU 2004-200629 20040218
 US 2005158713 A1 20050721 US 2005-30632 20050106
 PRAI US 1998-90393P P 19980623
 AU 1999-48280 A3 19990623
 WO 1999-US14119 W 19990623
 US 2001-720276 A1 20010307
 OS MARPAT 132:59135
 GI For diagram(s), see printed CA Issue.
 AB The invention provides an assay for determining the biochem. fitness of a biochem. species in a mutant replicating biol. entity relative to its predecessor. The invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The invention also provides a compound
 AXQN(R2)CH[(CH2)mR3]CH(R4)CH2N(R5)(WR
 6) (R = Q1, Q2, Q3, Q4; R1, R2, R3, R5, R6 = H, (substituted and/or heteroatom-bearing) alkyl, alkenyl, alkynyl, or cyclic group; Y, Z = CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl deriva. thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n = 1-5; X = bond, (substituted) methylene or ethylene, amino, O; S; Q = C(O), C(S), SO2; m = 0-6; R4 = OH, =O (keto), NH2, alkylamino, including esters, amides, and salts thereof; W = C(O), C(S), S(O), SO2; optionally, R5 and R6, together with the NW bond comprise a macrocyclic ring), or a

Absolute stereochemistry.




L9 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:819380 CAPLUS
 DN 132:64254
 TI Multidrug-resistant retroviral protease inhibitors and associated methods
 IN Erickson, John W.; Gulnik, Sergei V.; Ghosh, Arun K.; Hussain, Khaja A.
 PA United States Dept. of Health and Human Services, USA; Board of Trustees of the University of Illinois
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 9967254 A2 19991229 WO 1999-US14120 19990623
 WO 9967254 A3 20000210
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9948281 A 20000110 AU 1999-48281 19990623
 AU 2004200629 A1 20040311 AU 2004-200629 20040218
 PRAI US 1998-90393P P 19980623
 AU 1999-48280 A3 19990623
 WO 1999-US14120 W 19990623
 OS MARPAT 132:64254
 GI



AB Nonpeptidic, retroviral protease-inhibiting compds.
 A221NR2CH[(CH2)mR3]CH(R4)CH2N(R5)Z2R6 [I: A = heterocyclyl (structures specified); R2 = H, C1-6 alk(en)yl, C1-6 alkynyl; R3 = (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl; R4 = OH, O, NH2, NHMe;


L9 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 R5 = H, C1-6 alk(en)yl, etc.; R6 = (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl; R5R6 together with N22 bond can form a 12-18-membered ring contg. 21 addnl. heteroatom; Z = bond, CHR10, O, S, NR10, etc.; R10 = (un)substituted alk(en)yl or alkynyl; Z1, Z2 = C(O), S(O), SO2; m = 0-6) or their pharmaceutically acceptable salts, prodrugs, or esters, were prepd. Also provided are pharmaceutical compns.
 for, and therapeutic methods of treating a multidrug-resistant retroviral infection in a mammal. For example, azidoepoxybutane II (4-step prepn. from butadiene monooxide and PhMgBr given) was subjected to ring cleavage/amination with Me2CHCH2NH2, the amine amidated with p-MeOC6H4SO2Cl and the azide function of the resulting amide reduced by Pd-catalyzed hydrogenation to give aminosulfonamide III. Transamidation of the latter with (3R,3aS,6aR)-3-hydroxyhexahydrofuro[2,3-b]furyl succinimidyl carbonate (5-step prepn. from dihydrofuran and propargyl alc. given) gave a title inhibitor IV which showed nanomolar and sub-nanomolar potency against several multidrug-resistant HIV-1.
 IT 206362-00-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of multidrug-resistant retroviral protease inhibitors and associated methods)
 RN 206362-00-7 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:220237 CAPLUS
 DN 129:16069
 TI Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere
 AU Ghosh, Arun K.; Kincaid, John F.; Cho, Wonhwa; Walters, D. Eric; Krishnan, K.; Hussain, Khaja Azhar; Koo, Yumee; Cho, Hanna; Rudall, Clare; Holland, Louis; Buthod, Jim
 CS Department of Chemistry, Univ. of Illinois at Chicago, Chicago, IL, 60607, USA
 SO Bioorganic & Medicinal Chemistry Letters (1998), 8(6), 687-690
 CODEN: BMCLES; ISSN: 0960-894X
 DT Journal
 LA English
 GI



AB The preparation of the title protease inhibitors, e.g., I, is described.
 IT 206362-00-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere)
 RN 206362-00-7 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg

FILE 'REGISTRY' ENTERED AT 09:53:30 ON 04 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2007 HIGHEST RN 934264-62-7

DICTIONARY FILE UPDATES: 3 MAY 2007 HIGHEST RN 934264-62-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 206361-99-1/rn

L10 1 206361-99-1/RN


10/691,333

Page 455

=> d 68-75 bib abs hitstr

L11 ANSWER 68 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:781534 CAPLUS
 DN 140:174489
 TI Novel bis-tetrahydrofuranylethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro
 AU Koh, Yasuhiro; Nakata, Hiroto; Maeda, Kenji; Ogata, Hiromi; Bilcer, Geoffrey; Devasamudram, Thippeswamy; Kincaid, John F.; Borosa, Peter; Wang, Yuan-Fang; Tie, Yunfeng; Volarath, Patra; Gaddis, Laquasha; Harrison, Robert W.; Weber, Irene T.; Ghosh, Arun K.; Mitsuya, Hiroaki
 CS Department of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto, 860-8556, Japan
 SO Antimicrobial Agents and Chemotherapy (2003), 47(10), 3123-3129
 CODEN: AMACQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 AB We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylethane (bis-THF) and a sulfonamide isostere which is extremely potent against laboratory HIV-1 strains and primary clin. isolates (50% inhibitory concentration [IC50], .apprx.0.003 µM; IC90, .apprx.0.009 µM) with minimal cytotoxicity (50% cytotoxic concentration for CD4+ MT-2 cells, 74 µM). UIC-94017 blocked the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concns. up to 5 µM (IC50s, 0.003 to 0.029 µM), although it was less active against HIV-1NL4-3 variants selected for resistance to amprenavir (IC50, 0.22 µM). UIC-94017 was also potent against multi-PI-resistant clin. HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents. Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants. Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections.
 IT 206361-99-1D, TMC 114, complex with HIV1-protease
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (UIC 94017, TMC 114: novel bis-tetrahydrofuranylethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-protease inhibitor-resistant human immunodeficiency virus in vitro)
 RN 206361-99-1 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)
 Absolute stereochemistry.

L11 ANSWER 68 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 69 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:679015 CAPLUS
 DN 139:191388
 TI Methods for determining the influence of human plasma or serum protein binding on antiretroviral activity
 IN Azijn, Hilde; Wigerinck, Piet Tom Bert Paul; De Bethune, Marie-Pierre
 PA Tibotec BVBA, Belg.
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070976	A2	20030828	WO 2003-EP1846	20030221
WO 2003070976	A3	20031016		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2474671	A1	20030828	CA 2003-2474671	20030221
AU 2003208751	A1	20030909	AU 2003-208751	20030221
EP 1478766	A2	20041124	EP 2003-706562	20030221
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 200517454	T	20050616	JP 2003-569867	20030221
US 2005158709	A1	20050721	US 2003-504675	20030221
PRAI US 2002-358307P	P	20020222		
WO 2003-EP1846	W	20030221		

AB The invention provides methods for determining the influence of human plasma or serum protein binding on antiretroviral activity at physiol. achieved conditions, by using specific virus strains in a cell-based antiviral assay.
 IT 206361-99-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods for determining influence of human plasma or serum protein binding on antiretroviral activity)
 RN 206361-99-1 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)
 Absolute stereochemistry.

L11 ANSWER 69 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L11 ANSWER 70 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:47200 CAPLUS
 DN 139:47200
 TI Combination of cytochrome P 450 inhibitors and HIV protease inhibitors to treat retrovirus infections
 IN Van Der Geest, Ronald; Stoffels, Paul; Groen, Cornelis; Jochmans, Dirk Edward Desire
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049746	A2	20030619	WO 2002-EP14277	20021212
WO 2003049746	A3	20031231		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2469343	A1	20030619	CA 2002-2469343	20021212
AU 2002358713	A1	20030623	AU 2002-358713	20021212
EP 1459447	A2	20040922	EP 2002-793018	20021212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015043	A	20041103	BR 2002-15043	20021212
CN 1604803	A	20050406	CN 2002-824911	20021212
JP 200511723	T	20050428	JP 2003-550795	20021212
US 2005119338	A1	20050602	US 2003-498024	20021212
NZ 533826	A	20060428	NZ 2002-533826	20021212
ZA 2004004633	A	20050901	ZA 2004-4633	20040610
NO 2004002666	A	20040909	NO 2004-2666	20040624
PRAI EP 2001-204841	A	20011212		
WO 2002-EP14277	W	20021212		

OS MARPAT 139:47200
 AB The present invention relates to a method for improving the pharmacokinetics of hexahydrofuro[2,3-b]furan containing HIV protease inhibitors comprising administering to a human in need thereof a combination of a therapeutically effective amount of a hexahydrofuro[2,3-b]furan containing HIV protease inhibitor, and a therapeutically effective amount of a cytochrome P450 inhibitor.


IT 206361-99-1 206361-99-1D, esters
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of cytochrome P 450 inhibitors and HIV protease inhibitors to treat retrovirus infections and increase pharmacokinetics of HIV protease inhibitors in relation to resistance)
 RN 206361-99-1 CAPLUS

L11 ANSWER 71 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:302361 CAPLUS
 DN 139:345031
 TI New antiretroviral drugs
 AU Gulick, R. M.
 CS Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, 10024, USA
 SO Clinical Microbiology and Infection (2003), 9(3), 186-193
 CODEN: CMINF; ISSN: 1198-743X
 PB Blackwell Publishing Ltd.
 DT Journal; General Review
 LA English

AB A review. Despite the availability of 16 antiretroviral drugs approved for the treatment of HIV infection, current combination regimens present challenges. Newer antiretroviral drugs are needed to improve convenience, reduce toxicity and, of particular importance, to provide antiretroviral activity against viral strains resistant to the currently available antiretroviral agents. Candidate drugs with novel properties are in development in the two currently available drug classes: HIV reverse transcriptase inhibitors (nucleoside analogs, non-nucleoside analogs and nucleotide analogs) and HIV protease inhibitors (PI). Investigational nucleoside analog reverse transcriptase inhibitors (NRTI) include emtricitabine (FTC) and abacavir (DAPD), and investigational non-nucleoside reverse transcriptase inhibitors (NNRTI) include DPC 083 and TMC 125. New protease inhibitors under investigation include atazanavir (BMS-232 632), tipranavir, and TMC 114. In addition, newer agents with novel mechanisms of action such as HIV entry inhibitors (that inhibit the three steps of HIV entry: CD4 attachment, chemokine receptor binding and membrane fusion) and HIV integrase inhibitors are under investigation. Investigational entry inhibitors include PRO 542 (a CD4 attachment inhibitor), Schering C (a chemokine receptor inhibitor), enfuvirtide (T-20) and T-1249, inhibitors of membrane fusion. Investigational HIV integrase inhibitors include S-1360. Continued progress in the treatment of HIV disease will result from the development of new antiretroviral drugs.


IT 206361-99-1
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (new antiretroviral drugs)
 RN 206361-99-1 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 70 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, N-[(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 206361-99-1 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-3-[[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 71 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 72 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:944563 CAPLUS
 DN 138:11384
 TI Methods for determining plasma free drug concentration
 IN Xie, Dong; Cao, Wei; Erickson, John W.
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO Eur. Pat. Appl., 16 pp.
 CODEN: EPKXDW
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1265073	A2	20021211	EP 2002-77275	20020605
EP 1265073	A3	20031126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003113748	A1	20030619	US 2002-161613	20020605
US 7087373	B2	20060808		
US 2006205002	A1	20060914	US 2006-429481	20060505
PRAI US 2001-29557P	P	20010605		
US 2002-161613	A3	20020605		

AB The present invention relates to methods for isothermal titration calorimetry anal. of the binding affinity of protease inhibitors to plasma proteins.
 IT 206361-99-1
 RL: ANT (Analyte); ANST (Analytical study)
 (methods for determining plasma free drug concentration)
 RN 206361-99-1 CAPLUS
 CN Carbanic acid, N-[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 73 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AN 1999:819523 CAPLUS
 DN 132:59135
 TI Fitness assay and associated methods, and applications to drug resistance and HIV protease inhibitors and other drugs with reduced resistance
 IN Erickson, John W.; Gulnik, Sergei V.
 PA United States of America, Represented by the Secretary, Department of Health and Human Services, USA
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9967417	A2	19991229	WO 1999-US14119	19990623
WO 9967417	A3	20000928		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336160	A1	19991229	CA 1999-2336160	19990623
AU 9948280	A	20000110	AU 1999-48280	19990623
AU 771780	B2	20040401		
EP 1088098	A2	20010404	EP 1999-931861	19990623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518063	T	20020625	JP 2000-556057	19990623
AU 2004200629	A1	20040311	AU 2004-200629	20040218
US 2005158713	A1	20050721	US 2005-30632	20050106
PRAI US 1998-90393P	P	19980623		
AU 1999-48280	A3	19990623		
WO 1999-US14119	W	19990623		
US 2001-720276	A1	20010307		

OS MARPAT 132:59135
 GI For diagram(s), see printed CA Issue.
 AB The invention provides an assay for determining the biochem. fitness of a biochem. species in a mutant replicating biol. entity relative to its predecessor. The invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The invention also provides a compound
 A2QW(R2)CH[(CH2)mR3]CH(R4)CH2M(R5)(WR
 6) [A = Q1, Q2, Q3, Q4; R1, R2, R3, R5, R6 = H, (substituted and/or heteroatom-bearing) alkyl, alkenyl, alkynyl, or cyclic group; Y, Z = CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivs. thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n = 1-5; X = bond, (substituted) methylene or ethylene, amino, O, S; Q = C(O), C(S), SO2; m = 0-6; R4 = OH, =O (keto), NH2, alkylamino, including esters, amides, and salts thereof; W = C(O), C(S), S(O), SO2; optionally, R5 and R6, together with the NW bond comprise a macrocyclic ring], or a

Absolute stereochemistry.



L11 ANSWER 74 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:819380 CAPLUS
 DN 132:64254
 TI Multidrug-resistant retroviral protease inhibitors and associated methods
 IN Erickson, John W.; Gulnik, Sergei V.; Ghosh, Arun K.; Hussain, Khaja A.
 PA United States Dept. of Health and Human Services, USA; Board of Trustees of the University of Illinois
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9967254	A2	19991229	WO 1999-US14120	19990623
WO 9967254	A3	20000210		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9948281	A	20000110	AU 1999-48281	19990623
AU 2004200629	A1	20040311	AU 2004-200629	20040218
PRAI US 1998-90393P	P	19980623		
AU 1999-48280	A3	19990623		
WO 1999-US14120	W	19990623		


OS MARPAT 132:64254
 GI For diagram(s), see printed CA Issue.
 AB The invention provides an assay for determining the biochem. fitness of a biochem. species in a mutant replicating biol. entity relative to its predecessor. The invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The invention also provides a compound
 A2QW(R2)CH[(CH2)mR3]CH(R4)CH2M(R5)(WR
 6) [A = Q1, Q2, Q3, Q4; R1, R2, R3, R5, R6 = H, (substituted and/or heteroatom-bearing) alkyl, alkenyl, alkynyl, or cyclic group; Y, Z = CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivs. thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n = 1-5; X = bond, (substituted) methylene or ethylene, amino, O, S; Q = C(O), C(S), SO2; m = 0-6; R4 = OH, =O (keto), NH2, alkylamino, including esters, amides, and salts thereof; W = C(O), C(S), S(O), SO2; optionally, R5 and R6, together with the NW bond comprise a macrocyclic ring], or a

AB The invention provides an assay for determining the biochem. fitness of a biochem. species in a mutant replicating biol. entity relative to its predecessor. The invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The invention also provides a compound
 A2QW(R2)CH[(CH2)mR3]CH(R4)CH2M(R5)(WR
 6) [A = Q1, Q2, Q3, Q4; R1, R2, R3, R5, R6 = H, (substituted and/or heteroatom-bearing) alkyl, alkenyl, alkynyl, or cyclic group; Y, Z = CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivs. thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n = 1-5; X = bond, (substituted) methylene or ethylene, amino, O, S; Q = C(O), C(S), SO2; m = 0-6; R4 = OH, =O (keto), NH2, alkylamino, including esters, amides, and salts thereof; W = C(O), C(S), S(O), SO2; optionally, R5 and R6, together with the NW bond comprise a macrocyclic ring], or a

L11 ANSWER 74 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:819380 CAPLUS
 DN 132:64254
 TI Multidrug-resistant retroviral protease inhibitors and associated methods
 IN Erickson, John W.; Gulnik, Sergei V.; Ghosh, Arun K.; Hussain, Khaja A.
 PA United States Dept. of Health and Human Services, USA; Board of Trustees of the University of Illinois
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9967254	A2	19991229	WO 1999-US14120	19990623
WO 9967254	A3	20000210		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9948281	A	20000110	AU 1999-48281	19990623
AU 2004200629	A1	20040311	AU 2004-200629	20040218
PRAI US 1998-90393P	P	19980623		
AU 1999-48280	A3	19990623		
WO 1999-US14120	W	19990623		

OS MARPAT 132:64254
 GI For diagram(s), see printed CA Issue.
 AB The invention provides an assay for determining the biochem. fitness of a biochem. species in a mutant replicating biol. entity relative to its predecessor. The invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The invention also provides a compound
 A2QW(R2)CH[(CH2)mR3]CH(R4)CH2M(R5)(WR
 6) [A = Q1, Q2, Q3, Q4; R1, R2, R3, R5, R6 = H, (substituted and/or heteroatom-bearing) alkyl, alkenyl, alkynyl, or cyclic group; Y, Z = CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivs. thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n = 1-5; X = bond, (substituted) methylene or ethylene, amino, O, S; Q = C(O), C(S), SO2; m = 0-6; R4 = OH, =O (keto), NH2, alkylamino, including esters, amides, and salts thereof; W = C(O), C(S), S(O), SO2; optionally, R5 and R6, together with the NW bond comprise a macrocyclic ring], or a




AB Nonpeptidic, retroviral protease-inhibiting compds.
 A2Z1NR2CH[(CH2)mR3]CH(R4)CH2NR5Z2R6 (I; A = heterocyclyl (structures specified); R2 = H, C1-6 alk(en)yl, C1-6 alkynyl; R3 = (un)substituted (heterocycloalkyl, (un)substituted (hetero)aryl; R4 = OH, O, NH2, NHMe;


L11 ANSWER 74 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 R5 = H, C1-6 alk(en)yl, etc.; R6 = (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl; R5R6 together with N22 bond can form a 12-18-membered ring contg. 21 addnl. heteroatom; Z = bond, CHR10, O, S, NR10, etc.; R10 = (un)substituted alk(en)yl or alkynyl; Z1, Z2 = C(O), S(O), SO2; m = 0-6 or their pharmaceutically acceptable salts, prodrugs, or esters, were prepd. Also provided are pharmaceutical compns. for, and therapeutic methods of treating a multidrug-resistant retroviral infection in a mammal. For example, azidoepoxybutane II (4-step prepn. from butadiene monooxide and PhMgBr given) was subjected to ring cleavage/amination with Me2CHCH2NH2, the amine amidated with p-MeOC6H4SO2Cl and the azide function of the resulting amide reduced by Pd-catalyzed hydrogenation to give aminosulfonamide III. Transamidation of the latter with (3R,3aS,6aR)-3-hydroxyhexahydrofuro[2,3-b]furyl succinimidyl carbonate (5-step prepn. from dihydrofuran and propargyl alc. given) gave a title inhibitor IV which showed nanomolar and sub-nanomolar potency against several multidrug-resistant HIV-1.
 IT 206361-99-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses) (preparation of multidrug-resistant retroviral protease inhibitors and associated methods)
 RN 206361-99-1 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)
 Absolute stereochemistry.



L11 ANSWER 75 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:220237 CAPLUS
 DN 129:16069
 TI Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere
 AU Ghosh, Arun K.; Kincaid, John F.; Cho, Wonhwa; Walters, D. Eric; Krishnan, K.; Hussain, Khaja Azhar; Koo, Yumee; Cho, Hanna; Rudall, Clare; Holland, Louis; Buthod, Jim
 CS Department of Chemistry, Univ. of Illinois at Chicago, Chicago, IL, 60607, USA
 SO Bioorganic & Medicinal Chemistry Letters (1998), 8(6), 687-690
 CODEN: BMCLES; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 GI



AB The preparation of the title protease inhibitors, e.g., I, is described.
 IT 206361-99-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere)
 RN 206361-99-1 CAPLUS
 CN Carbamic acid, N-[(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (CA INDEX NAME)
 Absolute stereochemistry.



L11 ANSWER 75 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/691,333

Page 460

=> fil reg

FILE 'REGISTRY' ENTERED AT 09:54:29 ON 04 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2007 HIGHEST RN 934264-62-7

DICTIONARY FILE UPDATES: 3 MAY 2007 HIGHEST RN 934264-62-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 313682-08-5/rn

L12 1 313682-08-5/RN

10/691,333

Page 461


=> d 12-18 bib abs hitstr

L13 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:270625 CAPLUS
 DN 144:266897
 TI Discovery of next generation inhibitors of HIV protease
 AU Spaltenstein, Andrew; Kazmierski, Wieslaw M.; Miller, John F.; Samano, Vicente
 CS Division of Chemistry, MV CEDD, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SO Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2005), 5(16), 1589-1607
 CODEN: CTMCL; ISSN: 1568-0266
 PB Bentham Science Publishers Ltd.
 DT Journal; General Review
 LA English
 AB A review. Due to factors such as resistance and long-term side effects as well as dosing regimen-related adherence issues, HIV therapy is a constantly moving target. HIV-1 protease inhibitors had an immediate and dramatic impact on the outcome of HIV/AIDS when launched in late 1995, and the search for new and improved next generation mols. has been under way in many labs. At GlaxoSmithKline (GSK) and Vertex Pharmaceuticals, this effort focused on 2 key issues, patient compliance and viral resistance. Using a water-solubilizing prodrug approach, the pill burden in delivering a protease inhibitor, Amprenavir, was dramatically decreased. By eliminating the large amts. of excipients necessary for the original soft-gel formulation, Fosamprenavir (Lexiva/Telzir) delivers the clin. efficacious dose of Amprenavir with 2 compact tablets per dose, compared to 8 gel capsules. The efforts to overcome viral resistance to 1st generation protease inhibitors by further elaborating the SAR of the Amprenavir and related scaffolds led to successive and dramatic improvements in wild-type antiviral potencies, and ultimately to the discovery of ultra-potent mols. with very favorable overall resistance profiles. The selection of GW640385 (Brecanavir - USAN approved only) as a clin. candidate and its progression into current phase 2 dose ranging studies represents the culmination of the effort toward the next generation protease inhibitors.
 IT 313682-08-5, Brecanavir
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (discovery of next generation inhibitors of HIV protease)
 RN 313682-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L13 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:252581 CAPLUS
 DN 144:425067
 TI In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385
 AU Yates, P. J.; Hazen, R.; St. Clair, M.; Boone, L.; Tisdale, M.; Elston, R.
 C.
 CS GlaxoSmithKline Inc., Stevenage, UK
 SO Antimicrobial Agents and Chemotherapy (2006), 50(3), 1092-1095
 CODEN: AMACQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 AB Development of in vitro resistance to GW640385, a new human immunodeficiency virus type 1 protease inhibitor, was studied. Variants characterized included one with <4-fold resistance and amino acid substitutions Q58E/A71V (protease) and P452K (Gag) and one with >50-fold resistance and amino acid substitutions L10F/G16E/E21K/A28S/M46L/F53L/A71V (protease) and L449F/P453T (Gag). The A28S substitution substantially reduced replication capacity.
 IT 313682-08-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385)
 RN 313682-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:188865 CAPLUS
 DN 144:432712
 TI Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
 AU Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew;
 Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G.
 CS GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(7), 1788-1794
 CODEN: BMCLEB; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 144:432712
 AB A novel series of P1 modified HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and protease inhibitor-resistant viruses. Optimization of the P1 moiety resulted in compds. with femtomolar enzyme activities and cellular antiviral activities in the low nanomolar range culminating in the identification of clin. candidate GW0385.
 IT 313682-08-5P, GW0385
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of the dioxabicyclooctyl thiazolylmethoxybenzyl-substituted (benzodioxolylsulfonylamino)propylcarbamate GW0385 as an anti-HIV agent and its pharmacokinetics and behavior in resistant HIV strains)
 RN 313682-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L13 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:14172 CAPLUS
 DN 142:114047
 TI A preparation of furofuranyl derivative, useful as inhibitor of HIV
 aspartyl protease
 IN Roberts, John Charles; Toczko, Jennifer Fell
 PA SmithKline Beecham Corporation, USA; Martin, Michael Tolar
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN: CHT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005000249	A2	20050106	WO 2004-US20353	20040625
WO 2005000249	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AK, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1638960 A2 20060329 EP 2004-777060 20040625 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR US 2006148865 A1 20060706 US 2005-560500 20051212 PRAI US 2003-483002P P 20030627 WO 2004-US20353 W 20040625 OS CASREACT 142:114047 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of furofuranyl derivative I, useful as inhibitor of HIV aspartyl protease (no biol. data). For instance, I was prepared via deprotection of II and coupling with III with a yield of 90% (example 2).
 IT 313682-08-5P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of furofuranyl derivative useful as inhibitor of HIV aspartyl protease)
 RN 313682-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-(2-methylpropyl)amino]-2-hydroxy-1-[(4-[(2-methyl-4-thiazolyl)methoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

L13 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




L13 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:885959 CAPLUS
 DN 142:51214
 TI Inhibition of Wild-Type and Mutant Human Immunodeficiency Virus Type 1
 Proteases by GW0385 and Other Arylsulfonamides
 AU Hanlon, Mary H.; Porter, David J. T.; Furfine, Eric S.; Spaltenstein, Andrew; Carter, H. Luke; Danger, Dana; Shu, Arthur Y. L.; Kaldor, Istvan W.; Miller, John F.; Samano, Vicente A.
 CS GlaxoSmithKline, Research Triangle Park, PA, 19405, USA
 SO Biochemistry (2004), 43(45), 14500-14507
 CODEN: BICHAW; ISSN: 0006-2960
 FB American Chemical Society
 DT Journal
 LA English
 AB The arylsulfonamide deriva. described herein were such potent inhibitors of human immunodeficiency virus type 1 (HIV-1) protease (enzyme, E) that values for the inhibition consts. (K_i) could not be determined by conventional steady-state kinetic techniques (i.e., the minimal enzyme concentration usable for the activity assay was much greater than the value of the dissociation constant). Consequently, two alternative methods were developed for estimation of K_i values. The first method employed kinetic detns. of values for k₁ and k₋₁, from which K_i was determined (k₋₁/k₁). The second method was a competitive displacement assay used to determine binding affinities of other inhibitors relative to that of GW0385. In these assays, the inhibitor of unknown affinity was used to displace [3H]GW0385 from E·[3H]GW0385. From the concentration of E·[3H]GW0385 at equilibrium, the concns. of enzyme-bound and free inhibitors were calculated, and the ratio of the K_i value of the unknown to that of GW0385 was determined (K_i, unknown/K_i, GW0385). The values of k₁ were calculated from data in which changes in the intrinsic protein fluorescence of the enzyme associated with inhibitor binding were directly or indirectly monitored. In the case of saquinavir, the fluorescence changes associated with complex formation were large enough to monitor directly. The value of k₁ for saquinavir was 62±2 μM⁻¹ s⁻¹. In the case of GW0385, the fluorescence changes associated with complex formation were too small to monitor directly. Consequently, the value of k₁ was estimated from a competition experiment in which the effect of GW0385 on the binding of E to saquinavir was determined. The value of k₁ for GW0385 was estimated from these expts. to be 137±4 μM⁻¹ s⁻¹. Because E·[3H]GW0385 was stable in the standard buffer at room temperature for greater than 33 days, the value of the first-order rate constant for dissociation of E·[3H]GW0385 (k₋₁) could be estimated from the time-course for exchange of E·[3H]GW0385 with excess unlabeled GW0385. The value of k₋₁ calculated from these data was (2.1±0.1) × 10⁻⁶ s⁻¹ (t_{1/2} = 91 h). The K_i value of wild-type HIV-1 protease for GW0385, calculated from these values for k₁ and k₋₁, was 1511 nM. Three multidrug resistant enzymes had K_i values for GW0385 that were less than 5 pM.
 IT 313682-08-5, GW 0385
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)

L13 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (inhibition of wild-type and drug-resistant mutant human
 immunodeficiency virus type 1 proteases by GW0385 and other
 arylsulfonamides monitored by fluorescence)
 RN 313682-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)(2-
 methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-
 thiazolyl)methoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:142902 CAPLUS
 DN 140:187404
 TI Electrospon amorphous pharmaceutical compositions
 IN Ignatious, Francis; Sun, Linghong
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014304	A2	20040219	WO 2003-US24641	20030807
WO 2004014304	A3	20040624		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494865	A1	20040219	CA 2003-2494865	20030807
AU 2003258120	A1	20040225	AU 2003-258120	20030807
EP 1534250	A2	20050601	EP 2003-784959	20030807
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013222	A	20050614	BR 2003-13222	20030807
CN 1684673	A	20051019	CN 2003-823237	20030807
JP 2005534716	T	20051117	JP 2004-527797	20030807
US 2006013869	A1	20060119	US 2005-523835	20050207
US 2006083784	A1	20060420	US 2005-64890	20050224
NO 2005001123	A	20050506	NO 2005-1123	20050302
PRAI US 2002-401726P	P	20020807		
WO 2003-US24641	W	20030807		
US 2005-523835	A2	20050207		

AB The present invention is directed to use of electrosponning, i.e. the process of making polymer nanofibers from either a solution or melt under elec. forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers. Thus, carvedilol-HBr monohydrate wa dissolved in THF and water. The solution was added to Polyox WSR1105 in MeCN solution


This solution was spun to give nanofibers, and the morphol. of the drug was shown to be amorphous.

IT 313682-08-5
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (electrospon amorphous pharmaceutical compns.)

RN 313682-08-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonfyl)(2-
 methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-

L13 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 thiazolyl)methoxy]phenyl)methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-
 b]furan-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L13 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:900607 CAPLUS
 DN 134:56676
 TI Preparation of arylsulfonamides as inhibitors of aspartyl protease
 IN Hale, Michael Robin; Tung, Roger; Price, Stephen; Wilkes, Robin David; Schairer, Wayne Carl; Jarvis, Ashley Nicholas; Spaltenstein, Andrew; Furfine, Eric Steven; Samano, Vicente; Kaldor, Istvan; Miller, John Franklin; Brieger, Michael Stephen
 PA Vertex Pharmaceuticals Inc., USA; et al.
 SO PCT Int. Appl., 396 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076961	A1	20001221	WO 2000-US15781	20000608
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2380858	A1	20001221	CA 2000-2380858	20000608
BR 2000011745	A	20020319	BR 2000-11745	20000608
EP 1194404	A1	20020410	EP 2000-941279	20000608
EP 1194404	B1	20060503		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
TR 200200407	T2	20020821	TR 2002-407	20000608
JP 2003502309	T	20030121	JP 2001-503821	20000608
TR 200202528	T2	20030221	TR 2002-2528	20000608
HU 200300385	A2	20030728	HU 2003-385	20000608
NZ 516003	A	20040227	NZ 2000-516003	20000608
TW 533248	B	20040621	TW 2000-89111145	20000608
AU 779994	B2	20050224	AU 2000-56006	20000608
IN 2000CA00336	A	20050311	IN 2000-CA336	20000608
AT 325091	T	20060615	AT 2000-941279	20000608
EP 1686113	A1	20060802	EP 2006-9072	20000608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
PT 1194404	T	20060831	PT 2000-941279	20000608
ES 2263478	T3	20061216	ES 2000-941279	20000608
TR 200603871	T2	20070122	TR 2006-3871	20000608
US 6878728	B1	20050412	US 2000-591464	20000609
IN 2001KN01289	A	20050311	IN 2001-KN1289	20011206
NO 2001006034	A	20020118	NO 2001-6034	20011210
ZA 2001010177	A	20030113	ZA 2001-10177	20011211
HK 1046899	A1	20070302	HK 2002-106939	20020923
US 2004122000	A1	20040624	US 2003-691333	20031021
US 1999-139070P	P	19990611		
US 2000-190211P	P	20000317		
EP 2000-941279	A3	20000608		
WO 2000-US15781	W	20000608		
US 2000-591464	A3	20000609		
PRAI MARPAT 134:56676				
OS				
GI				

L13 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title arylsulfonamides, namely (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 3-arylsulfonylamino-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate derivs. (e.g. 1) are prepared. These compds. are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. They are useful for treating with a patient diagnosed with

AIDS, AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, or AIDS-related neuropathic conditions such as AIDS dementia complex, multiple sclerosis or tropical paraparesis, etc. Thus, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl

3-[N-(1,3-benzodioxol-5-ylsulfonyl)-N-isobutylamino]-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate underwent Mitsunobu reaction with phenethyl alc. using Ph3P and di-tert-Bu azodicarbonate in CH₂Cl₂ at room temperature for 1.5 h

to give 72% 1. 1 showed IC₅₀ of <0.001, <0.001, and 0.01-0.001 μM against drug-resistant HIV strains, i.e. wild type, mutant HIV-1 EP13,

and mutant D545701-14 HIV strains, resp., in MT-4 cells.

IT 313682-08-5P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonamides as inhibitors of HIV aspartyl

protease and


antiviral agents)

RN 313682-08-5 CAPLUS

CN Carbanic acid, [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d que l28 stat


```

L14      29 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("HALE MICHAEL R"/AU OR "HALE
        MICHAEL ROBIN"/AU)
L15      16 SEA FILE=CAPLUS ABB=ON  PLU=ON  "TUNG ROGER"/AU
L16      27 SEA FILE=CAPLUS ABB=ON  PLU=ON  "PRICE STEPHEN"/AU
L17      14 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("WILKES ROBIN D"/AU OR
        "WILKES ROBIN DAVID"/AU)
L18      18 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("SCHAIRER WAYNE"/AU OR
        "SCHAIRER WAYNE C"/AU OR "SCHAIRER WAYNE CARL"/AU)
L19      7 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("JARVIS ASHLEY"/AU OR "JARVIS
        ASHLEY N"/AU OR "JARVIS ASHLEY NICHOLAS"/AU)
L20      40 SEA FILE=CAPLUS ABB=ON  PLU=ON  "SPALTENSTEIN ANDREW"/AU
L21      65 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("FURFINE ERIC"/AU OR "FURFINE
        ERIC S"/AU OR "FURFINE ERIC STEVEN"/AU)
L22      44 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("SAMANO VICENTE"/AU OR
        "SAMANO VICENTE A"/AU)
L23      39 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("KALDOR ISTVAN"/AU OR "KALDOR
        ISTVAN W"/AU)
L24      55 SEA FILE=CAPLUS ABB=ON  PLU=ON  "MILLER JOHN F"/AU OR "MILLER
        JOHN FRANKLIN"/AU
L25      8 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("BRIEGER MICHAEL"/AU OR
        "BRIEGER MICHAEL S"/AU OR "BRIEGER MICHAEL STEPHEN"/AU)
L26      22 SEA FILE=CAPLUS ABB=ON  PLU=ON  "SHERRILL RONALD G"/AU OR
        "SHERRILL RONALD GEORGE"/AU
L27      307 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 OR L15 OR L16 OR L17 OR
        L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26
L28      10 SEA FILE=CAPLUS ABB=ON  PLU=ON  L27 AND (ASPARTYL PROTEASE)

```

=> d 1-10 bib abs

L28 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:653129 CAPLUS
 DW 142:56602
 TI Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties
 AU Kazmierski, Wieslaw M.; Andrews, Webb; Furfine, Eric; Spaltenstein, Andrew; Wright, Lois
 CS GlaxoSmithKline Research, Research Triangle Park, NC, 27709, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(22), 5689-5692
 CODEN: BMCLES; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 142:56602
 GI




AB An efficient synthesis of an HIV-1 protease inhibitor and its analogs, which incorporate the pyrrolidone scaffold 2 as P1-P2 moiety, was developed. Evaluation of these analogs in the HIV-1 protease enzyme assay resulted in the discovery of potent and more water soluble meta-amino- and meta-hydroxy inhibitors. The SAR observed in this class of PIs could be rationalized with aid of the X-ray structure of an inhibitor co-crystallized with the HIV-1 protease, which suggested that the polar meta- (but not para-) benzyl substituents in P2 could side-step the hydrophobic S2 enzyme active pocket by rotating the P2 moiety around its C β -C γ bond. Such reorientation allows to engage the unsubstituted, hydrophobic edge of benzyl moiety in P2 in the requisite P2/S2 hydrophobic interaction, and projects polar meta-substituent into the bound water. It appears that the meta-position can be chemical derivatized without potency loss of thus resulting inhibitors, as evidenced by potent deriva. Thus, pyrrolidone-based inhibitors were identified, which uniquely accommodate both high enzyme potency and which provide a platform for fine-tuning of drug-like properties in this class of PIs by addnl. chemical manipulations on the meta-position. The mol. structure of HIV-1 protease complex with complex with 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-

L28 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 y1]-5-[(3S,5R)-3-[3-[(aminocarbonyl)phenyl]methyl]-2-oxo-5-(phenylmethyl)-1-pyrrolidinyl]-2-[4-[(2-hydroxyethoxy)phenyl]methyl]-D-erythro-pentonamide (I) was reported.
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:900607 CAPLUS
 DW 134:56676
 TI Preparation of arylsulfonamides as inhibitors of aspartyl protease
 IN Hale, Michael Robin; Tung, Roger; Price, Stephen; Wilkes, Robin David; Schairer, Wayne Carl; Jarvis, Ashley Nicholas; Spaltenstein, Andrew; Furfine, Eric Steven; Samano, Vicente; Kaldor, Istvan; Miller, John Franklin; Brieger, Michael Stephen
 PA Vertex Pharmaceuticals Inc., USA; et al.
 SO PCT Int. Appl., 396 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076961	A1	20001221	WO 2000-US15781	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TG				
CA 2380858	A1	20001221	CA 2000-2380858	20000608
BR 2000011745	A	20020319	BR 2000-11745	20000608
EP 1194404	A1	20020410	EP 2000-941279	20000608
EP 1194404	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 20020407	T2	20020821	TR 2002-407	20000608
JP 2003502309	T	20030121	JP 2001-503821	20000608
TR 200202528	T2	20030221	TR 2002-2528	20000608
HU 200300385	A2	20030728	HU 2003-385	20000608
NZ 516003	A	20040227	NZ 2000-516003	20000608
TM 593248	B	20040621	TM 2000-89111145	20000608
AO 779994	B2	20050224	AO 2000-56006	20000608
IN 2000CA00336	A	20050311	IN 2000-CA336	20000608
AF 325091	T	20060615	AF 2000-941279	20000608
EP 1686113	A1	20060802	EP 2006-9072	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1194404	T	20060831	PT 2000-941279	20000608
ES 2263478	T3	20061216	ES 2000-941279	20000608
TR 200603871	T2	20070122	TR 2006-3871	20000608
US 6878728	B1	20050412	US 2000-591464	20000609
IN 2001KN01289	A	20050311	IN 2001-KN1289	20011206
NO 2001006034	A	20020118	NO 2001-6034	20011210
ZA 2001010177	A	20030113	ZA 2001-10177	20011211
HK 1046899	A1	20070302	HK 2002-106939	20020923
US 2004122000	A1	20040624	US 2003-691333	20031021
FRAI US 1999-139070P	P	19990611		
US 2000-190211P	P	20000317		
EP 2000-941279	A3	20000608		
WO 2000-US15781	W	20000608		
US 2000-591464	A3	20000609		

L28 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 OS MARPAT 134:56676
 GI



AB The title arylsulfonamides, namely (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 3-arylsulfonylamino-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate derivs. (e.g. I) are prepared. These compds. are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. They are useful for treating with a patient diagnosed with AIDS, AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, or AIDS-related neurop. conditions such as AIDS dementia complex, multiple sclerosis or tropical paraperesis, etc. Thus, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 3-[N-(1,3-benzodioxol-5-ylsulfonyl)-N-isobutylamino]-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate underwent Mitsunobu reaction with phenethyl alc. using Ph3P and di-tert-Bu azodicarbonate in CH2Cl2 at room temperature for 1.5 h to give 72% I. I showed IC50 of <0.001, <0.001, and 0.01-0.001 μ M against drug-resistant HIV strains, i.e. wild type, mutant HIV-1 EP13, and mutant D545701-14 HIV strains, resp., in MT-4 cells.
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:573770 CAPLUS
DN 133:177157
TI Preparation of [1-benzyl-2-hydroxy-3-(arylsulfonamido)propyl]carbamates

as HIV aspartyl protease inhibitors
IN Hale, Michael R.; Baker, Christopher T.; Stammers, Timothy A.;
Sherrill, Ronald G.; Spaltenstein, Andrew; Furfine,
Eric S.; Maltais, Francois; Andrews, Clarence Webster, III;
Miller, John F.; Samano, Vicente

PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 369 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000047551	A2	20000817	WO 2000-US3288	20000209
WO 2000047551	A3	20010816		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6319946	B1	20011120	US 2000-500781	20000209
EP 1159278	A2	20011205	EP 2000-913402	20000209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536430	T	20021029	JP 2000-598472	20000209
AT 311391	T	20051215	AT 2000-913402	20000209
EP 1637518	A2	20060322	EP 2005-25977	20000209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ES 2254156	T3	20060616	ES 2000-913402	20000209
PT 1159278	T	20060630	PT 2000-913402	20000209
TW 260322	B	20060821	TW 2000-89102108	20000209
US 2002189388	A1	20021226	US 2001-927271	20010809
US 6613350	B2	20030909		
US 2004127488	A1	20040701	US 2003-613650	20030702
PRAI US 1999-120047P	P	19990212		
SY 2000-1090	A	20000207		
EP 2000-913402	A3	20000209		
US 2000-500781	A3	20000209		
US 2000-53288	W	20000209		
US 2001-927271	A3	20010809		
OS MARPAT 133:177157				
GI				

L28 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB ABxN(Gx)CH(D)CH(OR7)CH2ND'E'E [wherein A = H, or (un)substituted Ht, R1Ht, or R1Ak; Ak = alkyl; Ht = cycloalkyl, cycloalkenyl, or (un)substituted aryl or heterocyclyl; R1 = CO(CO), (O)SO2, O2C, or (un)substituted NHSO2 or NHCO(CO); B = (un)substituted NHCH2CO; x = 0 or 1; G = H, R7, alkyl; or G may be bound to R7 to form a heterocyclic ring; R7 = H, (CH2O)xY(ZM)(X)2(M)x; etc.; M = H, Li, Na, K, Mg, Ca, Ba, alkyl, alkenyl, etc.; X = O or S; Y = P or S; Z = H, O, S, or (un)substituted NH2; D = independently Q or (un)substituted (cyclo)alkyl or (cyclo)alkenyl; Q = (un)substituted carbocyclyl or heterocyclyl; D' = (un)substituted alkyl, alkenyl, alkynyl; E = Ht, OHT, HtHt, alkoxy, (un)substituted NH2, alkyl, or carbocyclyl; E' = CO or SO2] were prepared as antiviral agents against HIV-1 and HIV-2 viruses. Thus, 3-NO2C6H4SO2Cl was added to tert-Bu (1S,2R)-N-[1-benzyl-3-[(4-cyano-2,2-dimethylbutyl)amino]-2-hydroxypropyl]carbamate (preparation given) to form the 3-nitrophenylsulfonamide (55%). Reduction to the 3-aminophenylsulfonamide (85%), followed by transesterification with (1S,3aR,6aS)-hexahydrofuro[2,3-b]furan-3-yl[(4-nitrophenyl)carbonate (65%), gave I.

In an antiviral activity assay, I inhibited HIV-1 protease in the MT4 cell line with Ki < 1 nM and IC50 < 0.1 μM.

L28 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:811207 CAPLUS
DN 132:49801
TI Preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compounds as inhibitors of HIV aspartyl protease.

IN Sherrill, Ronald George; Hale, Michael R.;
Spaltenstein, Andrew; Furfine, Eric Steven; Andrews,
Clarence Webster, III; Lowen, Gregory Thomas

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 344 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9965870	A2	19991223	WO 1999-US13744	19990617
WO 9965870	A3	20010315		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335477	A1	19991223	CA 1999-2335477	19990617
AU 5945760	A	20000105	AU 1999-45760	19990617
AU 767728	B2	20031120		
EP 1086076	B1	20041222	EP 1999-928769	19990617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9912169	A	20010410	BR 1999-12169	19990617
NZ 508855	A	20031031	NZ 1999-508855	19990617
AT 285396	T	20050115	AT 1999-928769	19990617
PT 1086076	T	20050531	PT 1999-928769	19990617
ES 2235492	T3	20050701	ES 1999-928769	19990617
US 2002049201	A1	20020425	US 2000-731129	20001206
US 6613743	B2	20030902		
NO 200006405	A	20010219	NO 2000-6405	20001215
HK 1037605	A1	20051007	HK 2001-106764	20010925
US 2004097594	A1	20040520	US 2003-600937	20030620
NZ 528074	A	20041126	NZ 2003-528074	20030908
AU 2004206636	A1	20040311	AU 2004-206636	20040219
US 2006172936	A1	20060803	US 2005-212045	20050825
PRAI US 1998-90094P	P	19980619		
WO 1999-US13744	W	19990617		
US 2000-731129	A3	20001206		
US 2003-600937	B3	20030620		
OS MARPAT 132:49801				

AB ABxN(Gx)CHDCHOR7CH2ND'SO2E [A = H, (substituted) Ht, R1Ht, R1Ak; Ak = alkyl; Ht = cycloalkyl, cycloalkenyl, (substituted) aryl, heterocyclyl; R1 = CO, SO2, COCO, O2C, NR2CO, NR2SO2, etc.; B = null, NR2C(R3)2CO; x = 0, 1; R2 = H, (substituted) Ht, alkyl; R3 = H, (substituted) Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl; G = null, H, R7, alkyl; G may be bound to R7; D = (substituted) Q, alkyl, alkenyl; Q = (substituted) carbocyclyl, heterocyclyl; D' = OR10, N:R10, N(R10)R1R3; E = Ht, OHT, OR3, NR2R3,



L28 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(substituted) alkyl, alkenyl, etc.; R7 = H, (CH2O)xY(ZM)(X)2(M)x, etc.;

M = null, H, Li, Na, K, Mg, Ca, Ba, alkyl, alkenyl, etc.; X = O, S; Y = P, S; Z = O, S, NR2)2, H], were prepd. as inhibitors of HIV aspartyl protease (no data). Thus, 3-H2NC6H4SO2NHCHMe2 (prepn. given), tert-Bu N-(1S)-1-[(2S)-oxiran-2-yl]-2-phenylethylcarbamate, and phosphazene base P4 tert-Bu were stirred in 8 h in THF to give 95% tert-Bu N-(1S,2R)-3-[[[3-aminophenyl]sulfonyl] (isopropoxy)amino]-1-benzyl-2-hydroxypropylcarbamate.

L28 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:561585 CAPLUS
 DN 131:185247
 TI Preparation of heterocyclylhydroxyalkanamides and related compounds as aspartyl protease inhibitors
 IN Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Bhisetti, Govinda Rao; Baker, Christopher Todd; Spaltenstein, Andrew
 PA Vertex Pharmaceuticals Incorporated, USA
 SO U.S., 69 pp., Cont.-in-part of U.S. Ser. No. 592,777.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5945413	A	19990831	US 1996-724563	19960930
US 5883252	A	19990316	US 1996-592777	19960126
CA 2243121	A1	19970731	CA 1997-2243121	19970122
WO 9727180	A1	19970731	WO 1997-US1610	19970122
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9717580	A	19970820	AU 1997-17580	19970122
AU 709239	B2	19990826		
EP 882022	A1	19981209	EP 1997-904911	19970122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9707086	A	19990413	BR 1997-7086	19970122
HU 9901024	A2	19990928	HU 1999-1024	19970122
JP 2000501111	T	20000202	JP 1997-527124	19970122
ZA 9700613	A	19970730	ZA 1997-613	19970124
AP 844	A	20000609	AP 1997-961	19970124
W: BW, GM, GH, KE, LS, MW, SD, SZ, UG, ZM, ZW				
NO 9803435	A	19980921	NO 1998-3435	19980724
US 1996-592777	A2	19960126		
US 1996-724563	A	19960930		
WO 1997-US1610	W	19970122		
OS MARPAT 131:185247				
GI				

L28 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [Z = (Q)R1X'R4, fragment II, etc., which may be fused with R6; X, X' = CO, COCO, SO, SO2; Y, Y' = (CR22)p, NR2, (CR22)pM, NR2CH2; Q = CH, N; R1, R2 = H, R6, alkyl, alkenyl, alkynyl, (fused) cycloalkyl, cycloalkenyl, etc.; R4 = (substituted) OR9, XR9, NR92, R6, alkyl, alkenyl, (fused) cycloalkyl, cycloalkenyl, etc.; R5 = H, OH, O, R1: R6 = (substituted) aryl, carbocyclyl, heterocyclyl; R7 = H, OH, O; R9 = H, alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heterocyclyl, aralkyl, carbocyclylalkyl, heterocyclylalkyl; M = NH, NR2, O, S, SO, SO2; n = 1, 2; x = 0-2] were prepared for use as aspartyl protease inhibitors. Thus, compound II (preparation given) inhibited HIV aspartyl protease with Ki = 160 nM.
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:460395 CAPLUS
 DN 131:106817
 TI Prodrugs of aspartyl protease inhibitors for treatment of HIV infections
 IN Hale, Michael R.; Tung, Roger D.; Baker, Christopher T.; Spaltenstein, Andrew; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9933795	A1	19990708	WO 1998-US27510	19981224
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9920121	A	19990719	AU 1999-20121	19981224
PRAI US 1997-70309P	P	19971224		
WO 1998-US27510	W	19981224		
OS MARPAT 131:106817				
AB Prodrugs of a class of sulfonamides which are HIV aspartyl protease inhibitors are described. The prodrugs are characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. The prodrugs and pharmaceutical compns. of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance in HIV infections. E.g., a pharmaceutical composition, in addition to a prodrug, may comprise an antiviral agent, a HIV protease inhibitor other than a compound of this invention, and an immunostimulant. RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L28 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:460393 CAPLUS
 DN 131:87804
 TI Preparation of 1,3-diacetylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
 IN Hale, Michael R.; Tung, Roger D.; Baker, Christopher T.; Spaltenstein, Andrew; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9933793	A2	19990708	WO 1998-US27424	19981223
WO 9933793	A3	19990910		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2316218	A1	19990708	CA 1998-2316218	19981223
AU 9920925	A	19990719	AU 1999-20925	19981223
BR 9814484	A	20001010	BR 1998-14484	19981223
EP 1042280	A2	20001011	EP 1998-965466	19981223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002402	T2	20010122	TR 2000-200002402	19981223
EE 200000386	A	20011217	EE 2000-386	19981223
JP 2001527062	T	20011225	JP 2000-526477	19981223
HU 200101598	A2	20020429	HU 2001-1598	19981223
HU 200101598	A3	20020828		
CN 1110492	B	20030604	CN 1998-813313	19981223
NO 2000003332	A	20000818	NO 2000-3332	20000626
IN 2000KN00131	A	20050311	IN 2000-KN131	20000713
HR 2000000499	A1	20010430	HR 2000-499	20000724
US 2002082249	A1	20020627	US 2001-998617	20011130
US 2003144217	A1	20030731	US 2002-226430	20020821
PRAI US 1997-68889P	P	19971224		
WO 1998-US27424	W	19981223		
US 2000-602984	A1	20000623		
US 2001-998617	B1	20011130		
OS MARPAT 131:87804				
GI				

L28 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. [I: R1 = CO, SO2, COCO, O2C, OSO2, NR2SO2, etc.; A = (benzo- or heterocyclo-fused) 5-7 membered heterocyclyl(alkyl); D, D1 = Q, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkenyl; G = H, R7, alkyl; E = Ht, OHT, HtHt, OR3, NR2R3, (substituted) alkyl, alkenyl, carbocyclyl, etc.; GR7 = atoms to form a heterocyclic ring; Q = (substituted) (unsatd.) 3-7 membered carbocyclyl, 5-7 membered heterocyclyl; R2 = H, (Q-substituted) alkyl; R3 = H, (substituted) Ht, alkyl, alkenyl; R7 = (CH2O)nY(ZM) (:X)ZMn, (CH2O)nCO(R9)nM1; M = H, Li, Na, K, Mg, Ca, Ba, ammonio, alkyl, alkenyl, etc.; M1 = H, (substituted) alkyl, alkenyl, etc.;

R9 = C(R2)2, O, NR2; Y = P, S, X = O, S; Ht = cycloalkyl, cycloalkenyl, (substituted) aryl, 5-7 membered heterocyclyl; n = 0, 1; with provisos, were prepared. Thus, title compound (II; R7 = H; R10 = NO2) was heated with H3PO3 and DCC in pyridine to give 96% II (R7 = OP(O)(OH)H; R10 = NO2). This was heated with TMSOOTMS and (TMS)2NH to give 88% II (R7 = OP(O)(OH)2; R10 = NO2). The latter was hydrogenated and salified to give II (R7 = OP(O)(ONa)2; R10 = NO2). The latter was hydrogenated and salified to give II (R7 = OP(O)(ONa)2; R10 = NH2) (III). III in a methylcellulose/EtOH/H2O formulation administered orally to dogs showed a relative availability of 60.4% relative to its metabolite VS-478.

L28 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyridine to give 96% I (R7 = OP(O)(OH)H; R10 = NO2). This was heated with TMSOOTMS and (TMS)2NH to give 88% I (R7 = OP(O)(OH)2; R10 = NO2). The latter was hydrogenated and salified to give I (R7 = OP(O)(ONa)2; R10 = NH2) (II). II in a methylcellulose/EtOH/H2O formulation administered orally to dogs showed a relative availability of 60.4% relative to its metabolite VS-478.

L28 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:460392 CAPLUS
DN 131:87803
TI Preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
IN Hale, Michael R.; Tung, Roger D.; Baker, Christopher T.; Spaltenstein, Andrew; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933792	A2	19990708	WO 1998-US27403	19981223
WO 9933792	A3	19990916		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NA, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9920102	A	19990719	AU 1999-20102	19981223
PRAI US 1997-68806P	P	19971224		
WO 1998-US27403	W	19981223		
OS HARPAT 131:87803				
GI				




AB 2[(CHD)pC(:G)(CX1)mC(G1)N(D1)SO2E1 [Z = N(D)SO2E, NHA, NDA, NHE, NHCONDE, NH(Ht), Ht, ND(Ht); A = H, Ht, R1Ht, (substituted) R1Alk; Alk = alkyl, alkenyl; Ht = (substituted) cycloalkyl, cycloalkenyl, aryl, benzoheterocyclyl, heterocyclyl; D, D1 = R6, N(R2)2, (substituted) alkyl, alkenyl, cycloalkyl, etc.; E, E1 = Ht, OHT, HtHt, OR3, NR2R3, (substituted) alkyl, alkenyl; R1 = CO, SO2, COCO, O2C, OSO2, NR2CO, etc.; R2 = H, R6, R6-substituted alkyl; R3 = H, (substituted) Ht, alkyl, alkenyl; R6 = (substituted) aryl, carbocyclyl, heterocyclyl; G, G1 = H2, O, X, X1 = H, OH, NH2, SH, etc.; CX1 = O; m = 1-3; p = 0, 1], were prepared. Thus, title compound (I; R7 = H; R10 = NO2) was heated with H3PO3 and DCC in

L28 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:213401 CAPLUS
Correction of: 1997:513626
DN 130:209597
Correction of: 127:205470
TI Preparation of heterocyclylhydroxyalkanamides and related compounds as protease inhibitors.
IN Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Bhisetti, Govinda Rao; Baker, Christopher Todd; Spaltenstein, Andrew; Kazmierski, Wieslaw M.; Andrews, Clarence Webster III
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN. CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727180	A1	19970731	WO 1997-US1610	19970122
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5883252	A	19990316	US 1996-592777	19960126
US 5945413	A	19990831	US 1996-724563	19960930
AU 9717580	A	19970820	AU 1997-17580	19970122
AU 709239	B2	19990826		
EP 882022	A1	19981209	EP 1997-904911	19970122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9707086	A	19990413	BR 1997-7086	19970122
JP 2000501111	T	20000202	JP 1997-527124	19970122
NO 9803435	A	19980921	NO 1998-3435	19980724
PRAI US 1996-592777	A	19960126		
US 1996-724563	A2	19960930		
WO 1997-US1610	W	19970122		
OS HARPAT 130:209597				
GI				

L28 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. [I; Z = (QR1)R1R4, Q1, etc.; ; X, X1 = CO, CO2, SO, SO2; Y, Y1 = [C(R2)2]p, NR2, C:C(R2)2, NR2CH2, etc.; Q = CH, N; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, (fused) cycloalkyl, cycloalkenyl, etc.; R4 = (substituted) OR9, XR9, N(R9)2, R6, alkyl, alkenyl, (fused) cycloalkyl, cycloalkenyl, etc.; R5 = H, OH, O, R1; R6 = (substituted) aryl, carbocyclyl, heterocyclyl; R7 = H, OH, O; R9 = H, alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heterocyclyl, aralkyl, carbocyclalkyl, heterocyclalkyl; n = 1, 2; r = 0-2], were prepared Thus, title compound (II) (preparation given) inhibited HIV protease with Ki = 1.5 nM.

L28 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:513626 CAPLUS

DN 127:205470

TI Preparation of heterocyclhydroxyalkanamides and related compounds as HIV

protease inhibitors.

IN Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Bhisetti, Govinda Rao; Baker, Christopher Todd; Spaltenstein, Andrew; et al.

PA Vertex Pharmaceuticals Inc., USA; Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Bhisetti, Govinda Rao


SO PCT Int. Appl., 336 pp.

CODEN: PIXXD2

DT Patent

LA English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9727180 A1		19970731	WO 1997-US1610	19970122
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG			
PRAI US 1996-592777		19960126		
US 1996-724563		19960930		
OS MARPAT 127:205470				
GI				



L28 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. [I; Z = (QR1)R1R4, Q1, etc.; ; X, X1 = CO, CO2, SO, SO2; Y, Y1 = [C(R2)2]p, NR2, C:C(R2)2, NR2CH2, etc.; Q = CH, N; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, (fused) cycloalkyl, cycloalkenyl, etc.; R4 = (substituted) OR9, XR9, N(R9)2, R6, alkyl, alkenyl, (fused) cycloalkyl, cycloalkenyl, etc.; R5 = H, OH, O, R1; R6 = (substituted) aryl, carbocyclyl, heterocyclyl; R7 = H, OH, O; R9 = H, alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heterocyclyl, aralkyl, carbocyclalkyl, heterocyclalkyl; n = 1, 2; r = 0-2], were prepared Thus, title compound (II) (preparation given) inhibited HIV protease with Ki = 1.5 nM.

=> d his full

(FILE 'HOME' ENTERED AT 09:36:01 ON 04 MAY 2007)

FILE 'REGISTRY' ENTERED AT 09:36:14 ON 04 MAY 2007

L1 STRUCTURE UPLOADED

D

L2 50 SEA SSS SAM L1

L3 1920 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 09:37:28 ON 04 MAY 2007

L4 129 SEA ABB=ON PLU=ON L3

FILE 'REGISTRY' ENTERED AT 09:38:18 ON 04 MAY 2007

L5 3 SEA ABB=ON PLU=ON L3 AND REF.CAPLUS>10

D 1-3

L6 1917 SEA ABB=ON PLU=ON L3 NOT L5

FILE 'CAPLUS' ENTERED AT 09:40:37 ON 04 MAY 2007

L7 51 SEA ABB=ON PLU=ON L6

D QUE L7 STAT

D 1-51 BIB ABS HITSTR

FILE 'REGISTRY' ENTERED AT 09:49:13 ON 04 MAY 2007

D L5 1-3

L8 1 SEA ABB=ON PLU=ON 206362-00-7/RN

FILE 'CAPLUS' ENTERED AT 09:52:04 ON 04 MAY 2007

L9 25 SEA ABB=ON PLU=ON L8

L19 E JARVIS ASHLEY/AU
7 SEA ABB=ON PLU=ON ("JARVIS ASHLEY"/AU OR "JARVIS ASHLEY
N"/AU OR "JARVIS ASHLEY NICHOLAS"/AU)
E SPALTENSTEIN ANDREW/AU
L20 40 SEA ABB=ON PLU=ON "SPALTENSTEIN ANDREW"/AU
E FURFINE ERIC/AU
L21 65 SEA ABB=ON PLU=ON ("FURFINE ERIC"/AU OR "FURFINE ERIC S"/AU
OR "FURFINE ERIC STEVEN"/AU)
E SAMANO VICENTE/AU
L22 44 SEA ABB=ON PLU=ON ("SAMANO VICENTE"/AU OR "SAMANO VICENTE
A"/AU)
E KALDOR ISTVAN/AU
L23 39 SEA ABB=ON PLU=ON ("KALDOR ISTVAN"/AU OR "KALDOR ISTVAN
W"/AU)
E MILLER JOHN F/AU
L24 55 SEA ABB=ON PLU=ON "MILLER JOHN F"/AU OR "MILLER JOHN
FRANKLIN"/AU
E BRIEGER MICHAEL/AU
L25 8 SEA ABB=ON PLU=ON ("BRIEGER MICHAEL"/AU OR "BRIEGER MICHAEL
S"/AU OR "BRIEGER MICHAEL STEPHEN"/AU)
E SHERRILL RONALD/AU
L26 22 SEA ABB=ON PLU=ON "SHERRILL RONALD G"/AU OR "SHERRILL RONALD
GEORGE"/AU
L27 307 SEA ABB=ON PLU=ON L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR
L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26
L28 10 SEA ABB=ON PLU=ON L27 AND (ASPARTYL PROTEASE)
D QUE L28 STAT
D 1-10 BIB ABS

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 May 2007 VOL 146 ISS 20
FILE LAST UPDATED: 3 May 2007 (20070503/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
132.88	673.30

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-13.26	-63.96

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:06:29 ON 04 MAY 2007